Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
34400.0 | 2012-08-30 00:00:00 UTC | Bio-Rad's New Digital Biology Center - Analyst Blog | ABT | https://www.nasdaq.com/articles/bio-rads-new-digital-biology-center-analyst-blog-2012-08-30 | nan | nan | Bio-Rad Laboratories, Inc. ( BIO ), a worldwide provider of life science research and clinical diagnostic products, recently inaugurated its Digital Biology Center for the development of products based on the droplet partitioning technology acquired by the company last year.
Following the acquisition, Bio-Rad introduced its first product with this technology, QX100 Droplet Digital PCR system, the third generation of the polymerase chain reaction (PCR) technology.
This new PCR technology, which adopts advanced methods for nucleic acid quantification, is widely accepted among researchers. The company claims that Droplet Digital PCR has the potential to provide new strategies for diagnosis of inherited disorders, cancer and infectious disease. Bio-Rad also expects the prospects of this instrument to extend the scope of the digital PCR market.
To increase its Life Science business, earlier in October 2011, Bio-Rad purchased QuantaLife, Inc., the developer of Droplet Digital PCR technology, for a total consideration of $179.4 million. Integrating with the QuantaLife business, Bio-Rad aimed to further expand its advanced methods of quantitative PCR. It also expected the portfolio of QuantaLife to complement its existing amplification business.
Bio-Rad is currently focused on expansion in both Life Science and Clinical Diagnostics segments through acquisitions and asset purchases. Apart from the QuantaLifeacquisition, in January 2012, the company purchased certain assets from a raw materials supplier for approximately $15.5 million.
This asset acquisition is expected to secure the supply of critical raw materials, thus lowering overall costs in the Clinical Diagnostics segment of the company. Earlier in 2011, Bio-Rad acquired DiaMed Thailand and DiaMed Spain.
Bio-Rad operates and conducts business in many countriesoutside the U.S. As a result, the company is exposed to movements in foreign currency exchange rates.
The company's major competitors in the Life Science market include Life Technologies ( LIFE ) and Thermo Fisher Scientific ( TMO ). In the Clinical Diagnostics market, the company competes with Roche ( RHHBY ) and Abbott Laboratories ( ABT ). The stock carries a Zacks #3 Rank (Hold rating in the short term).
ABBOTT LABS (ABT): Free Stock Analysis Report
BIO-RAD LABS -A (BIO): Free Stock Analysis Report
LIFE TECHNOLOGS (LIFE): Free Stock Analysis Report
(RHHBY): ETF Research Reports
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the Clinical Diagnostics market, the company competes with Roche ( RHHBY ) and Abbott Laboratories ( ABT ). ABBOTT LABS (ABT): Free Stock Analysis Report BIO-RAD LABS -A (BIO): Free Stock Analysis Report LIFE TECHNOLOGS (LIFE): Free Stock Analysis Report (RHHBY): ETF Research Reports To read this article on Zacks.com click here. The company claims that Droplet Digital PCR has the potential to provide new strategies for diagnosis of inherited disorders, cancer and infectious disease. | ABBOTT LABS (ABT): Free Stock Analysis Report BIO-RAD LABS -A (BIO): Free Stock Analysis Report LIFE TECHNOLOGS (LIFE): Free Stock Analysis Report (RHHBY): ETF Research Reports To read this article on Zacks.com click here. In the Clinical Diagnostics market, the company competes with Roche ( RHHBY ) and Abbott Laboratories ( ABT ). Bio-Rad Laboratories, Inc. ( BIO ), a worldwide provider of life science research and clinical diagnostic products, recently inaugurated its Digital Biology Center for the development of products based on the droplet partitioning technology acquired by the company last year. | ABBOTT LABS (ABT): Free Stock Analysis Report BIO-RAD LABS -A (BIO): Free Stock Analysis Report LIFE TECHNOLOGS (LIFE): Free Stock Analysis Report (RHHBY): ETF Research Reports To read this article on Zacks.com click here. In the Clinical Diagnostics market, the company competes with Roche ( RHHBY ) and Abbott Laboratories ( ABT ). Bio-Rad Laboratories, Inc. ( BIO ), a worldwide provider of life science research and clinical diagnostic products, recently inaugurated its Digital Biology Center for the development of products based on the droplet partitioning technology acquired by the company last year. | In the Clinical Diagnostics market, the company competes with Roche ( RHHBY ) and Abbott Laboratories ( ABT ). ABBOTT LABS (ABT): Free Stock Analysis Report BIO-RAD LABS -A (BIO): Free Stock Analysis Report LIFE TECHNOLOGS (LIFE): Free Stock Analysis Report (RHHBY): ETF Research Reports To read this article on Zacks.com click here. Bio-Rad Laboratories, Inc. ( BIO ), a worldwide provider of life science research and clinical diagnostic products, recently inaugurated its Digital Biology Center for the development of products based on the droplet partitioning technology acquired by the company last year. |
34401.0 | 2012-08-29 00:00:00 UTC | Pfizer Could Acquire India's Stride Acrolab's Injectables Unit | ABT | https://www.nasdaq.com/articles/pfizer-could-acquire-indias-stride-acrolabs-injectables-unit-2012-08-29 | nan | nan | Pfizer ( PFE ) is vying to acquire Indian company Stride Acrolab's specialty injectables unit, Agila. Injectables are high specialty drugs used as antibiotics and chemotherapy agents mainly in hospitals. Speculation is that other players, including Roche and Novartis, are interested in joining the bidding process. This doesn't come as a major surprise as the pharma companies are focusing on revenue sources to fend-off patents expiry.
See Full Analysis For Pfizer here
Of late, pharmaceutical giants including Pfizer have been grappling with patent cliffs and may continue to face this headwind. Pfizer's Lipitor, which generated close to $10 billion in 2011, is losing market share at an accelerating pace and sales have nearly halved in a relatively short time frame. The looming patent expiration for Viagra, Enbrel, Detrol, among others, in 2012 will also hurt the company's revenues. This has left the pharma companies looking for alternative revenue sources to fend off losses. They have been exploring the M&A route besides expansion in emerging markets.
Recently, many injectable businesses have seen M&A activities. The reason for the gold rush is a huge generic injectable market, which could zoom by high single digit growth to $17 billion by 2020 as more and more injectable drugs are set to lose patent protection in the next few years. Further, emerging markets will drive the growth in healthcare spending on the heels of rising income levels and increased government focus to provide healthcare facilities to everyone. About 95% of hospital drug spending goes to injectables and other non-oral drugs.
In addition, the competition is pretty low compared to the oral drug business due to high entry barriers. There is a shortage of injectables following the closure of many sterile plants after the FDA action and building new injectables plants takes nearly 4-5 years. Further, manufacturing injectables requires specialization. Margins are also better in injectables business.((ref:1))
Agila has the highest number of generic injectable approvals by the FDA. Therefore, the acquisition makes sense for pharmaceutical giants who are vying to expand their generics portfolios in order to fend-off losses from looming patents expiry. In addition, Agila has a number of big pharma companies, including Pfizer, in its client list. It supplies several sterile injectables for cancer treatment to Pfizer. Through this acquisition, Pfizer can exert better control on the supply while curbing costs.
But, at what price?
Past acquisitions in this space have been valued at 4-5 times their revenues. Therefore, with Agila's last year sales of approximately $185 million and estimated FY2013 (year ending March) sales of $250 million, the company can be valued at $1.6 to $2 billion. ((ref:1))
However, before strongly defending the acquisition, we would wait for some clarity on Pfizer's bid on the asset. One should not forget the importance of acquisition price in this generic and emerging market growth rush. A steep price, just to get hold of certain assets, could actually destroy shareholder value, which we discussed earlier . Hopefully, Pfizer has learned its lessons from Lipitor.
We currently have a $25 price estimate for Pfizer , which is 5% above the current market price. We are in the process of revising our price estimate to reflect the recent developments and the earnings. Last week, the company signed a deal with AstraZeneca to market an over-the-counter (OTC) version of the latter's blockbuster drug Nexium.
Submit a Post at Trefis Powered by Data and Interactive Charts| Understand What Drives a Stock at Trefis
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Pfizer's Lipitor, which generated close to $10 billion in 2011, is losing market share at an accelerating pace and sales have nearly halved in a relatively short time frame. Therefore, the acquisition makes sense for pharmaceutical giants who are vying to expand their generics portfolios in order to fend-off losses from looming patents expiry. Last week, the company signed a deal with AstraZeneca to market an over-the-counter (OTC) version of the latter's blockbuster drug Nexium. | This doesn't come as a major surprise as the pharma companies are focusing on revenue sources to fend-off patents expiry. Therefore, with Agila's last year sales of approximately $185 million and estimated FY2013 (year ending March) sales of $250 million, the company can be valued at $1.6 to $2 billion. One should not forget the importance of acquisition price in this generic and emerging market growth rush. | Pfizer ( PFE ) is vying to acquire Indian company Stride Acrolab's specialty injectables unit, Agila. The reason for the gold rush is a huge generic injectable market, which could zoom by high single digit growth to $17 billion by 2020 as more and more injectable drugs are set to lose patent protection in the next few years. We currently have a $25 price estimate for Pfizer , which is 5% above the current market price. | Pfizer's Lipitor, which generated close to $10 billion in 2011, is losing market share at an accelerating pace and sales have nearly halved in a relatively short time frame. In addition, Agila has a number of big pharma companies, including Pfizer, in its client list. One should not forget the importance of acquisition price in this generic and emerging market growth rush. |
34402.0 | 2012-08-27 00:00:00 UTC | DexCom Remains Neutral - Analyst Blog | ABT | https://www.nasdaq.com/articles/dexcom-remains-neutral-analyst-blog-2012-08-27 | nan | nan | We reiterate our Neutral recommendation on DexCom Inc. ( DXCM ).
Its second-quarter 2012 loss per share of 21 cents exceeded the Zacks Consensus Estimate of a loss of 20 cents per share. Net loss widened 99.4% year over year to $14.7 million, despite healthy revenue growth.
San Diego, California-based DexCom is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients.
DexCom is well placed in the industry that it serves. The comparison of the exponential rise of diabetes in recent years to the fraction of population using continuous glucose monitors implies that the market for the company's offerings remains considerably underpenetrated.
Further, the company can gain significant operating leverage from expansion of its footprint into new geographies as statistics suggest that the market in developing countries present a sizeable market opportunity.
However, we note that competition in the glucose monitoring market is intense and DexCom faces stiff challenges from much larger players such as Johnson & Johnson ( JNJ ), Medtronic ( MDT ) and Abbott Labs ( ABT ). We believe that the company's move to buy healthcare IT company SweetSpot Diabetes may allow it to compete more effectively with Medtronic through better data management systems.
DexCom is still in its early stage of operations and has incurred losses since inception in 1999. It is exposed to an increasingly strict regulatory environment. Also worth mentioning in this context is the high reimbursement risk which the company faces in the domestic market.
We still believe that DexCom is poised to gain a major share of the glucose monitoring market, driven by sustained product development initiatives, collaborations and increased need for continuous glucose monitoring. Our Neutral recommendation on the stock is backed by a short-term Zacks #3 Rank (Hold).
ABBOTT LABS (ABT): Free Stock Analysis Report
DEXCOM INC (DXCM): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
MEDTRONIC (MDT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | However, we note that competition in the glucose monitoring market is intense and DexCom faces stiff challenges from much larger players such as Johnson & Johnson ( JNJ ), Medtronic ( MDT ) and Abbott Labs ( ABT ). ABBOTT LABS (ABT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. San Diego, California-based DexCom is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. | However, we note that competition in the glucose monitoring market is intense and DexCom faces stiff challenges from much larger players such as Johnson & Johnson ( JNJ ), Medtronic ( MDT ) and Abbott Labs ( ABT ). ABBOTT LABS (ABT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABBOTT LABS (ABT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. However, we note that competition in the glucose monitoring market is intense and DexCom faces stiff challenges from much larger players such as Johnson & Johnson ( JNJ ), Medtronic ( MDT ) and Abbott Labs ( ABT ). San Diego, California-based DexCom is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. | However, we note that competition in the glucose monitoring market is intense and DexCom faces stiff challenges from much larger players such as Johnson & Johnson ( JNJ ), Medtronic ( MDT ) and Abbott Labs ( ABT ). ABBOTT LABS (ABT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. San Diego, California-based DexCom is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. |
34403.0 | 2012-08-22 00:00:00 UTC | FDA Extends PFE Drug Review Period - Analyst Blog | ABT | https://www.nasdaq.com/articles/fda-extends-pfe-drug-review-period-analyst-blog-2012-08-22 | nan | nan | The US Food and Drug Administration (FDA) recently extended its review period for Pfizer's ( PFE ) rheumatoid arthritis (RA) candidate, tofacitinib. The FDA will deliver a decision regarding the approvability of tofacitinib by November 21, 2012. Pfizer is looking to get tofacitinib approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis.
The 3-month extension in the review period does not come as a surprise. Earlier this year, the FDA's Arthritis Advisory Committee had voted 8-2 in favor of tofacitinib. However, the FDA later asked the company to submit additional analysis of the existing data as part of the new drug application (NDA). Importantly, the agency did not ask the company to conduct additional studies.
With Pfizer submitting the additional analysis earlier this month, the extension in the FDA review period was expected. In fact, Pfizer had mentioned on its second quarter call that it expects the FDA to require more time to review the additional analysis.
FDA approval would make tofacitinib the first new oral disease-modifying antirheumatic drug (DMARD) to be approved for rheumatoid arthritis in more than 10 years. Moreover, tofacitinib would be the first Janus kinase (JAK) inhibitor to be approved for rheumatoid arthritis. Pfizer is also seeking approval for tofacitinib in several other regions including the EU and Japan.
Tofacitinib is one of the most promising candidates in Pfizer's pipeline. In late July 2012, Pfizer had reported positive top-line results on tofacitinib from a phase III study (ORAL Start). The study, conducted in methotrexate (MTX)-naïve patients with moderate-to-severe active RA, met its primary endpoints at both doses of tofacitnib (5 and 10 mg) that were evaluated.
Last year, the company had presented encouraging data on tofacitinib from another phase III study. Tofacitinib met its primary endpoint in the ORAL Sync phase III study (A3921046), which was conducted with patients suffering from moderate-to-severe rheumatoid arthritis. Results showed that compared to placebo, tofacitinib achieved a statistically significant reduction in signs and symptoms of rheumatoid arthritis.
Being an oral treatment, tofacitinib could have an edge over existing therapies which need to be injected or administered through infusion. The rheumatoid arthritis market currently has treatments like Abbott 's ( ABT ) Humira and Johnson & Johnson 's ( JNJ ) Remicade and Simponi among others.
We currently have a Neutral recommendation on Pfizer, which carries a Zacks #3 Rank (short-term 'Hold' rating).
ABBOTT LABS (ABT): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The rheumatoid arthritis market currently has treatments like Abbott 's ( ABT ) Humira and Johnson & Johnson 's ( JNJ ) Remicade and Simponi among others. ABBOTT LABS (ABT): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. The US Food and Drug Administration (FDA) recently extended its review period for Pfizer's ( PFE ) rheumatoid arthritis (RA) candidate, tofacitinib. | ABBOTT LABS (ABT): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. The rheumatoid arthritis market currently has treatments like Abbott 's ( ABT ) Humira and Johnson & Johnson 's ( JNJ ) Remicade and Simponi among others. The US Food and Drug Administration (FDA) recently extended its review period for Pfizer's ( PFE ) rheumatoid arthritis (RA) candidate, tofacitinib. | ABBOTT LABS (ABT): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. The rheumatoid arthritis market currently has treatments like Abbott 's ( ABT ) Humira and Johnson & Johnson 's ( JNJ ) Remicade and Simponi among others. The US Food and Drug Administration (FDA) recently extended its review period for Pfizer's ( PFE ) rheumatoid arthritis (RA) candidate, tofacitinib. | The rheumatoid arthritis market currently has treatments like Abbott 's ( ABT ) Humira and Johnson & Johnson 's ( JNJ ) Remicade and Simponi among others. ABBOTT LABS (ABT): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Pfizer is looking to get tofacitinib approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis. |
34404.0 | 2012-08-21 00:00:00 UTC | Everything You Need To Know About The Apple Dividend | ABT | https://www.nasdaq.com/articles/everything-you-need-know-about-apple-dividend-2012-08-21 | nan | nan | As Apple ( AAPL ) piled up billion after billion of dollars of excess cash in the bank, questions swirled about how the company would use that cash. Of course, we now know at least part of the answer - Apple re-initiated a dividend and will begin returning some of that cash to its shareholders through quarterly dividends and a multi-year, multi-billion dollar buyback program. Here are some essential facts to consider with the Apple dividend.
Getting It All Started
Apple went ex-dividend on August 9th, with a scheduled record date of August 13th, and the first dividend will be $2.65 per share. This will mark the first dividend in 17 years for Apple shareholders, though the sub-2% yield is still relatively insubstantial by current market standards.
Perhaps not surprisingly, the Apple dividend is well within what the company can afford. At the current rate, the dividend will send almost $2.5 billion of cash flowing out of the company each quarter; a relative pittance for a company that has been generating over $10 billion in quarterly free cash flow with pretty solid regularity. Accordingly, whether you measure dividend coverage by earnings, operating income, or free cash flow, Apple will not be putting itself under any appreciable financial strain in paying this dividend.
How Does Apple Stack Up?
By way of comparison, a broad group of technology peers shows Microsoft ( MSFT ) paying a 2.6% yield, Intel ( INTC ) paying a 3.4% yield, Samsung paying 0.4%, and Google ( GOOG ) presently paying no dividend. So while Apple's dividend is not all that great by market-wide yield comparisons, it's reasonable within the technology sector.
For several years, Microsoft has consistently paid out about 20% of its free cash flow as dividends, though there have also been sizable share buybacks during that period as well. For Intel, the payout percentage of free cash flow has recently ranged from 30-40% as the company attempts to maintain a steady (or rising) dividend despite a large increase in capital spending.
This discrepancy is more pronounced when considering the relative growth expectations. Sell-side analysts project intermediate-term growth in the low teens for both Intel and Microsoft, and nearly double that for Apple. Accordingly, for a business that can still legitimately be called a growth company, Apple is paying out a pretty healthy percentage of its cash flow as dividends.
Where Can It Go From Here?
Successful dividend investing is not about simply collecting the highest yield on offer in the market. Rather, it's about selecting those companies that are likely to continue not only paying a dividend, but increasing that dividend. Companies like Coca-Cola ( KO ), Abbott Labs ( ABT ), and 3M ( MMM ), for instance, have excellent records of steadily (if slowly) increasing their payouts over time and sharing their success with shareholders.
To that end, it's hard to argue that Apple does not have above-average dividend growth prospects. For starters, while the company has lost some market share to Samsung in smartphones, the two companies stand head-and-shoulders above the competition in phones and tablets - two markets where global consumer penetration is still relatively low. Apple will need to continue to innovate and enter new markets to avoid going the route of one-time cellphone champion Nokia ( NOK ), but Apple ought to be a long way from the down slope of its potential.
Along similar lines, a maturing Apple will likely generate far more free cash flow than it can legitimately reinvest, particularly given its asset-light operating base. Consider, for instance, that Apple is able to generate 3.5 times as much revenue as Nokia with just half of the employees. Unless Apple chooses to go the route of large share buybacks or changes strategy and looks to add more manufacturing capabilities, a percentage of incremental ongoing operating cash flow can be directed to dividends.
What's more, if Congress passes a tax amnesty for corporate cash balances held abroad or, alternatively, decides to impose financial penalties on companies holding "excessive" cash balances, Apple may well be incentivized to increase its payout and accelerate its return of capital to shareholders.
What Would Threaten Apple's Dividend?
No story is perfect, and no company has a risk-free path to prosperity. Simply looking at Apple's history ought to be evidence enough of that; Apple has enjoyed past periods where it was an innovative darling that really zeroed in on consumer tastes, only to be outmanuevered.
Perhaps the biggest near-term risk to Apple comes in its somewhat limited targeted market within cellphones. Apple doesn't really do limited features or low-price versions, but there are only so many people in the world who need, want, or can afford a high-end phone. The risk, then, is that Samsung or another rival successively goes down-market, captures lucrative market share, and then chips away at Apple from below. At the same time, there is at least a theoretical risk that another partnership between Intel and Microsoft will lead to a repeat of the "WinTel" revolution that sucked away Apple's momentum in PCs so long ago.
There's also a risk that Apple finds a ceiling to its growth. Portable music and cellphones are large consumer markets where buyers basically expect to replace devices every few years. Unfortunately, there are not too many markets like that - consumers do not replace TVs or gaming systems nearly so often. That could put greater pressure on Apple to develop its streaming media capabilities at a faster clip, draining off cash and putting it into fiercer competition with Amazon ( AMZN ) and Netflix ( NFLX ), as well perhaps as cable companies and movie studios.
Last and not least, there's an ever-present risk that the company simply makes bad or dumb decisions. Microsoft and Intel found themselves caught flat-footed by the migration to mobile devices, and the list of companies who've destroyed shareholder value (and burnt up shareholders' cash) through bad product launches, unwise strategic shifts, and/or ill-fated acquisitions is too long to include in this column. Although it seems very "un-Apple-like" to think that the company could ever find itself throwing billions down a corporate sinkhole, few analysts or pundits ever predict the ultimate source of a company's doom while it is still riding high.
The Bottom Line
Careful due diligence is essential to all investment decisions, and no one article can truly supply you with everything you need to know. That said, Apple is a very much a newcomer (or new returnee, if you prefer) to the dividend game, but the combination of impressive operating margins, large addressable markets, solid competitive standing, and low asset intensity argue that Apple could be a significant dividend-payer for many years to come.
Disclosure : Author owns shares of 3M
Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Created by Dividend.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Companies like Coca-Cola ( KO ), Abbott Labs ( ABT ), and 3M ( MMM ), for instance, have excellent records of steadily (if slowly) increasing their payouts over time and sharing their success with shareholders. For Intel, the payout percentage of free cash flow has recently ranged from 30-40% as the company attempts to maintain a steady (or rising) dividend despite a large increase in capital spending. Unless Apple chooses to go the route of large share buybacks or changes strategy and looks to add more manufacturing capabilities, a percentage of incremental ongoing operating cash flow can be directed to dividends. | Companies like Coca-Cola ( KO ), Abbott Labs ( ABT ), and 3M ( MMM ), for instance, have excellent records of steadily (if slowly) increasing their payouts over time and sharing their success with shareholders. At the current rate, the dividend will send almost $2.5 billion of cash flowing out of the company each quarter; a relative pittance for a company that has been generating over $10 billion in quarterly free cash flow with pretty solid regularity. By way of comparison, a broad group of technology peers shows Microsoft ( MSFT ) paying a 2.6% yield, Intel ( INTC ) paying a 3.4% yield, Samsung paying 0.4%, and Google ( GOOG ) presently paying no dividend. | Companies like Coca-Cola ( KO ), Abbott Labs ( ABT ), and 3M ( MMM ), for instance, have excellent records of steadily (if slowly) increasing their payouts over time and sharing their success with shareholders. At the current rate, the dividend will send almost $2.5 billion of cash flowing out of the company each quarter; a relative pittance for a company that has been generating over $10 billion in quarterly free cash flow with pretty solid regularity. Accordingly, whether you measure dividend coverage by earnings, operating income, or free cash flow, Apple will not be putting itself under any appreciable financial strain in paying this dividend. | Companies like Coca-Cola ( KO ), Abbott Labs ( ABT ), and 3M ( MMM ), for instance, have excellent records of steadily (if slowly) increasing their payouts over time and sharing their success with shareholders. At the current rate, the dividend will send almost $2.5 billion of cash flowing out of the company each quarter; a relative pittance for a company that has been generating over $10 billion in quarterly free cash flow with pretty solid regularity. Accordingly, whether you measure dividend coverage by earnings, operating income, or free cash flow, Apple will not be putting itself under any appreciable financial strain in paying this dividend. |
34405.0 | 2012-08-21 00:00:00 UTC | Agilent Wins Patent in US - Analyst Blog | ABT | https://www.nasdaq.com/articles/agilent-wins-patent-in-us-analyst-blog-2012-08-21 | nan | nan | Agilent Technologies Inc. ( A ) has won the patent for comparative genomic hybridization (CGH) methods in the U.S.
CGH methods facilitate the basic and clinical study of genetics and cancer. Being a method of studying genes, it can also help to detect other diseases like developmental delays, mental retardation and autism in children.
The study of genes has gained popularity in medical research because many so-called incurable diseases appear to have their roots in unfavorable genetics. The most important aspect of genome testing is that it can detect disease in its early stages, thus facilitating better diagnosis.
The genetic testing market is, therefore, entering an exciting era where it can play a vital role in detecting diseases like cancer, cystic fibrosis and Alzheimer's and many other life-threatening diseases.
Agilent has been increasing its focus in the medial diagnostics segment because of the significant growth potential in the area. The company recently acquired a Danish cancer diagnostics company, Dako, for $2.2 billion. Dako deals in antibodies, scientific instruments and software used mainly in cancer-related diagnostic labs. It also collaborates with drug companies for the development of methods to identify patients likely to benefit from certain therapies.
In the health care sector, major players such as Abbott Laboratories ( ABT ), Genomic Health Inc. ( GHDX ), Life Technologies Corporation ( LIFE ) and others have all increased focus on the genetic testing market.
Agilent's revenue in the third quarter was flat sequentially and up 1.9% year over year, short of management's expectations for a 2-3% sequential increase ($1.77 billion to $1.79 billion). The Chemical Analysis segment generated 22.0% of third quarter revenue, down 8.8% sequentially and 7.0% year over year. The sequential decline was largely because of weakness in food testing, although chemical/energy was also down significantly and the forensics/environmental was flat. All three markets fared similarly when compared with the year-ago quarter. The newly- added Diagnostics and Genomics segment accounted for 6% of revenue in this quarter.
Currently, Agilent Technologies Inc. has a Zacks Rank of #3, implying a short-term 'Hold' recommendation.
AGILENT TECH (A): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
GENOMIC HEALTH (GHDX): Free Stock Analysis Report
LIFE TECHNOLOGS (LIFE): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the health care sector, major players such as Abbott Laboratories ( ABT ), Genomic Health Inc. ( GHDX ), Life Technologies Corporation ( LIFE ) and others have all increased focus on the genetic testing market. AGILENT TECH (A): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report GENOMIC HEALTH (GHDX): Free Stock Analysis Report LIFE TECHNOLOGS (LIFE): Free Stock Analysis Report To read this article on Zacks.com click here. Being a method of studying genes, it can also help to detect other diseases like developmental delays, mental retardation and autism in children. | In the health care sector, major players such as Abbott Laboratories ( ABT ), Genomic Health Inc. ( GHDX ), Life Technologies Corporation ( LIFE ) and others have all increased focus on the genetic testing market. AGILENT TECH (A): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report GENOMIC HEALTH (GHDX): Free Stock Analysis Report LIFE TECHNOLOGS (LIFE): Free Stock Analysis Report To read this article on Zacks.com click here. Agilent Technologies Inc. ( A ) has won the patent for comparative genomic hybridization (CGH) methods in the U.S. CGH methods facilitate the basic and clinical study of genetics and cancer. | AGILENT TECH (A): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report GENOMIC HEALTH (GHDX): Free Stock Analysis Report LIFE TECHNOLOGS (LIFE): Free Stock Analysis Report To read this article on Zacks.com click here. In the health care sector, major players such as Abbott Laboratories ( ABT ), Genomic Health Inc. ( GHDX ), Life Technologies Corporation ( LIFE ) and others have all increased focus on the genetic testing market. Agilent Technologies Inc. ( A ) has won the patent for comparative genomic hybridization (CGH) methods in the U.S. CGH methods facilitate the basic and clinical study of genetics and cancer. | In the health care sector, major players such as Abbott Laboratories ( ABT ), Genomic Health Inc. ( GHDX ), Life Technologies Corporation ( LIFE ) and others have all increased focus on the genetic testing market. AGILENT TECH (A): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report GENOMIC HEALTH (GHDX): Free Stock Analysis Report LIFE TECHNOLOGS (LIFE): Free Stock Analysis Report To read this article on Zacks.com click here. Being a method of studying genes, it can also help to detect other diseases like developmental delays, mental retardation and autism in children. |
34406.0 | 2012-08-20 00:00:00 UTC | Market Wrap-Up for Aug.20 (AET, LOW, HD, SWK, PSA, WM, more) | ABT | https://www.nasdaq.com/articles/market-wrap-aug20-aet-low-hd-swk-psa-wm-more-2012-08-20 | nan | nan | Global investors started the new week with a cautious approach. The recent pattern in the markets has consisted mostly of rumors and speculation as the main factors driving sentiment, so one-day moves tend to have little carryover. Of course, that doesn't mean more sellers necessarily step up, or vice-versa.
We did have news of a big deal this morning as HMO giant Aetna ( AET ) announced a take-over deal for Coventry Health ( CVH ). News of the merger helped lift Aetna shares over 5% by the close. In more big news, home improvement giant Lowe's ( LOW ) disappointed investors with their earnings results this morning. Shares of competitor Home Depot ( HD ) ended down just a bit on the news. Elsewhere, cautious Wall Street analyst commentary had stocks like Public Storage ( PSA ) and Stanley Black&Decker ( SWK ) trading in the red throughout much of the session.
The Ultimate Price of "Easy Money"
Wall Street scams are about as timeless as the human desire to become rich quickly. Baseball fans out may there remember Hall of Fame outfielder Eddie Murray (former Baltimore Oriole hitting great). Unfortunately, Mr. Murray was in the news recently for agreeing to pay $358,151 to settle civil charges of profiting in stock trades by using confidential information passed to him by a former teammate, Doug DeCinces. Apparently Mr. Murray was tipped off about a planned acquisition of Advanced Medical Optics by Abbott Laboratories ( ABT ) in early 2009, and decided he needed to make out on the last-minute investment advice.
In this case, Mr. Murray, who at one time in the 1980′s signed the richest contract in baseball history, decided he needed to boost his financial status a bit and make some "easy money." We're not sure how Mr. Murray is doing financially these days, but my guess is he can still rack up some big dollars from the autograph/appearance standpoint if he is willing to do the legwork. Maybe he does do that anyhow, but yet he still couldn't pass up the chance to make a quick buck.
The lessons from this story are obvious. Individuals often get themselves into big trouble when they decide to stomp the investment returns accelerator. Sure, when the markets ripping quickly higher, the gains may be there if one is willing to leave plenty of more gains on the table (since selling at the exact top is a fruitless endeavor). But we all know human nature, and the chance to leverage up to make more is too much for many to ignore.
We've seen the fallout from this strategy in the last decade with both stocks and real estate. The consequences have been severe for many, including the financial institutions that got caught playing along. Mr. Murray is just another real world example of how quickly one's legacy and financial standing can unravel when the eye is only on making a fast buck.
My Reaction to Barron's Weekend's Piece on Waste Management/MLP's
This past weekend's Barron's magazine had an article on the lack of potential upside for Waste Management ( WM ), digging into the company's headwinds and recent inability to beat analyst estimates. We've liked Waste Management and its 4%+ yield for over six months now, and while we agree the stock could be reaching a limit to its near-term upside, at least its yield is still attractive at currently levels.
Compare WM to some other dividend plays that have made big runs. Many of these stocks' yields now sit in the low 2% area - hardly an attractive entry point for dividend-minded investors. Yet Barron's fails to identify stocks like Wal-Mart ( WMT ), for example, whose 2.2% yield is somehow still attracting more buyers.
Our biggest concern these days, which has been holding us back from adding new recommendations onto our list, is the potential valuation issues that persist for many companies out there. The truth of the matter is Barrons' could have written posts about many other brands we currently track. That same negative piece could do even bigger damage from a share price drop standpoint than we can see with a stock that sports a 4% yield.
Regardless of whether we agree with all the points in the piece regarding Waste Management, we respect the fact there are analysts/fund managers paying attention to valuations. Part of our approach to taking current names off of our list, especially recently, is to find situations where we identify the downside is greater than the upside as far as share price and dividend growth is concerned. When we find these situations develop, we decide whether moving to the sidelines is the proper course of action (as far as putting any further capital into a name is concerned), or possibly examining a potential shift down that could ultimately benefit investors better by just selling out of a position altogether.
We of course will keep our subscribers updated of any moves we make, and yes, we will even consider stocks like Waste Management and their attractive yields as candidates that can use a break as well. It's all part of maneuvering investors through whatever the current market environment is and more importantly, where it could be headed.
Lastly, regarding the bullish piece in Barron's on MLP's and their abilities to provide yield/income for investors, we got cool on the sector months back, but have still been tracking the particular shares we had liked previously. The recent war rhetoric has reversed the oil price slide we had based part of our "sell call" on the sector. At this point, we are exploring several names very closely to see if it makes sense to consider for our Best Dividend Stocks list. We are certainly open to changing our opinion if need be, but it has to be based on a fundamental improvement to the MLP story, and not because they sport above-average market yields.
Our Beat The Markets with Dividend Stocks eBook Has Arrived!
We just debuted our brand new 275-page eBook, exclusively on Dividend.com! In this digital-only book, we look ahead to 2012 and the main factors that could affect dividend investors. A $39.95 value, the eBook is a free download for paid Dividend.com Premium subscribers.
Beat The Markets with Dividend Stocks contains a full economic forecast for 2012, including in-depth analysis on 65 of the biggest dividend stocks out there. It's a great way to get prepared for your investing next year! So head over to the Dividend.com Premium homepage now to download your copy.
I hope everyone had a chance to check out our Dividend.com Premium members-only weekend articles , including new features that highlight some of the biggest winners and losers from the week that was, such as analyst upgrades/downgrades and earnings/story stocks. These articles are a great way to catch up on the week that was in the markets. We also have a rundown of how various Dividend ETFs performed on the week.
Thanks for reading everybody. I'll see you tomorrow!
Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Created by Dividend.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Apparently Mr. Murray was tipped off about a planned acquisition of Advanced Medical Optics by Abbott Laboratories ( ABT ) in early 2009, and decided he needed to make out on the last-minute investment advice. Part of our approach to taking current names off of our list, especially recently, is to find situations where we identify the downside is greater than the upside as far as share price and dividend growth is concerned. When we find these situations develop, we decide whether moving to the sidelines is the proper course of action (as far as putting any further capital into a name is concerned), or possibly examining a potential shift down that could ultimately benefit investors better by just selling out of a position altogether. | Apparently Mr. Murray was tipped off about a planned acquisition of Advanced Medical Optics by Abbott Laboratories ( ABT ) in early 2009, and decided he needed to make out on the last-minute investment advice. In more big news, home improvement giant Lowe's ( LOW ) disappointed investors with their earnings results this morning. The Ultimate Price of "Easy Money" Wall Street scams are about as timeless as the human desire to become rich quickly. | Apparently Mr. Murray was tipped off about a planned acquisition of Advanced Medical Optics by Abbott Laboratories ( ABT ) in early 2009, and decided he needed to make out on the last-minute investment advice. My Reaction to Barron's Weekend's Piece on Waste Management/MLP's This past weekend's Barron's magazine had an article on the lack of potential upside for Waste Management ( WM ), digging into the company's headwinds and recent inability to beat analyst estimates. We of course will keep our subscribers updated of any moves we make, and yes, we will even consider stocks like Waste Management and their attractive yields as candidates that can use a break as well. | Apparently Mr. Murray was tipped off about a planned acquisition of Advanced Medical Optics by Abbott Laboratories ( ABT ) in early 2009, and decided he needed to make out on the last-minute investment advice. Part of our approach to taking current names off of our list, especially recently, is to find situations where we identify the downside is greater than the upside as far as share price and dividend growth is concerned. We are certainly open to changing our opinion if need be, but it has to be based on a fundamental improvement to the MLP story, and not because they sport above-average market yields. |
34407.0 | 2012-08-10 00:00:00 UTC | Abbott Labs Shows Slow Growth, Solid Dividends | ABT | https://www.nasdaq.com/articles/abbott-labs-shows-slow-growth-solid-dividends-2012-08-10 | nan | nan | Abbott Laboratories ( ABT ) shows many of the classic traits you'd want to see in a high-quality income stock: a broad array of enviable niches in its industry, a solid but unspectacular stock uptrend and a history of rising dividends.
Big-cap Abbott Labs produces generic drugs, research-based drugs, diagnostic systems and nutrients.
Abbott pays an annualized dividend of $2.04 a share, for a 3.1% yield. Abbot has upped its dividend every year since at least 1990, when the company paid just 20.3 cents per share.
Abbott's chart shows years of tight trading and a slow but steady incline. Some bases appear along the way, but the best guide the past few years has been the stock's 10-week moving average.
Abbott Labs' Q2 report, released July 18, showed results that pretty much met consensus estimates: Earnings of $1.23 a share beat the Street's consensus estimate by a penny, and reflected a 10% gain from a year ago.
Revenue advanced just 2% -- its weakest quarterly improvement in three years and fractionally shy of expectations.
Abbott confirmed its previous full-year EPS guidance of $5 to $5.10, tracking with the Street's consensus of $5.04, and up 8% from 2011's bottom line.
Abbott said in October that it will split into two publicly traded companies by the end of 2012.
One company will produce medical devices, generic drugs, diagnostic equipment and nutritional products. This company, with $22 billion a year in sales, will retain the Abbott Laboratories name.
The other company, with annual sales of $18 billion, will contain Abbott's research-based drug activities. It will focus on crucial areas such as multiple sclerosis, HIV treatments and hepatitis C.
Abbott Labs gapped up Oct. 19, the day investors heard the split-up plans. The stock ended its high-volume session -- which coincided with a quarterly report -- near the lower end of a wide range.
The stock later formed a base-on-base pattern. Shortly after Abbott Labs broke out from the base, on Feb. 28, it embarked on an uptrend that was noticeably steeper than that seen in its recent history.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) shows many of the classic traits you'd want to see in a high-quality income stock: a broad array of enviable niches in its industry, a solid but unspectacular stock uptrend and a history of rising dividends. Abbott confirmed its previous full-year EPS guidance of $5 to $5.10, tracking with the Street's consensus of $5.04, and up 8% from 2011's bottom line. It will focus on crucial areas such as multiple sclerosis, HIV treatments and hepatitis C. Abbott Labs gapped up Oct. 19, the day investors heard the split-up plans. | Abbott Laboratories ( ABT ) shows many of the classic traits you'd want to see in a high-quality income stock: a broad array of enviable niches in its industry, a solid but unspectacular stock uptrend and a history of rising dividends. Big-cap Abbott Labs produces generic drugs, research-based drugs, diagnostic systems and nutrients. The other company, with annual sales of $18 billion, will contain Abbott's research-based drug activities. | Abbott Laboratories ( ABT ) shows many of the classic traits you'd want to see in a high-quality income stock: a broad array of enviable niches in its industry, a solid but unspectacular stock uptrend and a history of rising dividends. Big-cap Abbott Labs produces generic drugs, research-based drugs, diagnostic systems and nutrients. Abbott Labs' Q2 report, released July 18, showed results that pretty much met consensus estimates: Earnings of $1.23 a share beat the Street's consensus estimate by a penny, and reflected a 10% gain from a year ago. | Abbott Laboratories ( ABT ) shows many of the classic traits you'd want to see in a high-quality income stock: a broad array of enviable niches in its industry, a solid but unspectacular stock uptrend and a history of rising dividends. Abbott said in October that it will split into two publicly traded companies by the end of 2012. The other company, with annual sales of $18 billion, will contain Abbott's research-based drug activities. |
34408.0 | 2012-08-09 00:00:00 UTC | Pharma & Biotech Stock Outlook - Aug. 2012 - Industry Outlook | ABT | https://www.nasdaq.com/articles/pharma-biotech-stock-outlook-aug.-2012-industry-outlook-2012-08-09-0 | nan | nan | The pharmaceutical industry is in the midst of one of the biggest patent cliffs with Pfizer's ( PFE ) multi-billion-dollar blockbuster drug Lipitor losing patent protection in the US in late November 2011. Besides Lipitor, other major branded drugs that lost patent protection in the past few months include Forest Laboratories' ( FRX ) Lexapro, Sanofi / Bristol-Myers' ( SNY / BMY ) Plavix and Eli Lilly's ( LLY ) Zyprexa.
These products alone represented branded sales worth more than $15 billion. Another product that will start facing generic competition shortly is Merck's ( MRK ) blockbuster Singulair.
The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. While generics will eat into sales, new products are not expected to generate the same level of sales as products losing patent protection. The next few years are expected to reflect a significant imbalance between new product introductions and patent losses.
Generic competition and insufficient new product sales are not the only factors impacting performance in 2012. Other headwinds include EU and Japan pricing pressure as well as negative currency movement. In fact, results of several companies including Johnson & Johnson ( JNJ ) were hit by negative currency movement in the June quarter.
Meanwhile, the US government is exploring options which will help increase the availability of generics. The Obama administration announced that it is looking to implement a proposal under which the exclusivity period for biologics will be cut down by 5 years, thereby allowing generics to enter the market sooner.
The government is also seeking to increase the availability of generics by preventing companies from entering into anti-competitive or "pay for delay" agreements which push out the availability of generics. These initiatives, if implemented, would result in additional pricing competition and genericization in the pharma industry. Moreover, the FDA is working on establishing a biosimilar pathway so that cheaper versions of biologics will be available.
With revenue growth stalling or slowing down, pharma companies have been resorting to cost-cutting and share buybacks to drive bottom-line growth. Mergers & acquisitions (M&As), licensing deals, restructuring, share buybacks and monetization of non-core assets have become recurring events in the pharma and biotech sector over the past few quarters.
M&A Activity
The M&A activity witnessed in the pharma sector in the last couple of years has continued in 2012, in-line with expectations. With most of the big pharma companies already facing or likely to face patent challenges for their blockbuster products, the companies have been looking toward M&A and in-licensing activities to make up for the loss of revenues resulting from the loss of patent exclusivity of key products.
Major deals so far in 2012 include Johnson & Johnson's acquisition of Synthes, which should help strengthen its medical device portfolio, Bristol-Myers Squibbs' upcoming acquisition of Amylin Pharmaceuticals, Inc. ( AMLN ), GlaxoSmithKline's ( GSK ) upcoming acquisition of Human Genome Sciences ( HGSI ).
Bristol-Myers has been pretty active on the acquisition front. The company has been looking to expand via acquisitions and partnerships to counter the loss of revenues arising from the genericization of blockbuster blood thinner Plavix. The Amylin acquisition should allow the company to expand its presence in the lucrative diabetes market.
The Amylin deal is the second major deal for Bristol-Myers this year, with the company having purchased Inhibitex, Inc., for $2.5 billion in February, thereby targeting the lucrative hepatitis C virus (HCV) market.
Oncology also remains a much sought-after therapeutic area, with companies like Sanofi and Celgene ( CELG ) strengthening their presence in this market through acquisitions. Meanwhile, generic players are not far behind in the acquisition game. While Teva ( TEVA ) acquired Cephalon, Inc., Watson Pharmaceuticals ( WPI ) acquired generic company Specifar Pharmaceuticals to expand and strengthen its presence in Europe. Watson recently announced its intention to acquire generic player, Actavis.
Elsewhere, companies have been looking toward biotech firms to build their product portfolios. A prime example is French pharma giant Sanofi's acquisition of biotech company Genzyme Corp. The Genzyme acquisition has boosted Sanofi's revenues as well as its pipeline. Meanwhile, AstraZeneca ( AZN ) acquired biotech company Ardea Biosciences. Another acquisition deal announced in April 2012 is Spectrum Pharma's ( SPPI ) upcoming acquisition of biopharma company Allos Therapeutics ( ALTH ).
Going forward, we expect the M&A trend to continue. We also expect a significant pickup in in-licensing activities and collaborations for the development of pipeline candidates. Instead of developing a product from scratch, which involves a lot of funds and time, pharma companies are shopping for mid-to-late stage pipeline candidates that look promising.
Small biotech companies are also game for in-licensing activities and collaborations. Most of these companies find it challenging to raise cash, thereby making it difficult for them to survive and continue with the development of promising pipeline candidates. Therefore, it makes sense for them to seek deals with pharma companies that are sitting on huge piles of cash.
We would recommend investors put their money in biotech stocks that have attractive pipeline candidates or technology that can be used for the development of novel therapeutics. Therapeutic areas which could see a lot of in-licensing activity include oncology, central nervous system disorders, diabetes and immunology/inflammation. The HCV market is also attracting a lot of attention.
Another trend that we are seeing lately is the divestment of non-core business segments. Pfizer sold its Capsugel unit in August 2011 and signed a deal for the divestment of its Nutrition business in April 2012. The company intends to spin-off its Animal Health business as well.
Meanwhile, GlaxoSmithKline is divesting non-core brands from its Consumer Healthcare segment. In August 2011, AstraZeneca sold its Astra Tech business to DENTSPLY ( XRAY ). The monetization of non-core assets will allow the pharma/biotech companies to focus on their areas of expertise.
2012 will see Abbott Labs splitting into two separate publicly traded companies. While one company will deal in diversified medical products, the other (AbbVie) will focus on research-based pharmaceuticals.
Obamacare Rules
A major event that will have a significant impact pharma and biotech stocks is the upholding of the Patient Protection and Affordable Care Act (ACA) by the Supreme Court in late June 2012. The Act, popularly referred to as "Obamacare," passed through Congress in 2010, represents major changes in the nation's healthcare sector.
The Act will provide coverage to 32 million uninsured Americans, make healthcare facilities more affordable, expand coverage for customers with pre-existing health conditions and keep a check on health insurers. The healthcare reform aims to end the discrimination policy of insurance companies, create competition amongst insurers through the establishment of health insurance exchanges, add value to the overall healthcare system and reduce premiums.
The upholding of the Act is a big win for pharma companies as the coverage base will increase.
Meanwhile, the signing of the Gaining Antiobiotic Incentives Now (GAIN) Act should benefit companies pursuing the development of novel antibiotics. Once approved, these products will enjoy an additional five years of marketing exclusivity. Companies that should benefit from this Act include The Medicines Company ( MDCO ), Optimer Pharma ( OPTR ) and Cubist Pharma ( CBST ) among others.
Another important event in the past few weeks was the signing of the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012. This new law includes the reauthorization of the Prescription Drug User Fee Act (PDUFA), under which the FDA is provided with funds and resources needed to ensure the smooth and timely review of drugs.
Emerging Markets
Another recent trend seen in the pharmaceutical sector is a focus on emerging markets. Companies like Mylan ( MYL ), Pfizer, Merck, Eli Lilly, Glaxo and Sanofi are all looking to expand their presence in India, China, Brazil and other emerging markets. Until recently, most of the commercialization efforts were focused on the US -- the largest pharmaceutical market -- along with Europe and Japan.
Emerging markets are slowly and steadily gaining more importance and several companies are now shifting their focus to these areas. According to the IMS Institute, spending on medicines in "pharmerging" markets will almost double to $345 billion - $375 billion in five years from $194 billion in 2011.
However, while higher demand for medicines, government initiatives for healthcare, new patient population, and increasing use of generics should help drive demand, we point out that emerging markets are also not immune from genericization.
Meanwhile, according to the IMS Institute, annual growth in the branded medicines market will remain flat or increase up to 3% to $615 billion - $645 billion through 2016 from $596 billion in 2011.
As far as developed nations are concerned, the IMS Institute expects US spending to go up by $35 billion - $45 billion (1-4%) in the next five years. The introduction of medicines targeting unmet needs and higher patient access resulting from Obamacare are expected to drive growth.
However, growth in Europe will continue to be pressurized by austerity and cost-containment measures. According to the IMS Institute, growth in Europe will range from negative 1% to positive 2%. The Japanese market is expected to grow at a slower pace annually (1-4%) through 2016 compared to the last five years.
OPPORTUNITIES
We continue to have a Neutral outlook on large-cap pharma stocks. While the companies will continue to face challenges like pricing pressure and genericization, growth in emerging markets and product approvals could help reduce the impact.
A few years down the line, the pharma industry should demonstrate signs of recovery. The industry should be out of the major patent cliff period, and new products should be contributing significantly to results. Increased pipeline visibility and appropriate utilization of cash should increase confidence in the sector.
In the biotech space, we are positive on Biogen Idec ( BIIB ). We are optimistic on BG-12, the company's oral multiple sclerosis candidate. Key products Avonex and Tysabri should continue contributing significantly to sales. Biogen's second quarter results were impressive and the company increased its guidance for 2012.
We are also positive on Amgen ( AMGN ). We are encouraged by the company's first half 2012 performance. Enbrel should continue performing well and Xgeva/Prolia should continue responding positively to the company's increased marketing efforts like DTC advertising. Amgen's late-stage pipeline is also moving along.
Another company that delivered a solid performance in the June quarter is Auxilium Pharma ( AUXL ). In addition to reporting a profit for the first time, the company increased its guidance. We expect the company's hypogonadism product, Testim, to continue performing well especially with the additional promotional effort from Glaxo.
Among generic companies, both Watson Pharma ( WPI ) and Mylan ( MYL ) carry a Zacks #2 Rank (short-term Buy rating). While Watson should benefit from its upcoming acquisition of Actavis, which should be immediately accretive, we are encouraged by Mylan's geographic reach and product depth along with a robust generic product pipeline.
WEAKNESSES
We recommend avoiding names that offer little growth or opportunity for a take-out. These include companies which are developing drugs that are likely to face regulatory hurdles. The FDA has been exercising more caution in granting approval to new products and several candidates are facing delays in receiving final approval.
Elan Corp ( ELN ) carries a Zacks #5 Rank (short-term Strong Sell rating). The company's second quarter loss per share was wider than expected mainly due to revenues coming in below expectations. Moreover, expectations from pipeline candidate bapineuzumab (Alzheimer's) are pretty low, with the candidate failing to meet its primary endpoint in one of four phase III studies.
Companies that currently carry a Zacks #4 Rank (short-term Sell rating) include Glaxo ( GSK ) and AstraZeneca ( AZN ). Both Glaxo and AstraZeneca presented weak second quarter results. Factors like generic competition, EU pricing pressure and negative currency movement will continue impacting the performances of these companies.
We are also concerned about the prospects of Cardiome Pharma Corp. ( CRME ) which carries a Zacks #4 Rank (short-term Sell rating). The company recently announced a major reduction in its workforce following Merck's decision to discontinue the development of an oral formulation of vernakalant. Merck and Cardiome were studying the candidate as a maintenance therapy for the long term prevention of atrial fibrillation recurrence.
The discontinuation of the development of oral vernakalant is a huge setback for Cardiome. The company has a weak pipeline consisting of a few early stage projects. We expect the shares to remain under pressure until the company provides a strategic update.
Looking Ahead...
The FDA has some major decisions coming up in the next few months. Some of the most interesting candidates currently under review include Medivation's ( MDVN ) enzalutamide (oncology), Biogen Idec's BG-12 (multiple sclerosis), United Therapeutic's ( UTHR ) oral Remodulin (treatment of pulmonary arterial hypertension), Gilead's ( GILD ) Quad pill (HIV), and Forest Labs' linaclotide (constipation-predominant irritable bowel syndrome and chronic constipation), Onyx Pharma ( ONXX ) and Bayer's ( BAYRY ) regorafenib (oncology) among others.
Important product approvals in the last few quarters include Johnson & Johnson's prostate cancer therapy Zytiga, Merck's HCV treatment Victrelis, Bristol-Myers' melanoma treatment Yervoy, AstraZeneca's Brilinta, Vertex Pharma's ( VRTX ) HCV treatment Incivek, Pfizer's lung cancer treatment Xalkori, and Glaxo/Human Genome's lupus drug Benlysta, among others. Potential blockbusters include Benlysta, Yervoy, Zytiga, Incivek and Xarelto.
ABBOTT LABS (ABT): Free Stock Analysis Report
BRISTOL-MYERS (BMY): Free Stock Analysis Report
CELGENE CORP (CELG): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
GLAXOSMITHKLINE (GSK): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
LILLY ELI & CO (LLY): Free Stock Analysis Report
MERCK & CO INC (MRK): Free Stock Analysis Report
MYLAN INC (MYL): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
TEVA PHARM ADR (TEVA): Free Stock Analysis Report
VERTEX PHARM (VRTX): Free Stock Analysis Report
WATSON PHARMA (WPI): Free Stock Analysis Report
DENTSPLY INTL (XRAY): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. Besides Lipitor, other major branded drugs that lost patent protection in the past few months include Forest Laboratories' ( FRX ) Lexapro, Sanofi / Bristol-Myers' ( SNY / BMY ) Plavix and Eli Lilly's ( LLY ) Zyprexa. Mergers & acquisitions (M&As), licensing deals, restructuring, share buybacks and monetization of non-core assets have become recurring events in the pharma and biotech sector over the past few quarters. | ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. Besides Lipitor, other major branded drugs that lost patent protection in the past few months include Forest Laboratories' ( FRX ) Lexapro, Sanofi / Bristol-Myers' ( SNY / BMY ) Plavix and Eli Lilly's ( LLY ) Zyprexa. Important product approvals in the last few quarters include Johnson & Johnson's prostate cancer therapy Zytiga, Merck's HCV treatment Victrelis, Bristol-Myers' melanoma treatment Yervoy, AstraZeneca's Brilinta, Vertex Pharma's ( VRTX ) HCV treatment Incivek, Pfizer's lung cancer treatment Xalkori, and Glaxo/Human Genome's lupus drug Benlysta, among others. | ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. With most of the big pharma companies already facing or likely to face patent challenges for their blockbuster products, the companies have been looking toward M&A and in-licensing activities to make up for the loss of revenues resulting from the loss of patent exclusivity of key products. Companies that should benefit from this Act include The Medicines Company ( MDCO ), Optimer Pharma ( OPTR ) and Cubist Pharma ( CBST ) among others. | ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. These initiatives, if implemented, would result in additional pricing competition and genericization in the pharma industry. With most of the big pharma companies already facing or likely to face patent challenges for their blockbuster products, the companies have been looking toward M&A and in-licensing activities to make up for the loss of revenues resulting from the loss of patent exclusivity of key products. |
34409.0 | 2012-08-09 00:00:00 UTC | Pharma & Biotech Stock Outlook - Aug. 2012 - Zacks Analyst Interviews | ABT | https://www.nasdaq.com/articles/pharma-biotech-stock-outlook-aug.-2012-zacks-analyst-interviews-2012-08-09 | nan | nan | The pharmaceutical industry is in the midst of one of the biggest patent cliffs with Pfizer's ( PFE ) multi-billion-dollar blockbuster drug Lipitor losing patent protection in the US in late November 2011. Besides Lipitor, other major branded drugs that lost patent protection in the past few months include Forest Laboratories' ( FRX ) Lexapro, Sanofi / Bristol-Myers' ( SNY / BMY ) Plavix and Eli Lilly's ( LLY ) Zyprexa.
These products alone represented branded sales worth more than $15 billion. Another product that will start facing generic competition shortly is Merck's ( MRK ) blockbuster Singulair.
The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. While generics will eat into sales, new products are not expected to generate the same level of sales as products losing patent protection. The next few years are expected to reflect a significant imbalance between new product introductions and patent losses.
Generic competition and insufficient new product sales are not the only factors impacting performance in 2012. Other headwinds include EU and Japan pricing pressure as well as negative currency movement. In fact, results of several companies including Johnson & Johnson ( JNJ ) were hit by negative currency movement in the June quarter.
Meanwhile, the US government is exploring options which will help increase the availability of generics. The Obama administration announced that it is looking to implement a proposal under which the exclusivity period for biologics will be cut down by 5 years, thereby allowing generics to enter the market sooner.
The government is also seeking to increase the availability of generics by preventing companies from entering into anti-competitive or "pay for delay" agreements which push out the availability of generics. These initiatives, if implemented, would result in additional pricing competition and genericization in the pharma industry. Moreover, the FDA is working on establishing a biosimilar pathway so that cheaper versions of biologics will be available.
With revenue growth stalling or slowing down, pharma companies have been resorting to cost-cutting and share buybacks to drive bottom-line growth. Mergers & acquisitions (M&As), licensing deals, restructuring, share buybacks and monetization of non-core assets have become recurring events in the pharma and biotech sector over the past few quarters.
M&A Activity
The M&A activity witnessed in the pharma sector in the last couple of years has continued in 2012, in-line with expectations. With most of the big pharma companies already facing or likely to face patent challenges for their blockbuster products, the companies have been looking toward M&A and in-licensing activities to make up for the loss of revenues resulting from the loss of patent exclusivity of key products.
Major deals so far in 2012 include Johnson & Johnson's acquisition of Synthes, which should help strengthen its medical device portfolio, Bristol-Myers Squibbs' upcoming acquisition of Amylin Pharmaceuticals, Inc. ( AMLN ), GlaxoSmithKline's ( GSK ) upcoming acquisition of Human Genome Sciences ( HGSI ).
Bristol-Myers has been pretty active on the acquisition front. The company has been looking to expand via acquisitions and partnerships to counter the loss of revenues arising from the genericization of blockbuster blood thinner Plavix. The Amylin acquisition should allow the company to expand its presence in the lucrative diabetes market.
The Amylin deal is the second major deal for Bristol-Myers this year, with the company having purchased Inhibitex, Inc., for $2.5 billion in February, thereby targeting the lucrative hepatitis C virus (HCV) market.
Oncology also remains a much sought-after therapeutic area, with companies like Sanofi and Celgene ( CELG ) strengthening their presence in this market through acquisitions. Meanwhile, generic players are not far behind in the acquisition game. While Teva ( TEVA ) acquired Cephalon, Inc., Watson Pharmaceuticals ( WPI ) acquired generic company Specifar Pharmaceuticals to expand and strengthen its presence in Europe. Watson recently announced its intention to acquire generic player, Actavis.
Elsewhere, companies have been looking toward biotech firms to build their product portfolios. A prime example is French pharma giant Sanofi's acquisition of biotech company Genzyme Corp. The Genzyme acquisition has boosted Sanofi's revenues as well as its pipeline. Meanwhile, AstraZeneca ( AZN ) acquired biotech company Ardea Biosciences. Another acquisition deal announced in April 2012 is Spectrum Pharma's ( SPPI ) upcoming acquisition of biopharma company Allos Therapeutics ( ALTH ).
Going forward, we expect the M&A trend to continue. We also expect a significant pickup in in-licensing activities and collaborations for the development of pipeline candidates. Instead of developing a product from scratch, which involves a lot of funds and time, pharma companies are shopping for mid-to-late stage pipeline candidates that look promising.
Small biotech companies are also game for in-licensing activities and collaborations. Most of these companies find it challenging to raise cash, thereby making it difficult for them to survive and continue with the development of promising pipeline candidates. Therefore, it makes sense for them to seek deals with pharma companies that are sitting on huge piles of cash.
We would recommend investors put their money in biotech stocks that have attractive pipeline candidates or technology that can be used for the development of novel therapeutics. Therapeutic areas which could see a lot of in-licensing activity include oncology, central nervous system disorders, diabetes and immunology/inflammation. The HCV market is also attracting a lot of attention.
Another trend that we are seeing lately is the divestment of non-core business segments. Pfizer sold its Capsugel unit in August 2011 and signed a deal for the divestment of its Nutrition business in April 2012. The company intends to spin-off its Animal Health business as well.
Meanwhile, GlaxoSmithKline is divesting non-core brands from its Consumer Healthcare segment. In August 2011, AstraZeneca sold its Astra Tech business to DENTSPLY ( XRAY ). The monetization of non-core assets will allow the pharma/biotech companies to focus on their areas of expertise.
2012 will see Abbott Labs splitting into two separate publicly traded companies. While one company will deal in diversified medical products, the other (AbbVie) will focus on research-based pharmaceuticals.
Obamacare Rules
A major event that will have a significant impact pharma and biotech stocks is the upholding of the Patient Protection and Affordable Care Act (ACA) by the Supreme Court in late June 2012. The Act, popularly referred to as "Obamacare," passed through Congress in 2010, represents major changes in the nation's healthcare sector.
The Act will provide coverage to 32 million uninsured Americans, make healthcare facilities more affordable, expand coverage for customers with pre-existing health conditions and keep a check on health insurers. The healthcare reform aims to end the discrimination policy of insurance companies, create competition amongst insurers through the establishment of health insurance exchanges, add value to the overall healthcare system and reduce premiums.
The upholding of the Act is a big win for pharma companies as the coverage base will increase.
Meanwhile, the signing of the Gaining Antiobiotic Incentives Now (GAIN) Act should benefit companies pursuing the development of novel antibiotics. Once approved, these products will enjoy an additional five years of marketing exclusivity. Companies that should benefit from this Act include The Medicines Company ( MDCO ), Optimer Pharma ( OPTR ) and Cubist Pharma ( CBST ) among others.
Another important event in the past few weeks was the signing of the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012. This new law includes the reauthorization of the Prescription Drug User Fee Act (PDUFA), under which the FDA is provided with funds and resources needed to ensure the smooth and timely review of drugs.
Emerging Markets
Another recent trend seen in the pharmaceutical sector is a focus on emerging markets. Companies like Mylan ( MYL ), Pfizer, Merck, Eli Lilly, Glaxo and Sanofi are all looking to expand their presence in India, China, Brazil and other emerging markets. Until recently, most of the commercialization efforts were focused on the US -- the largest pharmaceutical market -- along with Europe and Japan.
Emerging markets are slowly and steadily gaining more importance and several companies are now shifting their focus to these areas. According to the IMS Institute, spending on medicines in "pharmerging" markets will almost double to $345 billion - $375 billion in five years from $194 billion in 2011.
However, while higher demand for medicines, government initiatives for healthcare, new patient population, and increasing use of generics should help drive demand, we point out that emerging markets are also not immune from genericization.
Meanwhile, according to the IMS Institute, annual growth in the branded medicines market will remain flat or increase up to 3% to $615 billion - $645 billion through 2016 from $596 billion in 2011.
As far as developed nations are concerned, the IMS Institute expects US spending to go up by $35 billion - $45 billion (1-4%) in the next five years. The introduction of medicines targeting unmet needs and higher patient access resulting from Obamacare are expected to drive growth.
However, growth in Europe will continue to be pressurized by austerity and cost-containment measures. According to the IMS Institute, growth in Europe will range from negative 1% to positive 2%. The Japanese market is expected to grow at a slower pace annually (1-4%) through 2016 compared to the last five years.
OPPORTUNITIES
We continue to have a Neutral outlook on large-cap pharma stocks. While the companies will continue to face challenges like pricing pressure and genericization, growth in emerging markets and product approvals could help reduce the impact.
A few years down the line, the pharma industry should demonstrate signs of recovery. The industry should be out of the major patent cliff period, and new products should be contributing significantly to results. Increased pipeline visibility and appropriate utilization of cash should increase confidence in the sector.
In the biotech space, we are positive on Biogen Idec ( BIIB ). We are optimistic on BG-12, the company's oral multiple sclerosis candidate. Key products Avonex and Tysabri should continue contributing significantly to sales. Biogen's second quarter results were impressive and the company increased its guidance for 2012.
We are also positive on Amgen ( AMGN ). We are encouraged by the company's first half 2012 performance. Enbrel should continue performing well and Xgeva/Prolia should continue responding positively to the company's increased marketing efforts like DTC advertising. Amgen's late-stage pipeline is also moving along.
Another company that delivered a solid performance in the June quarter is Auxilium Pharma ( AUXL ). In addition to reporting a profit for the first time, the company increased its guidance. We expect the company's hypogonadism product, Testim, to continue performing well especially with the additional promotional effort from Glaxo.
Among generic companies, both Watson Pharma ( WPI ) and Mylan ( MYL ) carry a Zacks #2 Rank (short-term Buy rating). While Watson should benefit from its upcoming acquisition of Actavis, which should be immediately accretive, we are encouraged by Mylan's geographic reach and product depth along with a robust generic product pipeline.
WEAKNESSES
We recommend avoiding names that offer little growth or opportunity for a take-out. These include companies which are developing drugs that are likely to face regulatory hurdles. The FDA has been exercising more caution in granting approval to new products and several candidates are facing delays in receiving final approval.
Elan Corp ( ELN ) carries a Zacks #5 Rank (short-term Strong Sell rating). The company's second quarter loss per share was wider than expected mainly due to revenues coming in below expectations. Moreover, expectations from pipeline candidate bapineuzumab (Alzheimer's) are pretty low, with the candidate failing to meet its primary endpoint in one of four phase III studies.
Companies that currently carry a Zacks #4 Rank (short-term Sell rating) include Glaxo ( GSK ) and AstraZeneca ( AZN ). Both Glaxo and AstraZeneca presented weak second quarter results. Factors like generic competition, EU pricing pressure and negative currency movement will continue impacting the performances of these companies.
We are also concerned about the prospects of Cardiome Pharma Corp. ( CRME ) which carries a Zacks #4 Rank (short-term Sell rating). The company recently announced a major reduction in its workforce following Merck's decision to discontinue the development of an oral formulation of vernakalant. Merck and Cardiome were studying the candidate as a maintenance therapy for the long term prevention of atrial fibrillation recurrence.
The discontinuation of the development of oral vernakalant is a huge setback for Cardiome. The company has a weak pipeline consisting of a few early stage projects. We expect the shares to remain under pressure until the company provides a strategic update.
Looking Ahead...
The FDA has some major decisions coming up in the next few months. Some of the most interesting candidates currently under review include Medivation's ( MDVN ) enzalutamide (oncology), Biogen Idec's BG-12 (multiple sclerosis), United Therapeutic's ( UTHR ) oral Remodulin (treatment of pulmonary arterial hypertension), Gilead's ( GILD ) Quad pill (HIV), and Forest Labs' linaclotide (constipation-predominant irritable bowel syndrome and chronic constipation), Onyx Pharma ( ONXX ) and Bayer's ( BAYRY ) regorafenib (oncology) among others.
Important product approvals in the last few quarters include Johnson & Johnson's prostate cancer therapy Zytiga, Merck's HCV treatment Victrelis, Bristol-Myers' melanoma treatment Yervoy, AstraZeneca's Brilinta, Vertex Pharma's ( VRTX ) HCV treatment Incivek, Pfizer's lung cancer treatment Xalkori, and Glaxo/Human Genome's lupus drug Benlysta, among others. Potential blockbusters include Benlysta, Yervoy, Zytiga, Incivek and Xarelto.
ABBOTT LABS (ABT): Free Stock Analysis Report
BRISTOL-MYERS (BMY): Free Stock Analysis Report
CELGENE CORP (CELG): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
GLAXOSMITHKLINE (GSK): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
LILLY ELI & CO (LLY): Free Stock Analysis Report
MERCK & CO INC (MRK): Free Stock Analysis Report
MYLAN INC (MYL): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
TEVA PHARM ADR (TEVA): Free Stock Analysis Report
VERTEX PHARM (VRTX): Free Stock Analysis Report
WATSON PHARMA (WPI): Free Stock Analysis Report
DENTSPLY INTL (XRAY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. Besides Lipitor, other major branded drugs that lost patent protection in the past few months include Forest Laboratories' ( FRX ) Lexapro, Sanofi / Bristol-Myers' ( SNY / BMY ) Plavix and Eli Lilly's ( LLY ) Zyprexa. Mergers & acquisitions (M&As), licensing deals, restructuring, share buybacks and monetization of non-core assets have become recurring events in the pharma and biotech sector over the past few quarters. | ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. Besides Lipitor, other major branded drugs that lost patent protection in the past few months include Forest Laboratories' ( FRX ) Lexapro, Sanofi / Bristol-Myers' ( SNY / BMY ) Plavix and Eli Lilly's ( LLY ) Zyprexa. Important product approvals in the last few quarters include Johnson & Johnson's prostate cancer therapy Zytiga, Merck's HCV treatment Victrelis, Bristol-Myers' melanoma treatment Yervoy, AstraZeneca's Brilinta, Vertex Pharma's ( VRTX ) HCV treatment Incivek, Pfizer's lung cancer treatment Xalkori, and Glaxo/Human Genome's lupus drug Benlysta, among others. | ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. With most of the big pharma companies already facing or likely to face patent challenges for their blockbuster products, the companies have been looking toward M&A and in-licensing activities to make up for the loss of revenues resulting from the loss of patent exclusivity of key products. Companies that should benefit from this Act include The Medicines Company ( MDCO ), Optimer Pharma ( OPTR ) and Cubist Pharma ( CBST ) among others. | ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. These initiatives, if implemented, would result in additional pricing competition and genericization in the pharma industry. With most of the big pharma companies already facing or likely to face patent challenges for their blockbuster products, the companies have been looking toward M&A and in-licensing activities to make up for the loss of revenues resulting from the loss of patent exclusivity of key products. |
34410.0 | 2012-08-07 00:00:00 UTC | DexCom Misses on EPS, Losses Climb - Analyst Blog | ABT | https://www.nasdaq.com/articles/dexcom-misses-on-eps-losses-climb-analyst-blog-2012-08-07 | nan | nan | DexCom ( DXCM ), a player in the glucose monitoring market, reported second-quarter 2012 loss per share of 21 cents, higher than the Zacks Consensus Estimate of a loss of 20 cents per share and the year-ago loss of 11 cents a share. Net loss for the quarter jumped 99.4% year over year to $14.7 million (21 cents per share).
Revenues
Sales grew 9.4% year over year to $23.5 million in the first quarter, beating the Zacks Consensus Estimate of $22 million.
Product sales increased 41.8% to $21.5 million while development grant and other revenues were down 69.1% to $1.9 million in the reported quarter.
Margins and Expenses
Gross margin declined to 47.9% in the second quarter from 55.4% a year ago. Cost of sales increased 27.9% year over year to $12.2 million, mostly on account of higher cost of product sales. Operating expenses moved up 34.4% year over year to $25.9 million due to higher R&D spending and selling, general and administrative expenses, which grew 49.6% and 25.7%, respectively, in the reported quarter.
Balance Sheet
DexCom ended the quarter with cash and short-term marketable securities of $105 million, down 41.7% on a year over year basis.
Our Take
We believe DexCom is poised to gain a major share of the glucose monitoring market driven by sustained product development initiatives, collaborations, favorable reimbursement coverage and increased need for continuous glucose monitoring.
However, we note that competition in the glucose monitoring market is intense and DexCom faces stiff challenges from much larger players such as Johnson & Johnson ( JNJ ), Medtronic ( MDT ) and Abbott Labs ( ABT ). Moreover, the company has incurred losses since inception and is exposed to an increasingly strict regulatory environment. Our Neutral recommendation is supported by a short-term Zacks #3 Rank (Hold).
ABBOTT LABS (ABT): Free Stock Analysis Report
DEXCOM INC (DXCM): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
MEDTRONIC (MDT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | However, we note that competition in the glucose monitoring market is intense and DexCom faces stiff challenges from much larger players such as Johnson & Johnson ( JNJ ), Medtronic ( MDT ) and Abbott Labs ( ABT ). ABBOTT LABS (ABT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Our Take We believe DexCom is poised to gain a major share of the glucose monitoring market driven by sustained product development initiatives, collaborations, favorable reimbursement coverage and increased need for continuous glucose monitoring. | However, we note that competition in the glucose monitoring market is intense and DexCom faces stiff challenges from much larger players such as Johnson & Johnson ( JNJ ), Medtronic ( MDT ) and Abbott Labs ( ABT ). ABBOTT LABS (ABT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. DexCom ( DXCM ), a player in the glucose monitoring market, reported second-quarter 2012 loss per share of 21 cents, higher than the Zacks Consensus Estimate of a loss of 20 cents per share and the year-ago loss of 11 cents a share. | ABBOTT LABS (ABT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. However, we note that competition in the glucose monitoring market is intense and DexCom faces stiff challenges from much larger players such as Johnson & Johnson ( JNJ ), Medtronic ( MDT ) and Abbott Labs ( ABT ). DexCom ( DXCM ), a player in the glucose monitoring market, reported second-quarter 2012 loss per share of 21 cents, higher than the Zacks Consensus Estimate of a loss of 20 cents per share and the year-ago loss of 11 cents a share. | However, we note that competition in the glucose monitoring market is intense and DexCom faces stiff challenges from much larger players such as Johnson & Johnson ( JNJ ), Medtronic ( MDT ) and Abbott Labs ( ABT ). ABBOTT LABS (ABT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. DexCom ( DXCM ), a player in the glucose monitoring market, reported second-quarter 2012 loss per share of 21 cents, higher than the Zacks Consensus Estimate of a loss of 20 cents per share and the year-ago loss of 11 cents a share. |
34411.0 | 2012-07-27 00:00:00 UTC | Amgen Beats, Raises Guidance - Analyst Blog | ABT | https://www.nasdaq.com/articles/amgen-beats-raises-guidance-analyst-blog-2012-07-27 | nan | nan | Amgen ( AMGN ) continued its strong performance in 2012 with second quarter earnings coming in at $1.82 per share, 31 cents above the Zacks Consensus Estimate and 34.8% above the year-ago period. Higher revenues and a lower share count contributed to the year-over-year increase in earnings.
Total revenue increased 13% to $4,477 million in the second quarter of 2012. Revenues comfortably surpassed the Zacks Consensus Estimate of $4,082 million. However, second quarter 2012 revenues included $206 million recognized by Amgen under its amended agreement with Takeda for oncology candidate, motesanib.
The Quarter in Detail
Second quarter total product sales increased 8% to $4,200 million (US: $3,255 million, ex-US: $945 million).
Revenues of Amgen's erythropoiesis-stimulating agent (ESA) Aranesp fell 8% to $536 million (US: $215 million, down 11%; ex-US: $321 million, down 7%).
US sales were down mainly due to a decline in demand that was partially offset by a price increase and a change in accounting estimates. International sales were affected by a decline in average net sales price.
Revenues of Amgen's other ESA, Epogen, fell 3% to $525 million. The decrease in demand was mainly due to lower dose utilization. The decline reflected the impact of the implementation of the ESRD bundling strategy in 2011 and label changes in June 2011. However, Epogen sales increased 18% on a sequential basis mainly due to customer and wholesaler buying patterns. Amgen reported 2% growth in underlying unit demand.
We note that a new competitor, Affymax' ( AFFY ) Omontys (peginesatide), has entered the dialysis market. Amgen said that the impact of new competition on Epogen sales was limited. Epogen sales, however, are expected to remain volatile due to the overall market dynamics.
Worldwide revenues of Neulasta and Neupogen grew 2% to $1,347 million in the second quarter. An increase in average net sales price and unit demand boosted US revenues to $1,062 million, up 6%. International revenues, however, continued to decline with sales coming in at $285 million, down 13%. Sales were impacted by lower average net sales price and a decline in Neupogen units due to competition from biosimilars.
Enbrel, which is facing increased competition in the dermatology market, posted revenues of $1,058 million, up 11%. Higher average net sales price, increase in unit demand and wholesaler inventories drove the upside. The company said that over the last one year, it has been increasing its share among bio-naïve (patients new to biologics) patients. Enbrel's competitors include Abbott Labs' ( ABT ) Humira, Merck / Johnson & Johnson's ( MRK / JNJ ) Remicade and Johnson & Johnson's Stelara among others.
With Amgen and Pfizer's ( PFE ) collaboration for Enbrel set to expire in late 2013, Amgen has completed the consolidating of US field sales activities under its wing. The consolidated sales force is targeting both the rheumatology and dermatology segments. Amgen has also expanded DTC advertising and is working on ensuring appropriate access.
Second quarter 2012 Prolia sales came in at $120 million, up from first quarter 2012 sales of $88 million. Sales were driven by increased segment share as well as growth in the overall skeletal-related events segment. Amgen launched a DTC TV campaign this year which should drive sales further.
Meanwhile, Xgeva, which gained FDA approval in November 2010, delivered second quarter 2012 sales of $179 million, up from the $153 million, $134 million, and $100 million reported in the last three quarters. Sales were driven by overall segment growth. Xgeva gained EU approval in July 2011.
Sensipar/Mimpara revenues increased 17% to $232 million in the reported quarter. Higher demand helped drive Vectibix revenues to $90 million during the quarter, up 11%.
While second quarter 2012 R&D expenses remained flat, SG&A expenses increased 8%. SG&A spend increased due to higher Enbrel profit share expenses and expansion of international operations.
Amgen is currently conducting phase III studies with AMG 785 for the treatment of postmenopausal osteoporosis and expects to commence phase III studies with AMG145 (LDL cholesterol reduction) early next year.
Guidance Up
Based on its strong performance in the first half of 2012 results, Amgen raised its guidance for 2012. The company now expects earnings in the range of $6.20 - $6.35 per share on revenues of $16.9 - $17.2 billion. Earlier, the company had guided towards earnings of $5.90 - $6.15 per share on revenues of $16.1 - $16.5 billion. The Zacks Consensus Estimate stands well below the new guidance at $6.08 per share. The Zacks Consensus Revenue Estimate of $16.4 billion is also below the new guidance range.
Earnings guidance reflects the up-front and milestone payments received from Takeda, AstraZeneca ( AZN ) and Astellas Pharma in the first half of 2012. Meanwhile, the company expects R&D costs to increase in the second half of the year as it accelerates its late-stage development plans for AMG 785 and AMG 145.
Amgen repurchased about 17 million shares for $1.2 billion in the second quarter of 2012.
We are encouraged by the company's first half 2012 performance. Enbrel should continue performing well and Xgeva/Prolia should continue responding positively to the company's increased marketing efforts like DTC advertising. Amgen's late-stage pipeline is also moving along.
We currently have a Neutral recommendation on Amgen, which carries a Zacks #3 Rank (short-term 'Hold' rating).
ABBOTT LABS (ABT): Free Stock Analysis Report
AFFYMAX INC (AFFY): Free Stock Analysis Report
AMGEN INC (AMGN): Free Stock Analysis Report
ASTRAZENECA PLC (AZN): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
MERCK & CO INC (MRK): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Enbrel's competitors include Abbott Labs' ( ABT ) Humira, Merck / Johnson & Johnson's ( MRK / JNJ ) Remicade and Johnson & Johnson's Stelara among others. ABBOTT LABS (ABT): Free Stock Analysis Report AFFYMAX INC (AFFY): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Amgen ( AMGN ) continued its strong performance in 2012 with second quarter earnings coming in at $1.82 per share, 31 cents above the Zacks Consensus Estimate and 34.8% above the year-ago period. | Enbrel's competitors include Abbott Labs' ( ABT ) Humira, Merck / Johnson & Johnson's ( MRK / JNJ ) Remicade and Johnson & Johnson's Stelara among others. ABBOTT LABS (ABT): Free Stock Analysis Report AFFYMAX INC (AFFY): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Sales were impacted by lower average net sales price and a decline in Neupogen units due to competition from biosimilars. | ABBOTT LABS (ABT): Free Stock Analysis Report AFFYMAX INC (AFFY): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Enbrel's competitors include Abbott Labs' ( ABT ) Humira, Merck / Johnson & Johnson's ( MRK / JNJ ) Remicade and Johnson & Johnson's Stelara among others. The Quarter in Detail Second quarter total product sales increased 8% to $4,200 million (US: $3,255 million, ex-US: $945 million). | Enbrel's competitors include Abbott Labs' ( ABT ) Humira, Merck / Johnson & Johnson's ( MRK / JNJ ) Remicade and Johnson & Johnson's Stelara among others. ABBOTT LABS (ABT): Free Stock Analysis Report AFFYMAX INC (AFFY): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Sales were impacted by lower average net sales price and a decline in Neupogen units due to competition from biosimilars. |
34412.0 | 2012-07-23 00:00:00 UTC | Earnings are Up, but Will it Spark a Stock Market Rally? | ABT | https://www.nasdaq.com/articles/earnings-are-will-it-spark-stock-market-rally-2012-07-23 | nan | nan | The first month of each quarter brings the coveted earnings season in stocks. It's the time investors get all the need to know and updated information from CEOs and companies explaining what happened the last three months and why it will be better in the future.
But, how many times has a company announced great earnings, better future earnings, and then the stock still sells off? Positive earnings selloffs seem to occur as often as positive earnings rallies. Given the evidence, how do positive earnings then equate to good buying opportunities? Forgive me if I am not as gung-ho about earnings seasons, CEO rhetoric, or linear extrapolation as most traditional analysts. Like you, I was around in 2007 and 2008 as CEOs time and again stated ever-positive outlooks for the future as their share prices continued to fall.
News and company press releases typically try to frame the earnings into positive headlines as shown below:
"Abbott ( ABT ) Reports Strong Second Quarter Results" - Abbott Investor's Relations Press Release , July 18, 2012 (Even though earnings were a self-proclaimed "strong", the price stalled out that day at $65.93 with a popular candlestick pattern and as of today (7/23) was down 2.5% to $64.27, evidently "strong" earnings weren't enough to drive price higher.)
"Groupon Earnings Top Forecast; Shares Jump" - CNBC, May 2012 (After popping above $14.00 on the earnings announcement after hours, Groupon (NasdaqGS: GRPN) finished the next day selling from the get go ending the day at $12.25, slightly ahead of its pre-earnings share price of $11.75. It finished the month, 2 weeks later, at $10.60 and down significantly from its pre-earnings price. It currently sits in the $7 price range as we approach its earnings season yet again.)
Much of the information given during earnings season is from the past a nd doesn't help anyways. Learning about 2Q profits in July is best summed up by one of Shakespeare's quotes, "Better three hours too soon than a minute too late". There's really nothing anyone can do about the second quarter now.
Some look to earnings season to get guidance about upcoming quarters and years, but do CEOs really know much more than you about the future of stock prices? They may know more about how their individual company will perform fundamentally, but they do not know how people or stock prices will respond to that performance. They also do not control their multiples or other necessary valuation inputs. Once again I refer to the 2007 and 2008 time frame as an example. Unfortunately for company share prices, it seems the macro environment matters a whole lot more than many company insiders will admit.
Price is what makes you money and, along with dividends, is what really matters to investors and traders. Combining the current price with its recent history allows trends to be recognized through time. It also helps show us if earnings will be a catalyst for stock prices well before a CEO will tell us, or will even really know.
In a recent ETF Profit Strategy Update, shown in the chart below, key price levels are identified as important support and resistances that will help traders know if earnings are going to be a catalyst or a drag on stock prices. Currently there is a key technical formation taking place that sets up a trading opportunity in the S&P 500 for bears and another opportunity in another asset class for longpositions.
This month the ETF Profit Strategy Newsletter identified key support and resistance levels on the S&P 500 (SNP: ^GSPC - News) - (NYSEArca: SPY), the Volatility Index (ChicagoOptions: ^VIX), the CurrencyShares Euro Trust (NYSEArca: FXE), the SPDR Gold Shares (NYSEArca: GLD), and the iShares Silver Trust (NYSEArca: SLV). We also focus on popular ETPs such as the iShares 20+ Year Treasury Bond (NYSEArca: TLT), the iShares Russell 2000 (NYSEArca: IWM) and the SPDR Dow Jones Industrial Average (NYSEArca: DIA).
Price, not earnings, is all that matters when it comes to profitable trades. The ETF Profit Strategy Newsletter identifies those key price levels through comprehensive technical analysis along with practical and actionable commentary to help investors stay on the right side of the market during the volatile earning seasons.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | News and company press releases typically try to frame the earnings into positive headlines as shown below: "Abbott ( ABT ) Reports Strong Second Quarter Results" - Abbott Investor's Relations Press Release , July 18, 2012 (Even though earnings were a self-proclaimed "strong", the price stalled out that day at $65.93 with a popular candlestick pattern and as of today (7/23) was down 2.5% to $64.27, evidently "strong" earnings weren't enough to drive price higher.) "Groupon Earnings Top Forecast; Shares Jump" - CNBC, May 2012 (After popping above $14.00 on the earnings announcement after hours, Groupon (NasdaqGS: GRPN) finished the next day selling from the get go ending the day at $12.25, slightly ahead of its pre-earnings share price of $11.75. The ETF Profit Strategy Newsletter identifies those key price levels through comprehensive technical analysis along with practical and actionable commentary to help investors stay on the right side of the market during the volatile earning seasons. | News and company press releases typically try to frame the earnings into positive headlines as shown below: "Abbott ( ABT ) Reports Strong Second Quarter Results" - Abbott Investor's Relations Press Release , July 18, 2012 (Even though earnings were a self-proclaimed "strong", the price stalled out that day at $65.93 with a popular candlestick pattern and as of today (7/23) was down 2.5% to $64.27, evidently "strong" earnings weren't enough to drive price higher.) This month the ETF Profit Strategy Newsletter identified key support and resistance levels on the S&P 500 (SNP: ^GSPC - News) - (NYSEArca: SPY), the Volatility Index (ChicagoOptions: ^VIX), the CurrencyShares Euro Trust (NYSEArca: FXE), the SPDR Gold Shares (NYSEArca: GLD), and the iShares Silver Trust (NYSEArca: SLV). The ETF Profit Strategy Newsletter identifies those key price levels through comprehensive technical analysis along with practical and actionable commentary to help investors stay on the right side of the market during the volatile earning seasons. | News and company press releases typically try to frame the earnings into positive headlines as shown below: "Abbott ( ABT ) Reports Strong Second Quarter Results" - Abbott Investor's Relations Press Release , July 18, 2012 (Even though earnings were a self-proclaimed "strong", the price stalled out that day at $65.93 with a popular candlestick pattern and as of today (7/23) was down 2.5% to $64.27, evidently "strong" earnings weren't enough to drive price higher.) "Groupon Earnings Top Forecast; Shares Jump" - CNBC, May 2012 (After popping above $14.00 on the earnings announcement after hours, Groupon (NasdaqGS: GRPN) finished the next day selling from the get go ending the day at $12.25, slightly ahead of its pre-earnings share price of $11.75. In a recent ETF Profit Strategy Update, shown in the chart below, key price levels are identified as important support and resistances that will help traders know if earnings are going to be a catalyst or a drag on stock prices. | News and company press releases typically try to frame the earnings into positive headlines as shown below: "Abbott ( ABT ) Reports Strong Second Quarter Results" - Abbott Investor's Relations Press Release , July 18, 2012 (Even though earnings were a self-proclaimed "strong", the price stalled out that day at $65.93 with a popular candlestick pattern and as of today (7/23) was down 2.5% to $64.27, evidently "strong" earnings weren't enough to drive price higher.) But, how many times has a company announced great earnings, better future earnings, and then the stock still sells off? Some look to earnings season to get guidance about upcoming quarters and years, but do CEOs really know much more than you about the future of stock prices? |
34413.0 | 2012-07-19 00:00:00 UTC | Company News for July 19, 2012 - Corporate Summary | ABT | https://www.nasdaq.com/articles/company-news-for-july-19-2012-corporate-summary-2012-07-19 | nan | nan | • Yahoo! Inc. (NASDAQ: YHOO ) reported second quarter earnings per share of $0.27, higher than the Zacks Consensus Estimate of $0.23
• Abbott Laboratories (NYSE: ABT ) posted second quarter earnings per share of $1.23, beating the Zacks Consensus Estimate of $1.22 by a penny
• Bank of America Corp. (NYSE: BAC ) reported second quarter earnings per share of $0.19, surpassing the Zacks Consensus Estimate of $0.15
• U.S. Bancorp. (NYSE: USB ) posted second quarter earnings per share of $0.71, beating the Zacks Consensus Estimate of $0.69
ABBOTT LABS (ABT): Free Stock Analysis Report
BANK OF AMER CP (BAC): Free Stock Analysis Report
US BANCORP (USB): Free Stock Analysis Report
YAHOO! INC (YHOO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Inc. (NASDAQ: YHOO ) reported second quarter earnings per share of $0.27, higher than the Zacks Consensus Estimate of $0.23 • Abbott Laboratories (NYSE: ABT ) posted second quarter earnings per share of $1.23, beating the Zacks Consensus Estimate of $1.22 by a penny • Bank of America Corp. (NYSE: BAC ) reported second quarter earnings per share of $0.19, surpassing the Zacks Consensus Estimate of $0.15 • U.S. Bancorp. (NYSE: USB ) posted second quarter earnings per share of $0.71, beating the Zacks Consensus Estimate of $0.69 ABBOTT LABS (ABT): Free Stock Analysis Report BANK OF AMER CP (BAC): Free Stock Analysis Report US BANCORP (USB): Free Stock Analysis Report YAHOO! INC (YHOO): Free Stock Analysis Report To read this article on Zacks.com click here. | Inc. (NASDAQ: YHOO ) reported second quarter earnings per share of $0.27, higher than the Zacks Consensus Estimate of $0.23 • Abbott Laboratories (NYSE: ABT ) posted second quarter earnings per share of $1.23, beating the Zacks Consensus Estimate of $1.22 by a penny • Bank of America Corp. (NYSE: BAC ) reported second quarter earnings per share of $0.19, surpassing the Zacks Consensus Estimate of $0.15 • U.S. Bancorp. (NYSE: USB ) posted second quarter earnings per share of $0.71, beating the Zacks Consensus Estimate of $0.69 ABBOTT LABS (ABT): Free Stock Analysis Report BANK OF AMER CP (BAC): Free Stock Analysis Report US BANCORP (USB): Free Stock Analysis Report YAHOO! INC (YHOO): Free Stock Analysis Report To read this article on Zacks.com click here. | Inc. (NASDAQ: YHOO ) reported second quarter earnings per share of $0.27, higher than the Zacks Consensus Estimate of $0.23 • Abbott Laboratories (NYSE: ABT ) posted second quarter earnings per share of $1.23, beating the Zacks Consensus Estimate of $1.22 by a penny • Bank of America Corp. (NYSE: BAC ) reported second quarter earnings per share of $0.19, surpassing the Zacks Consensus Estimate of $0.15 • U.S. Bancorp. (NYSE: USB ) posted second quarter earnings per share of $0.71, beating the Zacks Consensus Estimate of $0.69 ABBOTT LABS (ABT): Free Stock Analysis Report BANK OF AMER CP (BAC): Free Stock Analysis Report US BANCORP (USB): Free Stock Analysis Report YAHOO! Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (NYSE: USB ) posted second quarter earnings per share of $0.71, beating the Zacks Consensus Estimate of $0.69 ABBOTT LABS (ABT): Free Stock Analysis Report BANK OF AMER CP (BAC): Free Stock Analysis Report US BANCORP (USB): Free Stock Analysis Report YAHOO! Inc. (NASDAQ: YHOO ) reported second quarter earnings per share of $0.27, higher than the Zacks Consensus Estimate of $0.23 • Abbott Laboratories (NYSE: ABT ) posted second quarter earnings per share of $1.23, beating the Zacks Consensus Estimate of $1.22 by a penny • Bank of America Corp. (NYSE: BAC ) reported second quarter earnings per share of $0.19, surpassing the Zacks Consensus Estimate of $0.15 • U.S. Bancorp. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
34414.0 | 2012-07-19 00:00:00 UTC | Dutch Approval for Hologic's HPV HR - Analyst Blog | ABT | https://www.nasdaq.com/articles/dutch-approval-for-hologics-hpv-hr-analyst-blog-2012-07-19 | nan | nan | Hologic ( HOLX ), a prominent player in the field of women's health, recently got the Netherlands Society for Pathology's ("NVVP") approval for its Human Papillomavirus ("HPV) high-risk test Cervista HPV HR for the use in the national cervical screening programme of Netherlands. The latest approval for HPV HR will help Hologic to tap the growing molecular diagnostic market in the Netherlands and will boost its international endeavors.
The Cervista HPV HR test helps detect HPV, one of the widely held sexually transmitted diseases ("STD") causing cervical cancer. This test uses sample collected through Hologic's ThinPrep Pap test and works on its Cervista MTA (Medium Throughput Automation) system for the extraction of DNA and HPV detection. Following the approval, The National Institute for Public Health and the Environment in The Netherlands ("RIVM") suggested routine Pap testing and HPV HR triage for ASCUS/LSIL testing for women aged 30 and above.
With a wide range of products, Hologic has become an industry giant in the field of women's health. The company is undertaking several steps, including acquisitions, international expansion and product development to bolster its top line. Moreover, the pending acquisition of Gen-Probe (GPRO) will position Hologic favorably in the molecular diagnostics segment with special focus on the women's health.
It is expected that the acquisition will prove to be valuable for Hologic over the long term. With 61% of revenues from molecular diagnostics, Gen-Probe is a major player in molecular diagnostics products and services that are deployed primarily to diagnose human diseases, screen donated human blood, and helps ensure transplant compatibility. Hologic will also have access to Gen-Probe's molecular diagnostic platforms of Tigris and Panther.
However, we are disappointed with Hologic's preliminary third quarter 2012 result. The company will report revenues of approximately $470 million in the quarter, up 4.2% year over year but lower than the current Zacks Consensus Estimate of $477 million. We also remain concerned about the high leverage of the company owing to the Gen-Probe deal. Hologic is also suffering from weak procedure volumes due to macro-economic issues and persistent unemployment. The company faces stiff competition from players such as Qiagen ( QGEN ) and Abbott Laboratories ( ABT ).
Currently with 80% market share in HPV space with its largest selling consumable product digene HC2 HPV Test, Qiagen is a dominant player in this market. The company also expects to strengthen its position further in this field with the recent acquisition of AmniSure International.
Qiagen currently retains a Zacks #3 Rank (short-term Hold), in line with Abbott. However, Hologic holds a Zacks #4 Rank (short-term Sell rating).
ABBOTT LABS (ABT): Free Stock Analysis Report
HOLOGIC INC (HOLX): Free Stock Analysis Report
QIAGEN NV (QGEN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company faces stiff competition from players such as Qiagen ( QGEN ) and Abbott Laboratories ( ABT ). ABBOTT LABS (ABT): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report QIAGEN NV (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. The latest approval for HPV HR will help Hologic to tap the growing molecular diagnostic market in the Netherlands and will boost its international endeavors. | ABBOTT LABS (ABT): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report QIAGEN NV (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. The company faces stiff competition from players such as Qiagen ( QGEN ) and Abbott Laboratories ( ABT ). The Cervista HPV HR test helps detect HPV, one of the widely held sexually transmitted diseases ("STD") causing cervical cancer. | ABBOTT LABS (ABT): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report QIAGEN NV (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. The company faces stiff competition from players such as Qiagen ( QGEN ) and Abbott Laboratories ( ABT ). Hologic ( HOLX ), a prominent player in the field of women's health, recently got the Netherlands Society for Pathology's ("NVVP") approval for its Human Papillomavirus ("HPV) high-risk test Cervista HPV HR for the use in the national cervical screening programme of Netherlands. | The company faces stiff competition from players such as Qiagen ( QGEN ) and Abbott Laboratories ( ABT ). ABBOTT LABS (ABT): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report QIAGEN NV (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Hologic ( HOLX ), a prominent player in the field of women's health, recently got the Netherlands Society for Pathology's ("NVVP") approval for its Human Papillomavirus ("HPV) high-risk test Cervista HPV HR for the use in the national cervical screening programme of Netherlands. |
34415.0 | 2012-07-18 00:00:00 UTC | Abbott Labs Q2 Profit Falls 11%, but Adjusted Net Beats View; Outlook Reaffirmed (ABT) | ABT | https://www.nasdaq.com/articles/abbott-labs-q2-profit-falls-11-adjusted-net-beats-view-outlook-reaffirmed-abt-2012-07-18 | nan | nan | Medical device maker Abbott Laboratories ( ABT ) on Wednesday posted lower second quarter earnings due to special items, but its adjusted profit beat Wall Street's view and the company reiterated its full-year outlook.
Abbott Park, Ill., health-care firm, reported on Wednesday that second-quarter net income fell 11% and it affirmed its estimate of adjusted earnings for the year.
The Abbott Park, IL-based company reported second quarter net income of $1.73 billion, or $1.08 per share, compared with $1.94 billion, or $1.23 per share, in the year-ago period. Excluding one-time items, adjusted profit was $1.23 per share.
Revenue rose 2% from last year to $9.81 billion.
On average, Wall Street analysts expected a slightly smaller profit of $1.22 per share, on slightly larger revenue of $9.84 billion.
Looking ahead, ABT affirmed its previously-announced full-year 2012 earnings outlook of $5 to $5.10 per share. Analysts currently expect $5.04 per share for the year.
Abbott shares were mostly flat in premarket trading Wednesday.
The Bottom Line
We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011. The company has a 3.07% dividend yield, based on last night's closing stock price of $46.32.
Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars.
Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Created by Dividend.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Medical device maker Abbott Laboratories ( ABT ) on Wednesday posted lower second quarter earnings due to special items, but its adjusted profit beat Wall Street's view and the company reiterated its full-year outlook. Looking ahead, ABT affirmed its previously-announced full-year 2012 earnings outlook of $5 to $5.10 per share. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011. | Medical device maker Abbott Laboratories ( ABT ) on Wednesday posted lower second quarter earnings due to special items, but its adjusted profit beat Wall Street's view and the company reiterated its full-year outlook. Looking ahead, ABT affirmed its previously-announced full-year 2012 earnings outlook of $5 to $5.10 per share. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011. | Medical device maker Abbott Laboratories ( ABT ) on Wednesday posted lower second quarter earnings due to special items, but its adjusted profit beat Wall Street's view and the company reiterated its full-year outlook. Looking ahead, ABT affirmed its previously-announced full-year 2012 earnings outlook of $5 to $5.10 per share. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011. | Medical device maker Abbott Laboratories ( ABT ) on Wednesday posted lower second quarter earnings due to special items, but its adjusted profit beat Wall Street's view and the company reiterated its full-year outlook. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars. Looking ahead, ABT affirmed its previously-announced full-year 2012 earnings outlook of $5 to $5.10 per share. |
34416.0 | 2012-07-17 00:00:00 UTC | Pre-Market Earnings Report for July 18, 2012 : ABT, BAC, BK, ERIC, BLK, ASML, DOV, CHKP, APH, FRC, HBI, FCFS | ABT | https://www.nasdaq.com/articles/pre-market-earnings-report-july-18-2012-abt-bac-bk-eric-blk-asml-dov-chkp-aph-frc-hbi-fcfs | nan | nan | The following companies are expected to report earnings prior to market open on 07/18/2012. Visit our Earnings Calendar for a full list of expected earnings releases.
Abbott Laboratories ( ABT ) is reporting for the quarter ending June 30, 2012. The large cap pharmaceutical company's consensus earnings per share forecast from the 16 analysts that follow the stock is $1.21. This value represents a 8.04% increase compared to the same quarter last year. In the past year ABT has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 3%. Zacks Investment Research reports that the 2012 Price to Earnings ratio for ABT is 12.97 vs. an industry ratio of 13.50.
Bank of America Corporation ( BAC ) is reporting for the quarter ending June 30, 2012. The bank company's consensus earnings per share forecast from the 22 analysts that follow the stock is $0.15. This value represents a -116.67% decrease compared to the same quarter last year. BAC missed the consensus earnings per share in the 4th calendar quarter by -34.78%. Zacks Investment Research reports that the 2012 Price to Earnings ratio for BAC is 14.20 vs. an industry ratio of 11.40, implying that they will have a higher earnings growth than their competitors in the same industry.
Bank Of New York Mellon Corporation ( BK ) is reporting for the quarter ending June 30, 2012. The bank company's consensus earnings per share forecast from the 16 analysts that follow the stock is $0.50. This value represents a -15.25% decrease compared to the same quarter last year. BK missed the consensus earnings per share in the 4th calendar quarter by -11.11%. Zacks Investment Research reports that the 2012 Price to Earnings ratio for BK is 10.07 vs. an industry ratio of 11.40.
Ericsson ( ERIC ) is reporting for the quarter ending June 30, 2012. The wireless equipment company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.12. This value represents a -42.86% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2012 Price to Earnings ratio for ERIC is 14.20 vs. an industry ratio of -16.30, implying that they will have a higher earnings growth than their competitors in the same industry.
BlackRock, Inc. ( BLK ) is reporting for the quarter ending June 30, 2012. The finance/investment management company's consensus earnings per share forecast from the 15 analysts that follow the stock is $3.05. This value represents a 1.67% increase compared to the same quarter last year. In the past year BLK has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 4.29%. Zacks Investment Research reports that the 2012 Price to Earnings ratio for BLK is 13.29 vs. an industry ratio of 16.20.
ASML Holding N.V. ( ASML ) is reporting for the quarter ending June 30, 2012. The capital goods company's consensus earnings per share forecast from the 5 analysts that follow the stock is $0.89. This value represents a -36.43% decrease compared to the same quarter last year. In the past year ASML has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 12.66%. Zacks Investment Research reports that the 2012 Price to Earnings ratio for ASML is 14.32 vs. an industry ratio of 13.30, implying that they will have a higher earnings growth than their competitors in the same industry.
Dover Corporation ( DOV ) is reporting for the quarter ending June 30, 2012. The machinery company's consensus earnings per share forecast from the 11 analysts that follow the stock is $1.14. This value represents a -4.20% decrease compared to the same quarter last year. In the past year DOV has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 3.96%. Zacks Investment Research reports that the 2012 Price to Earnings ratio for DOV is 10.78 vs. an industry ratio of 29.50.
Check Point Software Technologies Ltd. ( CHKP ) is reporting for the quarter ending June 30, 2012. The computer software company's consensus earnings per share forecast from the 9 analysts that follow the stock is $0.72. This value represents a 14.29% increase compared to the same quarter last year. In the past year CHKP has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2012 Price to Earnings ratio for CHKP is 15.05 vs. an industry ratio of 66.30.
Amphenol Corporation ( APH ) is reporting for the quarter ending June 30, 2012. The electrical connectors company's consensus earnings per share forecast from the 10 analysts that follow the stock is $0.84. This value represents a 6.33% increase compared to the same quarter last year. In the past year APH has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 1.32%. Zacks Investment Research reports that the 2012 Price to Earnings ratio for APH is 15.49 vs. an industry ratio of 14.80, implying that they will have a higher earnings growth than their competitors in the same industry.
FIRST REPUBLIC BANK ( FRC ) is reporting for the quarter ending June 30, 2012. The bank (west) company's consensus earnings per share forecast from the 12 analysts that follow the stock is $0.61. This value represents a -4.69% decrease compared to the same quarter last year. FRC missed the consensus earnings per share in the 2nd calendar quarter by -1.54%. Zacks Investment Research reports that the 2012 Price to Earnings ratio for FRC is 12.55 vs. an industry ratio of 15.10.
Hanesbrands Inc. ( HBI ) is reporting for the quarter ending June 30, 2012. The textile company's consensus earnings per share forecast from the 8 analysts that follow the stock is $0.49. This value represents a -43.68% decrease compared to the same quarter last year. HBI missed the consensus earnings per share in the 4th calendar quarter by -19.61%. The "days to cover" for this stock exceeds 11 days. Zacks Investment Research reports that the 2012 Price to Earnings ratio for HBI is 11.60 vs. an industry ratio of 16.00.
First Cash Financial Services, Inc. ( FCFS ) is reporting for the quarter ending June 30, 2012. The retail company's consensus earnings per share forecast from the 10 analysts that follow the stock is $0.56. This value represents a 16.67% increase compared to the same quarter last year. In the past year FCFS has met analyst expectations once and beat the expectations the other three quarters. The "days to cover" for this stock exceeds 15 days. Zacks Investment Research reports that the 2012 Price to Earnings ratio for FCFS is 15.11 vs. an industry ratio of 10.50, implying that they will have a higher earnings growth than their competitors in the same industry.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is reporting for the quarter ending June 30, 2012. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2012 Price to Earnings ratio for ABT is 12.97 vs. an industry ratio of 13.50. | Abbott Laboratories ( ABT ) is reporting for the quarter ending June 30, 2012. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2012 Price to Earnings ratio for ABT is 12.97 vs. an industry ratio of 13.50. | Abbott Laboratories ( ABT ) is reporting for the quarter ending June 30, 2012. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2012 Price to Earnings ratio for ABT is 12.97 vs. an industry ratio of 13.50. | In the past year ABT has beat the expectations every quarter. Abbott Laboratories ( ABT ) is reporting for the quarter ending June 30, 2012. Zacks Investment Research reports that the 2012 Price to Earnings ratio for ABT is 12.97 vs. an industry ratio of 13.50. |
34417.0 | 2012-07-09 00:00:00 UTC | After Hours Most Active for Jul 9, 2012 : PG, ABT, XOM, COP, VRSN, AA, HSH, MAKO, QQQ, INTC, MSFT, ASML | ABT | https://www.nasdaq.com/articles/after-hours-most-active-jul-9-2012-pg-abt-xom-cop-vrsn-aa-hsh-mako-qqq-intc-msft-asml-2012 | nan | nan | The NASDAQ 100 After Hours Indicator is down -1.4 to 2,608.91. The total After hours volume is currently 20,228,836 shares traded.
The following are the most active stocks for the after hours session :
Procter & Gamble Company (The) ( PG ) is +0.0402 at $61.59, with 4,021,547 shares traded. PG's current last sale is 91.24% of the target price of $67.5.
Abbott Laboratories ( ABT ) is unchanged at $65.61, with 3,005,464 shares traded., following a 52-week high recorded in today's regular session.
Exxon Mobil Corporation ( XOM ) is +0.05 at $83.70, with 2,854,243 shares traded. As reported by Zacks, the current mean recommendation for XOM is in the "buy range".
ConocoPhillips ( COP ) is +0.04 at $54.37, with 1,793,151 shares traded. COP's current last sale is 90.62% of the target price of $60.
VeriSign, Inc. ( VRSN ) is unchanged at $43.43, with 1,498,973 shares traded. VRSN's current last sale is 98.7% of the target price of $44.
Alcoa Inc. ( AA ) is +0.01 at $8.77, with 1,485,476 shares traded. RTT News Reports: Stocks Close Modestly Lower But Well Off Worst Levels - U.S. Commentary
Hillshire Brands Company (The) (HSH) is unchanged at $28.77, with 1,428,000 shares traded. HSH's current last sale is 91.33% of the target price of $31.5.
MAKO Surgical Corp. ( MAKO ) is -8.41 at $16.20, with 1,162,860 shares traded. MAKO's current last sale is 46.29% of the target price of $35.
PowerShares QQQ Trust, Series 1 ( QQQ ) is unchanged at $64.00, with 1,019,384 shares traded. This represents a 28.18% increase from its 52 Week Low.
Intel Corporation ( INTC ) is -0.27 at $25.90, with 633,471 shares traded. INTC's current last sale is 86.33% of the target price of $30.
Microsoft Corporation ( MSFT ) is unchanged at $30.00, with 433,216 shares traded. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2012. The consensus EPS forecast is $0.9. As reported by Zacks, the current mean recommendation for MSFT is in the "buy range".
ASML Holding N.V. ( ASML ) is +2.74 at $51.20, with 242,732 shares traded. As reported by Zacks, the current mean recommendation for ASML is in the "buy range".
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is unchanged at $65.61, with 3,005,464 shares traded., following a 52-week high recorded in today's regular session. The following are the most active stocks for the after hours session : Procter & Gamble Company (The) ( PG ) is +0.0402 at $61.59, with 4,021,547 shares traded. RTT News Reports: Stocks Close Modestly Lower But Well Off Worst Levels - U.S. Commentary Hillshire Brands Company (The) (HSH) is unchanged at $28.77, with 1,428,000 shares traded. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott Laboratories ( ABT ) is unchanged at $65.61, with 3,005,464 shares traded., following a 52-week high recorded in today's regular session. As reported by Zacks, the current mean recommendation for XOM is in the "buy range". | Abbott Laboratories ( ABT ) is unchanged at $65.61, with 3,005,464 shares traded., following a 52-week high recorded in today's regular session. RTT News Reports: Stocks Close Modestly Lower But Well Off Worst Levels - U.S. Commentary Hillshire Brands Company (The) (HSH) is unchanged at $28.77, with 1,428,000 shares traded. Microsoft Corporation ( MSFT ) is unchanged at $30.00, with 433,216 shares traded. | Abbott Laboratories ( ABT ) is unchanged at $65.61, with 3,005,464 shares traded., following a 52-week high recorded in today's regular session. The NASDAQ 100 After Hours Indicator is down -1.4 to 2,608.91. The following are the most active stocks for the after hours session : Procter & Gamble Company (The) ( PG ) is +0.0402 at $61.59, with 4,021,547 shares traded. |
34418.0 | 2012-07-06 00:00:00 UTC | Setback for Chelsea Therapeutics - Analyst Blog | ABT | https://www.nasdaq.com/articles/setback-for-chelsea-therapeutics-analyst-blog-2012-07-06 | nan | nan | Chelsea Therapeutics International, Ltd. ( CHTP ) recently suffered a setback when the US Food and Drug Administration (FDA), in a written statement, informed the company that it has to conduct a new trial with its candidate, Northera (droxidopa), before it can be considered for approval.
The US agency was of the opinion that data from the existing study (306B) was inadequate for approval. The news has negatively impacted the company's stock price.
Chelsea Therapeutics is looking to get Northera approved for treating symptomatic neurogenic orthostatic hypotension (neurogenic OH) in patients suffering from Parkinson's disease, multiple system atrophy, pure autonomic failure, dopamine beta hydroxylase deficiency and non-diabetic autonomic neuropathy. Neurogenic OH refers to a chronic neurogenic disorder that causes lightheadedness, dizziness, blurred vision, fainting etc.
We remind investors that Chelsea Therapeutics received a complete response letter (CRL) from the FDA in March 2012 declining to approve Northera on the basis of the submitted data. Chelsea Therapeutics had submitted the new drug application (NDA) seeking FDA approval of Northera for the above indication in September 2011.
The FDA asked for additional data while issuing the CRL. Following the receipt of the CRL, Chelsea Therapeutics met with the FDA in May 2012.
The latest advice from the FDA asking for an additional trial on Northera would push up the research & development (R&D) costs at Chelsea Therapeutics. Chelsea Therapeutics is currently evaluating various options to resubmit the NDA on Northera. Northera would be the first marketed product at Chelsea Therapeutics, if the FDA ultimately approves it.
Apart from Northera, the pipeline at Chelsea Therapeutics includes candidates such as CH-4051 and CH-1504, which are being developed primarily to treat patients suffering from rheumatoid arthritis (RA). The candidates, on approval, would have to compete with big players such as Abbott Labs ( ABT ), Johnson & Johnson ( JNJ ) and Bristol-Myers Squibb ( BMY ) among others in the RA space.
Our Recommendation
We currently have a Neutral recommendation on Chelsea Therapeutics in the long-run. The company carries a Zacks #3 Rank (Hold rating) in the short-run.
ABBOTT LABS (ABT): Free Stock Analysis Report
BRISTOL-MYERS (BMY): Free Stock Analysis Report
CHELSEA THERAP (CHTP): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The candidates, on approval, would have to compete with big players such as Abbott Labs ( ABT ), Johnson & Johnson ( JNJ ) and Bristol-Myers Squibb ( BMY ) among others in the RA space. ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report CHELSEA THERAP (CHTP): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. Chelsea Therapeutics International, Ltd. ( CHTP ) recently suffered a setback when the US Food and Drug Administration (FDA), in a written statement, informed the company that it has to conduct a new trial with its candidate, Northera (droxidopa), before it can be considered for approval. | The candidates, on approval, would have to compete with big players such as Abbott Labs ( ABT ), Johnson & Johnson ( JNJ ) and Bristol-Myers Squibb ( BMY ) among others in the RA space. ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report CHELSEA THERAP (CHTP): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report CHELSEA THERAP (CHTP): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. The candidates, on approval, would have to compete with big players such as Abbott Labs ( ABT ), Johnson & Johnson ( JNJ ) and Bristol-Myers Squibb ( BMY ) among others in the RA space. Chelsea Therapeutics International, Ltd. ( CHTP ) recently suffered a setback when the US Food and Drug Administration (FDA), in a written statement, informed the company that it has to conduct a new trial with its candidate, Northera (droxidopa), before it can be considered for approval. | The candidates, on approval, would have to compete with big players such as Abbott Labs ( ABT ), Johnson & Johnson ( JNJ ) and Bristol-Myers Squibb ( BMY ) among others in the RA space. ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report CHELSEA THERAP (CHTP): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. Chelsea Therapeutics had submitted the new drug application (NDA) seeking FDA approval of Northera for the above indication in September 2011. |
34419.0 | 2012-07-05 00:00:00 UTC | After Hours Most Active for Jul 5, 2012 : PG, ROSE, ABT, SXCI, BAC, COP, SAN, TWX, VIAB, ORCL, EZPW, QQQ | ABT | https://www.nasdaq.com/articles/after-hours-most-active-jul-5-2012-pg-rose-abt-sxci-bac-cop-san-twx-viab-orcl-ezpw-qqq | nan | nan | The NASDAQ 100 After Hours Indicator is down -1.72 to 2,645.75. The total After hours volume is currently 19,459,828 shares traded.
The following are the most active stocks for the after hours session :
Procter & Gamble Company (The) ( PG ) is +0.1413 at $61.49, with 3,934,084 shares traded. PG's current last sale is 91.1% of the target price of $67.5.
Rosetta Resources Inc. ( ROSE ) is -0.02 at $39.39, with 3,450,593 shares traded. ROSE's current last sale is 67.33% of the target price of $58.5.
Abbott Laboratories ( ABT ) is +0.08 at $64.83, with 3,019,400 shares traded. ABT's current last sale is 99.74% of the target price of $65.
SXC Health Solutions Corp. ( SXCI ) is +0.53 at $96.90, with 1,916,358 shares traded. As reported in the last short interest update the days to cover for SXCI is 7.320351; this calculation is based on the average trading volume of the stock.
Bank of America Corporation ( BAC ) is +0.01 at $7.83, with 1,902,442 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Jun 2012. The consensus EPS forecast is $0.16. BAC's current last sale is 78.3% of the target price of $10.
ConocoPhillips ( COP ) is +1.13 at $56.41, with 1,359,260 shares traded. COP's current last sale is 94.02% of the target price of $60.
Banco Santander, S.A. ( SAN ) is unchanged at $6.31, with 1,253,660 shares traded. SAN's current last sale is 43.61% of the target price of $14.47.
Time Warner Inc. ( TWX ) is +0.0853 at $38.38, with 873,224 shares traded. As reported by Zacks, the current mean recommendation for TWX is in the "buy range".
Viacom Inc. ( VIAB ) is unchanged at $47.75, with 857,041 shares traded. As reported by Zacks, the current mean recommendation for VIAB is in the "buy range".
Oracle Corporation ( ORCL ) is -0.21 at $29.51, with 676,361 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Nov 2012. The consensus EPS forecast is $0.59. As reported by Zacks, the current mean recommendation for ORCL is in the "buy range".
EZCORP, Inc. ( EZPW ) is unchanged at $23.85, with 652,816 shares traded. EZPW's current last sale is 65.34% of the target price of $36.5.
PowerShares QQQ Trust, Series 1 ( QQQ ) is +0.03 at $64.96, with 642,608 shares traded. This represents a 30.1% increase from its 52 Week Low.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is +0.08 at $64.83, with 3,019,400 shares traded. ABT's current last sale is 99.74% of the target price of $65. The following are the most active stocks for the after hours session : Procter & Gamble Company (The) ( PG ) is +0.1413 at $61.49, with 3,934,084 shares traded. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott Laboratories ( ABT ) is +0.08 at $64.83, with 3,019,400 shares traded. ABT's current last sale is 99.74% of the target price of $65. | Abbott Laboratories ( ABT ) is +0.08 at $64.83, with 3,019,400 shares traded. ABT's current last sale is 99.74% of the target price of $65. The total After hours volume is currently 19,459,828 shares traded. | ABT's current last sale is 99.74% of the target price of $65. Abbott Laboratories ( ABT ) is +0.08 at $64.83, with 3,019,400 shares traded. ROSE's current last sale is 67.33% of the target price of $58.5. |
34420.0 | 2012-07-02 00:00:00 UTC | Gilead Seeks FDA OK for Cobicistat - Analyst Blog | ABT | https://www.nasdaq.com/articles/gilead-seeks-fda-ok-for-cobicistat-analyst-blog-2012-07-02 | nan | nan | Recently, Gilead Sciences, Inc. ( GILD ) announced that it has filed a marketing application seeking approval for its HIV candidate, cobicistat, in the US.
Cobicistat acts as a "boosting" agent whose addition causes blood levels of protease inhibitors -- such as Bristol-Myers Squibb 's ( BMY ) HIV drug Reyataz and Johnson & Johnson 's ( JNJ ) Prezista -- to increase, thereby enabling the HIV therapy to be dosed once daily.
The new drug application (NDA) included data from a phase III study (114) which showed that cobicistat was non-inferior to Abbott Laboratories ' ( ABT ) HIV therapy Norvir over 48 weeks. The application also included pharmacokinetic data which revealed that the addition of cobicistat boosted the exposure of HIV therapies Reyataz and Prezista similar to Norvir. We note that Gilead is also seeking approval of cobicistat in the EU.
Gilead has partnerships with Janssen R&D Ireland (a unit of Johnson & Johnson) and Bristol-Myers for developing cobicistat as a fixed-dose combination therapy. While the deal with Johnson & Johnson pertains to the development of cobicistat with Prezista, the deal with Bristol-Myers pertains to the development of cobicistat in combination with Reyataz.
Moreover, cobicistat is one of the components of Gilead's potential blockbuster HIV combination pill Quad. The other components of the pill are elvitegravir and Truvada. Gilead is looking to get the Quad pill (once daily) approved as a first-line therapy for treating adults infected with the HIV virus.
The pill is under review in the US with a final decision expected by August 27, 2012. Positive news from the FDA in August would further boost the top line at Gilead and strengthen its already established HIV portfolio. The Quad pill is also under review in the EU, Australia and Canada.
Our Recommendation
We have a Neutral recommendation on Gilead. Our long-term stance is in line with the Zacks #3 Rank (Hold rating) carried by the company in the short run.
ABBOTT LABS (ABT): Free Stock Analysis Report
BRISTOL-MYERS (BMY): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The new drug application (NDA) included data from a phase III study (114) which showed that cobicistat was non-inferior to Abbott Laboratories ' ( ABT ) HIV therapy Norvir over 48 weeks. ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. Recently, Gilead Sciences, Inc. ( GILD ) announced that it has filed a marketing application seeking approval for its HIV candidate, cobicistat, in the US. | ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. The new drug application (NDA) included data from a phase III study (114) which showed that cobicistat was non-inferior to Abbott Laboratories ' ( ABT ) HIV therapy Norvir over 48 weeks. Cobicistat acts as a "boosting" agent whose addition causes blood levels of protease inhibitors -- such as Bristol-Myers Squibb 's ( BMY ) HIV drug Reyataz and Johnson & Johnson 's ( JNJ ) Prezista -- to increase, thereby enabling the HIV therapy to be dosed once daily. | ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. The new drug application (NDA) included data from a phase III study (114) which showed that cobicistat was non-inferior to Abbott Laboratories ' ( ABT ) HIV therapy Norvir over 48 weeks. Cobicistat acts as a "boosting" agent whose addition causes blood levels of protease inhibitors -- such as Bristol-Myers Squibb 's ( BMY ) HIV drug Reyataz and Johnson & Johnson 's ( JNJ ) Prezista -- to increase, thereby enabling the HIV therapy to be dosed once daily. | The new drug application (NDA) included data from a phase III study (114) which showed that cobicistat was non-inferior to Abbott Laboratories ' ( ABT ) HIV therapy Norvir over 48 weeks. ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. The application also included pharmacokinetic data which revealed that the addition of cobicistat boosted the exposure of HIV therapies Reyataz and Prezista similar to Norvir. |
34421.0 | 2012-06-28 00:00:00 UTC | Recognition for Hologic's Selenia - Analyst Blog | ABT | https://www.nasdaq.com/articles/recognition-for-hologics-selenia-analyst-blog-2012-06-28 | nan | nan | In a major achievement, Hologic ( HOLX ), a prominent player in the field of women's health, has won an award for its Selenia Dimensions (3D/2D) mammography systems in the digital mammography category in the KLAS annual survey. KLAS, a research firm tracking the performance of healthcare vendors, is committed to improving healthcare delivery.
Hologic's Selenia Dimensions (3D) digital tomosynthesis system has been getting positive feedback supported by gradual uptake subsequent to approval from the US Food and Drug Administration (FDA) in February 2011. Selenia has been developed on the Dimensions platform utilizing tomosynthesis technology to produce both 3D and the conventional 2D full field digital mammography ("FFDM") images. The images can be used to screen and diagnose breast cancer. Although increasing the patient's radiation exposure, a combination of both 2-D and 3-D images enhances the accuracy of detection of the disease.
Sales of Dimensions continued to gain traction and represented 67% of digital mammography revenue and 57% of units in the most recent quarter (ahead of 62% of revenues and 50% of units in the first quarter of 2012). Besides, Tomosynthesis upgrades represented approximately 20% of total tomosynthesis unit sales. Given the current status (35% accomplished till date and targeting 60% at the end of the current fiscal), the company is confident of placing the targeted 500-700 3D systems in the US within the first two years of approval. Going forward, we believe that the Dimensions portfolio would be an important growth driver at the Breast Health segment.
With a wide range of products, Hologic has become an industry giant in the field of women's health. The company is also undertaking several steps, including acquisitions, international expansion and product development, to bolster its top line. Moreover, the proposed acquisition of Gen-Probe (GPRO) will propel the company to a prominent position in the molecular diagnostics segment.
We were disappointed with the second quarter revenue number that missed the consensus estimate and was on the lower end of the company's guidance. We are nonetheless reassured by the company's reaffirmation of its fiscal 2012 guidance despite the discontinuation of Adiana.
However, procedure volumes are feeling the brunt of a weak economy and persistent unemployment, which adversely affect sales. Moreover, we remain concerned about the high leverage of the company owing to the Gen-Probe deal. The company also faces stiff competition from players such as Qiagen ( QGEN ) and Abbott Laboratories ( ABT ), among others.
We have a Neutral recommendation on Hologic. The stock retains a Zacks #3 Rank (hold) in the short term.
ABBOTT LABS (ABT): Free Stock Analysis Report
HOLOGIC INC (HOLX): Free Stock Analysis Report
QIAGEN NV (QGEN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company also faces stiff competition from players such as Qiagen ( QGEN ) and Abbott Laboratories ( ABT ), among others. ABBOTT LABS (ABT): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report QIAGEN NV (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Hologic's Selenia Dimensions (3D) digital tomosynthesis system has been getting positive feedback supported by gradual uptake subsequent to approval from the US Food and Drug Administration (FDA) in February 2011. | ABBOTT LABS (ABT): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report QIAGEN NV (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. The company also faces stiff competition from players such as Qiagen ( QGEN ) and Abbott Laboratories ( ABT ), among others. Hologic's Selenia Dimensions (3D) digital tomosynthesis system has been getting positive feedback supported by gradual uptake subsequent to approval from the US Food and Drug Administration (FDA) in February 2011. | ABBOTT LABS (ABT): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report QIAGEN NV (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. The company also faces stiff competition from players such as Qiagen ( QGEN ) and Abbott Laboratories ( ABT ), among others. In a major achievement, Hologic ( HOLX ), a prominent player in the field of women's health, has won an award for its Selenia Dimensions (3D/2D) mammography systems in the digital mammography category in the KLAS annual survey. | ABBOTT LABS (ABT): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report QIAGEN NV (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. The company also faces stiff competition from players such as Qiagen ( QGEN ) and Abbott Laboratories ( ABT ), among others. In a major achievement, Hologic ( HOLX ), a prominent player in the field of women's health, has won an award for its Selenia Dimensions (3D/2D) mammography systems in the digital mammography category in the KLAS annual survey. |
34422.0 | 2012-06-18 00:00:00 UTC | Vermillion Presents Positive Data - Analyst Blog | ABT | https://www.nasdaq.com/articles/vermillion-presents-positive-data-analyst-blog-2012-06-18 | nan | nan | Leading developer of diagnostics tests, Vermillion, Inc. ( VRML ) reported that it had presented the results for the intended use of Peripheral Artery Disease (PAD) multi-marker at the Society for Vascular Medicine's 23 rd Annual Scientific Sessions in Minneapolis, Minnesota. This annual session hosts the country's foremost vascular medicine specialists, along with sessions on PAD guidelines, policy trends and advances in the diagnosis and treatment of vascular diseases.
In the event of PAD, the flow of blood in the arteries is constricted by the narrowing of the peripheral arteries. It is commonly observed in the arteries of the pelvis and legs. As per statistics from National Institute of Health Publication, one in every 20 Americans over the age of 50 suffers from PAD. This implies a sizeable PAD market, which Vermillion can serve with its multi-marker.
The biomarker screen to identify PAD predicts the probability of PAD for the at-risk patients. The detection of undiagnosed or asymptomatic PAD by the marker will enable appropriate vascular testing and timely diagnosis to benefit patient health.
Vermillion also plans to submit a supporting manuscript to a leading medical journal by the end of this month. It expects to present the related results and the subsequent manuscript to support its discussions with the FDA for either 510(k) clearance, or 510(k) de novo clearance or PMA, in the near future.
As per the results, the multi-marker is expected to play a significant role in the assessment of individual risk for PAD. The clinical study involved 1,025 subjects in multiple centers. The subjects included PAD at-risk population aged 70 or older and also diabetics and smokers who are 50 or older.
Different multi-marker algorithms were evaluated in these subjects and compared with the Framingham Risk Score (FRS). A logistic regression model was also tested for its ability to identify PAD in patients below the high-risk FRS cutoff. The multi-marker model provided better clinical results when compared to FRS as it was able to detect PAD in 83 individuals out of the evaluable subjects. With the confirmation of its research from this large set of at-risk subjects, the company is optimistic about advancing the program.
The company operates in various segments such as oncology, hematology, cardiology and women's health. It competes with Abbott Laboratories ( ABT ), GenMark Diagnostics ( GNMK ), among others.
The stock currently retains a Zacks #3 Rank, which translates into a short-term Hold rating.
ABBOTT LABS (ABT): Free Stock Analysis Report
GENMARK DIAGNST (GNMK): Free Stock Analysis Report
(VRML): ETF Research Reports
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It competes with Abbott Laboratories ( ABT ), GenMark Diagnostics ( GNMK ), among others. ABBOTT LABS (ABT): Free Stock Analysis Report GENMARK DIAGNST (GNMK): Free Stock Analysis Report (VRML): ETF Research Reports To read this article on Zacks.com click here. Leading developer of diagnostics tests, Vermillion, Inc. ( VRML ) reported that it had presented the results for the intended use of Peripheral Artery Disease (PAD) multi-marker at the Society for Vascular Medicine's 23 rd Annual Scientific Sessions in Minneapolis, Minnesota. | ABBOTT LABS (ABT): Free Stock Analysis Report GENMARK DIAGNST (GNMK): Free Stock Analysis Report (VRML): ETF Research Reports To read this article on Zacks.com click here. It competes with Abbott Laboratories ( ABT ), GenMark Diagnostics ( GNMK ), among others. Leading developer of diagnostics tests, Vermillion, Inc. ( VRML ) reported that it had presented the results for the intended use of Peripheral Artery Disease (PAD) multi-marker at the Society for Vascular Medicine's 23 rd Annual Scientific Sessions in Minneapolis, Minnesota. | ABBOTT LABS (ABT): Free Stock Analysis Report GENMARK DIAGNST (GNMK): Free Stock Analysis Report (VRML): ETF Research Reports To read this article on Zacks.com click here. It competes with Abbott Laboratories ( ABT ), GenMark Diagnostics ( GNMK ), among others. Leading developer of diagnostics tests, Vermillion, Inc. ( VRML ) reported that it had presented the results for the intended use of Peripheral Artery Disease (PAD) multi-marker at the Society for Vascular Medicine's 23 rd Annual Scientific Sessions in Minneapolis, Minnesota. | It competes with Abbott Laboratories ( ABT ), GenMark Diagnostics ( GNMK ), among others. ABBOTT LABS (ABT): Free Stock Analysis Report GENMARK DIAGNST (GNMK): Free Stock Analysis Report (VRML): ETF Research Reports To read this article on Zacks.com click here. Leading developer of diagnostics tests, Vermillion, Inc. ( VRML ) reported that it had presented the results for the intended use of Peripheral Artery Disease (PAD) multi-marker at the Society for Vascular Medicine's 23 rd Annual Scientific Sessions in Minneapolis, Minnesota. |
34423.0 | 2012-06-17 00:00:00 UTC | 52-Week High Companies: HSY, CL, MNST, MJN, ABT | ABT | https://www.nasdaq.com/articles/52-week-high-companies-hsy-cl-mnst-mjn-abt-2012-06-17 | nan | nan | According to GuruFocus list of 52-week highs , these Guru stocks have reached their 52-Week Highs: The Hershey Company ( HSY ), Colgate-Palmolive Company ( CL ), Monster Beverage Corporation ( MNST ), Mead Johnson Nutrition Company ( MJN ), and Abbott Laboratories ( ABT ).
The Hershey Company ( HSY ) Reached the 52-Week High of $69.42
The Hershey Company is a snack food company and the largest North American manufacturer of quality chocolate and non-chocolate confectionery products. The Hershey Company has a market cap of $15.11 billion; its shares were traded at around $69.42 with a P/E ratio of 22.1 and P/S ratio of 2.5. The dividend yield of The Hershey Company stocks is 2.2%. The Hershey Company had an annual average earnings growth of 5.2% over the past 10 years. GuruFocus rated The Hershey Company the business predictability rank of 3-star .
On April 24, The Hershey Company announced sales and earnings for the first quarter ended April 1, 2012. Consolidated net sales were $1,732,064,000 compared with $1,564,223,000 for the first quarter of 2011. Reported net income for the first quarter of 2012 was $198,651,000 or $0.87 per share-diluted, compared with $160,115,000 or $0.70 per share-diluted for the comparable period of 2011.
This month, President and CEO John P Bilbrey sold 2,205 shares of HSY stock. EVP CFO & Chief Admin Officer Humberto P Alfonso , VP CAO David W Tacka, and SVP, Global Operations Terence L O'day sold shares in May. SVP, General Counsel & Sec Burton H Snyder sold 21,908 shares in April. Director James M Mead bought 500 shares in February.
Colgate-Palmolive Company ( CL ) Reached the 52-Week High of $101.55
Colgate-Palmolive Company is a global consumer products company, tightly focused on Oral Care, Personal Care, Household Surface Care, Fabric Care and Pet Nutrition. Colgate-Palmolive Company has a market cap of $47.81 billion; its shares were traded at around $101.55 with a P/E ratio of 19.6 and P/S ratio of 2.9. The dividend yield of Colgate-Palmolive Company stocks is 2.5%. Colgate-Palmolive Company had an annual average earnings growth of 8.4% over the past 10 years. GuruFocus rated Colgate-Palmolive Company the business predictability rank of 4.5-star.
On April 26, Colgate-Palmolive Company reported worldwide Net sales of $4,200 million in first quarter 2012, an increase of 5.0% versus first quarter 2011. Global unit volume grew 3.5%, pricing increased 3.5% and foreign exchange was negative 2.0%. Excluding divested businesses, global unit volume grew 4.5%. Net income and Diluted earnings per share in first quarter 2012 were $593 million and $1.23, respectively.
This month, Chief Legal Officer &Secretary Andrew D Hendry sold 4,000 shares of CL stock. Sr.V.P. Global Human Resources Daniel B Marsili, COO Emerging Mkts.& So. Pacif. Franck J Moison, and Pres. Colgate Latin America Justin Skala sold shares in May. Chairman, President & CEO Ian M Cook, Pres&CEO Hill's Pet Nutrition Neil Thompson, and CFO Dennis J Hickey sold shares in February.
Monster Beverage Corporation ( MNST ) Reached the 52-Week High of $78.58
Monster Beverage Corporation is a marketer and distributor of energy drinks and alternative beverages. Monster Beverage Corporation has a market cap of $13.41 billion; its shares were traded at around $78.58 with a P/E ratio of 46.1 and P/S ratio of 7.9. Monster Beverage Corporation had an annual average earnings growth of 60.8% over the past 10 years.
On May 9, Monster Beverage Corporation reported record sales and profits for the first quarter ended March 31, 2012. Gross sales for the 2012 first quarter increased 26.9 percent to $517.3 million from $407.6 million in the same period last year. Net sales for the three-months ended March 31, 2012 increased 27.5 percent to $454.6 million from $356.4 million a year ago. For the 2012 first quarter, gross profit as a percentage of net sales was 53.1 percent, compared with 52.1 percent for the comparable 2011 quarter. Operating expenses for the 2012 first quarter increased to $114.9 million from $97.1 million in the same quarter last year.
This month, Chairman and CEO Rodney C Sacks, Senior VP - Monster Energy Co. Thomas J Kelly, and Vice Chairman and President Hilton H Schlosberg sold shares of MNST stock. Director Sydney Selati sold 10,000 shares in May. Vice Chairman and President Hilton H Schlosberg sold 300,000 shares in March.
Mead Johnson Nutrition Company ( MJN ) Reached the 52-Week High of $85.3
Mead Johnson Nutrition Company is a pediatric nutrition company. Mead Johnson Nutrition Company has a market cap of $16.61 billion; its shares were traded at around $85.3 with a P/E ratio of 28.7 and P/S ratio of 4.5. The dividend yield of Mead Johnson Nutrition Company stocks is 1.5%.
On April 26, Mead Johnson Nutrition Company announced its financial results for the first quarter ended March 31, 2012. Net sales of $986.6 million in the quarter increased 9 percent versus the first quarter of 2011. GAAP net earnings of $0.80 per diluted share for the first quarter of 2012 were up by 13 percent from $0.71 per diluted share a year ago. Non-GAAP net earnings of $0.82 per diluted share increased 8 percent from $0.76 per diluted share for 2011.
In May, Director Clesteen A Clark and Director James M Cornelius bought shares of MJN stock. Sr. VP, Global Research & Dev Dirk Hondmann and Sr.VP, Global Supply Chain James J Jobe sold shares in June.
Abbott Laboratories ( ABT ) Reached the 52-Week High of $62.55
Abbott Laboratories is a global, broad-based health care company devoted to discovering new medicines, new technologies and new ways to manage health. Abbott Laboratories has a market cap of $97.37 billion; its shares were traded at around $62.55 with a P/E ratio of 13 and P/S ratio of 2.5. The dividend yield of Abbott Laboratories stocks is 3.3%. Abbott Laboratories had an annual average earnings growth of 7.9% over the past 10 years. GuruFocus rated Abbott Labs the business predictability rank of 5-star.
On April 18, Abbott Laboratories reported results for the first quarter of 2012. Diluted earnings per share, excluding specified items, were $1.03, reflecting 13.2 percent growth and exceeding Abbott's previous guidance range. Diluted earnings per share under GAAP were $0.78, including specified items, reflecting 41.8 percent growth.
This month, Senior Vice President Stephen R Fussell sold 6,000 shares of ABT stock. Senior Vice President James V Mazzo sold 49,235 shares in May. Senior Vice President J. Scott White sold 11,368 shares in April. Senior Vice President Michael J Warmuth and Vice President Greg W Linder sold shares in March.About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | According to GuruFocus list of 52-week highs , these Guru stocks have reached their 52-Week Highs: The Hershey Company ( HSY ), Colgate-Palmolive Company ( CL ), Monster Beverage Corporation ( MNST ), Mead Johnson Nutrition Company ( MJN ), and Abbott Laboratories ( ABT ). Abbott Laboratories ( ABT ) Reached the 52-Week High of $62.55 Abbott Laboratories is a global, broad-based health care company devoted to discovering new medicines, new technologies and new ways to manage health. This month, Senior Vice President Stephen R Fussell sold 6,000 shares of ABT stock. | According to GuruFocus list of 52-week highs , these Guru stocks have reached their 52-Week Highs: The Hershey Company ( HSY ), Colgate-Palmolive Company ( CL ), Monster Beverage Corporation ( MNST ), Mead Johnson Nutrition Company ( MJN ), and Abbott Laboratories ( ABT ). Abbott Laboratories ( ABT ) Reached the 52-Week High of $62.55 Abbott Laboratories is a global, broad-based health care company devoted to discovering new medicines, new technologies and new ways to manage health. This month, Senior Vice President Stephen R Fussell sold 6,000 shares of ABT stock. | According to GuruFocus list of 52-week highs , these Guru stocks have reached their 52-Week Highs: The Hershey Company ( HSY ), Colgate-Palmolive Company ( CL ), Monster Beverage Corporation ( MNST ), Mead Johnson Nutrition Company ( MJN ), and Abbott Laboratories ( ABT ). Abbott Laboratories ( ABT ) Reached the 52-Week High of $62.55 Abbott Laboratories is a global, broad-based health care company devoted to discovering new medicines, new technologies and new ways to manage health. This month, Senior Vice President Stephen R Fussell sold 6,000 shares of ABT stock. | According to GuruFocus list of 52-week highs , these Guru stocks have reached their 52-Week Highs: The Hershey Company ( HSY ), Colgate-Palmolive Company ( CL ), Monster Beverage Corporation ( MNST ), Mead Johnson Nutrition Company ( MJN ), and Abbott Laboratories ( ABT ). Abbott Laboratories ( ABT ) Reached the 52-Week High of $62.55 Abbott Laboratories is a global, broad-based health care company devoted to discovering new medicines, new technologies and new ways to manage health. This month, Senior Vice President Stephen R Fussell sold 6,000 shares of ABT stock. |
34424.0 | 2012-06-14 00:00:00 UTC | Echo Therapeutics to Join Russell Microcap Index - Analyst Blog | ABT | https://www.nasdaq.com/articles/echo-therapeutics-to-join-russell-microcap-index-analyst-blog-2012-06-14 | nan | nan | On June 13, Echo Therapeutics ( ECTE ), a transdermal medical device company, announced that it anticipates being included in the Russell Microcap Index.
It expects the inclusion on June 25, 2012, when Russell Investments rebalances its set of U.S. indexes. This assumption is based on a preliminary list of additions posted by Russell on June 8, 2012.
Management is enthusiastic about this opportunity as it . The inclusion in the Russell Microcap Index is expected to enhance awareness of the company to a larger number of institutions and investors by increasing the visibility and volume trading of the stock. It will mark a keystone as the Russell Microcap Index is an important weighted index that examines trends in relatively smaller companies. This should also enhance Echo's shareholder base. The annual recalculation of the Index can be relied upon to avoid any distortion in presenting the performance of Echo Therapeutics.
The Russell Microcap Index is well regarded and proactively used by investment managers as well as institutional investors. It serves as a benchmark for all investment strategies with assets worth $3.9 trillion in the institutional marketplace. The index covers almost 98% of the global investable market across 83 countries for more than 10,000 securities.
Membership in the Russell Microcap Index for its equity indexes depends on the market capitalization, objectives and style attributes of the company. This membership lasts for one year and implies inclusion in the appropriate growth and value style indexes.
The annual reconstitution of the Russell Indexes covers the largest 4000 stocks in the U.S. as of the end of May. The stocks are ranked according to the total market capitalization to create the Russell 3000 index and Russell Microcap Index.
Echo Therapeutics specializes in the production of medical devices with advanced skin permeation technology. Its competitors such as Abbott Laboratories ( ABT ) and DexCom Inc. ( DXCM ) are already a part of the family of Russell Indexes, being listed on the Russell 1000 Index and Russell 2000 Index respectively.
The stock currently retains a Zacks #4 Rank, which translates into a short-term Sell rating.
ABBOTT LABS (ABT): Free Stock Analysis Report
DEXCOM INC (DXCM): Free Stock Analysis Report
ECHO THERAPEUT (ECTE): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Its competitors such as Abbott Laboratories ( ABT ) and DexCom Inc. ( DXCM ) are already a part of the family of Russell Indexes, being listed on the Russell 1000 Index and Russell 2000 Index respectively. ABBOTT LABS (ABT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report To read this article on Zacks.com click here. On June 13, Echo Therapeutics ( ECTE ), a transdermal medical device company, announced that it anticipates being included in the Russell Microcap Index. | ABBOTT LABS (ABT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report To read this article on Zacks.com click here. Its competitors such as Abbott Laboratories ( ABT ) and DexCom Inc. ( DXCM ) are already a part of the family of Russell Indexes, being listed on the Russell 1000 Index and Russell 2000 Index respectively. On June 13, Echo Therapeutics ( ECTE ), a transdermal medical device company, announced that it anticipates being included in the Russell Microcap Index. | Its competitors such as Abbott Laboratories ( ABT ) and DexCom Inc. ( DXCM ) are already a part of the family of Russell Indexes, being listed on the Russell 1000 Index and Russell 2000 Index respectively. ABBOTT LABS (ABT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report To read this article on Zacks.com click here. Membership in the Russell Microcap Index for its equity indexes depends on the market capitalization, objectives and style attributes of the company. | Its competitors such as Abbott Laboratories ( ABT ) and DexCom Inc. ( DXCM ) are already a part of the family of Russell Indexes, being listed on the Russell 1000 Index and Russell 2000 Index respectively. ABBOTT LABS (ABT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report To read this article on Zacks.com click here. The Russell Microcap Index is well regarded and proactively used by investment managers as well as institutional investors. |
34425.0 | 2012-06-08 00:00:00 UTC | New Lease Agreements for Alexandria - Analyst Blog | ABT | https://www.nasdaq.com/articles/new-lease-agreements-for-alexandria-analyst-blog-2012-06-08 | nan | nan | Alexandria Real Estate Equities, Inc. ( ARE ), a real estate investment trust (REIT), recently entered into long-term agreements with six prestigious life science and technologies companies, to lease a total of 187,000 square feet of space at 'Alexandria Park at 128' located in the midst of Route 128 submarket of Greater Boston.
Alexandria Park at 128 is an eight-building science and Technology Park, spanning approximately 345,000 square feet. Strategically located near Hartwell Avenue, the property is well connected to various residential areas, restaurants, shops, and convenient amenities.
The property is already occupied by leading life science and advanced technology companies including TIAX LLC, RainDance Technologies, Inc., Diversified Technologies, Inc., Celgene Corp. ( CELG ) and Synta Pharmaceuticals Corp. ( SNTA ).
After the agreement, the property will now have six more renowned firms as its tenants. These include Cystic Fibrosis Foundation, QD Vision, Inc., Emerald BioStructures, 1366 Technologies, Inc., Microbia, Inc. and Life Technologies Corp. ( LIFE ).
The Greater Boston market is among the Alexandria Real Estate's core operational markets cluster. It owns and operates approximately 3.5 million square feet of office and high-quality laboratory space in close proximity to the renowned academic and medical institutions of world.
The company has around 100 client tenants in the area including the likes of GlaxoSmithKline plc ( GSK ), Abbott Laboratories ( ABT ), Biogen Idec Inc. ( BIIB ), Novartis AG ( NVS ), Quest Diagnostics Inc. ( DGX ), Thermo Fisher Scientific Inc. ( TMO ) and others.
Alexandria Real Estate's submarkets in the Great Boston area include Cambridge, Longwood Medical Area and Route 128. The Route 128 submarket has around 580,000 square feet of laboratory and office space in a viable suburban location having easy accessibility to the renowned medical and academic centers of Boston and Cambridge. The company currently has an occupancy rate of 95.2% in this submarket.
Pasadena, California-based, Alexandria Real Estate is the largest owner and leading life science real estate company, focused principally on science-driven cluster development through the ownership, operation, management, and selective acquisition, development, and redevelopment of properties containing life science laboratory space. The company leases the properties mainly to universities, pharmaceutical, medical device, life science product, biotechnology, service, biodefense, and translational research entities.
Alexandria Real Estate currently has Zacks #3 Rank, which translates into a short-term Hold rating. We are also maintaining our long-term Neutral recommendation on the stock.
ABBOTT LABS (ABT): Free Stock Analysis Report
ALEXANDRIA REAL (ARE): Free Stock Analysis Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis Report
CELGENE CORP (CELG): Free Stock Analysis Report
QUEST DIAGNOSTC (DGX): Free Stock Analysis Report
GLAXOSMITHKLINE (GSK): Free Stock Analysis Report
LIFE TECHNOLOGS (LIFE): Free Stock Analysis Report
NOVARTIS AG-ADR (NVS): Free Stock Analysis Report
SYNTA PHARMACT (SNTA): Free Stock Analysis Report
THERMO FISHER (TMO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company has around 100 client tenants in the area including the likes of GlaxoSmithKline plc ( GSK ), Abbott Laboratories ( ABT ), Biogen Idec Inc. ( BIIB ), Novartis AG ( NVS ), Quest Diagnostics Inc. ( DGX ), Thermo Fisher Scientific Inc. ( TMO ) and others. ABBOTT LABS (ABT): Free Stock Analysis Report ALEXANDRIA REAL (ARE): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report QUEST DIAGNOSTC (DGX): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report LIFE TECHNOLOGS (LIFE): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report SYNTA PHARMACT (SNTA): Free Stock Analysis Report THERMO FISHER (TMO): Free Stock Analysis Report To read this article on Zacks.com click here. It owns and operates approximately 3.5 million square feet of office and high-quality laboratory space in close proximity to the renowned academic and medical institutions of world. | The company has around 100 client tenants in the area including the likes of GlaxoSmithKline plc ( GSK ), Abbott Laboratories ( ABT ), Biogen Idec Inc. ( BIIB ), Novartis AG ( NVS ), Quest Diagnostics Inc. ( DGX ), Thermo Fisher Scientific Inc. ( TMO ) and others. ABBOTT LABS (ABT): Free Stock Analysis Report ALEXANDRIA REAL (ARE): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report QUEST DIAGNOSTC (DGX): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report LIFE TECHNOLOGS (LIFE): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report SYNTA PHARMACT (SNTA): Free Stock Analysis Report THERMO FISHER (TMO): Free Stock Analysis Report To read this article on Zacks.com click here. The property is already occupied by leading life science and advanced technology companies including TIAX LLC, RainDance Technologies, Inc., Diversified Technologies, Inc., Celgene Corp. ( CELG ) and Synta Pharmaceuticals Corp. ( SNTA ). | ABBOTT LABS (ABT): Free Stock Analysis Report ALEXANDRIA REAL (ARE): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report QUEST DIAGNOSTC (DGX): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report LIFE TECHNOLOGS (LIFE): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report SYNTA PHARMACT (SNTA): Free Stock Analysis Report THERMO FISHER (TMO): Free Stock Analysis Report To read this article on Zacks.com click here. The company has around 100 client tenants in the area including the likes of GlaxoSmithKline plc ( GSK ), Abbott Laboratories ( ABT ), Biogen Idec Inc. ( BIIB ), Novartis AG ( NVS ), Quest Diagnostics Inc. ( DGX ), Thermo Fisher Scientific Inc. ( TMO ) and others. Alexandria Real Estate Equities, Inc. ( ARE ), a real estate investment trust (REIT), recently entered into long-term agreements with six prestigious life science and technologies companies, to lease a total of 187,000 square feet of space at 'Alexandria Park at 128' located in the midst of Route 128 submarket of Greater Boston. | The company has around 100 client tenants in the area including the likes of GlaxoSmithKline plc ( GSK ), Abbott Laboratories ( ABT ), Biogen Idec Inc. ( BIIB ), Novartis AG ( NVS ), Quest Diagnostics Inc. ( DGX ), Thermo Fisher Scientific Inc. ( TMO ) and others. ABBOTT LABS (ABT): Free Stock Analysis Report ALEXANDRIA REAL (ARE): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report QUEST DIAGNOSTC (DGX): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report LIFE TECHNOLOGS (LIFE): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report SYNTA PHARMACT (SNTA): Free Stock Analysis Report THERMO FISHER (TMO): Free Stock Analysis Report To read this article on Zacks.com click here. Alexandria Real Estate Equities, Inc. ( ARE ), a real estate investment trust (REIT), recently entered into long-term agreements with six prestigious life science and technologies companies, to lease a total of 187,000 square feet of space at 'Alexandria Park at 128' located in the midst of Route 128 submarket of Greater Boston. |
34426.0 | 2012-06-07 00:00:00 UTC | Abbott Presents Data on Humira - Analyst Blog | ABT | https://www.nasdaq.com/articles/abbott-presents-data-on-humira-analyst-blog-2012-06-07 | nan | nan | Abbott Labs ( ABT ) recently presented phase III data on its blockbuster drug, Humira, from two studies. While ABILITY-2 is being conducted in patients with active peripheral spondyloarthritis (PSpA) who have not been diagnosed with psoriatic arthritis (PsA) or ankylosing spondylitis (AS), ABILITY-1 is being conducted in patients with axial spondyloarthritis (axSpA) who have no X-ray evidence of structural damage.
Abbott Labs said that 39.3% of patients in the Humira arm achieved the primary endpoint compared to 19.8% of patients on placebo. The primary endpoint was an improvement of at least 40% in the peripheral SpA response criteria (PSpARC 40).
Meanwhile, results from the ABILITY-1 study showed that 36.3% of patients in the Humira arm achieved ASAS 40 compared to 14.9% of patients in the placebo arm at 12 weeks.
Abbott Labs presented these results at the European League Against Rheumatism (EULAR) 2012 Congress.
Humira is a key product in Abbott Labs' pharmaceutical products portfolio. Humira is approved for several indications including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, juvenile idiopathic arthritis, and Crohn's disease. Humira sales increased 21.1% to $7.9 billion in 2011. Growing awareness, favorable clinical data, additional indications and expansion into new markets like China and Japan should help the product to continue contributing significantly to the top-line.
Moreover, approval for additional indications would boost peak sales forecasts for the drug significantly. Earlier this year, Humira gained approval for an additional indication in the EU. The European Commission cleared Humira for treating adults suffering from moderately to severely active ulcerative colitis (UC). The product gained approval for use in patients who did not respond satisfactorily to standard drugs for UC treatment.
Other players in the anti-inflammatory market include Pfizer / Amgen's ( PFE / AMGN ) Enbrel, Johnson & Johnson / Merck's ( JNJ / MRK ) Remicade and Simponi.
We currently have a Neutral recommendation on Abbott Labs, which carries a Zacks #3 Rank (short-term 'Hold' rating).
ABBOTT LABS (ABT): Free Stock Analysis Report
AMGEN INC (AMGN): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
MERCK & CO INC (MRK): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ( ABT ) recently presented phase III data on its blockbuster drug, Humira, from two studies. ABBOTT LABS (ABT): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Growing awareness, favorable clinical data, additional indications and expansion into new markets like China and Japan should help the product to continue contributing significantly to the top-line. | ABBOTT LABS (ABT): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ( ABT ) recently presented phase III data on its blockbuster drug, Humira, from two studies. Abbott Labs said that 39.3% of patients in the Humira arm achieved the primary endpoint compared to 19.8% of patients on placebo. | ABBOTT LABS (ABT): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ( ABT ) recently presented phase III data on its blockbuster drug, Humira, from two studies. Abbott Labs said that 39.3% of patients in the Humira arm achieved the primary endpoint compared to 19.8% of patients on placebo. | Abbott Labs ( ABT ) recently presented phase III data on its blockbuster drug, Humira, from two studies. ABBOTT LABS (ABT): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs said that 39.3% of patients in the Humira arm achieved the primary endpoint compared to 19.8% of patients on placebo. |
34427.0 | 2012-06-06 00:00:00 UTC | BMY Presents Positive Data - Analyst Blog | ABT | https://www.nasdaq.com/articles/bmy-presents-positive-data-analyst-blog-2012-06-06 | nan | nan | Bristol-Myers Squibb Company ( BMY ) recently presented encouraging data from a late-stage study (AMPLE: n=646), which evaluated the efficacy of the subcutaneous formulation of its rheumatoid arthritis (RA) drug Orencia versus Abbott Laboratories ' ( ABT ) anti-inflammatory drug Humira. The data was presented at the European League Against Rheumatism (EULAR) annual European congress of rheumatology.
The randomized, investigator-blinded multinational head-to-head study compared the efficacy of both the drugs in combination with methotrexate as a first-line therapy in patients suffering from moderate-to-severe RA. Data revealed that treatment with Orencia was as effective as that by Humira. Effectiveness was measured by the criteria laid down by the American College of Rheumatology - ACR20 response at 1 year. While 64.8% patients in the Orencia arm met the criteria, 63.4% did so in the Humira arm.
We note that the US Food and Drug Administration (FDA) cleared the subcutaneous formulation of Orencia last year. Only the intravenous version was available prior to that. Even though pleased with the positive data on Orencia, we believe that investor focus will remain on how Bristol-Myers fares following the US loss of exclusivity of its blockbuster blood thinner Plavix on May 17, 2012.
Bristol-Myers has co-developed Plavix with Sanofi ( SNY ). The loss of exclusivity is likely to result in substantial revenue losses for Bristol-Myers. Companies such as Mylan Inc. ( MYL ) and Dr. Reddy's Laboratories ( RDY ) have already launched their respective generic versions of the drug.
Bristol-Myers is looking to combat the generic threat through partnering deals and acquisitions. Apart from acquisitions and partnership deals, Bristol-Myers is looking to introduce new products to augment its product portfolio to combat the generic threat. Bristol-Myers has met with a fair amount of success towards achieving this objective. Many new products were launched/ approved in 2011.
A key action date is coming up at Bristol-Myers later this month when the FDA is scheduled to decide on blood thinner Eliquis, co-developed with Pfizer Inc. ( PFE ), for preventing stroke in patients suffering from atrial fibrillation. Positive news from the FDA will help boost the stock.
Our Recommendation
We currently have a Neutral recommendation on Bristol-Myers. The stock carries a Zacks #3 Rank (Hold rating) in the short run.
ABBOTT LABS (ABT): Free Stock Analysis Report
BRISTOL-MYERS (BMY): Free Stock Analysis Report
MYLAN INC (MYL): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
DOCTOR REDDYS (RDY): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Bristol-Myers Squibb Company ( BMY ) recently presented encouraging data from a late-stage study (AMPLE: n=646), which evaluated the efficacy of the subcutaneous formulation of its rheumatoid arthritis (RA) drug Orencia versus Abbott Laboratories ' ( ABT ) anti-inflammatory drug Humira. ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report DOCTOR REDDYS (RDY): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. The randomized, investigator-blinded multinational head-to-head study compared the efficacy of both the drugs in combination with methotrexate as a first-line therapy in patients suffering from moderate-to-severe RA. | Bristol-Myers Squibb Company ( BMY ) recently presented encouraging data from a late-stage study (AMPLE: n=646), which evaluated the efficacy of the subcutaneous formulation of its rheumatoid arthritis (RA) drug Orencia versus Abbott Laboratories ' ( ABT ) anti-inflammatory drug Humira. ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report DOCTOR REDDYS (RDY): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Companies such as Mylan Inc. ( MYL ) and Dr. Reddy's Laboratories ( RDY ) have already launched their respective generic versions of the drug. | Bristol-Myers Squibb Company ( BMY ) recently presented encouraging data from a late-stage study (AMPLE: n=646), which evaluated the efficacy of the subcutaneous formulation of its rheumatoid arthritis (RA) drug Orencia versus Abbott Laboratories ' ( ABT ) anti-inflammatory drug Humira. ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report DOCTOR REDDYS (RDY): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Even though pleased with the positive data on Orencia, we believe that investor focus will remain on how Bristol-Myers fares following the US loss of exclusivity of its blockbuster blood thinner Plavix on May 17, 2012. | Bristol-Myers Squibb Company ( BMY ) recently presented encouraging data from a late-stage study (AMPLE: n=646), which evaluated the efficacy of the subcutaneous formulation of its rheumatoid arthritis (RA) drug Orencia versus Abbott Laboratories ' ( ABT ) anti-inflammatory drug Humira. ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report DOCTOR REDDYS (RDY): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Data revealed that treatment with Orencia was as effective as that by Humira. |
34428.0 | 2012-06-06 00:00:00 UTC | Elagolix Enters Phase 3 - Analyst Blog | ABT | https://www.nasdaq.com/articles/elagolix-enters-phase-3-analyst-blog-2012-06-06 | nan | nan | Elagolix Enters Phase 3
By Jason Napodano, CFA
On June 5, 2012, Abbott Labs (NYSE:ABT) and Neurocrine Biosciences (NASDAQ:NBIX)announced that they had initiated a pivotal phase 3 clinical study designed to evaluate the safety and efficacy of elagolix in female patients with endometriosis. Abbott designed the protocol of the trial after over a year of back-and-forth discussion with the U.S. FDA, but chose not to pursue a formal SPA to avoid further delay in the start of the program.
The phase 3 trial, dubbed M12-665, is a randomized, double-blind, placebo-controlled study seeking to enroll 875 women, age 18 to 49, with moderate-to-severe endometriosis-associated pain. It will be conducted at approximately 160 sites in the U.S., Puerto Rico and Canada. The primary endpoint will be a dual-endpoint in reduction in Dysmenorrhea and Non-Menstrual Pelvic Pain (NMPP) for women on two doses of elagolix (150mg and a yet unannounced higher dose) vs. placebo in a 1:1:2 randomization over 3 months.
Efficacy will be assessed by a responder analysis for statistical evaluation. The inclusion of a yet unannounced higher dose of elagolix, perhaps 250mg or 300mg (150mg BID) is intriguing. Responder analysis from the phase 2b trial showed an 85% response rate with 150mg elagolix. We believe Abbott is looking for greater than 90% response rate in the phase 3 program through the inclusion of a higher dose.
Secondary endpoints include Dyspareunia and Patient Global Impression of Change (PGIC), as well as analgesic use. Following the 3 month controlled portion of the trial, patients will be eligible to enroll in a 6 month open-label extension study where Abbott will look for signs of persistent efficacy. For the safety analysis, patients will be followed for an additional 12 months, after which Abbott will conduct a DXA scan to assess changes in bone mineral density.
We expect that this program will take 12 months to enroll. Top-line data from the phase 3 trial should be available in the first half of 2014, with the full analysis in 2015. Abbott plans to conduct a second confirmatory phase 3 program mirroring the M12-665 trial expected to start in 2013. We expect that this program will include sites outside North America, with an emphasis on Western Europe. Full analysis from the second trial is expected in 2016, along with the New Drug Application (NDA) planned for 2016.
...Confident In Design...
We are confident in the design of the phase 3 trials, and the efficacy and safety previously seen with elagolix. In total, Neurocrine has presented data from 12 phase 1 programs and 6 phase 2 programs (2 phase 2a and 4 phase 2b) on roughly 1,000 patients. Results from the phase 2b (n=137) Daisy PETAL (Study-901) program first released in May 2010 provide the best proof-of-concept data for the planned phase 3 trials. Final results, released in November 2010, were statistically significant in all primary and secondary endpoints.
The planned phase 3 program will seek to enroll patients with more severe disease and employ a two-cycle (two-month) run-in period both designed to mitigate the placebo response. We note the 33% placebo response on both primary endpoints in the Daisy PETAL program was rather high, but elagolix at 63% for both was statistically significant at a p-value less than 0.01. All Abbott needs to do is replicated these results in the two phase 3 trials noted above and then show no clinically meaningful changes in bone mineral density and we think approval is likely.
Adjusting Target
While the above is all good news for Neurocrine shareholders, it comes about six months behind what we previously modeled. We remind investors that the end of phase 2 meeting took place in March 2011. The company's "Update on Elagolix" press release from May 2011 guided to the start of the phase 3 trial in the fourth quarter 2011. However, finalizing the SPA with the U.S. FDA took longer than expected. Ultimately, Abbott believes they have implemented all of the suggestions from the SPA discussions, but did not want any further delay in the start of the trial.
We also expected that both phase 3 trials would start concurrently. Instead, Abbott plans to stagger the second phase 3 trial so it starts one-year later, in 2013. This is so that the second trial can include sites outside North America.
As a result, the planned NDA filing, now expected in 2016, is 18+ months farther out then our model. Therefore, we have adjusted our DCF model to now account for the launch of elagolix at Abbott in 2017. The result is a decrease in our price target from $12 per share to $10 per share.
Our $10 per share target is now the lowest of the five published targets we see listed on Thomson/First Call (previous range was $11.50 to $14.00). However, this should not be misconstrued by investors. We remain quite optimistic on Neurocrine and elagolix, believing the drug - with a full label to include both endometriosis and uterine fibroids - has blockbuster potential. We've written previously as to why we see elagolix as one of the more interesting late-stage biotech products. We clarify our position on Neurocrine as "optimistic, yet realistic" with respect to the stock price.
For additional information, please visit: http://scr.zacks.com
ABBOTT LABS (ABT): Free Stock Analysis Report
NEUROCRINE BIOS (NBIX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Elagolix Enters Phase 3 By Jason Napodano, CFA On June 5, 2012, Abbott Labs (NYSE:ABT) and Neurocrine Biosciences (NASDAQ:NBIX)announced that they had initiated a pivotal phase 3 clinical study designed to evaluate the safety and efficacy of elagolix in female patients with endometriosis. For additional information, please visit: http://scr.zacks.com ABBOTT LABS (ABT): Free Stock Analysis Report NEUROCRINE BIOS (NBIX): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott designed the protocol of the trial after over a year of back-and-forth discussion with the U.S. FDA, but chose not to pursue a formal SPA to avoid further delay in the start of the program. | Elagolix Enters Phase 3 By Jason Napodano, CFA On June 5, 2012, Abbott Labs (NYSE:ABT) and Neurocrine Biosciences (NASDAQ:NBIX)announced that they had initiated a pivotal phase 3 clinical study designed to evaluate the safety and efficacy of elagolix in female patients with endometriosis. For additional information, please visit: http://scr.zacks.com ABBOTT LABS (ABT): Free Stock Analysis Report NEUROCRINE BIOS (NBIX): Free Stock Analysis Report To read this article on Zacks.com click here. Responder analysis from the phase 2b trial showed an 85% response rate with 150mg elagolix. | Elagolix Enters Phase 3 By Jason Napodano, CFA On June 5, 2012, Abbott Labs (NYSE:ABT) and Neurocrine Biosciences (NASDAQ:NBIX)announced that they had initiated a pivotal phase 3 clinical study designed to evaluate the safety and efficacy of elagolix in female patients with endometriosis. For additional information, please visit: http://scr.zacks.com ABBOTT LABS (ABT): Free Stock Analysis Report NEUROCRINE BIOS (NBIX): Free Stock Analysis Report To read this article on Zacks.com click here. In total, Neurocrine has presented data from 12 phase 1 programs and 6 phase 2 programs (2 phase 2a and 4 phase 2b) on roughly 1,000 patients. | Elagolix Enters Phase 3 By Jason Napodano, CFA On June 5, 2012, Abbott Labs (NYSE:ABT) and Neurocrine Biosciences (NASDAQ:NBIX)announced that they had initiated a pivotal phase 3 clinical study designed to evaluate the safety and efficacy of elagolix in female patients with endometriosis. For additional information, please visit: http://scr.zacks.com ABBOTT LABS (ABT): Free Stock Analysis Report NEUROCRINE BIOS (NBIX): Free Stock Analysis Report To read this article on Zacks.com click here. We expect that this program will take 12 months to enroll. |
34429.0 | 2012-06-05 00:00:00 UTC | LabCorp to Acquire Medtox Scientific - Analyst Blog | ABT | https://www.nasdaq.com/articles/labcorp-to-acquire-medtox-scientific-analyst-blog-2012-06-05 | nan | nan | In order to strengthen its foothold in the toxicology testing business, Laboratory Corporation of America Holdings ( LH ) has decided to acquire Medtox Scientific ( MTOX ) for $27 per share or a total enterprise value of $241 million. The offer price represents a 37% premium over the share price of Medtox as on June 1.
The board of directors of Medtox, a provider of high quality specialized laboratory testing services and on-site/point-of-collection testing devices, have unanimously approved the agreement. The transaction is expected to close in the third quarter of 2012.
Equipped with a strong cash balance along with its credit facility in place, LabCorp has been looking at suitable acquisitions to expand its portfolio. The company exited the first quarter of fiscal 2012 with cash and short-term investment of $129.9 million ($159.3 million at the end of 2011) and $460 million of borrowings outstanding under the $1 billion revolving credit facility. Cash flow trends of the company remain robust with free cash flow for the trailing twelve months coming in at $686.9 million. For fiscal 2012, the operating cash flow guidance remains at $950 million.
We are encouraged by the company's steady focus on pipeline expansion. In order to achieve this objective, it is also targeting suitable acquisitions in certain cases. The company is garnering approximately 41% of total revenues from the specialized testing business (including genomic, esoteric and anatomic pathology categories), which is expected to gradually scale up to 45% over the next 3−5 years.
The decision to acquire Medtox is not new for LabCorp as the company has been following this strategy over the recent past. In March 2012, the company signed an exclusive agreement with OPKO Health for intellectual property associated with a potential Alzheimer's disease diagnostic product. The company, to its advantage has other significant collaborations or agreements with leading companies and academic institutions such as Abbott ( ABT ) for lung cancer (Xalkori), Duke University (joint venture in biomarker development and lung cancer), John Hopkins (melanoma), and Roche ( RHHBY ) for melanoma (Zelboraf). Given the continuous focus on portfolio expansion, we are confident about the company garnering higher revenues from specialized testing, going forward.
We believe LabCorp's focus on acquisitions or agreements to expand specialized testing portfolio is necessary as its peer Quest Diagnostics ( DGX ) is also working towards the same goal. We currently have a Neutral recommendation on LabCorp over the long term. The stock retains a short-term Zacks #3 Rank (Hold).
ABBOTT LABS (ABT): Free Stock Analysis Report
QUEST DIAGNOSTC (DGX): Free Stock Analysis Report
LABORATORY CP (LH): Free Stock Analysis Report
MEDTOX SCIENTIF (MTOX): Free Stock Analysis Report
(RHHBY): ETF Research Reports
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company, to its advantage has other significant collaborations or agreements with leading companies and academic institutions such as Abbott ( ABT ) for lung cancer (Xalkori), Duke University (joint venture in biomarker development and lung cancer), John Hopkins (melanoma), and Roche ( RHHBY ) for melanoma (Zelboraf). ABBOTT LABS (ABT): Free Stock Analysis Report QUEST DIAGNOSTC (DGX): Free Stock Analysis Report LABORATORY CP (LH): Free Stock Analysis Report MEDTOX SCIENTIF (MTOX): Free Stock Analysis Report (RHHBY): ETF Research Reports To read this article on Zacks.com click here. In order to strengthen its foothold in the toxicology testing business, Laboratory Corporation of America Holdings ( LH ) has decided to acquire Medtox Scientific ( MTOX ) for $27 per share or a total enterprise value of $241 million. | ABBOTT LABS (ABT): Free Stock Analysis Report QUEST DIAGNOSTC (DGX): Free Stock Analysis Report LABORATORY CP (LH): Free Stock Analysis Report MEDTOX SCIENTIF (MTOX): Free Stock Analysis Report (RHHBY): ETF Research Reports To read this article on Zacks.com click here. The company, to its advantage has other significant collaborations or agreements with leading companies and academic institutions such as Abbott ( ABT ) for lung cancer (Xalkori), Duke University (joint venture in biomarker development and lung cancer), John Hopkins (melanoma), and Roche ( RHHBY ) for melanoma (Zelboraf). In order to strengthen its foothold in the toxicology testing business, Laboratory Corporation of America Holdings ( LH ) has decided to acquire Medtox Scientific ( MTOX ) for $27 per share or a total enterprise value of $241 million. | The company, to its advantage has other significant collaborations or agreements with leading companies and academic institutions such as Abbott ( ABT ) for lung cancer (Xalkori), Duke University (joint venture in biomarker development and lung cancer), John Hopkins (melanoma), and Roche ( RHHBY ) for melanoma (Zelboraf). ABBOTT LABS (ABT): Free Stock Analysis Report QUEST DIAGNOSTC (DGX): Free Stock Analysis Report LABORATORY CP (LH): Free Stock Analysis Report MEDTOX SCIENTIF (MTOX): Free Stock Analysis Report (RHHBY): ETF Research Reports To read this article on Zacks.com click here. The company exited the first quarter of fiscal 2012 with cash and short-term investment of $129.9 million ($159.3 million at the end of 2011) and $460 million of borrowings outstanding under the $1 billion revolving credit facility. | The company, to its advantage has other significant collaborations or agreements with leading companies and academic institutions such as Abbott ( ABT ) for lung cancer (Xalkori), Duke University (joint venture in biomarker development and lung cancer), John Hopkins (melanoma), and Roche ( RHHBY ) for melanoma (Zelboraf). ABBOTT LABS (ABT): Free Stock Analysis Report QUEST DIAGNOSTC (DGX): Free Stock Analysis Report LABORATORY CP (LH): Free Stock Analysis Report MEDTOX SCIENTIF (MTOX): Free Stock Analysis Report (RHHBY): ETF Research Reports To read this article on Zacks.com click here. In order to strengthen its foothold in the toxicology testing business, Laboratory Corporation of America Holdings ( LH ) has decided to acquire Medtox Scientific ( MTOX ) for $27 per share or a total enterprise value of $241 million. |
34430.0 | 2012-05-29 00:00:00 UTC | Auxilium Pharma Sues Watson - Analyst Blog | ABT | https://www.nasdaq.com/articles/auxilium-pharma-sues-watson-analyst-blog-2012-05-29 | nan | nan | Auxilium Pharmaceuticals, Inc. ( AUXL ) and FCB I LLC recently filed a patent infringement lawsuit against Watson Pharmaceuticals ( WPI ) and its subsidiary, Watson Laboratories, Inc. which is looking to launch a generic version of Auxilium Pharma's 1% testosterone gel, Testim.
Testim is the lead product at Auxilium Pharma. Testim sales came in at $207.9 million in 2011, accounting for 78.6% of the company's revenues. Testim's prescription share of the gel market was 20% in December 2011. However, the product faces stiff competition from Abbott Labs' ( ABT ) AndroGel. Testim is facing additional competition in the form of Endo Pharmaceutical's ( ENDP ) Fortesta and Eli Lilly's ( LLY ) Axiron.
The testosterone gel market will become even more competitive from 2015 when generic versions of AndroGel are scheduled to enter the market. The availability of a cheaper generic testosterone gel product could impact Testim's market share as well as its formulary status.
Our Take
The filing of the patent infringement lawsuit within 45 days from the date of receipt of notice from Watson is in line with our expectations. This will ensure that the FDA cannot grant final approval to Watson's generic for up to 30 months or the court's decision, whichever is earlier.
We note that Auxilium Pharma is leaving no stone unturned to drive Testim sales. The company recently signed a co-promotion agreement with GlaxoSmithKline ( GSK ) for Testim in the U.S. Following the announcement of the Glaxo co-promotion agreement, Auxilium Pharma increased its revenue guidance based on higher Testim revenues and trimmed its net loss guidance.
We currently have a Neutral recommendation on Auxilium Pharma, which carries a Zacks #3 Rank (short-term 'Hold' rating).
ABBOTT LABS (ABT): Free Stock Analysis Report
AUXILIUM PHARMA (AUXL): Free Stock Analysis Report
ENDO PHARMACEUT (ENDP): Free Stock Analysis Report
GLAXOSMITHKLINE (GSK): Free Stock Analysis Report
LILLY ELI & CO (LLY): Free Stock Analysis Report
WATSON PHARMA (WPI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | However, the product faces stiff competition from Abbott Labs' ( ABT ) AndroGel. ABBOTT LABS (ABT): Free Stock Analysis Report AUXILIUM PHARMA (AUXL): Free Stock Analysis Report ENDO PHARMACEUT (ENDP): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report To read this article on Zacks.com click here. Testim is facing additional competition in the form of Endo Pharmaceutical's ( ENDP ) Fortesta and Eli Lilly's ( LLY ) Axiron. | However, the product faces stiff competition from Abbott Labs' ( ABT ) AndroGel. ABBOTT LABS (ABT): Free Stock Analysis Report AUXILIUM PHARMA (AUXL): Free Stock Analysis Report ENDO PHARMACEUT (ENDP): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report To read this article on Zacks.com click here. Auxilium Pharmaceuticals, Inc. ( AUXL ) and FCB I LLC recently filed a patent infringement lawsuit against Watson Pharmaceuticals ( WPI ) and its subsidiary, Watson Laboratories, Inc. which is looking to launch a generic version of Auxilium Pharma's 1% testosterone gel, Testim. | ABBOTT LABS (ABT): Free Stock Analysis Report AUXILIUM PHARMA (AUXL): Free Stock Analysis Report ENDO PHARMACEUT (ENDP): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report To read this article on Zacks.com click here. However, the product faces stiff competition from Abbott Labs' ( ABT ) AndroGel. Auxilium Pharmaceuticals, Inc. ( AUXL ) and FCB I LLC recently filed a patent infringement lawsuit against Watson Pharmaceuticals ( WPI ) and its subsidiary, Watson Laboratories, Inc. which is looking to launch a generic version of Auxilium Pharma's 1% testosterone gel, Testim. | However, the product faces stiff competition from Abbott Labs' ( ABT ) AndroGel. ABBOTT LABS (ABT): Free Stock Analysis Report AUXILIUM PHARMA (AUXL): Free Stock Analysis Report ENDO PHARMACEUT (ENDP): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report To read this article on Zacks.com click here. Auxilium Pharmaceuticals, Inc. ( AUXL ) and FCB I LLC recently filed a patent infringement lawsuit against Watson Pharmaceuticals ( WPI ) and its subsidiary, Watson Laboratories, Inc. which is looking to launch a generic version of Auxilium Pharma's 1% testosterone gel, Testim. |
34431.0 | 2012-05-25 00:00:00 UTC | Gen-Probe Remains Neutral - Analyst Blog | ABT | https://www.nasdaq.com/articles/gen-probe-remains-neutral-analyst-blog-2012-05-25 | nan | nan | We reiterate our Neutral rating on Gen-Probe Inc. ( GPRO ) . Its first-quarter 2012 adjusted earnings of 55 cents per share beat the Zacks Consensus Estimate of 51 cents. Revenues of $153.4 million were ahead of the Zacks Consensus Estimate of $151 million.
Product sales increased 9% as healthy sales across Blood Screening and Clinical Diagnostics franchises were partially offset by lower revenues from the Research Products and Services and Collaborative Research businesses.
Revenues from Clinical Diagnostics segment grew 7% (up 8% in constant currency) year over year, led by strong sales of APTIMA Combo 2, APTIMA HPV and APTIMA Trichomonas assays. Blood Screening sales rose 12% (up 13% in constant currency) in the quarter, driven by higher shipping of TIGRIS devices to the company's partner Novartis ( NVS ).
Gen-Probe, in May 2012, received the U.S. Food and Drug Administration's (FDA) approval to launch its fully-automated molecular testing platform, PANTHER. The system has been given the initial approval to be used with its market-leading chlamydia and gonorrhea test APTIMA COMBO 2. The PANTHER system is expected to significantly contribute to the company's revenue growth in the coming years as it broadens the testing menu for the instrument.
Gen-Probe recently announced that women's healthcare major, Hologic Inc. ( HOLX ) will buy it for $3.7 billion (or $82.75 a share). The transaction is expected to be completed by second half of 2012, subject to certain clearances and approval of Gen-Probe's shareholders. Gen-Probe believes that the merger will leverage the women's Diagnostic product range of both the companies and thereby, increase the focus on the molecular diagnostics market. Further, the acquisition will benefit the shareholders as it will offer additional cash value to their shares.
However, the merger agreement with Hologic can also have a negative impact on Gen-Probe's operations, in case customers plan to postpone their orders and purchases or employees decide to resign in the face of acquisition-related uncertainties. In addition, management's focus on merger-related issues might divert their attention away from potential business plans resulting in failure of quarterly operating outcomes, which could lead to fall in share prices.
Also, if the merger is not completed due to some unforeseen circumstances, the company might run the risk of legal proceedings along with payment of a termination fee of $128 million to Hologic or reimburse Hologic for its transaction-related expenses of $20 million.
Gen-Probe's clinical diagnostics products are susceptible to considerable reimbursement risks. Third-party payers are increasingly seeking to curb health care costs by limiting both coverage and the level of reimbursement for medical products and services. Any unfavorable change in the reimbursement policies (or levels) by third-party payers may materially affect the demand and price levels of Gen-Probe's products and its revenues. In the most recent quarter, collaborative research sales plunged 61% on account of less reimbursement received from Novartis owing to the development of the PANTHER instrument.
Gen-Probe is a dominant player in the rapidly expanding nucleic acid testing ("NAT") market, the fastest growing segment in the clinical diagnostic market. It is a market leader in domestic gonorrhea and chlamydia testing with its PACE and APTIMA assay product lines. Gen-Probe competes with more established firms in the molecular diagnostic industry such as Roche ( RHHBY ), Becton, Dickinson ( BDX ) and Abbott Labs ( ABT ).
Our recommendation on Gen-Probe is in tandem with a short-term Zacks #3 Rank (Hold).
ABBOTT LABS (ABT): Free Stock Analysis Report
BECTON DICKINSO (BDX): Free Stock Analysis Report
GEN-PROBE INC (GPRO): Free Stock Analysis Report
HOLOGIC INC (HOLX): Free Stock Analysis Report
NOVARTIS AG-ADR (NVS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Gen-Probe competes with more established firms in the molecular diagnostic industry such as Roche ( RHHBY ), Becton, Dickinson ( BDX ) and Abbott Labs ( ABT ). ABBOTT LABS (ABT): Free Stock Analysis Report BECTON DICKINSO (BDX): Free Stock Analysis Report GEN-PROBE INC (GPRO): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. Blood Screening sales rose 12% (up 13% in constant currency) in the quarter, driven by higher shipping of TIGRIS devices to the company's partner Novartis ( NVS ). | ABBOTT LABS (ABT): Free Stock Analysis Report BECTON DICKINSO (BDX): Free Stock Analysis Report GEN-PROBE INC (GPRO): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. Gen-Probe competes with more established firms in the molecular diagnostic industry such as Roche ( RHHBY ), Becton, Dickinson ( BDX ) and Abbott Labs ( ABT ). Product sales increased 9% as healthy sales across Blood Screening and Clinical Diagnostics franchises were partially offset by lower revenues from the Research Products and Services and Collaborative Research businesses. | ABBOTT LABS (ABT): Free Stock Analysis Report BECTON DICKINSO (BDX): Free Stock Analysis Report GEN-PROBE INC (GPRO): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. Gen-Probe competes with more established firms in the molecular diagnostic industry such as Roche ( RHHBY ), Becton, Dickinson ( BDX ) and Abbott Labs ( ABT ). Product sales increased 9% as healthy sales across Blood Screening and Clinical Diagnostics franchises were partially offset by lower revenues from the Research Products and Services and Collaborative Research businesses. | Gen-Probe competes with more established firms in the molecular diagnostic industry such as Roche ( RHHBY ), Becton, Dickinson ( BDX ) and Abbott Labs ( ABT ). ABBOTT LABS (ABT): Free Stock Analysis Report BECTON DICKINSO (BDX): Free Stock Analysis Report GEN-PROBE INC (GPRO): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. Product sales increased 9% as healthy sales across Blood Screening and Clinical Diagnostics franchises were partially offset by lower revenues from the Research Products and Services and Collaborative Research businesses. |
34432.0 | 2012-05-24 00:00:00 UTC | Gilead Drug Up for European Review - Analyst Blog | ABT | https://www.nasdaq.com/articles/gilead-drug-up-for-european-review-analyst-blog-2012-05-24 | nan | nan | Recently, Gilead Sciences, Inc. ( GILD ) announced that its marketing application seeking approval for its candidate cobicistat in the EU has been validated by the European Medicines Agency (EMA).
Cobicistat acts as a "boosting" agent whose addition causes blood levels of protease inhibitors -- such as Bristol-Myers ' ( BMY ) HIV drug Reyataz and Johnson & Johnson 's ( JNJ ) Prezista -- to increase, thereby enabling the HIV therapy to be dosed once daily. We note that cobicistat only acts as a boosting agent without any antiviral activity.
The marketing authorization application (MAA) was filed by Gilead on April 26, 2012, the day the company disclosed its first quarter 2012 earnings results. The MAA was filed on the basis of pharmacokinetic data from a study which revealed that the addition of cobicistat boosted the exposure of HIV therapies Reyataz and Prezista similar to Abbott Laboratories ' ( ABT ) HIV therapy Norvir.
Currently, Norvir is the only boosting agent available for treating HIV. The MAA also contained data from a phase III study which showed that cobicistat was non-inferior to Norvir over 48 weeks. Gilead intends to seek approval from the U.S. Food and Drug Administration (FDA) for cobicistat in the third quarter of 2012. Positive news from the FDA and EMA regarding cobicistat would boost the HIV portfolio at Gilead further.
We note that Gilead has partnerships with Janssen R&D Ireland (a unit of Johnson & Johnson) and Bristol-Myers for developing cobicistat as a fixed-dose combination therapy. While the deal with Johnson & Johnson pertains to the development of cobicistat with Prezista, the deal with Bristol-Myers pertains to the development of cobicistat in combination with Reyataz.
Neutral on Gilead
We have a Neutral recommendation on Gilead. Our long-term stance is in line with the Zacks #3 Rank (Hold rating) carried by the company in the short run.
We remain optimistic on the growth prospects of Gilead's HIV drugs Truvada and Atripla. We are also encouraged by the approval of Complera/Eviplera, which together with Quad, once approved, will further fortify the HIV franchise and help mitigate the impact of the upcoming patent expirations.
Gilead is looking to combat the threat of genericization by inking deals and making acquisitions and introducing new products.
ABBOTT LABS (ABT): Free Stock Analysis Report
BRISTOL-MYERS (BMY): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The MAA was filed on the basis of pharmacokinetic data from a study which revealed that the addition of cobicistat boosted the exposure of HIV therapies Reyataz and Prezista similar to Abbott Laboratories ' ( ABT ) HIV therapy Norvir. ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. Recently, Gilead Sciences, Inc. ( GILD ) announced that its marketing application seeking approval for its candidate cobicistat in the EU has been validated by the European Medicines Agency (EMA). | ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. The MAA was filed on the basis of pharmacokinetic data from a study which revealed that the addition of cobicistat boosted the exposure of HIV therapies Reyataz and Prezista similar to Abbott Laboratories ' ( ABT ) HIV therapy Norvir. Cobicistat acts as a "boosting" agent whose addition causes blood levels of protease inhibitors -- such as Bristol-Myers ' ( BMY ) HIV drug Reyataz and Johnson & Johnson 's ( JNJ ) Prezista -- to increase, thereby enabling the HIV therapy to be dosed once daily. | The MAA was filed on the basis of pharmacokinetic data from a study which revealed that the addition of cobicistat boosted the exposure of HIV therapies Reyataz and Prezista similar to Abbott Laboratories ' ( ABT ) HIV therapy Norvir. ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. Cobicistat acts as a "boosting" agent whose addition causes blood levels of protease inhibitors -- such as Bristol-Myers ' ( BMY ) HIV drug Reyataz and Johnson & Johnson 's ( JNJ ) Prezista -- to increase, thereby enabling the HIV therapy to be dosed once daily. | The MAA was filed on the basis of pharmacokinetic data from a study which revealed that the addition of cobicistat boosted the exposure of HIV therapies Reyataz and Prezista similar to Abbott Laboratories ' ( ABT ) HIV therapy Norvir. ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. Recently, Gilead Sciences, Inc. ( GILD ) announced that its marketing application seeking approval for its candidate cobicistat in the EU has been validated by the European Medicines Agency (EMA). |
34433.0 | 2012-05-23 00:00:00 UTC | Zacks' Voice of the People highlights opportunities with Johnson & Johnson, Disney, Abbott Labs and Church & Dwight - Press Releases | ABT | https://www.nasdaq.com/articles/zacks-voice-of-the-people-highlights-opportunities-with-johnson-johnson-disney-abbott-labs | nan | nan | For Immediate Release
Chicago, IL - 05/23/2012 - Zacks highlights commentary from People and Picks Trader " RobMarketsBlind " .
For more Voice of the People, visit http://at.zacks.com/?id=5851
Featured Post
RobMarketsBlind's Latest Purchase
RTMB's public record on this site's blog is a perfect 100%, all trades have been winners, no losers. RTMB has been posting these trades here for over a year now!
RTMB strategy is utilizing a capital preservation approach with consistence and steady income growth. It's does this primarily by buying dividend paying stocks that has shown a proven record/history in strength, longevity, and ability to bounce back after an extended down market. The strategy also employs ultra conservation write options plays; that is, writing Put and Call options... and also hedges at times buying SPY puts.
Today we purchased Johnson & Johnson ( JNJ ), adding it to our real account portfolio, at 63.40 a share.
JNJ's current dividend yield is 3.84%. It's ex-dividend date is two days from today (May 24). It pays the dividend on June 12. It's share price is currently at the lower end of its support range.
JNJ has raised its dividend for 50th straight years. It has raised it during years of recessions, market bubbles, and wars. JNJ has excellent free cash flow and a relatively low payout ratio. It is the biggest company in its field. It was one of the very few companies to loss less than 10% during the 2008 recession. It's total returns last three years is 28%.
The most recent picks by «RobMarketsBlind» are:
A buy rating on Disney ( DIS ),
a buy rating on Abbott Labs ( ABT ) and
a buy rating on Church & Dwight ( CHD ).
About the Zacks Community
In 2008, Zacks Investment Research launched PeopleAndPicks.com, a stock-picking website where members of the Zacks community can test their strategies and share ideas with other members. Each user is scored on the accuracy of his or her picks, and top users are rewarded with free products from Zacks. Registration is free. To learn more about People And Picks, visit http://at.zacks.com/?id=5957
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Len Zacks. As a PhD from MIT Len knew he could find patterns instock market datathat would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3:1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit From the Pros by going to http://at.zacks.com/?id=5958 .
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Contact: Brent Billock
People & Picks Manager
Company: Zacks.com
Phone: 312-265-9307
Email: pandp@zacks.com
Visit: www.Zacks.com
ABBOTT LABS (ABT): Free Stock Analysis Report
CHURCH & DWIGHT (CHD): Free Stock Analysis Report
DISNEY WALT (DIS): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The most recent picks by «RobMarketsBlind» are: A buy rating on Disney ( DIS ), a buy rating on Abbott Labs ( ABT ) and a buy rating on Church & Dwight ( CHD ). Contact: Brent Billock People & Picks Manager Company: Zacks.com Phone: 312-265-9307 Email: pandp@zacks.com Visit: www.Zacks.com ABBOTT LABS (ABT): Free Stock Analysis Report CHURCH & DWIGHT (CHD): Free Stock Analysis Report DISNEY WALT (DIS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. For more Voice of the People, visit http://at.zacks.com/?id=5851 Featured Post RobMarketsBlind's Latest Purchase RTMB's public record on this site's blog is a perfect 100%, all trades have been winners, no losers. | The most recent picks by «RobMarketsBlind» are: A buy rating on Disney ( DIS ), a buy rating on Abbott Labs ( ABT ) and a buy rating on Church & Dwight ( CHD ). Contact: Brent Billock People & Picks Manager Company: Zacks.com Phone: 312-265-9307 Email: pandp@zacks.com Visit: www.Zacks.com ABBOTT LABS (ABT): Free Stock Analysis Report CHURCH & DWIGHT (CHD): Free Stock Analysis Report DISNEY WALT (DIS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. For more Voice of the People, visit http://at.zacks.com/?id=5851 Featured Post RobMarketsBlind's Latest Purchase RTMB's public record on this site's blog is a perfect 100%, all trades have been winners, no losers. | Contact: Brent Billock People & Picks Manager Company: Zacks.com Phone: 312-265-9307 Email: pandp@zacks.com Visit: www.Zacks.com ABBOTT LABS (ABT): Free Stock Analysis Report CHURCH & DWIGHT (CHD): Free Stock Analysis Report DISNEY WALT (DIS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. The most recent picks by «RobMarketsBlind» are: A buy rating on Disney ( DIS ), a buy rating on Abbott Labs ( ABT ) and a buy rating on Church & Dwight ( CHD ). About the Zacks Community In 2008, Zacks Investment Research launched PeopleAndPicks.com, a stock-picking website where members of the Zacks community can test their strategies and share ideas with other members. | The most recent picks by «RobMarketsBlind» are: A buy rating on Disney ( DIS ), a buy rating on Abbott Labs ( ABT ) and a buy rating on Church & Dwight ( CHD ). Contact: Brent Billock People & Picks Manager Company: Zacks.com Phone: 312-265-9307 Email: pandp@zacks.com Visit: www.Zacks.com ABBOTT LABS (ABT): Free Stock Analysis Report CHURCH & DWIGHT (CHD): Free Stock Analysis Report DISNEY WALT (DIS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. RTMB has been posting these trades here for over a year now! |
34434.0 | 2012-05-22 00:00:00 UTC | Auxilium-Glaxo to Drive Testim Sales - Analyst Blog | ABT | https://www.nasdaq.com/articles/auxilium-glaxo-to-drive-testim-sales-analyst-blog-2012-05-22 | nan | nan | Specialty biopharmaceutical company, Auxilium Pharmaceuticals, Inc. ( AUXL ) recently entered into a co-promotion agreement with GlaxoSmithKline plc's ( GSK ) U.S. subsidiary, GlaxoSmithKline LLC. The companies signed an agreement for the co-promotion of Auxilium Pharma's Testim (1% testosterone), which is approved for the treatment of hypogonadism or low testosterone level.
Deal Terms
The deal provides Glaxo with exclusive rights to co-promote Testim in the U.S. with Auxilium Pharma through September 30, 2015. Glaxo will use its established sales force to promote Testim to testosterone replacement therapy (TRT) prescribers, especially primary care physicians. Glaxo already has a presence in this market where its sales reps promote cardiovascular, metabolic and urology products.
The companies have settled on a baseline revenue forecast for the co-promotion period - once Testim sales exceed this forecast, Glaxo will be compensated by the amount that Testim net sales exceed the baseline. Moreover, Glaxo is entitled to specified tail payments in certain circumstances.
Glaxo's sales force will start promoting Testim early in the third quarter of 2012. Auxilium Pharma believes that the additional sales effort will increase the target audience to the top 25% of high-volume gel writers. Historically, the current Testim sales force has targeted the top 13% of the 159,000 US gel TRT prescribers.
Meanwhile, reach to primary care physicians, urologists and endocrinologists will increase with the additional detailing.
2012 Revenue Guidance Raised
Following the announcement of the Glaxo co-promotion agreement, Auxilium Pharma increased its revenue guidance for 2012 to $293 - $315 million (old guidance: $283 to $305 million). The company also trimmed its net loss guidance and now expects a loss in the range of $5 - $10 million (old guidance: $5 - $15 million). Testim revenues are now expected in the range of $225 million to $235 million (old guidance: $215 to $225 million). Testim sales were $207.9 million in 2011. Auxilium Pharma said that it expects SG&A spend towards the higher level of its previously issued guidance range of $180 - $190 million.
Our Take
We are pleased with Auxilium Pharma's efforts to drive Testim sales. With urology being a key focus area at Glaxo, Testim sales should benefit from the additional promotional effort. Moreover, it has been seen that TRTs are sensitive to promotional efforts. Given the increasingly competitive environment, the additional sales effort should come in handy. The testosterone therapy market, while lucrative, has several players like Abbott Labs' ( ABT ) AndroGel franchise (1% and 1.62%), Endo Pharmaceutical's ( ENDP ) Fortesta, and Eli Lilly / Acrux's ( LLY ) Axiron .
According to IMS Health data, annual testosterone therapy sales in the U.S. exceeded $1.6 billion, with testosterone gels posting sales of $1.4 billion. We believe the company will be able to achieve its raised revenue guidance range.
We currently have a Neutral recommendation on Auxilium Pharma, which carries a Zacks #3 Rank (short-term 'Hold' rating). We expect near-term investor focus to remain on top-line results on Xiaflex from phase III studies (IMPRESS) for Peyronie's disease. Results should be out in June 2012. Positive results would allow the company to file for approval by year end.
ABBOTT LABS (ABT): Free Stock Analysis Report
AUXILIUM PHARMA (AUXL): Free Stock Analysis Report
ENDO PHARMACEUT (ENDP): Free Stock Analysis Report
GLAXOSMITHKLINE (GSK): Free Stock Analysis Report
LILLY ELI & CO (LLY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The testosterone therapy market, while lucrative, has several players like Abbott Labs' ( ABT ) AndroGel franchise (1% and 1.62%), Endo Pharmaceutical's ( ENDP ) Fortesta, and Eli Lilly / Acrux's ( LLY ) Axiron . ABBOTT LABS (ABT): Free Stock Analysis Report AUXILIUM PHARMA (AUXL): Free Stock Analysis Report ENDO PHARMACEUT (ENDP): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. Glaxo will use its established sales force to promote Testim to testosterone replacement therapy (TRT) prescribers, especially primary care physicians. | ABBOTT LABS (ABT): Free Stock Analysis Report AUXILIUM PHARMA (AUXL): Free Stock Analysis Report ENDO PHARMACEUT (ENDP): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. The testosterone therapy market, while lucrative, has several players like Abbott Labs' ( ABT ) AndroGel franchise (1% and 1.62%), Endo Pharmaceutical's ( ENDP ) Fortesta, and Eli Lilly / Acrux's ( LLY ) Axiron . Glaxo will use its established sales force to promote Testim to testosterone replacement therapy (TRT) prescribers, especially primary care physicians. | ABBOTT LABS (ABT): Free Stock Analysis Report AUXILIUM PHARMA (AUXL): Free Stock Analysis Report ENDO PHARMACEUT (ENDP): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. The testosterone therapy market, while lucrative, has several players like Abbott Labs' ( ABT ) AndroGel franchise (1% and 1.62%), Endo Pharmaceutical's ( ENDP ) Fortesta, and Eli Lilly / Acrux's ( LLY ) Axiron . The companies have settled on a baseline revenue forecast for the co-promotion period - once Testim sales exceed this forecast, Glaxo will be compensated by the amount that Testim net sales exceed the baseline. | The testosterone therapy market, while lucrative, has several players like Abbott Labs' ( ABT ) AndroGel franchise (1% and 1.62%), Endo Pharmaceutical's ( ENDP ) Fortesta, and Eli Lilly / Acrux's ( LLY ) Axiron . ABBOTT LABS (ABT): Free Stock Analysis Report AUXILIUM PHARMA (AUXL): Free Stock Analysis Report ENDO PHARMACEUT (ENDP): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. The companies signed an agreement for the co-promotion of Auxilium Pharma's Testim (1% testosterone), which is approved for the treatment of hypogonadism or low testosterone level. |
34435.0 | 2012-05-22 00:00:00 UTC | RobMarketsBlind's Latest Purchase - Voice of the People | ABT | https://www.nasdaq.com/articles/robmarketsblinds-latest-purchase-voice-people-2012-05-22 | nan | nan | Zacks highlights commentary from People and Picks Member «RobMarketsBlind».
For more Voice of the People, visit http://at.zacks.com/?id=7872
Featured Post
JNJ: RTMB's latest purchase
RTMB's public record on this site's blog is a perfect 100%, all trades have been winners, no losers. RTMB has been posting these trades here for over a year now!
RTMB strategy is utilitizing a capital perservation approach with consistence and steady income growth. It's does this primarily by buying dividend paying stocks that has shown a proven record/history in strength, longevity, and ability to bounce back after an extended down market. The strategy also employs ultra conservation write options plays; that is, writing Put and Call options... and also hedges at times buying SPY puts.
Today we purchased Johnson & Johnson ( JNJ ), adding it to our real account portfolio, at 63.40 a share.
JNJ's current dividend yield is 3.84%. It's ex-dividend date is two days from today (May 24). It pays the dividend on June 12. It's share price is currently at the lower end of it's support range.
JNJ has raised it's dividend for 50th straight years. It has raised it during years of recessions, market bubbles, and wars. JNJ has excellent free cash flow and a relatively low payout ratio. It is the biggest company in it's field. It was one of the very few companies to loss less than 10% during the 2008 recession. It's total returns last three years is 28%.
The most recent picks by «RobMarketsBlind» are:
A buy rating on Disney ( DIS ),
a buy rating on Abbott Labs ( ABT ) and
a buy rating on Church & Dwight ( CHD ).
About the Zacks Community
In 2008, Zacks Investment Research launched PeopleAndPicks.com, a stock-picking website where members of the Zacks community can test their strategies and share ideas with other members. Each user is scored on the accuracy of his or her picks, and top users are rewarded with free products from Zacks. Registration is free. To learn more about People And Picks, visit http://at.zacks.com/?id=7870
Follow us on Twitter: http://www.twitter.com/PeopleAndPicks
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns instock market datathat would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3:1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit From the Pros by going to http://at.zacks.com/?id=7867 .
ABBOTT LABS (ABT): Free Stock Analysis Report
CHURCH & DWIGHT (CHD): Free Stock Analysis Report
DISNEY WALT (DIS): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The most recent picks by «RobMarketsBlind» are: A buy rating on Disney ( DIS ), a buy rating on Abbott Labs ( ABT ) and a buy rating on Church & Dwight ( CHD ). ABBOTT LABS (ABT): Free Stock Analysis Report CHURCH & DWIGHT (CHD): Free Stock Analysis Report DISNEY WALT (DIS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. It's does this primarily by buying dividend paying stocks that has shown a proven record/history in strength, longevity, and ability to bounce back after an extended down market. | The most recent picks by «RobMarketsBlind» are: A buy rating on Disney ( DIS ), a buy rating on Abbott Labs ( ABT ) and a buy rating on Church & Dwight ( CHD ). ABBOTT LABS (ABT): Free Stock Analysis Report CHURCH & DWIGHT (CHD): Free Stock Analysis Report DISNEY WALT (DIS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. For more Voice of the People, visit http://at.zacks.com/?id=7872 Featured Post JNJ: RTMB's latest purchase RTMB's public record on this site's blog is a perfect 100%, all trades have been winners, no losers. | ABBOTT LABS (ABT): Free Stock Analysis Report CHURCH & DWIGHT (CHD): Free Stock Analysis Report DISNEY WALT (DIS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. The most recent picks by «RobMarketsBlind» are: A buy rating on Disney ( DIS ), a buy rating on Abbott Labs ( ABT ) and a buy rating on Church & Dwight ( CHD ). About the Zacks Community In 2008, Zacks Investment Research launched PeopleAndPicks.com, a stock-picking website where members of the Zacks community can test their strategies and share ideas with other members. | The most recent picks by «RobMarketsBlind» are: A buy rating on Disney ( DIS ), a buy rating on Abbott Labs ( ABT ) and a buy rating on Church & Dwight ( CHD ). ABBOTT LABS (ABT): Free Stock Analysis Report CHURCH & DWIGHT (CHD): Free Stock Analysis Report DISNEY WALT (DIS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. RTMB has been posting these trades here for over a year now! |
34436.0 | 2012-05-15 00:00:00 UTC | The Zacks Analyst Blog Highlights: Gilead Sciences, Abbott Labs, Alliance Data Systems Corporation, Blue Nile and Bristol-Myers Squibb - Press Releases | ABT | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-sciences-abbott-labs-alliance-data-systems | nan | nan | For Immediate Release
Chicago, IL - May 15, 2012 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Gilead Sciences ( GILD ), Abbott Labs ( ABT ), Alliance Data Systems Corporation ( ADS ), Blue Nile ( NILE ) and Bristol-MyersSquibb ( BMY ).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Monday's Analyst Blog:
Good News for Gilead
Gilead Sciences ( GILD ) received some encouraging news recently when an advisory panel of the U.S. Food and Drug Administration (FDA) recommended the approval of the company's HIV combination pill Quad. A final decision from the FDA regarding the matter is expected by August 27, 2012 (target date).
We note that the Quad pill is a combination of elvitegravir, cobicistat and Truvada. Gilead is looking to get the pill (once daily) approved as a first-line therapy for treating adults infected with the HIV virus.
The FDA's advisory panel met to review the new drug application (NDA) submitted by Gilead in October 2011 for getting Quad approved in the U.S. The NDA included positive data from two late-stage studies - 102 which compared Quad to Atripla and 103 which compared Quad to Norvir (ritonavir)-boosted Reyataz plus Truvada. While Norvir is marketed by Abbott Labs ( ABT ), Reyataz is marketed by Bristol-MyersSquibb ( BMY ).
While reviewing the application, the panel voted overwhelmingly (13-1) in favor of clearing the combination pill (a single tablet regimen) in the U.S. Even though the U.S. agency is not bound to follow the advice of its advisory committee, the recommendation of the panel is usually considered by the agency while deciding the fate of a candidate.
Positive news from the FDA in August would further boost the top line at Gilead and strengthen its already established HIV portfolio. The Quad pill is also under review in the E.U, Australia and Canada. Approval in additional territories would increase the drug's sales potential.
Neutral on Gilead
We have a Neutral recommendation on Gilead. Our long-term stance is in line with the Zacks #3 Rank (Hold rating) carried by the company in the short run. We remain optimistic on the growth prospects of Gilead's HIV drugs, Truvada and Atripla. We are also encouraged by the approval of Complera/Eviplera, which together with Quad, once approved, will further fortify the HIV franchise and help mitigate the impact of the upcoming patent expirations.
Gilead is looking to combat the threat of genericization by inking deals and making acquisitions and introducing new products. To further strengthen its hepatitis C virus (HCV) portfolio, Gilead purchased Pharmasset in January 2012, for approximately $11.1 billion.
ADS-Blue Nile Ink Long-Term Deal
Alliance Data Systems Corporation ( ADS ) inked a long-term agreement with Blue Nile ( NILE ) in order to initiate and control a new private label credit card program for the latter. Seattle-based Blue Nile is the leading online retailer of diamonds and fine jewelry.
The card program will encompass customized financing options and online account management without charging any annual card fee. The program enables customers to choose from financial options including 6 and 12 months which would ultimately be equivalent to the cash payment that the customers had to pay. On the other hand, customers have the ease to make payments over a period of 24 or 48 months.
Alliance Data will also partner Blue Nile in bringing added incentives for cardholders and marketing initiatives through advanced analytics capabilities, direct mail and email, web and mobile channels.
In the first quarter of 2012, the Private Label Services and Credit segment revenue registered a 7% growth. We expect this transaction to help the company generate additional revenue as well as help the segment to continue delivering robust growth going forward.
Alliance Data posted strong first quarter results with operating earnings substantially ahead of the Zacks Consensus Estimate and year-ago earnings. The strong results came on the back of solid performances across all segments.
The quantitative Zacks #2 Rank (short-term Hold rating) for the company indicates no clear directional pressure on the stock over the near term.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515 .
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns instock market datathat would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518 .
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
ABBOTT LABS (ABT): Free Stock Analysis Report
ALLIANCE DATA (ADS): Free Stock Analysis Report
BRISTOL-MYERS (BMY): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
BLUE NILE INC (NILE): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include Gilead Sciences ( GILD ), Abbott Labs ( ABT ), Alliance Data Systems Corporation ( ADS ), Blue Nile ( NILE ) and Bristol-MyersSquibb ( BMY ). While Norvir is marketed by Abbott Labs ( ABT ), Reyataz is marketed by Bristol-MyersSquibb ( BMY ). 9339 support@zacks.com http://www.zacks.com ABBOTT LABS (ABT): Free Stock Analysis Report ALLIANCE DATA (ADS): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report BLUE NILE INC (NILE): Free Stock Analysis Report To read this article on Zacks.com click here. | Stocks recently featured in the blog include Gilead Sciences ( GILD ), Abbott Labs ( ABT ), Alliance Data Systems Corporation ( ADS ), Blue Nile ( NILE ) and Bristol-MyersSquibb ( BMY ). 9339 support@zacks.com http://www.zacks.com ABBOTT LABS (ABT): Free Stock Analysis Report ALLIANCE DATA (ADS): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report BLUE NILE INC (NILE): Free Stock Analysis Report To read this article on Zacks.com click here. While Norvir is marketed by Abbott Labs ( ABT ), Reyataz is marketed by Bristol-MyersSquibb ( BMY ). | 9339 support@zacks.com http://www.zacks.com ABBOTT LABS (ABT): Free Stock Analysis Report ALLIANCE DATA (ADS): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report BLUE NILE INC (NILE): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include Gilead Sciences ( GILD ), Abbott Labs ( ABT ), Alliance Data Systems Corporation ( ADS ), Blue Nile ( NILE ) and Bristol-MyersSquibb ( BMY ). While Norvir is marketed by Abbott Labs ( ABT ), Reyataz is marketed by Bristol-MyersSquibb ( BMY ). | Stocks recently featured in the blog include Gilead Sciences ( GILD ), Abbott Labs ( ABT ), Alliance Data Systems Corporation ( ADS ), Blue Nile ( NILE ) and Bristol-MyersSquibb ( BMY ). While Norvir is marketed by Abbott Labs ( ABT ), Reyataz is marketed by Bristol-MyersSquibb ( BMY ). 9339 support@zacks.com http://www.zacks.com ABBOTT LABS (ABT): Free Stock Analysis Report ALLIANCE DATA (ADS): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report BLUE NILE INC (NILE): Free Stock Analysis Report To read this article on Zacks.com click here. |
34437.0 | 2012-05-15 00:00:00 UTC | Panel Votes in Favor of Pfizer Drug - Analyst Blog | ABT | https://www.nasdaq.com/articles/panel-votes-in-favor-of-pfizer-drug-analyst-blog-2012-05-15 | nan | nan | Pfizer Inc. ( PFE ) recently received a boost with the U.S. Food and Drug Administration's (FDA) Arthritis Advisory Committee voting 8-2 in favor of the company's rheumatoid arthritis candidate, tofacitinib.
Pfizer is looking to get tofacitinib approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis.
While the FDA is not required to follow the advice of its advisory panels, it usually does so. A response on the approval status of tofacitinib should be out by August 2012.
FDA approval would make tofacitinib the first new oral disease-modifying antirheumatic drug (DMARD) to be approved for rheumatoid arthritis in more than 10 years. Moreover, tofacitinib would be the first Janus kinase (JAK) inhibitor to be approved for rheumatoid arthritis. Pfizer is also seeking approval for tofacitinib in several other regions including the E.U. and Japan.
Tofacitinib is one of the most promising candidates in Pfizer's pipeline. Last year, the company had presented encouraging data on tofacitinib from a phase III study.
Tofacitinib met its primary endpoint in the ORAL Sync phase III study (A3921046), which was conducted with patients suffering from moderate-to-severe rheumatoid arthritis. Results showed that compared to placebo, tofacitinib achieved a statistically significant reduction in signs and symptoms of rheumatoid arthritis.
Being an oral treatment, tofacitinib could have an edge over existing therapies which need to be injected or administered through infusion. The rheumatoid arthritis market currently has players like products like Abbott's ( ABT ) Humira and Johnson & Johnson's ( JNJ ) Remicade and Simponi among others.
We currently have a Neutral recommendation on Pfizer, which carries a Zacks #3 Rank (short-term Hold rating).
ABBOTT LABS (ABT): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The rheumatoid arthritis market currently has players like products like Abbott's ( ABT ) Humira and Johnson & Johnson's ( JNJ ) Remicade and Simponi among others. ABBOTT LABS (ABT): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Pfizer is looking to get tofacitinib approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis. | ABBOTT LABS (ABT): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. The rheumatoid arthritis market currently has players like products like Abbott's ( ABT ) Humira and Johnson & Johnson's ( JNJ ) Remicade and Simponi among others. Pfizer Inc. ( PFE ) recently received a boost with the U.S. Food and Drug Administration's (FDA) Arthritis Advisory Committee voting 8-2 in favor of the company's rheumatoid arthritis candidate, tofacitinib. | The rheumatoid arthritis market currently has players like products like Abbott's ( ABT ) Humira and Johnson & Johnson's ( JNJ ) Remicade and Simponi among others. ABBOTT LABS (ABT): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Pfizer Inc. ( PFE ) recently received a boost with the U.S. Food and Drug Administration's (FDA) Arthritis Advisory Committee voting 8-2 in favor of the company's rheumatoid arthritis candidate, tofacitinib. | The rheumatoid arthritis market currently has players like products like Abbott's ( ABT ) Humira and Johnson & Johnson's ( JNJ ) Remicade and Simponi among others. ABBOTT LABS (ABT): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Pfizer Inc. ( PFE ) recently received a boost with the U.S. Food and Drug Administration's (FDA) Arthritis Advisory Committee voting 8-2 in favor of the company's rheumatoid arthritis candidate, tofacitinib. |
34438.0 | 2012-05-14 00:00:00 UTC | Zacks Bull and Bear of the Day Highlights: Eastman Chemical, Kirkland's, Biogen Idec, Abbott, Novartis - Press Releases | ABT | https://www.nasdaq.com/articles/zacks-bull-and-bear-of-the-day-highlights%3A-eastman-chemical-kirklands-biogen-idec-abbott | nan | nan | Chicago, IL - May 14, 2012 - Zacks Equity Research highlights Eastman Chemical ( EMN ) as the Bull of the Day and Kirkland's ( KIRK ) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Biogen Idec ( BIIB ), Abbott ( ABT ) and Novartis ( NVS )
Full analysis of all these stocks is available at http://at.zacks.com/?id=2678 .
Here is a synopsis of all five stocks:
Bull of the Day :
We are retaining our Outperform recommendation on Eastman Chemical Co. ( EMN ). First quarter adjusted earnings of $1.22 per share beat the Zacks Consensus Estimate. Revenue growth was aided by higher selling prices.
Moving ahead, we believe that the company is well placed to benefit in the second-half of the year from the synergies of its impending acquisition of Solutia. Eastman Chemical's diversified chemical portfolio, along with its integrated and diverse downstream businesses, is driving its earnings.
The company also benefits from business restructuring, recent acquisitions, cost-cutting measures and increased capacity additions. Our long-term Outperform recommendation on the stock indicates that it will perform above the broader market. Our price target of $61 is based on 11.7x our fiscal 2012 earnings estimate.
Bear of the Day :
Kirkland's, Inc. ( KIRK ) posted fourth-quarter 2011 earnings of $0.72 per share, which missed the Zacks Consensus Estimate of $0.74. But it was above the prior-year earnings of $0.66, fueled by strong sales during Harvest and Christmas. High-rising prices of commodities as well as slow recovery of global economy is negatively impacting the company's margins.
The company has also lowered its earnings guidance for the first quarter 2012 on the back of lower comparative sales during the period. Moreover, overdependence on Chinese vendors poses a threat. Hence we maintain an Underperform rating on the stock.
Based on 2012 earnings estimate of $1.05, the stock is trading at 13.0x compared to the industry average of 20.5x. Our target price of $12.00 is based on approximately 11.4x our 2012 earnings estimate.
Latest Posts on the Zacks Analyst Blog :
Standard Review for Biogen's BG-12
Biogen Idec ( BIIB ) recently announced the acceptance of its regulatory filings in the U.S. and E.U. for its oral multiple sclerosis candidate, BG-12. The U.S. Food and Drug Administration (FDA) has granted standard review to the candidate, which means a response should be out in late 2012/early 2013.
The regulatory filings were based on data from the phase III DEFINE and CONFIRM studies which showed that treatment with BG-12 led to a significant reduction in disease activity in multiple sclerosis patients. Moreover, the candidate had a favorable safety and tolerability profile.
Biogen is also seeking approval for BG-12 in Canada and Switzerland.
Biogen is the market leader in therapies for the treatment of multiple sclerosis (MS). We believe the company will continue to retain a leading position in the MS market. Biogen is working on consolidating its position in the MS market and has an impressive late-stage pipeline of drugs including BG-12.
Meanwhile, Biogen and partner Abbott ( ABT ) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010. Daclizumab is being evaluated as a once-monthly or bi-weekly subcutaneous injection for relapsing-remitting MS. PEGylated interferon rounds up Biogen's late-stage MS pipeline. PEGylated interferon is currently in a phase III study (ADVANCE).
Our Take
We believe BG-12 could become a leader in the oral MS market once launched. BG-12 should help drive long-term growth. Biogen has been facing additional competition in the multiple sclerosis market in the form of Novartis' ( NVS ) Gilenya. Moreover, several companies besides Biogen are working on bringing an oral multiple sclerosis drug to market.
We currently have a Neutral recommendation on Biogen, which carries a Zacks #3 Rank (short-term Hold rating).
Get the full analysis of all these stocks by going to http://at.zacks.com/?id=2649 .
About the Bull and Bear of the Day
Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.
About the Analyst Blog
Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=7158 .
About Zacks
Zacks.com is a property of Zacks Investment Research , Inc., which was formed in 1978 by Leonard Zacks. As a PhD from MIT Len knew he could find patterns instock market datathat would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank , which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment
Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4582 .
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
ABBOTT LABS (ABT): Free Stock Analysis Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis Report
EASTMAN CHEM CO (EMN): Free Stock Analysis Report
KIRKLANDS INC (KIRK): Free Stock Analysis Report
NOVARTIS AG-ADR (NVS): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Meanwhile, Biogen and partner Abbott ( ABT ) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010. In addition, Zacks Equity Research provides analysis on Biogen Idec ( BIIB ), Abbott ( ABT ) and Novartis ( NVS ) Full analysis of all these stocks is available at http://at.zacks.com/?id=2678 . 9339 support@zacks.com http://www.zacks.com ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report EASTMAN CHEM CO (EMN): Free Stock Analysis Report KIRKLANDS INC (KIRK): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. | In addition, Zacks Equity Research provides analysis on Biogen Idec ( BIIB ), Abbott ( ABT ) and Novartis ( NVS ) Full analysis of all these stocks is available at http://at.zacks.com/?id=2678 . 9339 support@zacks.com http://www.zacks.com ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report EASTMAN CHEM CO (EMN): Free Stock Analysis Report KIRKLANDS INC (KIRK): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, Biogen and partner Abbott ( ABT ) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010. | In addition, Zacks Equity Research provides analysis on Biogen Idec ( BIIB ), Abbott ( ABT ) and Novartis ( NVS ) Full analysis of all these stocks is available at http://at.zacks.com/?id=2678 . 9339 support@zacks.com http://www.zacks.com ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report EASTMAN CHEM CO (EMN): Free Stock Analysis Report KIRKLANDS INC (KIRK): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, Biogen and partner Abbott ( ABT ) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010. | In addition, Zacks Equity Research provides analysis on Biogen Idec ( BIIB ), Abbott ( ABT ) and Novartis ( NVS ) Full analysis of all these stocks is available at http://at.zacks.com/?id=2678 . Meanwhile, Biogen and partner Abbott ( ABT ) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010. 9339 support@zacks.com http://www.zacks.com ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report EASTMAN CHEM CO (EMN): Free Stock Analysis Report KIRKLANDS INC (KIRK): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. |
34439.0 | 2012-05-14 00:00:00 UTC | Good News for Gilead - Analyst Blog | ABT | https://www.nasdaq.com/articles/good-news-for-gilead-analyst-blog-2012-05-14 | nan | nan | GileadSciences ( GILD ) received some encouraging news recently when an advisory panel of the U.S. Food and Drug Administration (FDA) recommended the approval of the company's HIV combination pill Quad. A final decision from the FDA regarding the matter is expected by August 27, 2012 (target date).
We note that the Quad pill is a combination of elvitegravir, cobicistat and Truvada. Gilead is looking to get the pill (once daily) approved as a first-line therapy for treating adults infected with the HIV virus.
The FDA's advisory panel met to review the new drug application (NDA) submitted by Gilead in October 2011 for getting Quad approved in the U.S. The NDA included positive data from two late-stage studies - 102 which compared Quad to Atripla and 103 which compared Quad to Norvir (ritonavir)-boosted Reyataz plus Truvada. While Norvir is marketed by Abbott Labs ( ABT ), Reyataz is marketed by Bristol-MyersSquibb ( BMY ).
While reviewing the application, the panel voted overwhelmingly (13-1) in favor of clearing the combination pill (a single tablet regimen) in the U.S. Even though the U.S. agency is not bound to follow the advice of its advisory committee, the recommendation of the panel is usually considered by the agency while deciding the fate of a candidate.
Positive news from the FDA in August would further boost the top line at Gilead and strengthen its already established HIV portfolio. The Quad pill is also under review in the E.U, Australia and Canada. Approval in additional territories would increase the drug's sales potential.
Neutral on Gilead
We have a Neutral recommendation on Gilead. Our long-term stance is in line with the Zacks #3 Rank (Hold rating) carried by the company in the short run. We remain optimistic on the growth prospects of Gilead's HIV drugs, Truvada and Atripla. We are also encouraged by the approval of Complera/Eviplera, which together with Quad, once approved, will further fortify the HIV franchise and help mitigate the impact of the upcoming patent expirations.
Gilead is looking to combat the threat of genericization by inking deals and making acquisitions and introducing new products. To further strengthen its hepatitis C virus (HCV) portfolio, Gilead purchased Pharmasset in January 2012, for approximately $11.1 billion.
ABBOTT LABS (ABT): Free Stock Analysis Report
BRISTOL-MYERS (BMY): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | While Norvir is marketed by Abbott Labs ( ABT ), Reyataz is marketed by Bristol-MyersSquibb ( BMY ). ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. GileadSciences ( GILD ) received some encouraging news recently when an advisory panel of the U.S. Food and Drug Administration (FDA) recommended the approval of the company's HIV combination pill Quad. | While Norvir is marketed by Abbott Labs ( ABT ), Reyataz is marketed by Bristol-MyersSquibb ( BMY ). ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. GileadSciences ( GILD ) received some encouraging news recently when an advisory panel of the U.S. Food and Drug Administration (FDA) recommended the approval of the company's HIV combination pill Quad. | ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. While Norvir is marketed by Abbott Labs ( ABT ), Reyataz is marketed by Bristol-MyersSquibb ( BMY ). GileadSciences ( GILD ) received some encouraging news recently when an advisory panel of the U.S. Food and Drug Administration (FDA) recommended the approval of the company's HIV combination pill Quad. | While Norvir is marketed by Abbott Labs ( ABT ), Reyataz is marketed by Bristol-MyersSquibb ( BMY ). ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. GileadSciences ( GILD ) received some encouraging news recently when an advisory panel of the U.S. Food and Drug Administration (FDA) recommended the approval of the company's HIV combination pill Quad. |
34440.0 | 2012-05-11 00:00:00 UTC | Standard Review for Biogen's BG-12 - Analyst Blog | ABT | https://www.nasdaq.com/articles/standard-review-for-biogens-bg-12-analyst-blog-2012-05-11 | nan | nan | Biogen Idec ( BIIB ) recently announced the acceptance of its regulatory filings in the U.S. and E.U. for its oral multiple sclerosis candidate, BG-12. The U.S. Food and Drug Administration (FDA) has granted standard review to the candidate, which means a response should be out in late 2012/early 2013.
The regulatory filings were based on data from the phase III DEFINE and CONFIRM studies which showed that treatment with BG-12 led to a significant reduction in disease activity in multiple sclerosis patients. Moreover, the candidate had a favorable safety and tolerability profile.
Biogen is also seeking approval for BG-12 in Canada and Switzerland.
Biogen is the market leader in therapies for the treatment of multiple sclerosis (MS). We believe the company will continue to retain a leading position in the MS market. Biogen is working on consolidating its position in the MS market and has an impressive late-stage pipeline of drugs including BG-12.
Meanwhile, Biogen and partner Abbott ( ABT ) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010. Daclizumab is being evaluated as a once-monthly or bi-weekly subcutaneous injection for relapsing-remitting MS. PEGylated interferon rounds up Biogen's late-stage MS pipeline. PEGylated interferon is currently in a phase III study (ADVANCE).
Our Take
We believe BG-12 could become a leader in the oral MS market once launched. BG-12 should help drive long-term growth. Biogen has been facing additional competition in the multiple sclerosis market in the form of Novartis' ( NVS ) Gilenya. Moreover, several companies besides Biogen are working on bringing an oral multiple sclerosis drug to market.
We currently have a Neutral recommendation on Biogen, which carries a Zacks #3 Rank (short-term 'Hold' rating).
ABBOTT LABS (ABT): Free Stock Analysis Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis Report
NOVARTIS AG-ADR (NVS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Meanwhile, Biogen and partner Abbott ( ABT ) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010. ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. The regulatory filings were based on data from the phase III DEFINE and CONFIRM studies which showed that treatment with BG-12 led to a significant reduction in disease activity in multiple sclerosis patients. | Meanwhile, Biogen and partner Abbott ( ABT ) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010. ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, several companies besides Biogen are working on bringing an oral multiple sclerosis drug to market. | ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, Biogen and partner Abbott ( ABT ) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010. Biogen is the market leader in therapies for the treatment of multiple sclerosis (MS). | Meanwhile, Biogen and partner Abbott ( ABT ) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010. ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. for its oral multiple sclerosis candidate, BG-12. |
34441.0 | 2012-05-11 00:00:00 UTC | FDA Approves Gen-Probe's PANTHER - Analyst Blog | ABT | https://www.nasdaq.com/articles/fda-approves-gen-probes-panther-analyst-blog-2012-05-11 | nan | nan | Gen-Probe Inc. ( GPRO ), a leading diagnostic devices company, recently announced the approval of the U.S. Food and Drug Administration ("FDA") for its PANTHER system, an immunoassay instrument for molecular diagnosis. The system has been given the initial approval to be used with its market-leading chlamydia and gonorrhea test APTIMA COMBO 2.
The PANTHER system can process a number of different molecular tests as well as generate results on all phases of nucleic acid testing ("NAT") on a single platform, with minimal human interference. The instrument can process roughly 275 tests in 8 hours and about 500 tests in 12 hours. The device, with its high level of automation, is expected to replace a full day's laboratory work with 4 hours of labor-free result processing.
The California-based company had filed a 510(k) approval to the FDA some time in May 2011. It received the European CE mark for the instrument in December 2010 and the Canadian approval in August 2011. With the U.S. clearance, a vital milestone has been achieved in the company's endeavor to make this breakthrough product available to the global blood screening market.
Gen-Probe has developed several assays designed to run on the PANTHER system. The PANTHER along with the TIGRIS system are among the most important devices in the company's product portfolio.
Gen-Probe's revenues rose 7% year over year to $153.4 million in the most recent quarter. Product sales increased 9% to $150.1 million as healthy sales across Blood Screening and Clinical Diagnostics franchises was partially offset by lower revenues from the Research Products and Services and Collaborative Research businesses. Revenues from Collaborative Research plunged 61% to $1.4 million, hurt by lower funding from Novartis ( NVS ) for the development of the PANTHER system for blood screening.
Gen-Probe is a dominant player in the rapidly expanding NAT market, the fastest growing segment in the clinical diagnostic market. It is a market leader in domestic gonorrhea and chlamydia testing with its PACE and APTIMA assay product lines. Gen-Probe competes with more established firms in the molecular diagnostic industry such as Roche ( RHHBY ), Becton, Dickinson ( BDX ) and Abbott Labs ( ABT ).
Currently, we have a long-term Neutral recommendation on Gen-Probe, which is in tandem with a short-term Zacks #3 Rank (Hold).
ABBOTT LABS (ABT): Free Stock Analysis Report
BECTON DICKINSO (BDX): Free Stock Analysis Report
GEN-PROBE INC (GPRO): Free Stock Analysis Report
NOVARTIS AG-ADR (NVS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Gen-Probe competes with more established firms in the molecular diagnostic industry such as Roche ( RHHBY ), Becton, Dickinson ( BDX ) and Abbott Labs ( ABT ). ABBOTT LABS (ABT): Free Stock Analysis Report BECTON DICKINSO (BDX): Free Stock Analysis Report GEN-PROBE INC (GPRO): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. Gen-Probe Inc. ( GPRO ), a leading diagnostic devices company, recently announced the approval of the U.S. Food and Drug Administration ("FDA") for its PANTHER system, an immunoassay instrument for molecular diagnosis. | ABBOTT LABS (ABT): Free Stock Analysis Report BECTON DICKINSO (BDX): Free Stock Analysis Report GEN-PROBE INC (GPRO): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. Gen-Probe competes with more established firms in the molecular diagnostic industry such as Roche ( RHHBY ), Becton, Dickinson ( BDX ) and Abbott Labs ( ABT ). Revenues from Collaborative Research plunged 61% to $1.4 million, hurt by lower funding from Novartis ( NVS ) for the development of the PANTHER system for blood screening. | ABBOTT LABS (ABT): Free Stock Analysis Report BECTON DICKINSO (BDX): Free Stock Analysis Report GEN-PROBE INC (GPRO): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. Gen-Probe competes with more established firms in the molecular diagnostic industry such as Roche ( RHHBY ), Becton, Dickinson ( BDX ) and Abbott Labs ( ABT ). Gen-Probe Inc. ( GPRO ), a leading diagnostic devices company, recently announced the approval of the U.S. Food and Drug Administration ("FDA") for its PANTHER system, an immunoassay instrument for molecular diagnosis. | Gen-Probe competes with more established firms in the molecular diagnostic industry such as Roche ( RHHBY ), Becton, Dickinson ( BDX ) and Abbott Labs ( ABT ). ABBOTT LABS (ABT): Free Stock Analysis Report BECTON DICKINSO (BDX): Free Stock Analysis Report GEN-PROBE INC (GPRO): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. The instrument can process roughly 275 tests in 8 hours and about 500 tests in 12 hours. |
34442.0 | 2012-05-07 00:00:00 UTC | DexCom Misses on EPS, Losses Mount - Analyst Blog | ABT | https://www.nasdaq.com/articles/dexcom-misses-on-eps-losses-mount-analyst-blog-2012-05-07 | nan | nan | DexCom ( DXCM ), a player in the glucose monitoring market, reported first-quarter 2012 loss per share of 21 cents, higher than the Zacks Consensus Estimate of a loss of 19 cents per share. Net loss for the quarter increased 18.7% year over year to $14.1 million (21 cents per share).
Revenues
Sales increased sharply 41.8% year over year to $20.1 million in the first quarter, narrowly beating the Zacks Consensus Estimate of $20 million.
Product sales jumped 42% to $18.6 million while development grant and other revenues were up 42.7% to $1.5 million in the reported quarter.
Margins and Expenses
Gross margin picked up to 46.7% in the first quarter from 36.1% a year ago. Cost of sales moved up 18.2% year over year to $10.7 million mostly on account of higher cost of product sales. Operating expenses increased 45.9% year over year to $24.8 million on account of higher R&D spending and selling, general and administrative expenses, which grew 55% and 40.6%, respectively, in the reported quarter.
Balance Sheet
DexCom exited the quarter with cash and short-term marketable securities of $70.2 million, down 14.3% on a sequential basis.
Our Take
We believe DexCom is poised to gain a major share of the glucose monitoring market driven by sustained product development initiatives, collaborations, favorable reimbursement coverage and increased need for continuous glucose monitoring.
However, we note that competition in the glucose monitoring market is intense and DexCom faces stiff challenges from much larger players such as Johnson & Johnson ( JNJ ), Medtronic ( MDT ) and Abbott Labs ( ABT ). Moreover, the company has incurred losses since inception and is exposed to a stricter regulatory environment. Our Neutral recommendation is supported by a short-term Zacks #3 Rank (Hold).
ABBOTT LABS (ABT): Free Stock Analysis Report
DEXCOM INC (DXCM): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
MEDTRONIC (MDT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | However, we note that competition in the glucose monitoring market is intense and DexCom faces stiff challenges from much larger players such as Johnson & Johnson ( JNJ ), Medtronic ( MDT ) and Abbott Labs ( ABT ). ABBOTT LABS (ABT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Balance Sheet DexCom exited the quarter with cash and short-term marketable securities of $70.2 million, down 14.3% on a sequential basis. | However, we note that competition in the glucose monitoring market is intense and DexCom faces stiff challenges from much larger players such as Johnson & Johnson ( JNJ ), Medtronic ( MDT ) and Abbott Labs ( ABT ). ABBOTT LABS (ABT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. DexCom ( DXCM ), a player in the glucose monitoring market, reported first-quarter 2012 loss per share of 21 cents, higher than the Zacks Consensus Estimate of a loss of 19 cents per share. | ABBOTT LABS (ABT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. However, we note that competition in the glucose monitoring market is intense and DexCom faces stiff challenges from much larger players such as Johnson & Johnson ( JNJ ), Medtronic ( MDT ) and Abbott Labs ( ABT ). DexCom ( DXCM ), a player in the glucose monitoring market, reported first-quarter 2012 loss per share of 21 cents, higher than the Zacks Consensus Estimate of a loss of 19 cents per share. | However, we note that competition in the glucose monitoring market is intense and DexCom faces stiff challenges from much larger players such as Johnson & Johnson ( JNJ ), Medtronic ( MDT ) and Abbott Labs ( ABT ). ABBOTT LABS (ABT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Revenues Sales increased sharply 41.8% year over year to $20.1 million in the first quarter, narrowly beating the Zacks Consensus Estimate of $20 million. |
34443.0 | 2012-04-26 00:00:00 UTC | The Zacks Analyst Blog Highlights: St. Jude Medical, Abbott Laboratories, Medtronic, Boston Scientific and Big Lots - Press Releases | ABT | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-st.-jude-medical-abbott-laboratories-medtronic-boston | nan | nan | For Immediate Release
Chicago, IL - April 26, 2012 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include St. Jude Medical Inc. ( STJ ), Abbott Laboratories ( ABT ), Medtronic ( MDT ), Boston Scientific ( BSX ) and Big Lots Inc . ( BIG ).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Wednesday's Analyst Blog:
St. Jude's Alliance with Abbott Labs
St. Jude Medical Inc. ( STJ ) recently disclosed its decision to build on its mutual agreement with Abbott Laboratories ( ABT ) by revealing the long-term Choice Alliance joint venture. This initiative provides St. Jude Medical the opportunity to incorporate Abbott's drug-eluting stents with its cardiovascular, cardiac rhythm management and electrophysiology offerings.
Both companies have agreed to endorse each other's products to their respective customers. Further, Abbott has received the rights to promote St. Jude's RadiAnalyze Xpress Measurement System and the ILUMIEN PCI Optimization System.
This alliance is expected to benefit patient outcomes, as doctors will be able to combine Abbott's XIENCE family of stents with St. Jude's optical coherence tomography (OCT) and fractional flow reserve ( FFR ) know-how to widen the scope of clinical treatments.
Abbott Laboratories is a global manufacturer of a vast array of health care products. Pharmaceuticals, medical and nutritional offerings, including cardiovascular devices, are the core franchises of the company. Within the vascular segment, the XIENCE family of products (Xience V, PRIME and nano) was the worldwide market leader of drug eluting stents in 2011.
St. Jude is consistently producing revenue growth and positive earnings surprises over the past several quarters. We are impressed by its solid fundamentals, healthy growth trajectory, strong product mix, robust pipeline and cost management initiatives.
While a host of new growth drivers (including new products and expansion in emerging markets) are expected to boost results in 2012 and beyond, we remain cautious about increased competition, a still-soft CRM market and the dilutive impact of acquisitions.
Th CRM space continues to thwart St. Jude as well as its peers Medtronic ( MDT ) and Boston Scientific ( BSX ). Our long-term Neutral recommendation on St. Jude is in agreement with the short-term Zacks #3 Rank (Hold) retained by the stock.
Big Lots Lowers Outlook
The largest broad-line closeout retailer Big Lots Inc .'s ( BIG ) latest release reminds us of the Dow theory, which says the market discounts everything. This stands perfectly true for the company as its shares plunged more than 14% after management lowered its first-quarter guidance on the key retail metric i.e., its comparable store sales.
Management now expects comparable store sales in the U.S. to be somewhat negative compared to its earlier guidance of an increase of 2% to 4%.
Big Lots experienced a sales decline in the month of April, with electronics sales bringing in the biggest disappointment. Management stated that the sales of furniture, hardlines and lawn and garden were quite good.
Big Lots also updated its guidance on the recently acquired Canadian operations. Management now expects retail sales to be marginally higher than its earlier projection of $25 to $30 million of sales for the first quarter.
The company has been exploring numerous options to enter the Canadian turf that ended with the acquisition of Liquidation World. Liquidation World operates approximately 89 stores and offers a broad assortment of closeout merchandise. Management believes the acquisition will be accretive to its top line in the coming years, and generate long-term growth prospects. The company also remains focused on enhancing its store operations capacity.
Big Lots implemented a new retail inventory system to value inventory based on the merchandise class level, instead of the merchandise department level. This would help in getting a much more clear view on the profitability of merchandising initiatives undertaken. The company also hinted of focusing on new warehouse management systems, HR systems and a real estate system in the next two years.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515 .
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns instock market datathat would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518 .
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
ABBOTT LABS ( ABT ): Free Stock Analysis Report
BIG LOTS INC ( BIG ): Free Stock Analysis Report
BOSTON SCIENTIF ( BSX ): Free Stock Analysis Report
MEDTRONIC ( MDT ): Free Stock Analysis Report
ST JUDE MEDICAL (STJ): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include St. Jude Medical Inc. ( STJ ), Abbott Laboratories ( ABT ), Medtronic ( MDT ), Boston Scientific ( BSX ) and Big Lots Inc . Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513 Here are highlights from Wednesday's Analyst Blog: St. Jude's Alliance with Abbott Labs St. Jude Medical Inc. ( STJ ) recently disclosed its decision to build on its mutual agreement with Abbott Laboratories ( ABT ) by revealing the long-term Choice Alliance joint venture. 9339 support@zacks.com http://www.zacks.com ABBOTT LABS ( ABT ): Free Stock Analysis Report BIG LOTS INC ( BIG ): Free Stock Analysis Report BOSTON SCIENTIF ( BSX ): Free Stock Analysis Report MEDTRONIC ( MDT ): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report To read this article on Zacks.com click here. | Stocks recently featured in the blog include St. Jude Medical Inc. ( STJ ), Abbott Laboratories ( ABT ), Medtronic ( MDT ), Boston Scientific ( BSX ) and Big Lots Inc . Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513 Here are highlights from Wednesday's Analyst Blog: St. Jude's Alliance with Abbott Labs St. Jude Medical Inc. ( STJ ) recently disclosed its decision to build on its mutual agreement with Abbott Laboratories ( ABT ) by revealing the long-term Choice Alliance joint venture. 9339 support@zacks.com http://www.zacks.com ABBOTT LABS ( ABT ): Free Stock Analysis Report BIG LOTS INC ( BIG ): Free Stock Analysis Report BOSTON SCIENTIF ( BSX ): Free Stock Analysis Report MEDTRONIC ( MDT ): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report To read this article on Zacks.com click here. | Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513 Here are highlights from Wednesday's Analyst Blog: St. Jude's Alliance with Abbott Labs St. Jude Medical Inc. ( STJ ) recently disclosed its decision to build on its mutual agreement with Abbott Laboratories ( ABT ) by revealing the long-term Choice Alliance joint venture. 9339 support@zacks.com http://www.zacks.com ABBOTT LABS ( ABT ): Free Stock Analysis Report BIG LOTS INC ( BIG ): Free Stock Analysis Report BOSTON SCIENTIF ( BSX ): Free Stock Analysis Report MEDTRONIC ( MDT ): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include St. Jude Medical Inc. ( STJ ), Abbott Laboratories ( ABT ), Medtronic ( MDT ), Boston Scientific ( BSX ) and Big Lots Inc . | Stocks recently featured in the blog include St. Jude Medical Inc. ( STJ ), Abbott Laboratories ( ABT ), Medtronic ( MDT ), Boston Scientific ( BSX ) and Big Lots Inc . Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513 Here are highlights from Wednesday's Analyst Blog: St. Jude's Alliance with Abbott Labs St. Jude Medical Inc. ( STJ ) recently disclosed its decision to build on its mutual agreement with Abbott Laboratories ( ABT ) by revealing the long-term Choice Alliance joint venture. 9339 support@zacks.com http://www.zacks.com ABBOTT LABS ( ABT ): Free Stock Analysis Report BIG LOTS INC ( BIG ): Free Stock Analysis Report BOSTON SCIENTIF ( BSX ): Free Stock Analysis Report MEDTRONIC ( MDT ): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report To read this article on Zacks.com click here. |
34444.0 | 2012-04-26 00:00:00 UTC | Pharma & Biotech Stock Outlook - April 2012 - Industry Outlook | ABT | https://www.nasdaq.com/articles/pharma-biotech-stock-outlook-april-2012-industry-outlook-2012-04-26 | nan | nan | The pharmaceutical industry is facing one of the biggest patent cliffs with Pfizer's ( PFE ) multi-billion-dollar blockbuster drug Lipitor losing patent protection in the US in late November 2011. Besides Lipitor, other major branded drugs that lost patent protection in the past few months include Forest Laboratories' ( FRX ) Lexapro and Eli Lilly's ( LLY ) Zyprexa. These products alone represented branded sales worth more than $15 billion.
The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. Two major products slated to lose patent protection in 2012 include Merck's ( MRK ) Singulair and Bristol-Myers Squibb ( BMY )/ Sanofi's ( SNY ) Plavix.
While generics will eat into sales, new products are not expected to generate the same level of sales as products losing patent protection. The next few years are expected to reflect a significant imbalance between new product introductions and patent losses.
Generic competition and insufficient new product sales will not be the only factors impacting performance in 2012. Other headwinds include EU and Japan pricing pressure.
Meanwhile, the US government is exploring options which will help increase the availability of generics. Recently, the Obama administration announced that it is looking to implement a proposal under which the exclusivity period for biologics will be cut down by 5 years, thereby allowing generics to enter the market sooner. The government is looking to bring this proposal into effect from 2012.
It is also seeking to increase the availability of generics by preventing companies from entering into anti-competitive or "pay for delay" agreements which push out the availability of generics. These initiatives, if implemented, would result in additional pricing competition and genericization in the pharma industry. Moreover, the FDA is working on establishing a biosimilar pathway so that cheaper versions of biologics will be available.
With revenue growth stalling or slowing down, pharma companies have been resorting to cost-cutting and share buybacks to drive bottom-line growth. 2011 was a year characterized by the loss of patent protection for blockbuster drugs, merger & acquisitions (M&As), licensing deals, restructuring, share buybacks and monetization of non-core assets.
M&A Activity
The M&A activity witnessed in the pharma sector in the last couple of years will continue in 2012. With most of the big pharma companies already facing or likely to face patent challenges for their blockbuster products, the companies have been looking toward M&A and in-licensing activities to make up for the loss of revenues that will arise with key products losing patent exclusivity.
Major deals include Johnson & Johnson's ( JNJ ) upcoming acquisition of Synthes, which should help strengthen its medical device portfolio.
Pharma giant Pfizer acquired King Pharmaceuticals to strengthen its presence in the pain management market. Pfizer has been adding to its portfolio with other acquisitions as well, including that of Icagen and Excaliard. Merck expanded its ophthalmology product portfolio through its acquisition of Inspire Pharmaceuticals, Inc.
Another pharma major, Bristol-Myers Squibb, is not far behind in acquisitions activity. The company has been looking to expand via acquisitions and partnerships to counter the loss of revenues that will arise following the genericization of its key drugs, including the blockbuster blood thinner Plavix.
Bristol-Myers was in the news recently, with rumors doing the rounds about the company's intention to acquire Amylin Pharmaceuticals ( AMLN ). Meanwhile, Roche ( RHHBY ) has been pursuing Illumina ( ILMN ), albeit without much success so far. Glaxo also did not meet with success in its attempt to acquire Human Genome Sciences, Inc. ( HGSI ).
Oncology also remains a much sought-after therapeutic area, with companies like Sanofi and Celgene ( CELG ) strengthening their presence in this market through acquisitions. Meanwhile, generic players are not far behind in the acquisition game. While Teva ( TEVA ) acquired Cephalon, Inc., Watson Pharmaceuticals ( WPI ) acquired generic company Specifar Pharmaceuticals to expand and strengthen its presence in Europe. Watson recently announced its intention to acquire generic player, Actavis.
Elsewhere, companies have been looking toward biotech firms to build their product portfolios. A prime example is French pharma giant Sanofi's acquisition of biotech company Genzyme Corp. The Genzyme acquisition has boosted Sanofi's revenues as well as its pipeline. Meanwhile, AstraZeneca ( AZN ) will be acquiring biotech company Ardea Biosciences ( RDEA ). Another acquisition deal announced in April 2012 is Spectrum Pharma's ( SPPI ) upcoming acquisition of biopharma company Allos Therapeutics ( ALTH ).
Going forward, we expect the M&A trend to continue. We also expect a significant pickup in in-licensing activities and collaborations for the development of pipeline candidates. Instead of developing a product from scratch, which involves a lot of funds and time, pharma companies are shopping for mid-to-late stage pipeline candidates that look promising.
Small biotech companies are also game for in-licensing activities and collaborations. Most of these companies find it challenging to raise cash, thereby making it difficult for them to survive and continue with the development of promising pipeline candidates. Therefore, it makes sense for them to seek deals with pharma companies that are sitting on huge piles of cash.
We would recommend investors to put their money in biotech stocks that have attractive pipeline candidates or technology that can be used for the development of novel therapeutics. Therapeutic areas which could see a lot of in-licensing activity include oncology, central nervous system disorders, diabetes and immunology/inflammation. The hepatitis C virus (HCV) market is also attracting a lot of attention.
Another trend that we are seeing in recent months is the divestment of non-core business segments. Pfizer sold its Capsugel unit in August 2011 and signed a deal for the divestment of its Nutrition business in April 2012. The company is currently exploring strategic alternatives for its Animal Health business.
Meanwhile, GlaxoSmithKline ( GSK ) is divesting non-core brands from its Consumer Healthcare segment. In August 2011, AstraZeneca sold its Astra Tech business to DENTSPLY ( XRAY ). The monetization of non-core assets will allow the pharma/biotech companies to focus on their areas of expertise. 2012 will see Abbott Labs splitting into two separate publicly traded companies. While one company will deal in diversified medical products, the other (AbbVie) will focus on research-based pharmaceuticals.
Emerging Markets
Another recent trend seen in the pharmaceutical sector is a focus on emerging markets. Companies like Mylan ( MYL ), Pfizer, Merck, Eli Lilly, Glaxo and Sanofi are all looking to expand their presence in India, China, Brazil and other emerging markets. Until recently, most of the commercialization efforts were focused on the US market -- the largest pharmaceutical market -- along with Europe and Japan.
Emerging markets are slowly and steadily gaining more importance and several companies are now shifting their focus to these areas. According to the IMS Institute, spending on medicines in "pharmerging" markets will double to $285-$315 billion in the next five years from $151 billion in 2010. This will catapult pharmerging markets to the second position where spending on medicines is concerned.
However, while higher demand for medicines, government initiatives for healthcare, new patient population, and increasing use of generics should help drive demand, we point out that emerging markets are also not immune from genericization.
Branded Drugs Market Share to Decline
According to the IMS Institute, market share for branded drugs will continue declining in the next five years. Branded drugs' market share, which declined from 70% in 2005 to 64% in 2010, is expected to decline to 53% by 2015. The decline will be driven by patent expiries, with generics accounting for a significant part of pharma spending. Spending on branded medicines in 2015 is expected to remain at the same level as in 2010.
While the US will witness a major increase in generic spending, generic spending in Japan will continue to be low, even though significant efforts are being made to increase the use of generics there. Overall spending in generics is expected to increase from 20% in 2005 to 39% in 2015.
Global spending for medicines is expected to reach almost $1.1 trillion by 2015, according to the IMS Institute. However, the five-year compound annual growth rate of 3-6% represents a significant slowdown from the 6.2% annual growth seen in the last five years.
Moreover, the US' share of global spending is expected to decline from 41% in 2005 to 31% in 2015. The share of spending from the top 5 European countries is also expected to decline (from 20% in 2005 to 13% in 2015) with spending by pharmerging markets expected to increase from 12% in 2005 to 28% by 2015. (Source of growth forecasts: IMS.)
OPPORTUNITIES
We continue to have a Neutral outlook on large-cap pharma stocks. While the companies will continue to face challenges like pricing pressure and genericization, growth in emerging markets and product approvals could help reduce the impact.
A few years down the line, the pharma industry should show some signs of recovery. The industry should be out of the major patent cliff period, and new products should be contributing significantly to results. Increased pipeline visibility and appropriate utilization of cash should increase confidence in the sector.
About 35 new molecular entities were approved by the FDA up to mid-November 2011. Important product approvals include Johnson & Johnson's prostate cancer therapy Zytiga, Merck's hepatitis C virus (HCV) treatment Victrelis, Bristol-Myers' melanoma treatment Yervoy, AstraZeneca's Brilinta, Vertex Pharma's ( VRTX ) HCV treatment Incivek, Pfizer's lung cancer treatment Xalkori, and Glaxo/Human Genome's lupus drug Benlysta, among others. Potential blockbusters include Benlysta, Yervoy, Zytiga, Incivek and Xarelto.
In the biotech space, we are positive on Biogen Idec ( BIIB ). We are optimistic on BG-12, the company's oral multiple sclerosis candidate.
In spite of a Neutral recommendation on Bristol-Myers, we are positive on the stock. Although Bristol-Myers is facing a major patent cliff with Plavix losing exclusivity later this year, the company's pipeline represents a lot of potential. 2011 has been a fruitful year for Bristol-Myers, with many key drugs getting approved.
We are positive on specialty biopharma company, Jazz Pharmaceuticals ( JAZZ ), which carries a Zacks #2 Rank. The company's fourth quarter results exceeded expectations, and we believe Xyrem has impressive growth potential.
WEAKNESSES
We recommend avoiding names that offer little growth or opportunity for a take-out. These include companies which are developing drugs that are likely to face regulatory hurdles. The FDA has been exercising more caution in granting approval to new products and several candidates are facing delays in receiving final approval.
We would also avoid companies like Eli Lilly ( LLY ), which are facing patent expirations on key products and whose new products may not be enough to make up for the loss of revenues that will take place once generics enter the market. 2012 will be a challenging year for Eli Lilly, with the company losing patent exclusivity on Zyprexa in October 2011. Zyprexa sales should erode rapidly with the entry of generics. Moreover, we expect continued erosion of Gemzar sales due to genericization. Another company that is highly exposed to a patent cliff is Forest Labs ( FRX ).
Another company facing generic competition is ViroPharma ( VPHM ). Estimates are down significantly as the company's lead product, Vancocin, began facing generic competition recently. The entry of generic versions will lead to a rapid decline in branded Vancocin sales. We expect ViroPharma to remain under pressure as generic players launch their versions of the drug.
We currently have a Zacks #4 Rank on Novartis ( NVS ). We expect 2012 to be a challenging year for the company given manufacturing issues, pricing headwinds, generic competition and unfavorable currency movement. The company's first quarter 2012 results were below expectations.
United Therapeutics ( UTHR ) also carries a Zacks #4 Rank. We are not too bullish on the company's chances of gaining US approval for oral treprostinil, given the mixed data on the candidate. Moreover, the company's weak late-stage pipeline concerns us.
ABBOTT LABS ( ABT ): Free Stock Analysis Report
BRISTOL-MYERS ( BMY ): Free Stock Analysis Report
CELGENE CORP ( CELG ): Free Stock Analysis Report
GILEAD SCIENCES ( GILD ): Free Stock Analysis Report
GLAXOSMITHKLINE ( GSK ): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
LILLY ELI & CO (LLY): Free Stock Analysis Report
MERCK & CO INC (MRK): Free Stock Analysis Report
MYLAN INC (MYL): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
TEVA PHARM ADR (TEVA): Free Stock Analysis Report
VERTEX PHARM (VRTX): Free Stock Analysis Report
WATSON PHARMA (WPI): Free Stock Analysis Report
DENTSPLY INTL (XRAY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABBOTT LABS ( ABT ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report CELGENE CORP ( CELG ): Free Stock Analysis Report GILEAD SCIENCES ( GILD ): Free Stock Analysis Report GLAXOSMITHKLINE ( GSK ): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. Besides Lipitor, other major branded drugs that lost patent protection in the past few months include Forest Laboratories' ( FRX ) Lexapro and Eli Lilly's ( LLY ) Zyprexa. Two major products slated to lose patent protection in 2012 include Merck's ( MRK ) Singulair and Bristol-Myers Squibb ( BMY )/ Sanofi's ( SNY ) Plavix. | ABBOTT LABS ( ABT ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report CELGENE CORP ( CELG ): Free Stock Analysis Report GILEAD SCIENCES ( GILD ): Free Stock Analysis Report GLAXOSMITHKLINE ( GSK ): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. Two major products slated to lose patent protection in 2012 include Merck's ( MRK ) Singulair and Bristol-Myers Squibb ( BMY )/ Sanofi's ( SNY ) Plavix. Important product approvals include Johnson & Johnson's prostate cancer therapy Zytiga, Merck's hepatitis C virus (HCV) treatment Victrelis, Bristol-Myers' melanoma treatment Yervoy, AstraZeneca's Brilinta, Vertex Pharma's ( VRTX ) HCV treatment Incivek, Pfizer's lung cancer treatment Xalkori, and Glaxo/Human Genome's lupus drug Benlysta, among others. | ABBOTT LABS ( ABT ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report CELGENE CORP ( CELG ): Free Stock Analysis Report GILEAD SCIENCES ( GILD ): Free Stock Analysis Report GLAXOSMITHKLINE ( GSK ): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. With most of the big pharma companies already facing or likely to face patent challenges for their blockbuster products, the companies have been looking toward M&A and in-licensing activities to make up for the loss of revenues that will arise with key products losing patent exclusivity. We would also avoid companies like Eli Lilly ( LLY ), which are facing patent expirations on key products and whose new products may not be enough to make up for the loss of revenues that will take place once generics enter the market. | ABBOTT LABS ( ABT ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report CELGENE CORP ( CELG ): Free Stock Analysis Report GILEAD SCIENCES ( GILD ): Free Stock Analysis Report GLAXOSMITHKLINE ( GSK ): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. With most of the big pharma companies already facing or likely to face patent challenges for their blockbuster products, the companies have been looking toward M&A and in-licensing activities to make up for the loss of revenues that will arise with key products losing patent exclusivity. Overall spending in generics is expected to increase from 20% in 2005 to 39% in 2015. |
34445.0 | 2012-04-25 00:00:00 UTC | Amgen Beats but Maintains Outlook - Analyst Blog | ABT | https://www.nasdaq.com/articles/amgen-beats-but-maintains-outlook-analyst-blog-2012-04-25 | nan | nan | Amgen ( AMGN ) reported first quarter earnings per share of $1.59, 16 cents above the Zacks Consensus Estimate and 20.5% above the year-ago period. A lower tax rate, lower share count and higher revenues contributed to the year-over-year increase in earnings.
Total revenue increased 9.2% to $4,048 million in the first quarter of 2012. Revenues comfortably surpassed the Zacks Consensus Estimate of $3,936 million. However, revenues included a $50 million payment received from AstraZeneca ( AZN ) for their inflammation collaboration and a $22 million milestone payment from Astellas for the approval of AMG 223 (a phosphate binder for patients on dialysis with chronic kidney disease) in Japan.
The Quarter in Detail
First quarter total product sales increased 8% to $3,901 million. US product revenues increased 8% during the quarter to $2,997 million. Meanwhile, international product revenues increased 8% to $904 million.
Revenues of Amgen's erythropoiesis-stimulating agent ( ESA ) Aranesp fell 11% to $518 million (US: $202 million, down 19%; ex-US: $316 million, down 4%).
US sales were down mainly due to a decline in demand that was partially offset by a price increase. The decline reflected segment contraction due to changes in the product label and the reimbursement environment. International sales were affected by a decline the average net sales price. The company expects practice patterns to stabilize by mid-2012.
Revenues of Amgen's other ESA, Epogen, fell 17% to $446 million, reflecting a 30% decline in unit demand. The decrease in demand was mainly due to lower dose utilization. The decline reflected the impact of the implementation of the ESRD bundling strategy in 2011 and label changes in June 2011.
Sales declined 8% on a sequential basis as well. We note that a new competitor, Affymax' ( AFFY ) Omontys (peginesatide), has entered the dialysis market.
Worldwide revenues of Neulasta and Neupogen grew 9% to $1,344 million in the first quarter. An increase in average net sales price and unit demand boosted US revenues to $1,053 million, up 13%. International revenues, however, continued to decline with sales coming in at $291 million, down 4%. Sales were impacted by lower average net sales price and a decline in Neupogen units due to competition from biosimilars.
Enbrel, which is facing increased competition in the dermatology market, posted revenues of $938 million, up 7%. Higher average net sales price drove the upside. The company said that over the last one year, it has been increasing its share among bio-naïve (patients new to biologics) patients, especially in the rheumatology space. Enbrel's competitors include Abbott Labs' ( ABT ) Humira, Merck / Johnson & Johnson's ( MRK / JNJ ) Remicade and Johnson & Johnson's Stelara among others.
With Amgen and Pfizer's ( PFE ) collaboration set to expire in late 2013, the companies intend to consolidate US field sales activities under Amgen from July 23, 2012. The consolidated sales force will target both the rheumatology and dermatology segments.
First quarter 2012 Prolia sales came in at $88 million, up slightly from fourth quarter 2011 sales of $81 million. Amgen launched a DTC TV campaign this year which should drive sales further.
Meanwhile, Xgeva, which gained FDA approval on November 18, 2010, delivered first quarter sales of $153 million, up from the $134 million, $100 million and $73 million reported in the fourth, third and second quarters of 2011, respectively. Sales were driven by overall segment growth and increased segment share. Xgeva gained EU approval on July 15, 2011.
Combined Prolia and Xgeva sales lagged expectations for the first quarter of 2012.
Sensipar/Mimpara revenues increased 17% to $219 million in the reported quarter. Global demand helped drive Vectibix revenues to $90 million during the quarter, up 20%.
While Amgen recorded a 3% increase in R&D expenses during the quarter, SG&A expenses increased 5%. Costs increased due to higher marketing spend, higher Enbrel profit share expenses, expansion of international operations and phase III clinical programs.
Amgen recently initiated a phase III study with AMG 785 for the treatment of postmenopausal osteoporosis and expects to commence phase III studies with brodalumab (AMG 827) this year.
Guidance Maintained
Amgen maintained its guidance for 2012. The company expects earnings in the range of $5.90 - $6.15 per share on revenues of $16.1 - $16.5 billion. The Zacks Consensus Estimate currently stands towards the lower end of the earnings guidance at $5.94 per share. Meanwhile, the Zacks Consensus Estimate for revenues is $16.2 billion.
Amgen intends to continue buying back shares in 2012. The company repurchased about 21 million shares for $1.4 billion in the first quarter of 2012 and has about $3.6 billion remaining under its current share buyback program.
The company is also working on growing its presence in international markets. Amgen, in fact, signed a deal recently to acquire 95.6% of the shares of Turkish company, Mustafa Nevzat Pharmaceuticals for $700 million. With this acquisition, Amgen will expand its presence in Turkey and other rapidly growing important markets. This deal is a step towards achieving Amgen's target of having a presence in 75 countries by 2015 - the company currently has a presence in 54-56 countries.
Mustafa Nevzat's 2011 revenues came in at $200 million, growing in double-digits (at local currencies) over a 5-year period.
Neutral on Amgen
We currently have a Neutral recommendation on Amgen. Although first quarter results were well above expectations, it remains to be seen whether the performance is sustainable. We note that despite the huge beat, the company maintained its guidance. Amgen's ESA franchise is under pressure and we expect sales to continue declining. With several key products expected to lose patent protection in the next few years, Amgen has a lot riding on Prolia/Xgeva's successful commercialization. Share repurchases and cost control should help the company achieve at least the lower end of its guidance range. Amgen carries a Zacks #2 Rank (short-term 'Buy' rating).
ABBOTT LABS ( ABT ): Free Stock Analysis Report
AFFYMAX INC ( AFFY ): Free Stock Analysis Report
AMGEN INC ( AMGN ): Free Stock Analysis Report
ASTRAZENECA PLC ( AZN ): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
MERCK & CO INC (MRK): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Enbrel's competitors include Abbott Labs' ( ABT ) Humira, Merck / Johnson & Johnson's ( MRK / JNJ ) Remicade and Johnson & Johnson's Stelara among others. ABBOTT LABS ( ABT ): Free Stock Analysis Report AFFYMAX INC ( AFFY ): Free Stock Analysis Report AMGEN INC ( AMGN ): Free Stock Analysis Report ASTRAZENECA PLC ( AZN ): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Amgen ( AMGN ) reported first quarter earnings per share of $1.59, 16 cents above the Zacks Consensus Estimate and 20.5% above the year-ago period. | Enbrel's competitors include Abbott Labs' ( ABT ) Humira, Merck / Johnson & Johnson's ( MRK / JNJ ) Remicade and Johnson & Johnson's Stelara among others. ABBOTT LABS ( ABT ): Free Stock Analysis Report AFFYMAX INC ( AFFY ): Free Stock Analysis Report AMGEN INC ( AMGN ): Free Stock Analysis Report ASTRAZENECA PLC ( AZN ): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Costs increased due to higher marketing spend, higher Enbrel profit share expenses, expansion of international operations and phase III clinical programs. | ABBOTT LABS ( ABT ): Free Stock Analysis Report AFFYMAX INC ( AFFY ): Free Stock Analysis Report AMGEN INC ( AMGN ): Free Stock Analysis Report ASTRAZENECA PLC ( AZN ): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Enbrel's competitors include Abbott Labs' ( ABT ) Humira, Merck / Johnson & Johnson's ( MRK / JNJ ) Remicade and Johnson & Johnson's Stelara among others. First quarter 2012 Prolia sales came in at $88 million, up slightly from fourth quarter 2011 sales of $81 million. | Enbrel's competitors include Abbott Labs' ( ABT ) Humira, Merck / Johnson & Johnson's ( MRK / JNJ ) Remicade and Johnson & Johnson's Stelara among others. ABBOTT LABS ( ABT ): Free Stock Analysis Report AFFYMAX INC ( AFFY ): Free Stock Analysis Report AMGEN INC ( AMGN ): Free Stock Analysis Report ASTRAZENECA PLC ( AZN ): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. US product revenues increased 8% during the quarter to $2,997 million. |
34446.0 | 2012-04-25 00:00:00 UTC | St. Jude's Alliance with Abbott - Analyst Blog | ABT | https://www.nasdaq.com/articles/st.-judes-alliance-with-abbott-analyst-blog-2012-04-25 | nan | nan | St. Jude Medical Inc. ( STJ ) recently disclosed its decision to build on its mutual agreement with Abbott Laboratories ( ABT ) by revealing the long-term Choice Alliance joint venture. This initiative provides St. Jude Medical the opportunity to incorporate Abbott's drug-eluting stents with its cardiovascular, cardiac rhythm management and electrophysiology offerings.
Both companies have agreed to endorse each other's products to their respective customers. Further, Abbott has received the rights to promote St. Jude's RadiAnalyze Xpress Measurement System and the ILUMIEN PCI Optimization System.
This alliance is expected to benefit patient outcomes, as doctors will be able to combine Abbott's XIENCE family of stents with St. Jude's optical coherence tomography (OCT) and fractional flow reserve ( FFR ) know-how to widen the scope of clinical treatments.
Abbott Laboratories is a global manufacturer of a vast array of health care products. Pharmaceuticals, medical and nutritional offerings, including cardiovascular devices, are the core franchises of the company. Within the vascular segment, the XIENCE family of products (Xience V, PRIME and nano) was the worldwide market leader of drug eluting stents in 2011.
St. Jude is consistently producing revenue growth and positive earnings surprises over the past several quarters. We are impressed by its solid fundamentals, healthy growth trajectory, strong product mix, robust pipeline and cost management initiatives.
While a host of new growth drivers (including new products and expansion in emerging markets) are expected to boost results in 2012 and beyond, we remain cautious about increased competition, a still-soft CRM market and the dilutive impact of acquisitions.
Th CRM space continues to thwart St. Jude as well as its peers Medtronic ( MDT ) and Boston Scientific ( BSX ). Our long-term Neutral recommendation on St. Jude is in agreement with the short-term Zacks #3 Rank (Hold) retained by the stock.
ABBOTT LABS ( ABT ): Free Stock Analysis Report
BOSTON SCIENTIF ( BSX ): Free Stock Analysis Report
MEDTRONIC ( MDT ): Free Stock Analysis Report
ST JUDE MEDICAL ( STJ ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | St. Jude Medical Inc. ( STJ ) recently disclosed its decision to build on its mutual agreement with Abbott Laboratories ( ABT ) by revealing the long-term Choice Alliance joint venture. ABBOTT LABS ( ABT ): Free Stock Analysis Report BOSTON SCIENTIF ( BSX ): Free Stock Analysis Report MEDTRONIC ( MDT ): Free Stock Analysis Report ST JUDE MEDICAL ( STJ ): Free Stock Analysis Report To read this article on Zacks.com click here. This initiative provides St. Jude Medical the opportunity to incorporate Abbott's drug-eluting stents with its cardiovascular, cardiac rhythm management and electrophysiology offerings. | ABBOTT LABS ( ABT ): Free Stock Analysis Report BOSTON SCIENTIF ( BSX ): Free Stock Analysis Report MEDTRONIC ( MDT ): Free Stock Analysis Report ST JUDE MEDICAL ( STJ ): Free Stock Analysis Report To read this article on Zacks.com click here. St. Jude Medical Inc. ( STJ ) recently disclosed its decision to build on its mutual agreement with Abbott Laboratories ( ABT ) by revealing the long-term Choice Alliance joint venture. Th CRM space continues to thwart St. Jude as well as its peers Medtronic ( MDT ) and Boston Scientific ( BSX ). | ABBOTT LABS ( ABT ): Free Stock Analysis Report BOSTON SCIENTIF ( BSX ): Free Stock Analysis Report MEDTRONIC ( MDT ): Free Stock Analysis Report ST JUDE MEDICAL ( STJ ): Free Stock Analysis Report To read this article on Zacks.com click here. St. Jude Medical Inc. ( STJ ) recently disclosed its decision to build on its mutual agreement with Abbott Laboratories ( ABT ) by revealing the long-term Choice Alliance joint venture. This initiative provides St. Jude Medical the opportunity to incorporate Abbott's drug-eluting stents with its cardiovascular, cardiac rhythm management and electrophysiology offerings. | St. Jude Medical Inc. ( STJ ) recently disclosed its decision to build on its mutual agreement with Abbott Laboratories ( ABT ) by revealing the long-term Choice Alliance joint venture. ABBOTT LABS ( ABT ): Free Stock Analysis Report BOSTON SCIENTIF ( BSX ): Free Stock Analysis Report MEDTRONIC ( MDT ): Free Stock Analysis Report ST JUDE MEDICAL ( STJ ): Free Stock Analysis Report To read this article on Zacks.com click here. This initiative provides St. Jude Medical the opportunity to incorporate Abbott's drug-eluting stents with its cardiovascular, cardiac rhythm management and electrophysiology offerings. |
34447.0 | 2012-04-20 00:00:00 UTC | Patent Challenge for Auxilium Pharma - Analyst Blog | ABT | https://www.nasdaq.com/articles/patent-challenge-for-auxilium-pharma-analyst-blog-2012-04-20 | nan | nan | Auxilium Pharmaceuticals, Inc. ( AUXL ) and FCB I LLC ("FCB") recently announced that Watson Laboratories, Inc. is seeking US Food and Drug Administration (FDA) approval for its generic version of Auxilium Pharma's 1% testosterone gel, Testim. Watson Lab is challenging nine US patents which are slated to expire in the 2023-2025 timeframe.
Testim is the lead product at Auxilium Pharma. Testim sales came in at $207.9 million in 2011, accounting for 78.6% of the company's revenues. Testim's prescription share of the gel market was 20% in December 2011. However, Testim faces stiff competition from Abbott Labs' ( ABT ) AndroGel. We expect Testim sales to slow down given the entry of additional competitors like Endo Pharmaceutical's ( ENDP ) Fortesta and Eli Lilly's ( LLY ) Axiron.
The testosterone gel market will become even more competitive from 2015 when generic versions of AndroGel are scheduled to enter the market. The availability of a cheaper generic testosterone gel product could impact Testim's market share as well as its formulary status.
Our Take
We expect Auxilium Pharma and FCB to file a patent infringement lawsuit against Watson Labs. The filing of the lawsuit within 45 days from the date of receipt of notice from Watson Labs will ensure that the FDA cannot grant final approval to Watson Labs' generic for up to 30 months or the court's decision, whichever is earlier. With Testim sales expected to slow down in the next few years, we do not expect the filing of the patent challenge to have a major impact on the company.
Given the eventual slowdown in Testim growth, Auxilium Pharma's future relies heavily on Xiaflex. With Auxilium Pharma working on driving sales of the product, we expect investor focus to remain on the successful commercialization of Xiaflex/Xiapex, and label expansion of the product for additional indications. We currently have a Neutral recommendation on Auxilium Pharma, which carries a Zacks #3 Rank (short-term 'Hold' rating).
ABBOTT LABS ( ABT ): Free Stock Analysis Report
AUXILIUM PHARMA ( AUXL ): Free Stock Analysis Report
ENDO PHARMACEUT ( ENDP ): Free Stock Analysis Report
LILLY ELI & CO ( LLY ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | However, Testim faces stiff competition from Abbott Labs' ( ABT ) AndroGel. ABBOTT LABS ( ABT ): Free Stock Analysis Report AUXILIUM PHARMA ( AUXL ): Free Stock Analysis Report ENDO PHARMACEUT ( ENDP ): Free Stock Analysis Report LILLY ELI & CO ( LLY ): Free Stock Analysis Report To read this article on Zacks.com click here. We expect Testim sales to slow down given the entry of additional competitors like Endo Pharmaceutical's ( ENDP ) Fortesta and Eli Lilly's ( LLY ) Axiron. | ABBOTT LABS ( ABT ): Free Stock Analysis Report AUXILIUM PHARMA ( AUXL ): Free Stock Analysis Report ENDO PHARMACEUT ( ENDP ): Free Stock Analysis Report LILLY ELI & CO ( LLY ): Free Stock Analysis Report To read this article on Zacks.com click here. However, Testim faces stiff competition from Abbott Labs' ( ABT ) AndroGel. Auxilium Pharmaceuticals, Inc. ( AUXL ) and FCB I LLC ("FCB") recently announced that Watson Laboratories, Inc. is seeking US Food and Drug Administration (FDA) approval for its generic version of Auxilium Pharma's 1% testosterone gel, Testim. | ABBOTT LABS ( ABT ): Free Stock Analysis Report AUXILIUM PHARMA ( AUXL ): Free Stock Analysis Report ENDO PHARMACEUT ( ENDP ): Free Stock Analysis Report LILLY ELI & CO ( LLY ): Free Stock Analysis Report To read this article on Zacks.com click here. However, Testim faces stiff competition from Abbott Labs' ( ABT ) AndroGel. Auxilium Pharmaceuticals, Inc. ( AUXL ) and FCB I LLC ("FCB") recently announced that Watson Laboratories, Inc. is seeking US Food and Drug Administration (FDA) approval for its generic version of Auxilium Pharma's 1% testosterone gel, Testim. | However, Testim faces stiff competition from Abbott Labs' ( ABT ) AndroGel. ABBOTT LABS ( ABT ): Free Stock Analysis Report AUXILIUM PHARMA ( AUXL ): Free Stock Analysis Report ENDO PHARMACEUT ( ENDP ): Free Stock Analysis Report LILLY ELI & CO ( LLY ): Free Stock Analysis Report To read this article on Zacks.com click here. The testosterone gel market will become even more competitive from 2015 when generic versions of AndroGel are scheduled to enter the market. |
34448.0 | 2012-04-18 00:00:00 UTC | Ahead of Wall Street - April 18, 2012 - Ahead of Wall Street | ABT | https://www.nasdaq.com/articles/ahead-wall-street-april-18-2012-ahead-wall-street-2012-04-18 | nan | nan | Wednesday, April 18, 2012
Stocks will likely take a breather today following the strong gains on Tuesday, particularly given the absence of any major economic reports on the docket. It is quite out of Spain today as well following that country's over-subscribed auction of shorter maturity bonds on Tuesday. A key test comes on Thursday when Spain has to auction two and 10-year government bonds, which will provide a better measure of investor confidence in the country's outlook.
On the earnings front, the first quarter reporting season is off to a fairly good start, both relative to expectations as well as relative to where we were at this stage in the preceding quarter. With about 10% of the results already in, earnings are up 3.7% from the year-earlier level. At this admittedly early stage, roughly 77% of the companies have come out ahead of expectations, with a median earnings surprise of 3.9%. We will have a much better sense of the aggregate earnings picture in the coming days, but some of the exaggerated pre-season fears were likely off the mark.
Of this morning's major earnings releases, we got positive earnings and revenue surprises from Halliburton ( HAL ) and Abbot Labs ( ABT ). Yahoo ( YHOO ) came out with better than expected results after the close on Tuesday, while results from Intel ( INTC ) and IBM ( IBM ) proved less inspiring. We have results from eBay ( EBAY ) coming out after the close today.
In corporate news, Pfizer ( PFE ) is reportedly close to finalizing a deal to sell its infant formula business for $9 billion to Nestle . This is part of Pfizer's ongoing plan to shed non-core businesses to focus more on its core drugs franchise. Headlines about Warren Buffet's health will likely keep Berkshire Hathaway ( BRK.B ) in the spotlight today.
Sheraz Mian
Director of Research
ABBOTT LABS ( ABT ): Free Stock Analysis Report
BERKSHIRE HTH-B (BRK.B): Free Stock Analysis Report
EBAY INC ( EBAY ): Free Stock Analysis Report
HALLIBURTON CO ( HAL ): Free Stock Analysis Report
INTL BUS MACH ( IBM ): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
YAHOO! INC (YHOO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of this morning's major earnings releases, we got positive earnings and revenue surprises from Halliburton ( HAL ) and Abbot Labs ( ABT ). Sheraz Mian Director of Research ABBOTT LABS ( ABT ): Free Stock Analysis Report BERKSHIRE HTH-B (BRK.B): Free Stock Analysis Report EBAY INC ( EBAY ): Free Stock Analysis Report HALLIBURTON CO ( HAL ): Free Stock Analysis Report INTL BUS MACH ( IBM ): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report YAHOO! Wednesday, April 18, 2012 Stocks will likely take a breather today following the strong gains on Tuesday, particularly given the absence of any major economic reports on the docket. | Sheraz Mian Director of Research ABBOTT LABS ( ABT ): Free Stock Analysis Report BERKSHIRE HTH-B (BRK.B): Free Stock Analysis Report EBAY INC ( EBAY ): Free Stock Analysis Report HALLIBURTON CO ( HAL ): Free Stock Analysis Report INTL BUS MACH ( IBM ): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report YAHOO! Of this morning's major earnings releases, we got positive earnings and revenue surprises from Halliburton ( HAL ) and Abbot Labs ( ABT ). INC (YHOO): Free Stock Analysis Report To read this article on Zacks.com click here. | Sheraz Mian Director of Research ABBOTT LABS ( ABT ): Free Stock Analysis Report BERKSHIRE HTH-B (BRK.B): Free Stock Analysis Report EBAY INC ( EBAY ): Free Stock Analysis Report HALLIBURTON CO ( HAL ): Free Stock Analysis Report INTL BUS MACH ( IBM ): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report YAHOO! Of this morning's major earnings releases, we got positive earnings and revenue surprises from Halliburton ( HAL ) and Abbot Labs ( ABT ). On the earnings front, the first quarter reporting season is off to a fairly good start, both relative to expectations as well as relative to where we were at this stage in the preceding quarter. | Sheraz Mian Director of Research ABBOTT LABS ( ABT ): Free Stock Analysis Report BERKSHIRE HTH-B (BRK.B): Free Stock Analysis Report EBAY INC ( EBAY ): Free Stock Analysis Report HALLIBURTON CO ( HAL ): Free Stock Analysis Report INTL BUS MACH ( IBM ): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report YAHOO! Of this morning's major earnings releases, we got positive earnings and revenue surprises from Halliburton ( HAL ) and Abbot Labs ( ABT ). At this admittedly early stage, roughly 77% of the companies have come out ahead of expectations, with a median earnings surprise of 3.9%. |
34449.0 | 2012-04-18 00:00:00 UTC | Market May Take a Breather - Analyst Blog | ABT | https://www.nasdaq.com/articles/market-may-take-breather-analyst-blog-2012-04-18 | nan | nan | Stocks will likely take a breather today following the strong gains on Tuesday, particularly given the absence of any major economic reports on the docket. It is quiet out of Spain today as well following that country's over-subscribed auction of shorter maturity bonds on Tuesday. A key test comes on Thursday when Spain has to auction two and 10-year government bonds, which will provide a better measure of investor confidence in the country's outlook.
On the earnings front, the first quarter reporting season is off to a fairly good start, both relative to expectations as well as relative to where we were at this stage in the preceding quarter. With about 10% of the results already in, earnings are up 3.7% from the year-earlier level. At this admittedly early stage, roughly 77% of the companies have come out ahead of expectations, with a median earnings surprise of 3.9%. We will have a much better sense of the aggregate earnings picture in the coming days, but some of the exaggerated pre-season fears were likely off the mark.
Of this morning's major earnings releases, we got positive earnings and revenue surprises from Halliburton ( HAL ) and Abbot Labs ( ABT ). Yahoo ( YHOO ) came out with better than expected results after the close on Tuesday, while results from Intel ( INTC ) and IBM ( IBM ) proved less inspiring. We have results from eBay ( EBAY ) coming out after the close today.
In corporate news, Pfizer ( PFE ) is reportedly close to finalizing a deal to sell its infant formula business for $9 billion to Nestle . This is part of Pfizer's ongoing plan to shed non-core businesses to focus more on its core drugs franchise. Headlines about Warren Buffet's health will likely keep Berkshire Hathaway ( BRK.B ) in the spotlight today.
ABBOTT LABS ( ABT ): Free Stock Analysis Report
BERKSHIRE HTH-B (BRK.B): Free Stock Analysis Report
EBAY INC ( EBAY ): Free Stock Analysis Report
HALLIBURTON CO ( HAL ): Free Stock Analysis Report
INTL BUS MACH ( IBM ): Free Stock Analysis Report
PFIZER INC ( PFE ): Free Stock Analysis Report
YAHOO! INC (YHOO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of this morning's major earnings releases, we got positive earnings and revenue surprises from Halliburton ( HAL ) and Abbot Labs ( ABT ). ABBOTT LABS ( ABT ): Free Stock Analysis Report BERKSHIRE HTH-B (BRK.B): Free Stock Analysis Report EBAY INC ( EBAY ): Free Stock Analysis Report HALLIBURTON CO ( HAL ): Free Stock Analysis Report INTL BUS MACH ( IBM ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report YAHOO! A key test comes on Thursday when Spain has to auction two and 10-year government bonds, which will provide a better measure of investor confidence in the country's outlook. | ABBOTT LABS ( ABT ): Free Stock Analysis Report BERKSHIRE HTH-B (BRK.B): Free Stock Analysis Report EBAY INC ( EBAY ): Free Stock Analysis Report HALLIBURTON CO ( HAL ): Free Stock Analysis Report INTL BUS MACH ( IBM ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report YAHOO! Of this morning's major earnings releases, we got positive earnings and revenue surprises from Halliburton ( HAL ) and Abbot Labs ( ABT ). INC (YHOO): Free Stock Analysis Report To read this article on Zacks.com click here. | ABBOTT LABS ( ABT ): Free Stock Analysis Report BERKSHIRE HTH-B (BRK.B): Free Stock Analysis Report EBAY INC ( EBAY ): Free Stock Analysis Report HALLIBURTON CO ( HAL ): Free Stock Analysis Report INTL BUS MACH ( IBM ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report YAHOO! Of this morning's major earnings releases, we got positive earnings and revenue surprises from Halliburton ( HAL ) and Abbot Labs ( ABT ). On the earnings front, the first quarter reporting season is off to a fairly good start, both relative to expectations as well as relative to where we were at this stage in the preceding quarter. | Of this morning's major earnings releases, we got positive earnings and revenue surprises from Halliburton ( HAL ) and Abbot Labs ( ABT ). ABBOTT LABS ( ABT ): Free Stock Analysis Report BERKSHIRE HTH-B (BRK.B): Free Stock Analysis Report EBAY INC ( EBAY ): Free Stock Analysis Report HALLIBURTON CO ( HAL ): Free Stock Analysis Report INTL BUS MACH ( IBM ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report YAHOO! Stocks will likely take a breather today following the strong gains on Tuesday, particularly given the absence of any major economic reports on the docket. |
34450.0 | 2012-04-18 00:00:00 UTC | Abbott Beats, Raises Outlook - Analyst Blog | ABT | https://www.nasdaq.com/articles/abbott-beats-raises-outlook-analyst-blog-2012-04-18 | nan | nan | Abbott Labs ( ABT ) reported first quarter earnings of $1.03 per share, three cents above the Zacks Consensus Estimate of $1.00 and 13.2% above the year-earlier earnings. Including one-time items, first quarter earnings increased 41.8% to 78 cents per share. Higher revenues led to the improvement.
First quarter revenues increased 4.6% to $9.5 billion, just above the Zacks Consensus Estimate of $9.3 billion. Foreign exchange fluctuations negatively impacted sales by 1.3%.
The Quarter in Detail
Several of the business categories performed well during the quarter. Proprietary Pharmaceutical sales were $4.1 billion, up 7.1%. Humira was a major contributor with sales coming in at $1.9 billion, up 17.4%. Humira recorded sales growth in both the US (22.7%) and international markets (14.2%) during the quarter.
Abbott Labs is looking to get Humira approved for additional indications which would help drive growth further. The company recently gained EU approval for Humira for ulcerative colitis. Abbott Labs is currently evaluating Humira's safety and efficacy in adult patients with moderate to severe hidradenitis suppurativa (HS).
Lupron, Androgel, Creon and Synthroid also contributed to Proprietary Pharmaceutical sales growth.
The Nutritionals business grew 10.1% to $1.6 billion. Nutrition sales in the US increased 11% to $707 million. The company said that it continued to recover the share it had lost in the US due to the late 2010 Similac recall. Outside the US, Nutrition sales experienced single-digit growth with sales increasing 9.3% to $859 million. Strong performance of pediatric nutritionals in emerging markets helped drive international nutrition sales.
Other areas that witnessed growth include the Core Laboratory Diagnostics, Molecular Diagnostics, Medical Optics and Point of Care Diagnostics businesses.
Established Pharmaceuticals sales, however, continued to decline with sales coming in at $1.3 billion, down 1.6%.
2012 Outlook Raised
Based on first quarter results, Abbott Labs increased its earnings guidance for 2012. The company now expects 2012 earnings in the range of $5.00 to $5.10, up from the earlier guidance of $4.95 to $5.05 per share. The Zacks Consensus Estimate currently stands at $5.02 per share, towards the lower end of the new guidance range.
Abbott Labs provided an update on its intention to split into two separate publicly traded companies: the company said that it expects to complete the separation by year end. While one company will deal in diversified medical products, the other (AbbVie) will focus on research-based pharmaceuticals.
The company also declared a quarterly dividend of 51 cents per share.
Pipeline Update
Abbott Labs also provided an update on its pipeline. The company currently has 20 candidates in phase II/phase III development. The acquisition of Facet Biotech has helped strengthen Abbott Labs' early- and mid-stage oncology portfolio.
Abbott Labs is also working on strengthening its neuroscience portfolio and has several candidates in different stages of development for the treatment of diseases like schizophrenia, pain, Parkinson's, Alzheimer's and multiple sclerosis. Abbott Labs, along with partner Biogen ( BIIB ), is evaluating daclizumab in a phase III study for the treatment of relapsing-remitting multiple sclerosis ( RRMS ).
Abbott Labs is also working on an intestinal gel for advanced Parkinson's disease - positive phase III results were reported on this candidate recently and Abbott Labs expects to file for US approval later this year.
Another promising pipeline candidate is bardoxolone, which is in phase III studies for chronic kidney disease.
We currently have a Neutral recommendation on Abbott Labs, which carries a Zacks #3 Rank (short-term Hold rating). Shares were up 1.27% in pre-market trading.
ABBOTT LABS ( ABT ): Free Stock Analysis Report
BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ( ABT ) reported first quarter earnings of $1.03 per share, three cents above the Zacks Consensus Estimate of $1.00 and 13.2% above the year-earlier earnings. ABBOTT LABS ( ABT ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs is currently evaluating Humira's safety and efficacy in adult patients with moderate to severe hidradenitis suppurativa (HS). | Abbott Labs ( ABT ) reported first quarter earnings of $1.03 per share, three cents above the Zacks Consensus Estimate of $1.00 and 13.2% above the year-earlier earnings. ABBOTT LABS ( ABT ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs is also working on an intestinal gel for advanced Parkinson's disease - positive phase III results were reported on this candidate recently and Abbott Labs expects to file for US approval later this year. | Abbott Labs ( ABT ) reported first quarter earnings of $1.03 per share, three cents above the Zacks Consensus Estimate of $1.00 and 13.2% above the year-earlier earnings. ABBOTT LABS ( ABT ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs provided an update on its intention to split into two separate publicly traded companies: the company said that it expects to complete the separation by year end. | Abbott Labs ( ABT ) reported first quarter earnings of $1.03 per share, three cents above the Zacks Consensus Estimate of $1.00 and 13.2% above the year-earlier earnings. ABBOTT LABS ( ABT ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report To read this article on Zacks.com click here. First quarter revenues increased 4.6% to $9.5 billion, just above the Zacks Consensus Estimate of $9.3 billion. |
34451.0 | 2012-04-17 00:00:00 UTC | Earnings Preview: Abbott Labs - Analyst Blog | ABT | https://www.nasdaq.com/articles/earnings-preview%3A-abbott-labs-analyst-blog-2012-04-17 | nan | nan | Abbott Laboratories ( ABT ) is set to release its first quarter 2012 results on April 18, 2012 before the opening bell. The Zacks Consensus Estimate for the first quarter is $1.00, representing a year-over-year increase of 9.9%. Abbott Labs has surpassed earnings estimates consistently in the last four quarters with a trailing four-quarter average of 0.89%.
Fourth Quarter 2011 Flashback
Abbott Labs reported fourth quarter earnings of $1.45 per share, a penny above the Zacks Consensus Estimate and at the higher end of the guidance range provided by the company. Fourth quarter earnings increased 11.5% from the year-earlier period. Including one-time items, fourth quarter earnings increased 10.9% to $1.02 per share.
Fourth quarter revenues increased 4.1% to $10.4 billion, just shy of the Zacks Consensus Estimate of $10.6 billion. (Read our full coverage of the fourth quarter and full year 2011 earnings report at Abbott Beats on EPS, Guides In-Line ).
Agreement of Estimate Revisions
Estimate revisions for Abbott Labs have been scarce over the past month. Over the past 30 days, only 3 of the 16 analysts covering Abbott Labs have revised their earnings estimates for the first quarter of 2012. While 2 of have them have increased their estimates, 1 has moved in the opposite direction. We believe that most analysts prefer to remain on the sidelines until Abbott Labs announces its first quarter 2012 results before adjusting their estimates.
The annual estimates for 2012 have not been revised by the majority of analysts either. Only 3 of the 20 analysts following Abbott Labs for 2012 have revised their estimates. While 2 analysts have trimmed their estimates, 1 has moved in the opposite direction.
We believe that although concerns like the impact of US health care reform, product recalls, foreign exchange headwinds and EU pricing austerity and generic competition will continue to hurt Abbott Labs, its pharmaceutical products should continue driving growth led by key drug Humira, an anti-inflammatory product.
Humira is quickly becoming the anti-tumor necrosis factor (TNF) drug of choice, gaining sizable market share despite the presence of Amgen/Pfizer's ( AMGN / PFE ) Enbrel and Johnson & Johnson 's ( JNJ ) Remicade. Growing awareness, favorable clinical data, additional indications and expansion into new markets like China and Japan should help the product to continue contributing significantly to the top-line.
Magnitude of Estimate Revisions
Estimates for the first quarter of 2012 have gone up by only 1 cent to $1.00 over the last 30 days due to a lack of significant estimate revisions by the analysts following the stock. Estimates for 2012 have gone down only by 1 cent over a similar time period and stands at $5.02 .
Neutral on Abbott Labs
We currently have a Neutral recommendation on Abbott Labs, which carries a Zacks #3 Rank (short-term Hold rating). Abbott Labs remains on track to split into two separate publicly traded companies by the end of 2012. While one company will deal in diversified medical products, the other will focus on research-based pharmaceuticals. We are positive on the split, which should allow the two separate entities to perform in a more focused manner.
ABBOTT LABS ( ABT ): Free Stock Analysis Report
AMGEN INC ( AMGN ): Free Stock Analysis Report
JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report
PFIZER INC ( PFE ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is set to release its first quarter 2012 results on April 18, 2012 before the opening bell. ABBOTT LABS ( ABT ): Free Stock Analysis Report AMGEN INC ( AMGN ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report To read this article on Zacks.com click here. Over the past 30 days, only 3 of the 16 analysts covering Abbott Labs have revised their earnings estimates for the first quarter of 2012. | ABBOTT LABS ( ABT ): Free Stock Analysis Report AMGEN INC ( AMGN ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) is set to release its first quarter 2012 results on April 18, 2012 before the opening bell. Fourth Quarter 2011 Flashback Abbott Labs reported fourth quarter earnings of $1.45 per share, a penny above the Zacks Consensus Estimate and at the higher end of the guidance range provided by the company. | ABBOTT LABS ( ABT ): Free Stock Analysis Report AMGEN INC ( AMGN ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) is set to release its first quarter 2012 results on April 18, 2012 before the opening bell. Fourth Quarter 2011 Flashback Abbott Labs reported fourth quarter earnings of $1.45 per share, a penny above the Zacks Consensus Estimate and at the higher end of the guidance range provided by the company. | Abbott Laboratories ( ABT ) is set to release its first quarter 2012 results on April 18, 2012 before the opening bell. ABBOTT LABS ( ABT ): Free Stock Analysis Report AMGEN INC ( AMGN ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report To read this article on Zacks.com click here. Fourth quarter earnings increased 11.5% from the year-earlier period. |
34452.0 | 2012-04-13 00:00:00 UTC | Biogen's Fampyra Launched in Canada - Analyst Blog | ABT | https://www.nasdaq.com/articles/biogens-fampyra-launched-in-canada-analyst-blog-2012-04-13 | nan | nan | Biogen Idec ( BIIB ) recently announced the launch of Fampyra in Canada. Fampyra gained approval in Canada in February 2012 for the symptomatic improvement of walking ability in adult multiple sclerosis ( MS ) patients.
Biogen has a licensing deal with Acorda Therapeutics, Inc. ( ACOR ) for the development and commercialization of Fampyra in ex-US markets. Biogen is currently working on launching Fampyra in additional markets in the EU, where it gained conditional approval in July 2011.
Fampyra, which was launched in Australia, Denmark, Germany, Norway and the UK in 2011, posted sales of $13.6 million in 2011. Sales should increase in 2012 as Biogen launches the product in additional countries.
Fampyra is available in the US, under the trade name Ampyra, where it is being marketed by Acorda. Acorda received FDA approval in late January 2010, for the marketing of Ampyra in the US for improving walking speed in patients suffering from multiple sclerosis. Ampyra sales increased 58.2% to $210.5 million in 2011. Acorda expects Ampyra sales to increase to $255 - $275 million in 2012.
Neutral on Biogen
We currently have a Neutral recommendation on Biogen. The company is the market leader in therapies for the treatment of multiple sclerosis. We believe Biogen will continue to retain a leading position in the multiple sclerosis market. The company has been working on consolidating its position in the multiple sclerosis market and has an impressive late-stage pipeline of multiple sclerosis drugs including BG-12 (new drug application filed in the US in Feb 2012).
Besides BG-12, Biogen is developing other multiple sclerosis candidates like daclizumab, in partnership with Abbott Labs ( ABT ), and PEGylated interferon. Biogen recently signed an exclusive, worldwide option and collaboration agreement with privately held MAKScientific, LLC for the development and commercialization of drug candidates for the treatment of multiple sclerosis and other neurodegenerative diseases.
However, Biogen's multiple sclerosis products face significant competition from products like Teva's ( TEVA ) Copaxone, Pfizer /Serono's ( PFE ) Rebif, Bayer's ( BAYRY ) Betaseron and Novartis' ( NVS ) Gilenya. Additional competition could come in the form of Sanofi's ( SNY ) teriflunomide and Lemtrada.
ABBOTT LABS ( ABT ): Free Stock Analysis Report
ACORDA THERAPT ( ACOR ): Free Stock Analysis Report
BAYER A G -ADR ( BAYRY ): Free Stock Analysis Report
BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report
NOVARTIS AG-ADR (NVS): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
TEVA PHARM ADR (TEVA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Besides BG-12, Biogen is developing other multiple sclerosis candidates like daclizumab, in partnership with Abbott Labs ( ABT ), and PEGylated interferon. ABBOTT LABS ( ABT ): Free Stock Analysis Report ACORDA THERAPT ( ACOR ): Free Stock Analysis Report BAYER A G -ADR ( BAYRY ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Fampyra gained approval in Canada in February 2012 for the symptomatic improvement of walking ability in adult multiple sclerosis ( MS ) patients. | ABBOTT LABS ( ABT ): Free Stock Analysis Report ACORDA THERAPT ( ACOR ): Free Stock Analysis Report BAYER A G -ADR ( BAYRY ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Besides BG-12, Biogen is developing other multiple sclerosis candidates like daclizumab, in partnership with Abbott Labs ( ABT ), and PEGylated interferon. Biogen Idec ( BIIB ) recently announced the launch of Fampyra in Canada. | ABBOTT LABS ( ABT ): Free Stock Analysis Report ACORDA THERAPT ( ACOR ): Free Stock Analysis Report BAYER A G -ADR ( BAYRY ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Besides BG-12, Biogen is developing other multiple sclerosis candidates like daclizumab, in partnership with Abbott Labs ( ABT ), and PEGylated interferon. The company has been working on consolidating its position in the multiple sclerosis market and has an impressive late-stage pipeline of multiple sclerosis drugs including BG-12 (new drug application filed in the US in Feb 2012). | Besides BG-12, Biogen is developing other multiple sclerosis candidates like daclizumab, in partnership with Abbott Labs ( ABT ), and PEGylated interferon. ABBOTT LABS ( ABT ): Free Stock Analysis Report ACORDA THERAPT ( ACOR ): Free Stock Analysis Report BAYER A G -ADR ( BAYRY ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Sales should increase in 2012 as Biogen launches the product in additional countries. |
34453.0 | 2012-04-02 00:00:00 UTC | Myriad Inks Deal with Cephalon - Analyst Blog | ABT | https://www.nasdaq.com/articles/myriad-inks-deal-with-cephalon-analyst-blog-2012-04-02 | nan | nan | The recent agreement with Cephalon is another attempt by Myriad Genetics ( MYGN ) to establish itself as a strong player in the companion diagnostic market. Cephalon is a subsidiary of Teva Pharmaceuticals ( TEVA ). Under the agreement, Myriad will conduct BRCA1 and BRCA2 mutation testing on patients with Bracanalysis before being enrolled in a phase I/II clinical study.
Over the recent past, the company has entered into similar agreements with players such as Abbott ( ABT ), Astra Zeneca ( AZN ) and BioMarin Pharmaceuticals ( BMRN ) to provide companion diagnostic tests for clinical trial enrollment. Bracanalysis is Myriad's flagship product, which analyzes the BRCA1 and BRCA2 genes to assess a woman's risk for hereditary breast and ovarian cancer.
Moreover, the acquisition of RBM (Rules-Based Medicine), made in 2011 would better place Myriad in this arena on account of the former's proprietary protein technology and immunoassays. RBM has provided custom assay development and companion biomarker discovery for several pharmaceutical companies. Through these collaborations, RBM has obtained companion diagnostic rights to many of the drugs under development, which should augur well for the long-term development of the company. During the last reported quarter, Myriad recorded $5.2 million in revenues from companion diagnostic business.
We consider Myriad's Bracanalysis as a valuable asset for top-line growth as it has the potential to tap a widely unexplored market. Besides, a strong cash balance enables the company to buy back shares, expand into new markets and introduce more products. We are also impressed with the recent in-licensing deals that will bring some promising candidates for growth.
In addition to its focus on companion diagnostic business, Myriad has made commendable progress with respect to its expansion in Europe. The company's laboratory in Munich, Germany is operational since January and capable of generating $50 million in revenues each year within the next five years. With its headquarters in Switzerland, hiring of country managers for the five major markets of Germany, France, Italy, Spain and Switzerland have been done. While reimbursement for Bracanalysis, Colaris and Colaris AP have already been received in these markets, Myriad is working to receive reimbursemnet for Prolaris. The stock retains a Zacks # 2 Rank (Buy) in the short term.
However, European expansion and pipeline development have pushed up operating expenses fostering pressure on margins. Over the long term, we are Neutral on Myriad.
ABBOTT LABS ( ABT ): Free Stock Analysis Report
ASTRAZENECA PLC ( AZN ): Free Stock Analysis Report
BIOMARIN PHARMA ( BMRN ): Free Stock Analysis Report
MYRIAD GENETICS ( MYGN ): Free Stock Analysis Report
TEVA PHARM ADR ( TEVA ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Over the recent past, the company has entered into similar agreements with players such as Abbott ( ABT ), Astra Zeneca ( AZN ) and BioMarin Pharmaceuticals ( BMRN ) to provide companion diagnostic tests for clinical trial enrollment. ABBOTT LABS ( ABT ): Free Stock Analysis Report ASTRAZENECA PLC ( AZN ): Free Stock Analysis Report BIOMARIN PHARMA ( BMRN ): Free Stock Analysis Report MYRIAD GENETICS ( MYGN ): Free Stock Analysis Report TEVA PHARM ADR ( TEVA ): Free Stock Analysis Report To read this article on Zacks.com click here. The recent agreement with Cephalon is another attempt by Myriad Genetics ( MYGN ) to establish itself as a strong player in the companion diagnostic market. | Over the recent past, the company has entered into similar agreements with players such as Abbott ( ABT ), Astra Zeneca ( AZN ) and BioMarin Pharmaceuticals ( BMRN ) to provide companion diagnostic tests for clinical trial enrollment. ABBOTT LABS ( ABT ): Free Stock Analysis Report ASTRAZENECA PLC ( AZN ): Free Stock Analysis Report BIOMARIN PHARMA ( BMRN ): Free Stock Analysis Report MYRIAD GENETICS ( MYGN ): Free Stock Analysis Report TEVA PHARM ADR ( TEVA ): Free Stock Analysis Report To read this article on Zacks.com click here. During the last reported quarter, Myriad recorded $5.2 million in revenues from companion diagnostic business. | Over the recent past, the company has entered into similar agreements with players such as Abbott ( ABT ), Astra Zeneca ( AZN ) and BioMarin Pharmaceuticals ( BMRN ) to provide companion diagnostic tests for clinical trial enrollment. ABBOTT LABS ( ABT ): Free Stock Analysis Report ASTRAZENECA PLC ( AZN ): Free Stock Analysis Report BIOMARIN PHARMA ( BMRN ): Free Stock Analysis Report MYRIAD GENETICS ( MYGN ): Free Stock Analysis Report TEVA PHARM ADR ( TEVA ): Free Stock Analysis Report To read this article on Zacks.com click here. The recent agreement with Cephalon is another attempt by Myriad Genetics ( MYGN ) to establish itself as a strong player in the companion diagnostic market. | Over the recent past, the company has entered into similar agreements with players such as Abbott ( ABT ), Astra Zeneca ( AZN ) and BioMarin Pharmaceuticals ( BMRN ) to provide companion diagnostic tests for clinical trial enrollment. ABBOTT LABS ( ABT ): Free Stock Analysis Report ASTRAZENECA PLC ( AZN ): Free Stock Analysis Report BIOMARIN PHARMA ( BMRN ): Free Stock Analysis Report MYRIAD GENETICS ( MYGN ): Free Stock Analysis Report TEVA PHARM ADR ( TEVA ): Free Stock Analysis Report To read this article on Zacks.com click here. The recent agreement with Cephalon is another attempt by Myriad Genetics ( MYGN ) to establish itself as a strong player in the companion diagnostic market. |
34454.0 | 2012-03-30 00:00:00 UTC | 5 Safe Stocks to Own Before the Next Market Crash | ABT | https://www.nasdaq.com/articles/5-safe-stocks-own-next-market-crash-2012-03-30 | nan | nan | There's a tried-and-true maxim on Wall Street : Stocks fall a lot faster than they rise. There are myriad examples, and the sharp plunge of 1987 is just one.
The economy was growing at a nice clip, corporate profits were on the rise, and investors were pouring into the market . And then, " Black Friday " came on October 19, 1987, pushing the S&P 500 down more than 20% in a single day. The fact that stocks had risen 250% in the previous five years led to a great deal of complacency, as few potential land mines stood on the horizon.
Looking back, we still don't even know what caused the crash. Some think it was due to computer-driven trading programs that fed off each other in a cycle of negativity, or that maybe underlying derivatives had lost enough value to cause a cascading effect of unwinding contracts. Others simply suggest that the market was due for a breather and a mild sell-off turned into a panic-driven rush for the exits as they day wore on.
We'll never know.
Fast-forward to 2012, and the skies are again seemingly clear. In fact, we've just emerged from a risky phase for the global economy, and the economic backdrop holds few land mines in the near-term. But still waters run deep, and you have to always think about the risks of a seemingly benign market mood. So it's simply prudent to make sure that, at this phase in the market cycle, your portfolio also contains a handful of deeply defensive stocks that will more likely hold their own if the major indices slump badly.
Here are five stocks that have "bomb shelter"-like qualities...
1. Abbott Labs ( ABT )
While many health care-related companies tend to focus on one core strengths such as insurance, hospital ownership, niche drug development or specialized medical devices, Abbott plays the field by selling hundreds of products to a range of customers. This will never be a fast-grower. Then again, sales have never fallen in any of the past 20 years. The current $40 billion revenue base benefits from a huge degree of recurring revenue and, thanks to modest annual price increases, management is always able to maintain 20% to 25% EBITDA margins regardless of any cost pressures the company may face.
2. Archer Daniels Midland ( ADM )
The agricultural titan has its share of challenges. Profit margins can fluctuate as input prices and end-market prices gyrate back and forth. But because ADM controls so much of the agro-industrial complex, it is better insulated from the booms and busts that would rock its smaller rivals in the farm belt.
The timing for this stock is good. Analysts think margin trends will soon swing back in ADM's favor, which is why they think earnings per share (EPS) will rise from around $2.50 in fiscal (June) 2012 to around $3 in fiscal 2013 and $3.50 in fiscal 2014.
3. Verizon ( VZ )
No company has handled the migration from wire-line to wireless phones as adroitly as Verizon. Management has been steadily reducing expenses at the legacy wire-line business, freeing up resources to further cement its gains in the industry-leading wireless business. Even in adverse economic times, consumers would be loathe to cut back on their need to stay connected. Indeed today's smartphones are a lot like an addictive drug. Try going a week without one. The fact that Verizon currently sports a 5% dividend yield means shares have ample downside protection. Any sell-off in the stock would simply boost the yield , making it newly attractive to a fresh base of investors (whose buying would presumably push shares back up.)
4. Loews ( L )
There are plenty of insurance stocks that would represent safety in a plunging market. But Loews is so broadly diversified that it is insulated from the vagaries of any one particular insurance niche. Not only is Loews involved in all kinds of insurance, it also owns a hefty slate of energy assets, such as offshore drilling rigs and natural gas rigs and pipelines. The fact that the stock's current market value of $15.7 billion is actually lower than the book value of $18.8 billion just underscores the relative safety of this stock.
5. Southern Co. ( SO )
I could mention almost any power utility, but Southern Co. is an exemplary industry play. The company's 4.6% return on assets (ROA) and 12.3% return on equity (ROE) are among the best in the business. The fact that the company's dividend grows about 4% every year would surely be noticed by investors as they made a flight to safety. If you buy shares today, you'll be getting a yield of about 4%, but thanks to the power of compounding , you could be scoring double-digit annual yields (based on your original cost ) if you hold this stock into the next decade.
Risks to Consider: These stocks are unlikely to fall nearly as much as the broader market in a major sell-off, but would likely take a moderate hit as investors pull funds.
Action to take --> Building a portfolio around these kinds of stocks is suitable for the most conservative investors, especially those nearing retirement. For more aggressive investors, you need simply to think about having a degree of exposure to these safer stocks, even as you remain more squarely focused on high-beta stocks that are leveraged to a growing economy.
David Sterman does not personally hold positions in any securities mentioned in this article. StreetAuthority LLC does not hold positions in any securities mentioned in this article.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© Copyright 2001-2010 StreetAuthority, LLC. All Rights Reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ( ABT ) While many health care-related companies tend to focus on one core strengths such as insurance, hospital ownership, niche drug development or specialized medical devices, Abbott plays the field by selling hundreds of products to a range of customers. Some think it was due to computer-driven trading programs that fed off each other in a cycle of negativity, or that maybe underlying derivatives had lost enough value to cause a cascading effect of unwinding contracts. So it's simply prudent to make sure that, at this phase in the market cycle, your portfolio also contains a handful of deeply defensive stocks that will more likely hold their own if the major indices slump badly. | Abbott Labs ( ABT ) While many health care-related companies tend to focus on one core strengths such as insurance, hospital ownership, niche drug development or specialized medical devices, Abbott plays the field by selling hundreds of products to a range of customers. The current $40 billion revenue base benefits from a huge degree of recurring revenue and, thanks to modest annual price increases, management is always able to maintain 20% to 25% EBITDA margins regardless of any cost pressures the company may face. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. © Copyright 2001-2010 StreetAuthority, LLC. | Abbott Labs ( ABT ) While many health care-related companies tend to focus on one core strengths such as insurance, hospital ownership, niche drug development or specialized medical devices, Abbott plays the field by selling hundreds of products to a range of customers. Any sell-off in the stock would simply boost the yield , making it newly attractive to a fresh base of investors (whose buying would presumably push shares back up.) The fact that the stock's current market value of $15.7 billion is actually lower than the book value of $18.8 billion just underscores the relative safety of this stock. | Abbott Labs ( ABT ) While many health care-related companies tend to focus on one core strengths such as insurance, hospital ownership, niche drug development or specialized medical devices, Abbott plays the field by selling hundreds of products to a range of customers. Any sell-off in the stock would simply boost the yield , making it newly attractive to a fresh base of investors (whose buying would presumably push shares back up.) Loews ( L ) There are plenty of insurance stocks that would represent safety in a plunging market. |
34455.0 | 2012-03-28 00:00:00 UTC | Stock Market News for March 28, 2012 - Market News | ABT | https://www.nasdaq.com/articles/stock-market-news-for-march-28-2012-market-news-2012-03-28 | nan | nan | Amidst the absence of any positive catalysts, disappointing consumer confidence data dragged the benchmarks marginally lower on Tuesday. The decline came just a day after Ben Bernanke's comments had helped benchmarks gain at least 1.2%. Markets have performed significantly better so far this year, thus setting the tone for a positive finish in the first quarter.
The Dow Jones Industrial Average (DJI) edged down 0.3% to settle at 13,197.73. The Standard & Poor 500 (S&P 500) declined modestly, by 0.3% to finish yesterday's trading session at 1,412.52. The tech-laden Nasdaq Composite Index dropped only 2.2 points or 0.07% to close almost unchanged at 3,120.35. The fear-gauge CBOE Volatility Index (VIX) surged 9.3% and settled at 15.59. Consolidated volumes on the New York Stock Exchange, Nasdaq and Amex were 6.07 billion shares, lower than this year's daily average of 6.83 billion. On the NYSE, decliners outnumbered the advancers by a ratio of 4:3.
While Apple Inc. (NASDAQ: AAPL ) hit an all-time high, closing at $614.48, a whopping 175 stocks trading on the NYSE jumped to their 52-weeks highs. This included the likes of Abbott Laboratories (NYSE: ABT ), American Express Company (NYSE: AXP ), Big Lots, Inc. (NYSE: BIG ), The Coca-Cola Company (NYSE: KO ), The Walt Disney Company (NYSE: DIS ), EMC Corporation (NYSE: EMC ), Fortune Brands Home & Security (NYSE: FBHS ), The Home Depot, Inc. (NYSE: HD ), International Business Machines (NYSE: IBM ), Lockheed Martin Corporation (NYSE: LMT ), Lowe's Companies, Inc. (NYSE: LOW ), Pfizer, Inc. (NYSE: PFE ) and Western Digital Corporation (NYSE: WDC ) and they hit 52-week highs of $61.49, $59.18, $47.22, $71.98, $44.50, $29.79, $21.95, $50.35, $208.66, $91.09, $31.49, $22.80 and $43.10, respectively.
However, many of these stocks had to settle in negative territory for the day, after dismal consumer reading dented sentiment. The Conference Board reported that the Consumer Confidence Index had dropped to 70.2 from 71.6 in February. The Present Situation Index, moved up sharply to 51.0 from 46.4. Lynn Franco, Director of The Conference Board Consumer Research Center, said: "Consumer Confidence pulled back slightly in March, after rising sharply in February. The moderate decline was due solely to a less favorable short-term outlook, while consumers' assessment of current conditions, on the other hand, continued to improve". As for the Present Situation Index, he said: "… despite this month's dip in confidence, consumers feels the economy is not losing momentum".
Consumer data was an instant drag on the benchmarks. Tuesday's drop came just a day after when the benchmarks witnessed robust increases, following Ben Bernanke's comments regarding the need for economic support to help drive unemployment lower. In his speech at the National Association for Business Economics on Monday, Bernanke had said: "Further significant improvements in the unemployment rate will likely require a more rapid expansion of production and demand from consumers and businesses, a process that can be supported by continued accommodative policies". Investors believe that a third round of bond buying might be in the offing, and the benchmarks jumped accordingly. Yesterday, in an interview to a news house, the central bank chairman said that possibilities of quantitative easing could not be ruled out.
Markets have enjoyed a strong run so far this year and till yesterday the Dow, S&P 500 and Nasdaq are up 8.0%, 12.3% and 19.8%. Once again it is evident the Nasdaq has enjoyed most of the gains and outperformed the other two. With such decent gains for 2012, investors would be further buoyed if the benchmarks achieve a robust quarterly finish this Friday. Economic data has come in strong this quarter and the labor market in particular has showcased a consistent strong performance. Housing data has also mostly been on the positive side and a green finish for the quarter would encourage investors' belief in brighter economic prospects.
APPLE INC ( AAPL ): Free Stock Analysis Report
ABBOTT LABS ( ABT ): Free Stock Analysis Report
AMER EXPRESS CO ( AXP ): Free Stock Analysis Report
BIG LOTS INC ( BIG ): Free Stock Analysis Report
DISNEY WALT ( DIS ): Free Stock Analysis Report
EMC CORP -MASS (EMC): Free Stock Analysis Report
FORTUNE BRD H&S (FBHS): Free Stock Analysis Report
HOME DEPOT (HD): Free Stock Analysis Report
INTL BUS MACH (IBM): Free Stock Analysis Report
COCA COLA CO (KO): Free Stock Analysis Report
LOCKHEED MARTIN (LMT): Free Stock Analysis Report
LOWES COS (LOW): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
WESTERN DIGITAL (WDC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | This included the likes of Abbott Laboratories (NYSE: ABT ), American Express Company (NYSE: AXP ), Big Lots, Inc. (NYSE: BIG ), The Coca-Cola Company (NYSE: KO ), The Walt Disney Company (NYSE: DIS ), EMC Corporation (NYSE: EMC ), Fortune Brands Home & Security (NYSE: FBHS ), The Home Depot, Inc. (NYSE: HD ), International Business Machines (NYSE: IBM ), Lockheed Martin Corporation (NYSE: LMT ), Lowe's Companies, Inc. (NYSE: LOW ), Pfizer, Inc. (NYSE: PFE ) and Western Digital Corporation (NYSE: WDC ) and they hit 52-week highs of $61.49, $59.18, $47.22, $71.98, $44.50, $29.79, $21.95, $50.35, $208.66, $91.09, $31.49, $22.80 and $43.10, respectively. APPLE INC ( AAPL ): Free Stock Analysis Report ABBOTT LABS ( ABT ): Free Stock Analysis Report AMER EXPRESS CO ( AXP ): Free Stock Analysis Report BIG LOTS INC ( BIG ): Free Stock Analysis Report DISNEY WALT ( DIS ): Free Stock Analysis Report EMC CORP -MASS (EMC): Free Stock Analysis Report FORTUNE BRD H&S (FBHS): Free Stock Analysis Report HOME DEPOT (HD): Free Stock Analysis Report INTL BUS MACH (IBM): Free Stock Analysis Report COCA COLA CO (KO): Free Stock Analysis Report LOCKHEED MARTIN (LMT): Free Stock Analysis Report LOWES COS (LOW): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report WESTERN DIGITAL (WDC): Free Stock Analysis Report To read this article on Zacks.com click here. Amidst the absence of any positive catalysts, disappointing consumer confidence data dragged the benchmarks marginally lower on Tuesday. | This included the likes of Abbott Laboratories (NYSE: ABT ), American Express Company (NYSE: AXP ), Big Lots, Inc. (NYSE: BIG ), The Coca-Cola Company (NYSE: KO ), The Walt Disney Company (NYSE: DIS ), EMC Corporation (NYSE: EMC ), Fortune Brands Home & Security (NYSE: FBHS ), The Home Depot, Inc. (NYSE: HD ), International Business Machines (NYSE: IBM ), Lockheed Martin Corporation (NYSE: LMT ), Lowe's Companies, Inc. (NYSE: LOW ), Pfizer, Inc. (NYSE: PFE ) and Western Digital Corporation (NYSE: WDC ) and they hit 52-week highs of $61.49, $59.18, $47.22, $71.98, $44.50, $29.79, $21.95, $50.35, $208.66, $91.09, $31.49, $22.80 and $43.10, respectively. APPLE INC ( AAPL ): Free Stock Analysis Report ABBOTT LABS ( ABT ): Free Stock Analysis Report AMER EXPRESS CO ( AXP ): Free Stock Analysis Report BIG LOTS INC ( BIG ): Free Stock Analysis Report DISNEY WALT ( DIS ): Free Stock Analysis Report EMC CORP -MASS (EMC): Free Stock Analysis Report FORTUNE BRD H&S (FBHS): Free Stock Analysis Report HOME DEPOT (HD): Free Stock Analysis Report INTL BUS MACH (IBM): Free Stock Analysis Report COCA COLA CO (KO): Free Stock Analysis Report LOCKHEED MARTIN (LMT): Free Stock Analysis Report LOWES COS (LOW): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report WESTERN DIGITAL (WDC): Free Stock Analysis Report To read this article on Zacks.com click here. While Apple Inc. (NASDAQ: AAPL ) hit an all-time high, closing at $614.48, a whopping 175 stocks trading on the NYSE jumped to their 52-weeks highs. | This included the likes of Abbott Laboratories (NYSE: ABT ), American Express Company (NYSE: AXP ), Big Lots, Inc. (NYSE: BIG ), The Coca-Cola Company (NYSE: KO ), The Walt Disney Company (NYSE: DIS ), EMC Corporation (NYSE: EMC ), Fortune Brands Home & Security (NYSE: FBHS ), The Home Depot, Inc. (NYSE: HD ), International Business Machines (NYSE: IBM ), Lockheed Martin Corporation (NYSE: LMT ), Lowe's Companies, Inc. (NYSE: LOW ), Pfizer, Inc. (NYSE: PFE ) and Western Digital Corporation (NYSE: WDC ) and they hit 52-week highs of $61.49, $59.18, $47.22, $71.98, $44.50, $29.79, $21.95, $50.35, $208.66, $91.09, $31.49, $22.80 and $43.10, respectively. APPLE INC ( AAPL ): Free Stock Analysis Report ABBOTT LABS ( ABT ): Free Stock Analysis Report AMER EXPRESS CO ( AXP ): Free Stock Analysis Report BIG LOTS INC ( BIG ): Free Stock Analysis Report DISNEY WALT ( DIS ): Free Stock Analysis Report EMC CORP -MASS (EMC): Free Stock Analysis Report FORTUNE BRD H&S (FBHS): Free Stock Analysis Report HOME DEPOT (HD): Free Stock Analysis Report INTL BUS MACH (IBM): Free Stock Analysis Report COCA COLA CO (KO): Free Stock Analysis Report LOCKHEED MARTIN (LMT): Free Stock Analysis Report LOWES COS (LOW): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report WESTERN DIGITAL (WDC): Free Stock Analysis Report To read this article on Zacks.com click here. Amidst the absence of any positive catalysts, disappointing consumer confidence data dragged the benchmarks marginally lower on Tuesday. | This included the likes of Abbott Laboratories (NYSE: ABT ), American Express Company (NYSE: AXP ), Big Lots, Inc. (NYSE: BIG ), The Coca-Cola Company (NYSE: KO ), The Walt Disney Company (NYSE: DIS ), EMC Corporation (NYSE: EMC ), Fortune Brands Home & Security (NYSE: FBHS ), The Home Depot, Inc. (NYSE: HD ), International Business Machines (NYSE: IBM ), Lockheed Martin Corporation (NYSE: LMT ), Lowe's Companies, Inc. (NYSE: LOW ), Pfizer, Inc. (NYSE: PFE ) and Western Digital Corporation (NYSE: WDC ) and they hit 52-week highs of $61.49, $59.18, $47.22, $71.98, $44.50, $29.79, $21.95, $50.35, $208.66, $91.09, $31.49, $22.80 and $43.10, respectively. APPLE INC ( AAPL ): Free Stock Analysis Report ABBOTT LABS ( ABT ): Free Stock Analysis Report AMER EXPRESS CO ( AXP ): Free Stock Analysis Report BIG LOTS INC ( BIG ): Free Stock Analysis Report DISNEY WALT ( DIS ): Free Stock Analysis Report EMC CORP -MASS (EMC): Free Stock Analysis Report FORTUNE BRD H&S (FBHS): Free Stock Analysis Report HOME DEPOT (HD): Free Stock Analysis Report INTL BUS MACH (IBM): Free Stock Analysis Report COCA COLA CO (KO): Free Stock Analysis Report LOCKHEED MARTIN (LMT): Free Stock Analysis Report LOWES COS (LOW): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report WESTERN DIGITAL (WDC): Free Stock Analysis Report To read this article on Zacks.com click here. The Conference Board reported that the Consumer Confidence Index had dropped to 70.2 from 71.6 in February. |
34456.0 | 2012-03-27 00:00:00 UTC | The Right Stocks for Today's Market | ABT | https://www.nasdaq.com/articles/right-stocks-todays-market-2012-03-27 | nan | nan | Another week, another rally? The market began the current trading week on a high note once again, and it seems as if this bull just can't be stopped. The S&P 500 has moved higher in 13 out of the last 15 weeks, and the current week looks like it will extend that streak. Yet with that index now firmly ensconced above the 1,400 mark, the bull and bear cases are beginning to sharpen.
Thebullish case
On the bullish side, money is pouring into the market at a fevered clip as formerly bearishhedge funds shift their bias to bullishness. Individual investors are playing their part as well: The weekly sentiment snapshot conducted by the American Association of Individual Investors (AAII) shows bullish investors holding a 13 percentage point lead over bearish investors.
To be sure, stock prices are simply a function of supply and demand, and demand is quite strong right now.
Thebearish case
The bearish side also has some merit. Economists express concern that the recent run of positive economic data may have run its course and fear the U.S. economy will cool in coming months. This is precisely the scenario that played out in 2011, as a strong start to the year met with a cooling off period in the spring that led to a market rout in the summer.
Technical analysts also talk of an over-bought market right now, and a number of measures suggest we're due for a pullback.
For now, investor enthusiasm is the overarching theme, though who knows how long that will last? What is known: a certain group of stocks should benefit from a rising market, while also offering much more robust downside protection.
I'm talking about low-beta stocks. Beta measures how a stock moves in relation to the broader market, and those with a beta of less than 1.0 means that they are fairly decoupled from the broader market. [My colleague Tim Begany recently touched on this theme. You can read his take on the best stock to own for a correctionhere .]
I went searching among stocks in the S&P 500 (large cap stocks) and S&P 400 ( mid-cap stocks), and found 38 of them to have a beta below 1.0 and also have a price-to-earnings (P/E) ratio below 12. Even if the economy slows and earnings growth becomes a real challenge, these low-priced stocks won't get penalized for their valuations.
Below is a table of 20 stocks that sport a beta of less than 0.7.
Here's what this list is telling me...
1. Remember Wal-Mart...
A low beta doesn't mean a stock won't budge. Shares of Wal-Mart ( WMT ) , which sport a beta of just 0.34, have still managed to rise more than 20% since bottoming out last summer. That's due to slightly better operating trends, especially in the retailer's grocery division.
2. Health care is seemingly safe
A number of drug and medical device companies are in this group. Companies such as Abbott Labs ( ABT ) , Watson Pharmaceuticals ( WPI ) , Amgen (Nasdaq: AMGN) , Gilead Sciences (Nasdaq: GILD) and Baxter International ( BAX ) all have a beta below 0.5, largely due to the fact that they have a high degree of recurring revenue and rarely tend to deliver quarterly results far from the consensus forecasts. They all trade for around 10 times earnings, which is well below the broader market's multiple, which is closer to 15.
3. Steer clear of defense and for-profit education
The list of low-beta stocks also carries a lot of defense sector and for-profit education stocks. Each of these groups faces real headwinds and may see limited (or even negative) sales growth in coming years. In this instance, the low beta tells you that these stocks are likely dead money -- at best.
4. The winners
So what's left? You'll note a handful of insurers on the list, including Chubb ( CB ) , Hanover Insurance (THG) , Aon Corp. (NYSE: AON ) and Travelers (TRV) . These could all prove to have solid upside if the economy gets much better, as pricing becomes less competitive in this business when an economy expands. Their low betas mean these insurers are unlikely to fall much if the economy slips backward, either.
Perhaps my favorite name on this table is Archer Daniels Midland (ADM) , which may soon come out of a multi-year phase of operational challenges. Many of this agricultural processor's divisions have been caught on the wrong end of the cycle, crushing profit margins in the process. The company's EBITDA margins have fallen 200 basis points in the past six years to just 4.5% in fiscal (June) 2011. Yet analysts at Citigroup think the company "...is in store for sequentially improving profits across the majority of its businesses over the coming quarters, with the exception of ethanol." They see earnings per share rising from $2.60 in fiscal 2012 to $3.25 in fiscal 2013 and $3.50 in fiscal 2014.
Shares of ADM have hovered right around the $30 mark during the past three years, but that earnings strength could finally move the stock up toward the $40 mark.
I also think investors continue to overlook a solid current turnaround that is underway at tax prep firm H&R Block (HRB) . [I also wrote about this back in January.] I am not expecting an overly-robust tax season for the company, but I think the company's long-term strategy should yield solid benefits.
Risks to Consider: A low beta wouldn't necessarily keep these stocks from falling in a down market. If that happens, then you'd likely need to focus on negative beta stocks that move in the opposite direction of the market.
Action to Take --> The rising market doesn't mean you should sell your stocks. But replacing high-beta stocks in your portfolio with low-beta stocks should provide a buffer of comfort if the market turns choppy. Any of the stocks I mentioned above are a good place to start looking.
[ Note: If you haven't heard about this unique opportunity, then I want to tell you about it now. StreetAuthority has staked me with $100,000 of real money to invest in my absolute best ideas. For a limited time, you'll be able to follow along with me completely free. Go here to learn more .]
-- David Sterman
David Sterman does not personally hold positions in any securities mentioned in this article. StreetAuthority LLC owns shares of ABT, GILD in one or more if its "real money" portfolios.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© Copyright 2001-2010 StreetAuthority, LLC. All Rights Reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Companies such as Abbott Labs ( ABT ) , Watson Pharmaceuticals ( WPI ) , Amgen (Nasdaq: AMGN) , Gilead Sciences (Nasdaq: GILD) and Baxter International ( BAX ) all have a beta below 0.5, largely due to the fact that they have a high degree of recurring revenue and rarely tend to deliver quarterly results far from the consensus forecasts. StreetAuthority LLC owns shares of ABT, GILD in one or more if its "real money" portfolios. This is precisely the scenario that played out in 2011, as a strong start to the year met with a cooling off period in the spring that led to a market rout in the summer. | Companies such as Abbott Labs ( ABT ) , Watson Pharmaceuticals ( WPI ) , Amgen (Nasdaq: AMGN) , Gilead Sciences (Nasdaq: GILD) and Baxter International ( BAX ) all have a beta below 0.5, largely due to the fact that they have a high degree of recurring revenue and rarely tend to deliver quarterly results far from the consensus forecasts. StreetAuthority LLC owns shares of ABT, GILD in one or more if its "real money" portfolios. Individual investors are playing their part as well: The weekly sentiment snapshot conducted by the American Association of Individual Investors (AAII) shows bullish investors holding a 13 percentage point lead over bearish investors. | Companies such as Abbott Labs ( ABT ) , Watson Pharmaceuticals ( WPI ) , Amgen (Nasdaq: AMGN) , Gilead Sciences (Nasdaq: GILD) and Baxter International ( BAX ) all have a beta below 0.5, largely due to the fact that they have a high degree of recurring revenue and rarely tend to deliver quarterly results far from the consensus forecasts. StreetAuthority LLC owns shares of ABT, GILD in one or more if its "real money" portfolios. Beta measures how a stock moves in relation to the broader market, and those with a beta of less than 1.0 means that they are fairly decoupled from the broader market. | StreetAuthority LLC owns shares of ABT, GILD in one or more if its "real money" portfolios. Companies such as Abbott Labs ( ABT ) , Watson Pharmaceuticals ( WPI ) , Amgen (Nasdaq: AMGN) , Gilead Sciences (Nasdaq: GILD) and Baxter International ( BAX ) all have a beta below 0.5, largely due to the fact that they have a high degree of recurring revenue and rarely tend to deliver quarterly results far from the consensus forecasts. The market began the current trading week on a high note once again, and it seems as if this bull just can't be stopped. |
34457.0 | 2012-03-22 00:00:00 UTC | Abbott Unveils Pharma Co. Name - Analyst Blog | ABT | https://www.nasdaq.com/articles/abbott-unveils-pharma-co.-name-analyst-blog-2012-03-22 | nan | nan | Abbott Labs ( ABT ) recently zeroed in on a name for its research-based pharmaceutical company that will be launched later this year. Abbott Labs has decided to name the pharma co. AbbVie, which is a combination of Abbott and vie (Latin for life).
Abbott Labs had first announced its intention to split into two separate publicly traded companies in October 2011. While one company will deal in diversified medical products, the other will focus on research-based pharmaceuticals.
The diversified medical products company will retain the company name and will include Abbott Labs' branded generic pharmaceutical, devices, diagnostic and nutritional businesses.
The research-based pharmaceutical company, AbbVie, will include Abbott Labs' current portfolio of proprietary pharmaceuticals and biologics including products like Humira, Lupron, Synagis, Kaletra, Creon and Synthroid. The research-based pharmaceutical company's annual sales are estimated to be almost $18 billion.
Abbott Labs has been investing in its pipeline which should contribute to the long-term growth of the pharma spinoff. Abbott Labs has a number of early-to-mid stage oncology candidates. The company has numerous programs in clinical development for the treatment of immunology, oncology, neuroscience, pain management and infectious diseases.
Neutral on Abbott Labs
We currently have a Neutral recommendation on Abbott Labs, which carries a Zacks #3 Rank (short-term Hold rating). The new company's shares will be distributed to Abbott Labs' shareholders in a tax-free transaction. The split is scheduled to close by the end of 2012.
The company is looking to ensure growth through this split. We are positive on the split which should allow the two separate entities to perform in a more focused manner.
ABBOTT LABS ( ABT ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ( ABT ) recently zeroed in on a name for its research-based pharmaceutical company that will be launched later this year. ABBOTT LABS ( ABT ): Free Stock Analysis Report To read this article on Zacks.com click here. The company has numerous programs in clinical development for the treatment of immunology, oncology, neuroscience, pain management and infectious diseases. | Abbott Labs ( ABT ) recently zeroed in on a name for its research-based pharmaceutical company that will be launched later this year. ABBOTT LABS ( ABT ): Free Stock Analysis Report To read this article on Zacks.com click here. The diversified medical products company will retain the company name and will include Abbott Labs' branded generic pharmaceutical, devices, diagnostic and nutritional businesses. | Abbott Labs ( ABT ) recently zeroed in on a name for its research-based pharmaceutical company that will be launched later this year. ABBOTT LABS ( ABT ): Free Stock Analysis Report To read this article on Zacks.com click here. The diversified medical products company will retain the company name and will include Abbott Labs' branded generic pharmaceutical, devices, diagnostic and nutritional businesses. | Abbott Labs ( ABT ) recently zeroed in on a name for its research-based pharmaceutical company that will be launched later this year. ABBOTT LABS ( ABT ): Free Stock Analysis Report To read this article on Zacks.com click here. While one company will deal in diversified medical products, the other will focus on research-based pharmaceuticals. |
34458.0 | 2012-03-21 00:00:00 UTC | Watson's Generic Boniva Approved - Analyst Blog | ABT | https://www.nasdaq.com/articles/watsons-generic-boniva-approved-analyst-blog-2012-03-21 | nan | nan | Watson Pharmaceuticals Inc. ( WPI ) recently announced that the US Food and Drug Administration (FDA) has approved the company's abbreviated new drug application (ANDA) for a generic version of Roche Holding Ltd. 's ( RHHBY ) drug, Boniva. Boniva is currently approved for the treatment of postmenopausal osteoporosis.
Watson Pharma plans to begin shipping its generic version (150 mg) in the second quarter of 2012. Roche and Watson Pharma are currently fighting a patent infringement lawsuit for the ANDA of Boniva.
According to IMS Health, US sales of Boniva amounted to $510 million for the year ended January 31, 2012.
Earlier during the week, Watson Pharma filed an ANDA with the FDA to market a generic version of Abbott Laboratories' ( ABT ) cholesterol drug, Niaspan.
In response, Abbott Labs filed a lawsuit against Watson Pharma in the United States District Court for the District of Delaware. Abbott Labs is seeking to prevent the generic company from commercializing its product before the patents expire. Since the lawsuit was filed under the provisions of the Hatch-Waxman Act, therefore the FDA cannot approve Watson Pharma's ANDA until 30 months from the date Abbott Labs received the notice for the ANDA filing or until the court order, whichever is earlier.
Our View
We currently have a Neutral recommendation on Watson Pharma. The stock carries a Zacks #3 Rank (Hold rating) in the short run.
We expect new generic product launches over regular intervals to help drive the company's Global Generic segment's sales, which climbed 46% during 2011 to $3.32 billion, driven by the generic launch of Pfizer Inc. 's ( PFE ) Lipitor and Johnson & Johnson 's ( JNJ ) Concerta.
ABBOTT LABS ( ABT ): Free Stock Analysis Report
JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report
PFIZER INC ( PFE ): Free Stock Analysis Report
WATSON PHARMA ( WPI ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Earlier during the week, Watson Pharma filed an ANDA with the FDA to market a generic version of Abbott Laboratories' ( ABT ) cholesterol drug, Niaspan. ABBOTT LABS ( ABT ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report WATSON PHARMA ( WPI ): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs is seeking to prevent the generic company from commercializing its product before the patents expire. | Earlier during the week, Watson Pharma filed an ANDA with the FDA to market a generic version of Abbott Laboratories' ( ABT ) cholesterol drug, Niaspan. ABBOTT LABS ( ABT ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report WATSON PHARMA ( WPI ): Free Stock Analysis Report To read this article on Zacks.com click here. Watson Pharmaceuticals Inc. ( WPI ) recently announced that the US Food and Drug Administration (FDA) has approved the company's abbreviated new drug application (ANDA) for a generic version of Roche Holding Ltd. 's ( RHHBY ) drug, Boniva. | ABBOTT LABS ( ABT ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report WATSON PHARMA ( WPI ): Free Stock Analysis Report To read this article on Zacks.com click here. Earlier during the week, Watson Pharma filed an ANDA with the FDA to market a generic version of Abbott Laboratories' ( ABT ) cholesterol drug, Niaspan. Watson Pharmaceuticals Inc. ( WPI ) recently announced that the US Food and Drug Administration (FDA) has approved the company's abbreviated new drug application (ANDA) for a generic version of Roche Holding Ltd. 's ( RHHBY ) drug, Boniva. | Earlier during the week, Watson Pharma filed an ANDA with the FDA to market a generic version of Abbott Laboratories' ( ABT ) cholesterol drug, Niaspan. ABBOTT LABS ( ABT ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report WATSON PHARMA ( WPI ): Free Stock Analysis Report To read this article on Zacks.com click here. Roche and Watson Pharma are currently fighting a patent infringement lawsuit for the ANDA of Boniva. |
34459.0 | 2012-03-20 00:00:00 UTC | Watson Files ANDA, Attracts Lawsuit - Analyst Blog | ABT | https://www.nasdaq.com/articles/watson-files-anda-attracts-lawsuit-analyst-blog-2012-03-20 | nan | nan | Watson Pharmaceuticals Inc. ( WPI ) recently confirmed that it has filed an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA) to market a generic version of Abbott Laboratories' ( ABT ) cholesterol drug, Niaspan.
In response, Abbott Labs has filed a lawsuit against Watson Pharma in the United States District Court for the District of Delaware. The company is seeking to prevent the generic company from commercializing its product before the patents expire. Since the lawsuit was filed under the provisions of the Hatch-Waxman Act, therefore the FDA cannot approve Watson Pharma's ANDA until 30 months from the date Abbott Labs received the notice for the ANDA filing or until the court order, whichever is earlier.
According to IMS Health, US sales of Niaspan amounted to $1.2 billion for the twelve months ended January 31, 2012.
We note that Watson Pharma has an agreement with Abbott Labs to market the authorized generic version of Prometrium in the US. Earlier during the month, Watson Pharma launched its authorized generic version of Prometrium, which is used for the prevention of endometrial hyperplasia in non-hysterectomized postmenopausal women who are receiving conjugated estrogen tablets. The drug is also used for the treatment of secondary amenorrhea.
According to the agreement, Abbott Labs will manufacture and supply all dosages of the authorized generic product to Watson Pharma, who will then market and distribute the same in the US. The companies will be sharing the profits depending on sales figures.
According to IMS Health data, Prometrium sales amounted to $198 million for the twelve months ended January 31, 2012.
Our View
We currently have a Neutral recommendation on Watson Pharma. The stock carries a Zacks #3 Rank (Hold rating) in the short run.
We expect new generic product launches over regular intervals to help drive the company's Global Generic segment's sales, which climbed 46% during 2011 to $3.32 billion, driven by the generic launch of Pfizer Inc. 's ( PFE ) Lipitor and Johnson & Johnson 's ( JNJ ) Concerta.
ABBOTT LABS ( ABT ): Free Stock Analysis Report
JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report
PFIZER INC ( PFE ): Free Stock Analysis Report
WATSON PHARMA ( WPI ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Watson Pharmaceuticals Inc. ( WPI ) recently confirmed that it has filed an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA) to market a generic version of Abbott Laboratories' ( ABT ) cholesterol drug, Niaspan. ABBOTT LABS ( ABT ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report WATSON PHARMA ( WPI ): Free Stock Analysis Report To read this article on Zacks.com click here. Earlier during the month, Watson Pharma launched its authorized generic version of Prometrium, which is used for the prevention of endometrial hyperplasia in non-hysterectomized postmenopausal women who are receiving conjugated estrogen tablets. | ABBOTT LABS ( ABT ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report WATSON PHARMA ( WPI ): Free Stock Analysis Report To read this article on Zacks.com click here. Watson Pharmaceuticals Inc. ( WPI ) recently confirmed that it has filed an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA) to market a generic version of Abbott Laboratories' ( ABT ) cholesterol drug, Niaspan. According to IMS Health, US sales of Niaspan amounted to $1.2 billion for the twelve months ended January 31, 2012. | Watson Pharmaceuticals Inc. ( WPI ) recently confirmed that it has filed an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA) to market a generic version of Abbott Laboratories' ( ABT ) cholesterol drug, Niaspan. ABBOTT LABS ( ABT ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report WATSON PHARMA ( WPI ): Free Stock Analysis Report To read this article on Zacks.com click here. We expect new generic product launches over regular intervals to help drive the company's Global Generic segment's sales, which climbed 46% during 2011 to $3.32 billion, driven by the generic launch of Pfizer Inc. 's ( PFE ) Lipitor and Johnson & Johnson 's ( JNJ ) Concerta. | Watson Pharmaceuticals Inc. ( WPI ) recently confirmed that it has filed an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA) to market a generic version of Abbott Laboratories' ( ABT ) cholesterol drug, Niaspan. ABBOTT LABS ( ABT ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report WATSON PHARMA ( WPI ): Free Stock Analysis Report To read this article on Zacks.com click here. Since the lawsuit was filed under the provisions of the Hatch-Waxman Act, therefore the FDA cannot approve Watson Pharma's ANDA until 30 months from the date Abbott Labs received the notice for the ANDA filing or until the court order, whichever is earlier. |
34460.0 | 2012-03-19 00:00:00 UTC | Abbott Laboratories Now Rated a “Buy” at Deutsche Bank (ABT) | ABT | https://www.nasdaq.com/articles/abbott-laboratories-now-rated-buy-deutsche-bank-abt-2012-03-19 | nan | nan | Health care products maker Abbott Laboratories ( ABT ) on Monday caught a big upgrade from analysts at Deutsche Bank.
The firm said it boosted its rating on ABT to "Buy" with a $70 price target, suggesting an 18% upside to the stock's Friday closing price of $59.42.
A Deutsche analyst commented, "ABT's now dominant low growth pharma business has precluded its attractive growth diversified portfolio from getting an appropriate and higher multiple. With the planned split, pharma's value could be anchored by a juicy dividend, and the ABT Medical Products business could run with a higher mid teens multiple. In our view, as more transparency is given on the financials of these two businesses (mid-yr), ABT's shares are likely to move up in sympathy with the higher value we expect to be created for shareholders by this transaction."
Abbott shares posted modest gains in premarket trading Monday.
The Bottom Line
We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. The company has a 3.43% dividend yield, based on Friday's closing stock price of $59.42.
Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars.
Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Created by Dividend.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Health care products maker Abbott Laboratories ( ABT ) on Monday caught a big upgrade from analysts at Deutsche Bank. With the planned split, pharma's value could be anchored by a juicy dividend, and the ABT Medical Products business could run with a higher mid teens multiple. In our view, as more transparency is given on the financials of these two businesses (mid-yr), ABT's shares are likely to move up in sympathy with the higher value we expect to be created for shareholders by this transaction." | The firm said it boosted its rating on ABT to "Buy" with a $70 price target, suggesting an 18% upside to the stock's Friday closing price of $59.42. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars. Health care products maker Abbott Laboratories ( ABT ) on Monday caught a big upgrade from analysts at Deutsche Bank. | The firm said it boosted its rating on ABT to "Buy" with a $70 price target, suggesting an 18% upside to the stock's Friday closing price of $59.42. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars. | Health care products maker Abbott Laboratories ( ABT ) on Monday caught a big upgrade from analysts at Deutsche Bank. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars. The firm said it boosted its rating on ABT to "Buy" with a $70 price target, suggesting an 18% upside to the stock's Friday closing price of $59.42. |
34461.0 | 2012-03-19 00:00:00 UTC | Market Wrap-Up for Mar. 19 (AAPL, UPS, ABT, COF, APA, more) | ABT | https://www.nasdaq.com/articles/market-wrap-mar-19-aapl-ups-abt-cof-apa-more-2012-03-19 | nan | nan | It is a big dividend-centric news day with Apple ( AAPL ) announcing it will join the ever-expanding list of big brands paying dividends.
Not to overlook another big headline, but United Parcel Service ( UPS ) has announced a big acquisition that will significantly expand its international reach. The market seemed to like the move, with shares closing up by nearly $3.
Meanwhile, Wall Street analyst upgrades helped some stocks come of the gate strongly this week, including Devon Energy ( DVN ), Abbott Labs ( ABT ), Capital One Financial ( COF ), and U.S. Steel ( X ). One stock that lagged, courtesy of a cautious note out this morning, was Apache Corp ( APA ).
Apple to Pay Dividends!
Well, all the speculation about what Apple ( AAPL ) will do with its $100 billion cash hoard is over. This morning the company said it would initiate a quarterly dividend of $2.65 per share, which amounts to an estimated 1.75% dividend yield. The dividend is expected to begin in July, while the company's new $10 billion share buyback plan will start in September. We will be initiating coverage of the stock once we get the official dividend dates.
Will this development open the door for more major non-dividend stocks (Google, Amazon, EMC, eBay, etc.) to come forth with their own dividend programs? It's certainly a greater possibility, although income-seekers should not get their hopes up on a high dividend yield. As we saw with Apple's announcement today, tech companies are wary of offering high payout levels. Now that Apple will be paying a dividend, how soon before the stock is considered to be put in the Dow 30? Surely that move can't be too far off. The leading candidates to be dropped from the Dow 30 list , in my opinion, would be Bank of America ( BAC ) and Alcoa ( AA ).
On Any Given Day
For college basketball fanatics, March Madness is the biggest time of the year. Teams from all over the county gather to see who can bring home the coveted NCAA championship title.
The format is simple: lose and you go home. Teams get seeded according to the their rankings and usually the best teams in the country (1 through 3 seeds) playing the smaller schools (lowest seeds 14-16). On the second day of this year's tournament, we saw two #15 seeds knock off two #2 seeds (Lehigh beating Duke and Norfolk State defeating Missouri). That event marked the first time a #2 seed lost to a #15 seed since 2001. For the record, a #1 seed has never lost to a #16 seed, but there have been some near upsets over the last couple of decades.
Whenever we hear about these long-shot victories and then hear the commentary, especially from the smaller school's winning coaches, they tend to repeat the same message: believe in yourself, believe in your teammates, and you can achieve what others see as impossible.
I find great inspiration from these small teams which are often labeled "Cinderella stories." We all want to believe in our dreams and imagine ourselves in a perfect situation - I don't care what the age is. Actress/comedian Betty White, who is nearing her 90′s, has never been more popular in Hollywood. She's refused to slow down or stop pursuing her passion. Whatever the age, whatever the purpose, whatever the passion, you must always believe in yourself and your drive to achieve what others think you can not.
In moments of doubt, treat the situation like its do-or-die. For some of those players on those Cinderella teams, you can bet that was their mindset as they took the floor knowing those next 40 minutes could be something they will never forget about for the rest of their lives. All the effort they brought day after day, leading up to their moment to shine, was what set up their opportunity to do the unthinkable.
For all of us, each day brings us a new opportunity to seek the same glory and desire to succeed. On any given day it could be our moment if we put in the same effort.
Funny Line of the Day (Thanks to My Mom)
I was talking to my parents last night after they came back from my cousin's twins' Christening. Unfortunately my wife and I were unable to attend due to prior engagements, so my mother broke the event down for me.
She kept saying how nice the reception was, as that part of the family isn't shy about spending big money on special occasions. In the wit that only old school immigrants can provide, my mom quipped "When these people do something, you gotta get dressed " (meaning wearing something fancy). It's a Seinfeld-like moment for me when I hear something like that. Thanks, Mom!
Our Beat The Markets with Dividend Stocks eBook Has Arrived!
We just debuted our brand new 275-page eBook, exclusively on Dividend.com! In this digital-only book, we look ahead to 2012 and the main factors that could affect dividend investors. A $39.95 value, the eBook is a free download for paid Dividend.com Premium subscribers.
Beat The Markets with Dividend Stocks contains a full economic forecast for 2012, including in-depth analysis on 65 of the biggest dividend stocks out there. It's a great way to get prepared for your investing next year! So head over to the Dividend.com Premium homepage now to download your copy.
I hope everyone had a chance to check out our Dividend.com Premium members-only weekend articles , including new features that highlight some of the biggest winners and losers from the week that was, such as analyst upgrades/downgrades and earnings/story stocks. These articles are a great way to catch up on the week that was in the markets. We also have a rundown of how various Dividend ETFs performed on the week.
Thanks for reading everybody. I'll see you tomorrow!
Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Created by Dividend.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Meanwhile, Wall Street analyst upgrades helped some stocks come of the gate strongly this week, including Devon Energy ( DVN ), Abbott Labs ( ABT ), Capital One Financial ( COF ), and U.S. Steel ( X ). In the wit that only old school immigrants can provide, my mom quipped "When these people do something, you gotta get dressed " (meaning wearing something fancy). I hope everyone had a chance to check out our Dividend.com Premium members-only weekend articles , including new features that highlight some of the biggest winners and losers from the week that was, such as analyst upgrades/downgrades and earnings/story stocks. | Meanwhile, Wall Street analyst upgrades helped some stocks come of the gate strongly this week, including Devon Energy ( DVN ), Abbott Labs ( ABT ), Capital One Financial ( COF ), and U.S. Steel ( X ). It is a big dividend-centric news day with Apple ( AAPL ) announcing it will join the ever-expanding list of big brands paying dividends. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Meanwhile, Wall Street analyst upgrades helped some stocks come of the gate strongly this week, including Devon Energy ( DVN ), Abbott Labs ( ABT ), Capital One Financial ( COF ), and U.S. Steel ( X ). It is a big dividend-centric news day with Apple ( AAPL ) announcing it will join the ever-expanding list of big brands paying dividends. Teams get seeded according to the their rankings and usually the best teams in the country (1 through 3 seeds) playing the smaller schools (lowest seeds 14-16). | Meanwhile, Wall Street analyst upgrades helped some stocks come of the gate strongly this week, including Devon Energy ( DVN ), Abbott Labs ( ABT ), Capital One Financial ( COF ), and U.S. Steel ( X ). It is a big dividend-centric news day with Apple ( AAPL ) announcing it will join the ever-expanding list of big brands paying dividends. This morning the company said it would initiate a quarterly dividend of $2.65 per share, which amounts to an estimated 1.75% dividend yield. |
34462.0 | 2012-03-19 00:00:00 UTC | Biogen Inks Deal with MAKScientific - Analyst Blog | ABT | https://www.nasdaq.com/articles/biogen-inks-deal-with-makscientific-analyst-blog-2012-03-19 | nan | nan | Biogen Idec ( BIIB ) recently signed an exclusive, worldwide option and collaboration agreement with privately held MAKScientific, LLC. MAKScientific focuses on the creation of novel and highly effective medications modulating cannabinoid pathways.
The deal relates to the development and commercialization of drug candidates for the treatment of multiple sclerosis ( MS ) and other neurodegenerative diseases.
Terms of the Agreement
Per the terms of the agreement, Biogen has the option to gain an exclusive global license to certain discovery-stage MAKScientific drug candidates for all indications. Once Biogen exercises its option,it will have to pay an exercise fee of up to $3 million to MAKScientific. Biogen will also be liable to pay up to an additional $31 million on the achievement of milestones related to the development of the candidate. Besides this, the company will also pay royalties on net sales worldwide.
With this deal, MAKScientific is gaining a partner with vast experience in the multiple sclerosis market.
Meanwhile, Biogen has been working on consolidating its position in the multiple sclerosis market. The company has an impressive late-stage pipeline of multiple sclerosis drugs including BG-12 (new drug application filed in the US in Feb 2012). Besides BG-12, Biogen is developing other multiple sclerosis candidates like daclizumab, in partnership with Abbott Labs ( ABT ), and PEGylated interferon.
Biogen has also been pretty active on the deal-making/acquisition front so far in 2012. Besides the MAKScientific deal, Biogen has signed other deals in 2012 to expand its early/mid-stage pipeline. In early Jan, the company joined hands with Isis Pharmaceuticals, Inc. ( ISIS ) for the development and commercialization of an antisense drug for the treatment of spinal muscular atrophy ( SMA ). Biogen also signed a deal to acquire privately-held biotech company, Stromedix, Inc. With this acquisition, Biogen will gain access to treatments being developed for fibrosis and organ failure.
We currently have a Neutral recommendation on Biogen, which carries a Zacks #3 Rank (short-term "Hold" rating).
ABBOTT LABS ( ABT ): Free Stock Analysis Report
BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report
ISIS PHARMACEUT ( ISIS ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Besides BG-12, Biogen is developing other multiple sclerosis candidates like daclizumab, in partnership with Abbott Labs ( ABT ), and PEGylated interferon. ABBOTT LABS ( ABT ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report ISIS PHARMACEUT ( ISIS ): Free Stock Analysis Report To read this article on Zacks.com click here. Biogen Idec ( BIIB ) recently signed an exclusive, worldwide option and collaboration agreement with privately held MAKScientific, LLC. | ABBOTT LABS ( ABT ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report ISIS PHARMACEUT ( ISIS ): Free Stock Analysis Report To read this article on Zacks.com click here. Besides BG-12, Biogen is developing other multiple sclerosis candidates like daclizumab, in partnership with Abbott Labs ( ABT ), and PEGylated interferon. Biogen Idec ( BIIB ) recently signed an exclusive, worldwide option and collaboration agreement with privately held MAKScientific, LLC. | ABBOTT LABS ( ABT ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report ISIS PHARMACEUT ( ISIS ): Free Stock Analysis Report To read this article on Zacks.com click here. Besides BG-12, Biogen is developing other multiple sclerosis candidates like daclizumab, in partnership with Abbott Labs ( ABT ), and PEGylated interferon. Terms of the Agreement Per the terms of the agreement, Biogen has the option to gain an exclusive global license to certain discovery-stage MAKScientific drug candidates for all indications. | Besides BG-12, Biogen is developing other multiple sclerosis candidates like daclizumab, in partnership with Abbott Labs ( ABT ), and PEGylated interferon. ABBOTT LABS ( ABT ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report ISIS PHARMACEUT ( ISIS ): Free Stock Analysis Report To read this article on Zacks.com click here. Biogen Idec ( BIIB ) recently signed an exclusive, worldwide option and collaboration agreement with privately held MAKScientific, LLC. |
34463.0 | 2012-03-13 00:00:00 UTC | Watson Ups Generic Count - Analyst Blog | ABT | https://www.nasdaq.com/articles/watson-ups-generic-count-analyst-blog-2012-03-13 | nan | nan | Watson Pharmaceuticals Inc. ( WPI ) recently announced the launch of an authorized generic version of Abbott Laboratories' ( ABT ) drug Prometrium. Prometrium is available for use in the prevention of endometrial hyperplasia in non hysterectomized postmenopausal women who are receiving conjugated estrogen tablets. The drug is also used for the treatment of secondary amenorrhea.
Watson Pharma launched its generic drug under a supply agreement with Abbott Labs. According to the agreement, Abbott Labs will manufacture and supply all dosages of the authorized generic product to Watson Pharma, who will then market and distribute the same in the US. The companies will be sharing the profits depending on sales figures.
According to IMS Health data, Prometrium sales amounted to $198 million for the twelve months ended January 31, 2012.
We note that Watson Pharma also has an agreement with Pfizer Inc. ( PFE ) to market the authorized generic version of Lipitor in the US. Last year in November, Watson Pharma launched its authorized generic version of Lipitor, which is used as an adjunct to diet to reduce elevated total cholesterol, LDL (bad cholesterol), triglycerides and to increase HDL (good) cholesterol.
According to the supply and distribution agreement, Pfizer manufactures and supplies all dosage strengths of the authorized generic product to Watson Pharma, who, thereafter, markets and distributes the drug in the US. In return, Pfizer receives a share of the net sales from Watson Pharma. The agreement, which runs until November 30, 2016, is expected to add about 75 cents per share to Watson Pharma's 2012 earnings.
Our View
We currently have a Neutral recommendation on Watson Pharma. The stock carries a Zacks #3 Rank (Hold rating) in the short run.
We expect new generic product launches over regular intervals to help drive the company's Global Generic segment's sales, which climbed 46% during 2011 to $3.32 billion, driven by the generic launch of Lipitor and Concerta. Concerta is originally marketed by Johnson & Johnson ( JNJ ) for the treatment of attention deficit hyperactivity disorder (ADHD).
ABBOTT LABS ( ABT ): Free Stock Analysis Report
JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report
PFIZER INC ( PFE ): Free Stock Analysis Report
WATSON PHARMA ( WPI ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Watson Pharmaceuticals Inc. ( WPI ) recently announced the launch of an authorized generic version of Abbott Laboratories' ( ABT ) drug Prometrium. ABBOTT LABS ( ABT ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report WATSON PHARMA ( WPI ): Free Stock Analysis Report To read this article on Zacks.com click here. According to the agreement, Abbott Labs will manufacture and supply all dosages of the authorized generic product to Watson Pharma, who will then market and distribute the same in the US. | ABBOTT LABS ( ABT ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report WATSON PHARMA ( WPI ): Free Stock Analysis Report To read this article on Zacks.com click here. Watson Pharmaceuticals Inc. ( WPI ) recently announced the launch of an authorized generic version of Abbott Laboratories' ( ABT ) drug Prometrium. According to the agreement, Abbott Labs will manufacture and supply all dosages of the authorized generic product to Watson Pharma, who will then market and distribute the same in the US. | ABBOTT LABS ( ABT ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report WATSON PHARMA ( WPI ): Free Stock Analysis Report To read this article on Zacks.com click here. Watson Pharmaceuticals Inc. ( WPI ) recently announced the launch of an authorized generic version of Abbott Laboratories' ( ABT ) drug Prometrium. According to the agreement, Abbott Labs will manufacture and supply all dosages of the authorized generic product to Watson Pharma, who will then market and distribute the same in the US. | Watson Pharmaceuticals Inc. ( WPI ) recently announced the launch of an authorized generic version of Abbott Laboratories' ( ABT ) drug Prometrium. ABBOTT LABS ( ABT ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report WATSON PHARMA ( WPI ): Free Stock Analysis Report To read this article on Zacks.com click here. Watson Pharma launched its generic drug under a supply agreement with Abbott Labs. |
34464.0 | 2012-03-08 00:00:00 UTC | Abbott Laboratories’ Target Raised at Jefferies; Break-up Potential is Strong (ABT) | ABT | https://www.nasdaq.com/articles/abbott-laboratories-target-raised-jefferies-break-potential-strong-abt-2012-03-08 | nan | nan | Health care products maker Abbott Laboratories ( ABT ) on Thursday saw its price target raised significantly by analysts at Jefferies & Co.
The firm maintained its "Buy" rating on ABT and lifted its price target $65 to $76, suggesting a 35% upside to the stock's Wednesday closing price of $56.26.
A Jefferies analyst commented, "The market significantly undervalues the break-up valuation of Abbott post the spin-off of the Pharma unit in our view. Growth investors will be attracted to the DMP business where we estimate valuation of $35 per share. The Proprietary Pharmaceuticals spin-off will be targeted by income funds, where a sector average yield implies a valuation of $41 per share. Combined we use this sum-of-the-parts approach to drive our new PT of $76."
Back in October, ABT announced it would split into two publicly-traded companies in 2012.
Abbott shares rose 55 cents, or +1%, in premarket trading Thursday.
The Bottom Line
We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. The company has a 3.63% dividend yield, based on last night's closing stock price of $56.26.
Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars.
Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Created by Dividend.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Health care products maker Abbott Laboratories ( ABT ) on Thursday saw its price target raised significantly by analysts at Jefferies & Co. The firm maintained its "Buy" rating on ABT and lifted its price target $65 to $76, suggesting a 35% upside to the stock's Wednesday closing price of $56.26. Back in October, ABT announced it would split into two publicly-traded companies in 2012. | Health care products maker Abbott Laboratories ( ABT ) on Thursday saw its price target raised significantly by analysts at Jefferies & Co. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars. The firm maintained its "Buy" rating on ABT and lifted its price target $65 to $76, suggesting a 35% upside to the stock's Wednesday closing price of $56.26. | The firm maintained its "Buy" rating on ABT and lifted its price target $65 to $76, suggesting a 35% upside to the stock's Wednesday closing price of $56.26. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars. | Health care products maker Abbott Laboratories ( ABT ) on Thursday saw its price target raised significantly by analysts at Jefferies & Co. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars. The firm maintained its "Buy" rating on ABT and lifted its price target $65 to $76, suggesting a 35% upside to the stock's Wednesday closing price of $56.26. |
34465.0 | 2012-03-08 00:00:00 UTC | Abbott, Galapagos Team Up - Analyst Blog | ABT | https://www.nasdaq.com/articles/abbott-galapagos-team-up-analyst-blog-2012-03-08 | nan | nan | Abbott Laboratories ( ABT ) recently signed a deal to expand its pharma portfolio. The company entered into a collaboration agreement with biotech company Galapagos for the development and commercialization of an oral, next-generation JAK1 inhibitor.
The Candidate
GLPG0634 is currently in phase II development for the treatment of rheumatoid arthritis ( RA ) and other autoimmune diseases.
Results from a 4-week phase IIa study showed that GLPG0634's efficacy was among the best seen in RA. Galapagos reported that all patients completed the study with very few of them experiencing any side effects. The company said that no anemia, change in blood pressure or lipids were observed.
GLPG0634 is scheduled to move into a phase IIa dose-range finding study shortly. Galapagos expects to report top-line results from this study before the end of 2012. The full phase II package will be delivered to Abbott Labs in 2014.
This deal makes sense for Abbott Labs which already has a strong presence in the market for autoimmune diseases thanks to its blockbuster drug, Humira. Moreover, Abbott Labs needs to build its pharma pipeline.
Terms of the Agreement
Per the terms of the agreement, Abbott Labs is required to make an upfront payment of $150 million to Galapagos. Once the phase II RA studies are done, Abbott Labs will pay a one-time license fee of $200 million, provided the studies meet certain pre-determined criteria.
Once the phase II package is handed over, Abbott Labs will be responsible for the phase III development and manufacturing of the candidate. Abbott Labs could end up paying up to $1 billion on the achievement of developmental, regulatory, commercial and sales-based milestones.
Galapagos will also receive tiered double-digit royalties on net sales once the product is commercialized. Galapagos has co-promotion rights in Belgium, the Netherlands and Luxembourg.
Neutral on Abbott Labs
We currently have a Neutral recommendation on Abbott Labs, which carries a Zacks #3 Rank (short-term Hold rating). Abbott Labs remains on track to split into two separate publicly traded companies by the end of 2012.
While one company will deal in diversified medical products, the other will focus on research-based pharmaceuticals. We are positive on the split, which should allow the two separate entities to perform in a more focused manner.
ABBOTT LABS ( ABT ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABBOTT LABS ( ABT ): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) recently signed a deal to expand its pharma portfolio. This deal makes sense for Abbott Labs which already has a strong presence in the market for autoimmune diseases thanks to its blockbuster drug, Humira. | Abbott Laboratories ( ABT ) recently signed a deal to expand its pharma portfolio. ABBOTT LABS ( ABT ): Free Stock Analysis Report To read this article on Zacks.com click here. Once the phase II RA studies are done, Abbott Labs will pay a one-time license fee of $200 million, provided the studies meet certain pre-determined criteria. | Abbott Laboratories ( ABT ) recently signed a deal to expand its pharma portfolio. ABBOTT LABS ( ABT ): Free Stock Analysis Report To read this article on Zacks.com click here. Once the phase II RA studies are done, Abbott Labs will pay a one-time license fee of $200 million, provided the studies meet certain pre-determined criteria. | Abbott Laboratories ( ABT ) recently signed a deal to expand its pharma portfolio. ABBOTT LABS ( ABT ): Free Stock Analysis Report To read this article on Zacks.com click here. The company entered into a collaboration agreement with biotech company Galapagos for the development and commercialization of an oral, next-generation JAK1 inhibitor. |
34466.0 | 2012-03-08 00:00:00 UTC | Market Wrap-Up for Mar.8 (COH, MCD, WSM, MW, JPM, ABT, more) | ABT | https://www.nasdaq.com/articles/market-wrap-mar8-coh-mcd-wsm-mw-jpm-abt-more-2012-03-08 | nan | nan | Today's rally was being tied to the confidence seen earlier in the Asian and European markets that Greece is going to see its troubles subside - and more importantly, the rest of Europe as well.
Earnings results however didn't lift stocks like Williams-Sonoma ( WSM ) ( report here ) and Men's Wearhouse ( MW ) ( read more ), which both ended in the red. McDonald's ( MCD ) also didn't participate in the rally after the company gave a cautious outlook for its global sales.
Wall Street analyst upgrades helped boost stocks like J.P. Morgan ( JPM ) ( read more ) and Abbott Lab | Today's rally was being tied to the confidence seen earlier in the Asian and European markets that Greece is going to see its troubles subside - and more importantly, the rest of Europe as well. Earnings results however didn't lift stocks like Williams-Sonoma ( WSM ) ( report here ) and Men's Wearhouse ( MW ) ( read more ), which both ended in the red. Wall Street analyst upgrades helped boost stocks like J.P. Morgan ( JPM ) ( read more ) and Abbott Lab | Earnings results however didn't lift stocks like Williams-Sonoma ( WSM ) ( report here ) and Men's Wearhouse ( MW ) ( read more ), which both ended in the red. McDonald's ( MCD ) also didn't participate in the rally after the company gave a cautious outlook for its global sales. Wall Street analyst upgrades helped boost stocks like J.P. Morgan ( JPM ) ( read more ) and Abbott Lab | Today's rally was being tied to the confidence seen earlier in the Asian and European markets that Greece is going to see its troubles subside - and more importantly, the rest of Europe as well. Earnings results however didn't lift stocks like Williams-Sonoma ( WSM ) ( report here ) and Men's Wearhouse ( MW ) ( read more ), which both ended in the red. Wall Street analyst upgrades helped boost stocks like J.P. Morgan ( JPM ) ( read more ) and Abbott Lab | Today's rally was being tied to the confidence seen earlier in the Asian and European markets that Greece is going to see its troubles subside - and more importantly, the rest of Europe as well. Earnings results however didn't lift stocks like Williams-Sonoma ( WSM ) ( report here ) and Men's Wearhouse ( MW ) ( read more ), which both ended in the red. McDonald's ( MCD ) also didn't participate in the rally after the company gave a cautious outlook for its global sales. |
34467.0 | 2012-03-02 00:00:00 UTC | BSX Unveils Promus Element in Japan - Analyst Blog | ABT | https://www.nasdaq.com/articles/bsx-unveils-promus-element-in-japan-analyst-blog-2012-03-02 | nan | nan | Boston Scientific Corporation ( BSX ) has launched the Promus Element stent in Japan following its recent approval by the Ministry of Health, Labor and Welfare. The company plans to begin marketing the product immediately. This launch comes much ahead of the company's expectation of a mid-2012 approval. Boston Scientific's portfolio in Japan got a further fillip with this latest inclusion.
Under an agreement with Abbott Laboratories ( ABT ), Boston Scientific markets its everolimus eluting stent Xience under the brand name Promus in Japan until the second quarter of 2012. However, with the launch of the internally-developed and self-manufactured stent, the company could expand its gross margin.
Defibrillators and stents are the company's core businesses. However, global sales of coronary stent system at $381 million, during the most recent quarter, declined 6.8% year over year due to disappointing performance from both drug-eluting stents ("DES") that declined 5.6% to $356 million and bare-metal stents that dropped 21.8% to $25 million. Revenues fell short of the company's guidance due to continued softness in procedure volumes.
However, the approval of Promus Element Plus stent in the US last year came well ahead of the original expectation of a mid-2012 timeline.Boston Scientific expects that the approval of Promus Element represents $200 million in additional annualized gross margin contribution from the US and Japan at the end of 2012. This is a part of the targeted $650-$750 million opportunity for improvement in operating profit over the next few years. The success of Promus Element Plus in the US along with its launch in Japan and Johnson & Johnson 's ( JNJ ) decision to exit the DES business should enable the company to improve its DES market share.
The Element platform continues to perform well in the emerging markets, primarily in India and Brazil. With the recent launch of Promus Element in China and some anticipated pricing approvals in India, contribution from these regions is expected to rise further in 2012.
Based on the investments made in sales representatives, dealers and infrastructure, the company is well placed to increase its single-digit market share in China and India. The combined DES market is estimated at $700 million with a 20% growth rate. Boston Scientific is also making headway in Brazil following the launch of Promus Element in late 2010. Ever since the Promus to Promus Element conversion, market share has expanded by almost 800 basis points, exiting 2011 with more than 60% of the pie. We believe the strategies implemented by the company would help reap the immense potential embedded in the emerging markets.
We have a Neutral recommendation on Boston Scientific. The stock retains a Zacks #3 Rank (Hold) in the short term.
ABBOTT LABS ( ABT ): Free Stock Analysis Report
BOSTON SCIENTIF ( BSX ): Free Stock Analysis Report
JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Under an agreement with Abbott Laboratories ( ABT ), Boston Scientific markets its everolimus eluting stent Xience under the brand name Promus in Japan until the second quarter of 2012. ABBOTT LABS ( ABT ): Free Stock Analysis Report BOSTON SCIENTIF ( BSX ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report To read this article on Zacks.com click here. Boston Scientific Corporation ( BSX ) has launched the Promus Element stent in Japan following its recent approval by the Ministry of Health, Labor and Welfare. | ABBOTT LABS ( ABT ): Free Stock Analysis Report BOSTON SCIENTIF ( BSX ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report To read this article on Zacks.com click here. Under an agreement with Abbott Laboratories ( ABT ), Boston Scientific markets its everolimus eluting stent Xience under the brand name Promus in Japan until the second quarter of 2012. However, global sales of coronary stent system at $381 million, during the most recent quarter, declined 6.8% year over year due to disappointing performance from both drug-eluting stents ("DES") that declined 5.6% to $356 million and bare-metal stents that dropped 21.8% to $25 million. | Under an agreement with Abbott Laboratories ( ABT ), Boston Scientific markets its everolimus eluting stent Xience under the brand name Promus in Japan until the second quarter of 2012. ABBOTT LABS ( ABT ): Free Stock Analysis Report BOSTON SCIENTIF ( BSX ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report To read this article on Zacks.com click here. However, global sales of coronary stent system at $381 million, during the most recent quarter, declined 6.8% year over year due to disappointing performance from both drug-eluting stents ("DES") that declined 5.6% to $356 million and bare-metal stents that dropped 21.8% to $25 million. | Under an agreement with Abbott Laboratories ( ABT ), Boston Scientific markets its everolimus eluting stent Xience under the brand name Promus in Japan until the second quarter of 2012. ABBOTT LABS ( ABT ): Free Stock Analysis Report BOSTON SCIENTIF ( BSX ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report To read this article on Zacks.com click here. However, the approval of Promus Element Plus stent in the US last year came well ahead of the original expectation of a mid-2012 timeline.Boston Scientific expects that the approval of Promus Element represents $200 million in additional annualized gross margin contribution from the US and Japan at the end of 2012. |
34468.0 | 2012-02-29 00:00:00 UTC | Meridian's Legionella Test Cleared - Analyst Blog | ABT | https://www.nasdaq.com/articles/meridians-legionella-test-cleared-analyst-blog-2012-02-29 | nan | nan | Diagnostic test kit maker Meridian Bioscience ( VIVO ) has won the approval of the U.S. Food and Drug Administration (FDA) for its new test for detection of Legionnaire's disease (legionellosis), a potentially fatal form of pneumonia.
The test, dubbed TRU Legionella, is a rapid lateral flow device which offers optimized detection of Legionella pneumophila serogroup that is most commonly associated with Legionnaire's disease, which is caused by a type of bacteria called Legionella.
The infection is characterized by symptoms which are typically similar to a severe flu including fever, headache, breathing problems, muscle aches/pains and occasionally a dry cough. Legionnaire's disease affects around 100,000 Americans annually with roughly 10,000 to 20,000 hospitalizations.
According to Meridian, Legionella is implicated in 5%-8% of the roughly 4 million to 5 million cases of community acquired pneumonia that occur annually in the U.S. However, many infections are left undiagnosed given the poor diagnostic options.
Meridian believes that the TRU Legionella test will provide a much needed solution for the often under-diagnosed Legionnaire's disease. The test is expected to offer laboratories with a powerful tool for accurate, cost-effective and fast detection of this disease condition, thereby expediting treatment for the affected patients.
Meridian specializes in developing diagnostic test kits for multiple serious and infectious diseases. The company's diagnostics business faces strong competition from Abbott Laboratories ( ABT ), Becton, Dickinson and Company ( BDX ), Thermo Fisher ( TMO ) and Siemens ( SI ).
Meridian, in December 2011, received the FDA approval for the illumigene GBS (Group B streptococcus) test, its second in the illumigene molecular test platform. Successively, the company received the U.S. approval for its new C. difficile(Clostridium difficile) test called ImmunoCard C. difficile GDH.
The TRU Legionella test represents a key addition to the company's respiratory product range. The test reinforces its leadership position in rapid and accurate testing methods for infectious diseases.
ABBOTT LABS ( ABT ): Free Stock Analysis Report
BECTON DICKINSO ( BDX ): Free Stock Analysis Report
SIEMENS AG-ADR ( SI ): Free Stock Analysis Report
THERMO FISHER ( TMO ): Free Stock Analysis Report
MERIDIAN BIOSCI ( VIVO ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company's diagnostics business faces strong competition from Abbott Laboratories ( ABT ), Becton, Dickinson and Company ( BDX ), Thermo Fisher ( TMO ) and Siemens ( SI ). ABBOTT LABS ( ABT ): Free Stock Analysis Report BECTON DICKINSO ( BDX ): Free Stock Analysis Report SIEMENS AG-ADR ( SI ): Free Stock Analysis Report THERMO FISHER ( TMO ): Free Stock Analysis Report MERIDIAN BIOSCI ( VIVO ): Free Stock Analysis Report To read this article on Zacks.com click here. The infection is characterized by symptoms which are typically similar to a severe flu including fever, headache, breathing problems, muscle aches/pains and occasionally a dry cough. | The company's diagnostics business faces strong competition from Abbott Laboratories ( ABT ), Becton, Dickinson and Company ( BDX ), Thermo Fisher ( TMO ) and Siemens ( SI ). ABBOTT LABS ( ABT ): Free Stock Analysis Report BECTON DICKINSO ( BDX ): Free Stock Analysis Report SIEMENS AG-ADR ( SI ): Free Stock Analysis Report THERMO FISHER ( TMO ): Free Stock Analysis Report MERIDIAN BIOSCI ( VIVO ): Free Stock Analysis Report To read this article on Zacks.com click here. Successively, the company received the U.S. approval for its new C. difficile(Clostridium difficile) test called ImmunoCard C. difficile GDH. | ABBOTT LABS ( ABT ): Free Stock Analysis Report BECTON DICKINSO ( BDX ): Free Stock Analysis Report SIEMENS AG-ADR ( SI ): Free Stock Analysis Report THERMO FISHER ( TMO ): Free Stock Analysis Report MERIDIAN BIOSCI ( VIVO ): Free Stock Analysis Report To read this article on Zacks.com click here. The company's diagnostics business faces strong competition from Abbott Laboratories ( ABT ), Becton, Dickinson and Company ( BDX ), Thermo Fisher ( TMO ) and Siemens ( SI ). Diagnostic test kit maker Meridian Bioscience ( VIVO ) has won the approval of the U.S. Food and Drug Administration (FDA) for its new test for detection of Legionnaire's disease (legionellosis), a potentially fatal form of pneumonia. | The company's diagnostics business faces strong competition from Abbott Laboratories ( ABT ), Becton, Dickinson and Company ( BDX ), Thermo Fisher ( TMO ) and Siemens ( SI ). ABBOTT LABS ( ABT ): Free Stock Analysis Report BECTON DICKINSO ( BDX ): Free Stock Analysis Report SIEMENS AG-ADR ( SI ): Free Stock Analysis Report THERMO FISHER ( TMO ): Free Stock Analysis Report MERIDIAN BIOSCI ( VIVO ): Free Stock Analysis Report To read this article on Zacks.com click here. Diagnostic test kit maker Meridian Bioscience ( VIVO ) has won the approval of the U.S. Food and Drug Administration (FDA) for its new test for detection of Legionnaire's disease (legionellosis), a potentially fatal form of pneumonia. |
34469.0 | 2012-02-27 00:00:00 UTC | Auxilium Misses 4Q Estimates - Analyst Blog | ABT | https://www.nasdaq.com/articles/auxilium-misses-4q-estimates-analyst-blog-2012-02-27 | nan | nan | Auxilium Pharmaceuticals, Inc. ( AUXL ) reported a fourth quarter loss of 25 cents per share, well below the year-ago loss of 34 cents. Fourth quarter 2011 loss, however, was well above the Zacks Consensus Estimate of a loss of 16 cents. Revenues, which increased 19% to $73.3 million, were just shy of the Zacks Consensus Estimate of $74 million.
Full year loss was 69 cents, well below the year-ago loss of $1.08 per share. However, 2011 loss was higher than the Zacks Consensus Estimate of a loss of 59 cents. Full year revenues came in at $264.3 million, up 25%, and in line with the Zacks Consensus Estimate.
Quarter in Detail
During the reported quarter, total Testim sales increased 8% to $57.6 million. Testim revenues in the US were $56.9 million.
However, Testim faces significant competition in the form of Abbott's ( ABT ) AndroGel. With the entry of additional competition in the market, Testim's market share in the US at the end of Dec 2011 was 20%, down from 22% in the year-ago period. Auxilium Pharma expects Testim revenues of $215 - $225 million in 2012, up from $207.9 million in 2011. The company intends to focus on payors, physicians, and patients with Testim in 2012.
Meanwhile, Xiaflex sales came in at $15.7 million, including contract and ex-US revenues. US revenues came in at $13.4 million. In addition to the US, Xiaflex is available in several other countries including the UK (trade name Xiapex), Germany, Austria, Denmark, Finland, Norway and Sweden.
Auxilium Pharma is working on creating and increasing awareness among physicians and patients about Xiaflex. The company continues to present data on the clinical profile of Xiaflex. Xiaflex is also in a phase IIIb Dupuytren's contracture multicord study - top-line results should be out in the second quarter of 2012. Besides this, a direct response TV campaign is ongoing in select cities.
While the January 2012 implementation of a permanent CPT code could help smoothen the reimbursement process, we expect the implementation of the CPT code to have a modest impact on Xiaflex sales.
Auxilium Pharma is working on expanding Xiaflex' label. The company is currently conducting phase III studies with Xiaflex for Peyronie's disease. Top-line results from the phase III program should be out late in the second quarter of 2012. Positive results would allow the company to file for approval in the second half of 2012.
Auxilium Pharma initiated a phase Ib study in Jan 2012 for the treatment of cellulite (edematous fibrosclerotic panniculopathy) - top-line results are expected in late 2012. Xiaflex is currently in a phase IIa study for the treatment of frozen shoulder syndrome with top-line results expected in the first half of 2013.
Meanwhile, research and development expenses for the reported quarter increased 33.6% to $18.7 million due to costs related to the development of a larger scale production process for Xiaflex and additional studies being conducted with the product. Selling, general and administrative expenses increased 6.6% to $50.1 million mainly due to charges related to the CEO change.
2012 Guidance Looks Achievable
The company expects net revenues in the range of $283 to $305 million in 2012. While Testim revenues are expected to increase to $215 - $225 million, Xiaflex revenues in the US are expected to increase to $55 - $65 million. Meanwhile, ex-US and deferred revenues for Xiaflex are expected in the range of $13 to $15 million.
Research and development spend will be in the range of $55 to $65 million in 2012. Selling, general and administrative expenses are expected in the range of $180 to $190 million. The company expects a net loss of $5 to $15 million.
Signs Agreement with Actelion
In addition to announcing fourth quarter and full year 2011 results, Auxilium Pharma announced an agreement with Swiss biopharma company, Actelion Pharmaceuticals Ltd. ( ALIOF ), for the development, supply and commercialization of Xiaflex for the potential treatment of Dupuytren's contracture and Peyronie's disease.
Actelion will have exclusive rights for the commercialization of Xiaflex in Canada (regulatory review ongoing with a response expected in the second half of 2012), Australia, Brazil and Mexico. Regulatory filings for the Dupuytren's indication in Australia, Brazil and Mexico are scheduled to take place in the next 12 months.
Besides receiving an upfront payment of $10 million, Auxilium Pharma will also be eligible to receive up to $58.5 million on the achievement of regulatory, pricing, reimbursement and sales milestones. The company will also be entitled to receive increasing tiered double-digit royalties based on Xiaflex sales.
This deal is in-line with Auxilium Pharma's strategy of partnering Xiaflex in ex-US territories. Besides Actelion, Auxilium Pharma's partners for Xiaflex include Pfizer ( PFE ) and Asahi Kasei Pharma Corporation.
Neutral on Auxilium Pharma
We currently have a Neutral recommendation on Auxilium Pharma, which carries a Zacks #3 Rank (short-term "Hold" rating). Although Testim has been performing well , tough competition could limit the ultimate potential of the drug. Given the eventual slowdown in Testim growth, Auxilium Pharma's future relies heavily on Xiaflex. However, Xiaflex' performance continues to lag expectations. With Auxilium Pharma working on driving sales of the product, we expect investor focus to remain on the successful commercialization of Xiaflex/Xiapex, and label expansion of the product for additional indications.
ABBOTT LABS ( ABT ): Free Stock Analysis Report
AUXILIUM PHARMA ( AUXL ): Free Stock Analysis Report
PFIZER INC ( PFE ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | However, Testim faces significant competition in the form of Abbott's ( ABT ) AndroGel. ABBOTT LABS ( ABT ): Free Stock Analysis Report AUXILIUM PHARMA ( AUXL ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report To read this article on Zacks.com click here. In addition to the US, Xiaflex is available in several other countries including the UK (trade name Xiapex), Germany, Austria, Denmark, Finland, Norway and Sweden. | ABBOTT LABS ( ABT ): Free Stock Analysis Report AUXILIUM PHARMA ( AUXL ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report To read this article on Zacks.com click here. However, Testim faces significant competition in the form of Abbott's ( ABT ) AndroGel. Auxilium Pharmaceuticals, Inc. ( AUXL ) reported a fourth quarter loss of 25 cents per share, well below the year-ago loss of 34 cents. | However, Testim faces significant competition in the form of Abbott's ( ABT ) AndroGel. ABBOTT LABS ( ABT ): Free Stock Analysis Report AUXILIUM PHARMA ( AUXL ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report To read this article on Zacks.com click here. Auxilium Pharma expects Testim revenues of $215 - $225 million in 2012, up from $207.9 million in 2011. | However, Testim faces significant competition in the form of Abbott's ( ABT ) AndroGel. ABBOTT LABS ( ABT ): Free Stock Analysis Report AUXILIUM PHARMA ( AUXL ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report To read this article on Zacks.com click here. Testim revenues in the US were $56.9 million. |
34470.0 | 2012-02-24 00:00:00 UTC | DexCom's EPS Misses, Sales Beat - Analyst Blog | ABT | https://www.nasdaq.com/articles/dexcoms-eps-misses-sales-beat-analyst-blog-2012-02-24 | nan | nan | DexCom ( DXCM ), a player in the glucose monitoring market, reported fourth-quarter 2011 loss per share of 18 cents, higher than both the Zacks Consensus Estimate of a loss of 17 cents and the year-ago loss of 16 cents per share. Net loss for the quarter increased 24.9% year over year to $12.3 million.
For fiscal 2011, loss per share of 68 cents was also above the Zacks Consensus Estimate of a loss of 67 cents but much lower than the year-ago loss of 97 cents per share.
Revenues
Sales increased sharply 43% year over year to $22.4 million in the fourth quarter, beating the Zacks Consensus Estimate of $22 million. Revenue was $76.3 million in fiscal 2011, up 57% year over year, surpassing the Zacks Consensus Estimate of $75 million.
Product sales climbed 54% to $20.9 million while development grant and other revenues were down 27% to $1.5 million in the reported quarter.
Margins and Expenses
Gross margin improved to 47.7% in the fourth quarter from 44.7% a year ago. Cost of sales moved up 35.6% year over year to $11.7 million on account of higher cost of product sales. Operating expenses increased 36.1% year over year to $23 million on account of higher R&D spending and selling, general and administrative expenses, which grew 33.8% and 37.7%, respectively, in the quarter.
Balance Sheet
At the end of the quarter, DexCom had cash and short-term marketable securities of $81.9 million, up 74% y/y.
Our Take
We believe DexCom is poised to gain a major share of the glucose monitoring market, driven by sustained product development initiatives, collaborations, favorable reimbursement coverage and increased need for continuous glucose monitoring.
However, we note that competition in the glucose monitoring market is intense and DexCom faces stiff challenges from much larger players such as Johnson & Johnson ( JNJ ), Medtronic ( MDT ) and Abbott Labs ( ABT ). Moreover, the company has incurred losses since inception and is exposed to a stricter regulatory environment. Our Neutral recommendation is supported by a short-term Zacks #3 Rank (Hold).
ABBOTT LABS ( ABT ): Free Stock Analysis Report
DEXCOM INC ( DXCM ): Free Stock Analysis Report
JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report
MEDTRONIC ( MDT ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | However, we note that competition in the glucose monitoring market is intense and DexCom faces stiff challenges from much larger players such as Johnson & Johnson ( JNJ ), Medtronic ( MDT ) and Abbott Labs ( ABT ). ABBOTT LABS ( ABT ): Free Stock Analysis Report DEXCOM INC ( DXCM ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report MEDTRONIC ( MDT ): Free Stock Analysis Report To read this article on Zacks.com click here. Balance Sheet At the end of the quarter, DexCom had cash and short-term marketable securities of $81.9 million, up 74% y/y. | ABBOTT LABS ( ABT ): Free Stock Analysis Report DEXCOM INC ( DXCM ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report MEDTRONIC ( MDT ): Free Stock Analysis Report To read this article on Zacks.com click here. However, we note that competition in the glucose monitoring market is intense and DexCom faces stiff challenges from much larger players such as Johnson & Johnson ( JNJ ), Medtronic ( MDT ) and Abbott Labs ( ABT ). DexCom ( DXCM ), a player in the glucose monitoring market, reported fourth-quarter 2011 loss per share of 18 cents, higher than both the Zacks Consensus Estimate of a loss of 17 cents and the year-ago loss of 16 cents per share. | ABBOTT LABS ( ABT ): Free Stock Analysis Report DEXCOM INC ( DXCM ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report MEDTRONIC ( MDT ): Free Stock Analysis Report To read this article on Zacks.com click here. However, we note that competition in the glucose monitoring market is intense and DexCom faces stiff challenges from much larger players such as Johnson & Johnson ( JNJ ), Medtronic ( MDT ) and Abbott Labs ( ABT ). DexCom ( DXCM ), a player in the glucose monitoring market, reported fourth-quarter 2011 loss per share of 18 cents, higher than both the Zacks Consensus Estimate of a loss of 17 cents and the year-ago loss of 16 cents per share. | However, we note that competition in the glucose monitoring market is intense and DexCom faces stiff challenges from much larger players such as Johnson & Johnson ( JNJ ), Medtronic ( MDT ) and Abbott Labs ( ABT ). ABBOTT LABS ( ABT ): Free Stock Analysis Report DEXCOM INC ( DXCM ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report MEDTRONIC ( MDT ): Free Stock Analysis Report To read this article on Zacks.com click here. Net loss for the quarter increased 24.9% year over year to $12.3 million. |
34471.0 | 2012-02-17 00:00:00 UTC | FDA Nod for Gen-Probe's PROGENSA - Analyst Blog | ABT | https://www.nasdaq.com/articles/fda-nod-for-gen-probes-progensa-analyst-blog-2012-02-17 | nan | nan | Diagnostic products maker Gen-Probe Inc . ( GPRO ) has secured the approval of the U.S. Food and Drug Administration ("FDA") for its PROGENSA PCA3 assay, a novel molecular test designed to aid the diagnosis of prostate cancer.
The assay is geared for testing urine specimens from men who earlier had a negative prostate biopsy.
Gen-Probe submitted a Pre-market Approval ("PMA") application to the FDA for PROGENSA PCA3 in September 2010. The California-based company, in November 2011, said that it received a notice from the FDA that stated the regulator had concluded that a panel review was no longer necessary in the review process of the PMA. The panel review was expected in October 2011.
Gen-Probe acquired the exclusive global rights to the PCA3 (a genetic marker for prostate cancer) from Canadian cancer diagnostic tests company DiagnoCure in November 2003. The PROGENSA PCA3 assay, the first urine-based molecular diagnostic assay for prostate cancer, is currently marketed in the European Union and Canada.
Prostate cancer is the second most prevalent cancer (after skin cancer) among American men and the second-leading cause (after lung cancer) of cancer-related death. According to the American Cancer Society (ACS), roughly 241,000 people were diagnosed with prostate cancer in the U.S. in 2011 and around 34,000 of them succumbed to the disease.
The PROGENSA PCA3 assay detects the presence of cell-associated PCA3 in urine. PCA3 is over-expressed in 90% of prostate tumors (quantifiable in urine samples) and predicts biopsy results better than traditional prostate-specific antigen ( PSA ) testing, as observed in clinical studies. The assay is expected to help reduce unnecessary repeat prostate biopsies in men who have had at least one previous negative biopsy.
Gen-Probe has been a pioneer in the commercial and scientific development of nucleic acid testing ("NAT") for the diagnosis of infectious diseases. It competes with larger, more established players in the molecular diagnostic industry such as Roche ( RHHBY ), Becton Dickinson ( BDX ), and Abbott Labs ( ABT ).
Gen-Probe is a leading pure-play molecular diagnostics company. The company's molecular diagnostic tests and instruments are designed to improve results and increase laboratory operating efficiency.
Molecular testing enables real-time detection of the primary cause of a disease at the molecular level. Gen-Probe is positioned to benefit from the ongoing market shift away from traditional diagnostic methods (such as antibody-based assays) toward molecular testing, which offers greater precision and sensitivity in detecting biological events.
Gen-Probe's clinical diagnostics business posted healthy results in the most recent quarter with revenues soaring nearly 13% year over year. The company expects double-digit organic sales and earnings growth in 2012 riding on new product launches (including PROGENSA PCA3). We are currently Neutral on the stock, backed by a short-term Zacks #3 Rank (Hold).
ABBOTT LABS ( ABT ): Free Stock Analysis Report
BECTON DICKINSO ( BDX ): Free Stock Analysis Report
GEN-PROBE INC ( GPRO ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It competes with larger, more established players in the molecular diagnostic industry such as Roche ( RHHBY ), Becton Dickinson ( BDX ), and Abbott Labs ( ABT ). ABBOTT LABS ( ABT ): Free Stock Analysis Report BECTON DICKINSO ( BDX ): Free Stock Analysis Report GEN-PROBE INC ( GPRO ): Free Stock Analysis Report To read this article on Zacks.com click here. ( GPRO ) has secured the approval of the U.S. Food and Drug Administration ("FDA") for its PROGENSA PCA3 assay, a novel molecular test designed to aid the diagnosis of prostate cancer. | ABBOTT LABS ( ABT ): Free Stock Analysis Report BECTON DICKINSO ( BDX ): Free Stock Analysis Report GEN-PROBE INC ( GPRO ): Free Stock Analysis Report To read this article on Zacks.com click here. It competes with larger, more established players in the molecular diagnostic industry such as Roche ( RHHBY ), Becton Dickinson ( BDX ), and Abbott Labs ( ABT ). ( GPRO ) has secured the approval of the U.S. Food and Drug Administration ("FDA") for its PROGENSA PCA3 assay, a novel molecular test designed to aid the diagnosis of prostate cancer. | It competes with larger, more established players in the molecular diagnostic industry such as Roche ( RHHBY ), Becton Dickinson ( BDX ), and Abbott Labs ( ABT ). ABBOTT LABS ( ABT ): Free Stock Analysis Report BECTON DICKINSO ( BDX ): Free Stock Analysis Report GEN-PROBE INC ( GPRO ): Free Stock Analysis Report To read this article on Zacks.com click here. ( GPRO ) has secured the approval of the U.S. Food and Drug Administration ("FDA") for its PROGENSA PCA3 assay, a novel molecular test designed to aid the diagnosis of prostate cancer. | ABBOTT LABS ( ABT ): Free Stock Analysis Report BECTON DICKINSO ( BDX ): Free Stock Analysis Report GEN-PROBE INC ( GPRO ): Free Stock Analysis Report To read this article on Zacks.com click here. It competes with larger, more established players in the molecular diagnostic industry such as Roche ( RHHBY ), Becton Dickinson ( BDX ), and Abbott Labs ( ABT ). ( GPRO ) has secured the approval of the U.S. Food and Drug Administration ("FDA") for its PROGENSA PCA3 assay, a novel molecular test designed to aid the diagnosis of prostate cancer. |
34472.0 | 2012-02-15 00:00:00 UTC | Gen-Probe's EPS Trounces, Net Slips - Analyst Blog | ABT | https://www.nasdaq.com/articles/gen-probes-eps-trounces-net-slips-analyst-blog-2012-02-15 | nan | nan | Diagnostic products maker Gen-Probe 's ( GPRO ) fourth-quarter fiscal 2011 adjusted (excluding one-time charges) earnings of 72 cents a share topped the Zacks Consensus Estimate by 4 cents while exceeded the year-ago adjusted earnings of 61 cents.
However, the California-based company's profit (as reported) plummeted 27% in the quarter to $19.9 million (or 42 cents a share), hammered by a $12.7 millioncharge related to the impairment of goodwill and intangible assets .
For the full year, adjusted earnings of $2.34 a share outperformed the Zacks Consensus Estimate of $2.31 and surpassed the year-ago earnings of $2.19. Profit (as reported) for the year more than halved year over year to $50.1 million or $1.04 a share.
Revenue Analysis
Revenues for the quarter surged 16% year over year to $158.2 million, essentially in line with the Zacks Consensus Estimate. For the fiscal, sales rose 6% year over year to $576.2 million, just missing the Zacks Consensus Estimate of $577 million.
Product sales soared 18% to $155.2 million in the fourth quarter as double-digit growth across clinical diagnostic and blood screening businesses more than neutralized the decline in revenues from research products and services.
Clinical diagnostic revenues spiked 13% year over year to $90.6 million, boosted by higher sales of APTIMA Combo 2 assay across domestic and overseas markets and GTI Diagnostics acquisition. However, foreign exchange swings trimmed sales by roughly $0.1 million. The APTIMA women's health business remains the key growth engine for the clinical diagnostic franchise.
Gen-Probe clocked solid growth in its blood screening business in the quarter with sales zooming 30% year over year to $62.1 million, paced by higher shipment of assays and instruments (including the TIGRIS systems) to Gen-Probe's partner Novartis ( NVS ). Foreign exchange movements had a favorable impact of $0.2 million on blood screening sales.
Revenues from research products and services slid 29% year over year to $2.4 million. Collaborative research sales tanked 62% year over year to $1.4 million, hurt by lower funding from Novartis for the development of the fully automated PANTHER instrument for blood screening.
Gen-Probe expects to launch the PANTHER system in international blood screening markets in 2012. Royalty and license revenues dipped 16% to $1.6 million on account of lower royalties from Novartis associated with the plasma testing market.
Margins & Expenses
Gross margin on product sales slipped to 66.7% in the quarter from 69.4% a year-ago, resulting from unfavorable sales mix. Total operating expenses jumped 29% year over year to $128.7 million. Research and development expenses rose 5% year over year to $28.2 million.
Marketing and sales expenses climbed 13% to $17.1 million due to the investment in European commercial infrastructure and addition of GTI Diagnostics. General and administrative expenses rose 6% to $16.2 million as a result of the GTI acquisition.
Financial Health
Gen-Probe ended the fiscal with cash and cash equivalents and marketable securities of $368 million, down 25% year over year, and short-term debt of $248 million (up 3% year over year). The company generated $53.4 million in cash flows from operations during the fourth quarter and invested $7.2 million in capital expenditure, resulting in a free cash flow of $46.2 million.
The company bought back 1.7 million shares during the fourth quarter for $100 million, thereby completing the $100 million repurchase program announced in November 2011.
Guidance and Recommendation
Moving ahead, Gen-Probe expects to register low double-digit organic sales and earnings growth in 2012 on the back of multiple new products (including APTIMA Trichomonas and APTIMA HPV). The company envisions modest growth in its blood screening business in 2012 while clinical diagnostic revenues are expected to be boosted by strong sales from APTIMA Combo 2 assay.
For 2012, Gen-Probe expects revenues in the range of $630 million to $655 million. Adjusted earnings per share target for the year have been pegged between $2.50 and $2.68. The current Zacks Consensus Estimates for 2012 revenue and earnings are $641 million and $2.59, respectively.
Gen-Probe expects operating margin (on a reported basis) in the band of 24.5% to 26% and adjusted operating margin of between 26.5% and 28% for 2012. Product gross margin (both reported and adjusted basis) is expected between of 68% and 69.5%.
For first-quarter 2012, the company expects sales between $148 million and $152 million and earnings in the range of 48 cents and 52 cents a share.
Gen-Probe is a dominant player in the rapidly expanding nucleic acid test ("NAT") market, the fastest growing segment of the clinical diagnostic market. It is a market leader in domestic gonorrhea and chlamydia testing with its PACE and APTIMA assay product lines.
We believe Gen-Probe is well placed with a strong cadence of new products that are expected to support growth in the years ahead. Moreover, Gen-Probe's PANTHER molecular testing platform will significantly contribute to its revenues as it broadens the testing menu for the instrument.
However, Gen-Probe competes with more established firms such as Roche ( RHHBY ), Becton Dickinson ( BDX ), and Abbott Labs ( ABT ) in the maturing molecular diagnostic industry. Moreover, the company is exposed to foreign exchange headwinds which may hurt its sales and margins in 2012. Higher tax is also expected to weigh on its bottom line this year.
Currently, we have a long-term Neutral recommendation on Gen-Probe, which is in tandem with a short-term Zacks #3 Rank (Hold).
ABBOTT LABS ( ABT ): Free Stock Analysis Report
BECTON DICKINSO ( BDX ): Free Stock Analysis Report
GEN-PROBE INC ( GPRO ): Free Stock Analysis Report
NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | However, Gen-Probe competes with more established firms such as Roche ( RHHBY ), Becton Dickinson ( BDX ), and Abbott Labs ( ABT ) in the maturing molecular diagnostic industry. ABBOTT LABS ( ABT ): Free Stock Analysis Report BECTON DICKINSO ( BDX ): Free Stock Analysis Report GEN-PROBE INC ( GPRO ): Free Stock Analysis Report NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report To read this article on Zacks.com click here. However, the California-based company's profit (as reported) plummeted 27% in the quarter to $19.9 million (or 42 cents a share), hammered by a $12.7 millioncharge related to the impairment of goodwill and intangible assets . | ABBOTT LABS ( ABT ): Free Stock Analysis Report BECTON DICKINSO ( BDX ): Free Stock Analysis Report GEN-PROBE INC ( GPRO ): Free Stock Analysis Report NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report To read this article on Zacks.com click here. However, Gen-Probe competes with more established firms such as Roche ( RHHBY ), Becton Dickinson ( BDX ), and Abbott Labs ( ABT ) in the maturing molecular diagnostic industry. Clinical diagnostic revenues spiked 13% year over year to $90.6 million, boosted by higher sales of APTIMA Combo 2 assay across domestic and overseas markets and GTI Diagnostics acquisition. | However, Gen-Probe competes with more established firms such as Roche ( RHHBY ), Becton Dickinson ( BDX ), and Abbott Labs ( ABT ) in the maturing molecular diagnostic industry. ABBOTT LABS ( ABT ): Free Stock Analysis Report BECTON DICKINSO ( BDX ): Free Stock Analysis Report GEN-PROBE INC ( GPRO ): Free Stock Analysis Report NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report To read this article on Zacks.com click here. For the fiscal, sales rose 6% year over year to $576.2 million, just missing the Zacks Consensus Estimate of $577 million. | However, Gen-Probe competes with more established firms such as Roche ( RHHBY ), Becton Dickinson ( BDX ), and Abbott Labs ( ABT ) in the maturing molecular diagnostic industry. ABBOTT LABS ( ABT ): Free Stock Analysis Report BECTON DICKINSO ( BDX ): Free Stock Analysis Report GEN-PROBE INC ( GPRO ): Free Stock Analysis Report NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report To read this article on Zacks.com click here. Profit (as reported) for the year more than halved year over year to $50.1 million or $1.04 a share. |
34473.0 | 2012-02-08 00:00:00 UTC | How to Earn 12.9% Yields From Stocks Paying 5.4% | ABT | https://www.nasdaq.com/articles/how-earn-129-yields-stocks-paying-54-2012-02-08 | nan | nan | The story was picked up by the major news sources as a "cute" human interest feature. You might have seen the headlines like "How a Secretary Made and Gave Away $7 Million."
But for me, this wasn't some light news piece. This was a story that resonated deeply with me.
I didn't know Grace Groner, from Lake Forest, Illinois. From the stories, she was a woman who lived frugally. Her passing was of interest because her three shares of Abbott Laboratories (NYSE: ABT ) grew into thousands of shares through decades of stock splits and dividend reinvestment. In total, her estate came in at roughly $7 million when she passed.
And while I didn't know Grace Groner, I did know Lillian Calistri.
The last time I saw Aunt Lillian was in 1990. I remember that a nephew had the misfortune of addressing her as "Lillian." She promptly looked us all in the eye and said, "You will continue tocall me Aunt Lillian." We were all over 25 years old at the time, but in Aunt Lillian's world, adulthood was no excuse for bad manners.
Aunt Lillian taught home economics at Charleroi High School in Pennsylvania. After she retired in the 1950s, she moved to Tucson, Ariz. I remember thinking it was nice that she had been able to live comfortably in her golden years -- aided by a teacher's retirement and a nest egg from the 1952 sale of the family's ice cream business.
Here's the kicker. When Lillian died in 1993, her estate was worth north of $5 million.
Her broker was the only one who wasn't shocked. "They should have that kind of discipline on Wall Street ," he said. Dividend reinvestment? You bet.
But there's something else to this story, and it's something that can help you earn larger dividends soon -- helpful if you don't have a lifetime to invest as Aunt Lillian and Grace Groner did.
They may not have realized it at the time, but both the women in this story chose their investments wisely.
Abbott Laboratories, the company Grace Groner invested in, has paid more than 350 consecutive dividends since 1924. In 1990, the company paid $0.203 per share in dividends. Today, that amount has grown 826% to $1.88 per share.
One of Aunt Lillian's investments was International Business Machines (NYSE: IBM ) . IBM dished out its first dividend in 1913. Since then, it has gone on to pay nearly 400 more. In the past decade, IBM's dividend has increased 436%.
Neither ABT nor IBM had a particularly juicy yield at the time these women bought their shares. But they had something equally powerful: a corporate culture dedicated to rewarding shareholders -- especially with growing dividends.
And those growing dividends add up a lot quicker than you'd think.
In my Daily Paycheck portfolio, I already have two classic dividend payers that I put in the same class as Abbott and IBM -- AT&T (NYSE: T ) and Kinder Morgan (NYSE: KMP ) .
If you had put $5,000 into AT&T five years ago, you'd have earned a 3.8% yield at the time. That amounted to $188 per year. But today, that $5,000 investment would be paying $305 a year if you simply reinvested your dividends. That's a 6.1% yield on your original investment.
Kinder Morgan is an even better story. Right now the shares pay a solid 5.4%. It's nothing to sneeze at, but thanks to the company's commitment to dividend growth, $5,000 invested just five years ago -- plus reinvested dividends -- is now earning 12.9% on your original investment, or about $650 every year.
Action to Take --> It's doubtful most of us will have decades and decades to invest like Grace Groner or Aunt Lillian. But this doesn't mean we can't see our dividends grow enormously in a span of just a few short years.
[ Note: In December, StreetAuthority co-founder Paul Tracy used a dividend reinvestment strategy to collect more than $6,000 a month in dividends . To learn more about how to put this strategy to work -- no matter the size of your portfolio -- you can visit this link. ]
-- Amy Calistri
Amy Calistri does not personally hold positions in any securities mentioned in this article. StreetAuthority LLC owns shares of T, KMP in one or more if its "real money" portfolios.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© Copyright 2001-2010 StreetAuthority, LLC. All Rights Reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Her passing was of interest because her three shares of Abbott Laboratories (NYSE: ABT ) grew into thousands of shares through decades of stock splits and dividend reinvestment. Neither ABT nor IBM had a particularly juicy yield at the time these women bought their shares. The story was picked up by the major news sources as a "cute" human interest feature. | Her passing was of interest because her three shares of Abbott Laboratories (NYSE: ABT ) grew into thousands of shares through decades of stock splits and dividend reinvestment. Neither ABT nor IBM had a particularly juicy yield at the time these women bought their shares. Abbott Laboratories, the company Grace Groner invested in, has paid more than 350 consecutive dividends since 1924. | Her passing was of interest because her three shares of Abbott Laboratories (NYSE: ABT ) grew into thousands of shares through decades of stock splits and dividend reinvestment. Neither ABT nor IBM had a particularly juicy yield at the time these women bought their shares. But there's something else to this story, and it's something that can help you earn larger dividends soon -- helpful if you don't have a lifetime to invest as Aunt Lillian and Grace Groner did. | Her passing was of interest because her three shares of Abbott Laboratories (NYSE: ABT ) grew into thousands of shares through decades of stock splits and dividend reinvestment. Neither ABT nor IBM had a particularly juicy yield at the time these women bought their shares. The last time I saw Aunt Lillian was in 1990. |
34474.0 | 2012-02-03 00:00:00 UTC | How to Stop “Off-Label” Marketing and Sales of Prescription Drugs | ABT | https://www.nasdaq.com/articles/how-stop-label-marketing-and-sales-prescription-drugs-2012-02-03 | nan | nan | This article was submitted by Pharma Reform as part of our contributors program
I'm a little tired of reading about "off-label" promotion of prescription drugs, especially in the context of whistleblower instigated fraud cases and lawyer/patient driven product liability cases. I'm not a lawyer but here are some solutions that would discourage inappropriate "off-label" promotion and would consume far fewer resources and certainly cost a lot less than is being spent now on litigating these types of offenses.
First, Pharma companies should not promote products for uses that are not approved by the FDA. If a company is found guilty of "off-label" promotion, in addition to any corporate fines (which should equal total product revenues during the time of illegal promotion) , responsible individuals should be held legally accountable and convicted, with personal fines, disgorgement of incentive compensation during the time of illegal activities, and even incarceration if warranted. No corporate settlements. It is very likely that criminally charged front line employees directed or even trained to promote for off-label uses may be more than willing to offer up and provide evidence against culpable higher level executives who encouraged or approved of the promotion. I'm pretty sure this would increase executive management oversight to ensure compliance.
To remove the financial incentives for "off-label" promotion, government programs (Centers for Medicare and Medicaid Services and states) should not reimburse for unapproved uses of prescription drugs. If the patient wants to pay for the unapproved use of a prescription drug that a physicians has prescribed, that should be their choice. At the same time, that choice carries the liability that if something should go wrong; the only legal recourse for the patient should be to hold the prescribing physician and perhaps their healthcare provider accountable. Because "off-label" use is an informed decision, neither the patient nor the physician (or healthcare provider system) could sue the pharmaceutical company for any negative consequences resulting from the unapproved use. Physicians who prescribe for unapproved uses but post a diagnosis that aligns with approved uses just so the patient can get it reimbursed would face fraud charges and be held personally liable. Similarly, there would be no need for federal or state litigation against pharmaceutical companies for False Claims that inappropriately causing taxpayers to fund unapproved uses.
If physicians and patients have made a choice to use a product "off-label" and private payers (insurance companies, employers, or PBMs) choose to pay for the unapproved use then they should assume the same liabilities as stated above. They are making an informed decision and the payer is agreeing with that choice by reimbursing for the unapproved use. The patient could sue the prescribing physician, healthcare system, and perhaps the payer, but they would have no legal recourse against the pharmaceutical company should a harmful event occur from the unapproved use.
But what about all the "medically established" unapproved uses in treating things like cancer? The same rules and legal liabilities should apply. Physicians have the choice to prescribe, patients have the choice to take, and payers have the choice to reimburse for the unapproved use if they want to assume the liabilities with the inability to sue the pharmaceutical company. If the medical experts, patient advocacy groups, or government programs and insurance companies feel a prescription drug should be approved and reimbursable for a particular use, they should petition the FDA and submit their clinical proof of efficacy and safety to obtain an FDA approved label claim for the product.
While preserving physician, patient, and payer choice these recommendations remove a major financial incentive (reimbursement) for pharmaceutical companies and increase the legal consequences for individuals who inappropriately promote for off-label uses of prescription drugs. More importantly, it appropriately shifts product liability for unapproved uses to healthcare providers and payers.
Submit a Post at Trefis Powered by Data and Interactive Charts | Understand What Drives a Stock at Trefis
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | To remove the financial incentives for "off-label" promotion, government programs (Centers for Medicare and Medicaid Services and states) should not reimburse for unapproved uses of prescription drugs. If physicians and patients have made a choice to use a product "off-label" and private payers (insurance companies, employers, or PBMs) choose to pay for the unapproved use then they should assume the same liabilities as stated above. While preserving physician, patient, and payer choice these recommendations remove a major financial incentive (reimbursement) for pharmaceutical companies and increase the legal consequences for individuals who inappropriately promote for off-label uses of prescription drugs. | If a company is found guilty of "off-label" promotion, in addition to any corporate fines (which should equal total product revenues during the time of illegal promotion) , responsible individuals should be held legally accountable and convicted, with personal fines, disgorgement of incentive compensation during the time of illegal activities, and even incarceration if warranted. Because "off-label" use is an informed decision, neither the patient nor the physician (or healthcare provider system) could sue the pharmaceutical company for any negative consequences resulting from the unapproved use. While preserving physician, patient, and payer choice these recommendations remove a major financial incentive (reimbursement) for pharmaceutical companies and increase the legal consequences for individuals who inappropriately promote for off-label uses of prescription drugs. | If physicians and patients have made a choice to use a product "off-label" and private payers (insurance companies, employers, or PBMs) choose to pay for the unapproved use then they should assume the same liabilities as stated above. Physicians have the choice to prescribe, patients have the choice to take, and payers have the choice to reimburse for the unapproved use if they want to assume the liabilities with the inability to sue the pharmaceutical company. While preserving physician, patient, and payer choice these recommendations remove a major financial incentive (reimbursement) for pharmaceutical companies and increase the legal consequences for individuals who inappropriately promote for off-label uses of prescription drugs. | If the patient wants to pay for the unapproved use of a prescription drug that a physicians has prescribed, that should be their choice. At the same time, that choice carries the liability that if something should go wrong; the only legal recourse for the patient should be to hold the prescribing physician and perhaps their healthcare provider accountable. Physicians have the choice to prescribe, patients have the choice to take, and payers have the choice to reimburse for the unapproved use if they want to assume the liabilities with the inability to sue the pharmaceutical company. |
34475.0 | 2012-01-30 00:00:00 UTC | Q4 Preview: Pfizer (PFE) May Suffer Same Ailment as Peers: Strong Dollar Syndrome | ABT | https://www.nasdaq.com/articles/q4-preview-pfizer-pfe-may-suffer-same-ailment-peers-strong-dollar-syndrome-2012-01-30 | nan | nan | Pfizer Inc. ( PFE ) is trading lower Monday afternoon heading into its fourth-quarter report, which are expected out before the market opens on Tuesday.
The Street sees earnings of 47 cents per share on revenue of $16.61 billion. Earnings would be a 13 percent drop from the same period last year. On average, Pfizer has beat earnings views by 4.6 percent over the last 5 quarters.
Shares gained 23.7 percent in the quarter, to $21.64 at the end of December. Shares have been relatively flat since the, but Pfizer did end 2011 about 29 percent better.
Competitors like Abbott ( ABT ), Bristol Myers-Squibb ( BMY ), and -- to a lesser extent -- Johnson & Johnson ( JNJ ) have all signaled warnings following quarterly reports. Even Lilly ( LLY ) said it expected to miss 2012 revenue expectations. With Pfizer trading near annual highs of $22.17, investors might end up being cautious this quarter.
Data from Bloomberg has 21 analysts at Buy on Pfizer, 4 with a Hold, and 2 at Sell. The Street's price target average is $24, with a low of $19 and high of $30.
Goldman Sachs issued a bit of a preview for Pfizer heading into results. The firm is modeling earnings of 46 cents per share, expecting head winds from foreign exchange fluctuations.
Due to the strengthening U.S. dollar, Goldman is expecting management to guide fiscal 2012 EPS expectations lower, from $2.35 - $2.25 to a range of $2.15 - $2.25. The Street currently expects $3.30. Key topics on the call will be: (1) Lipitor market share during the first 180 days; (2) gross margin impact from LOEs; (3) decisions and timing related to Nutritionals/animal health divestitures; (4) Eliquis launch plans; and (5) pipeline updates, including bapineuzumab timeline.
Stay tuned to StreetInsider.com's EPS Insider section to see our analysis of the highly-anticipated quarterly results within seconds of their release. You can also check out Pfizer's past performance at Streetinsider's Pfizer's Income Statement .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Competitors like Abbott ( ABT ), Bristol Myers-Squibb ( BMY ), and -- to a lesser extent -- Johnson & Johnson ( JNJ ) have all signaled warnings following quarterly reports. Pfizer Inc. ( PFE ) is trading lower Monday afternoon heading into its fourth-quarter report, which are expected out before the market opens on Tuesday. Key topics on the call will be: (1) Lipitor market share during the first 180 days; (2) gross margin impact from LOEs; (3) decisions and timing related to Nutritionals/animal health divestitures; (4) Eliquis launch plans; and (5) pipeline updates, including bapineuzumab timeline. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Competitors like Abbott ( ABT ), Bristol Myers-Squibb ( BMY ), and -- to a lesser extent -- Johnson & Johnson ( JNJ ) have all signaled warnings following quarterly reports. The firm is modeling earnings of 46 cents per share, expecting head winds from foreign exchange fluctuations. | Competitors like Abbott ( ABT ), Bristol Myers-Squibb ( BMY ), and -- to a lesser extent -- Johnson & Johnson ( JNJ ) have all signaled warnings following quarterly reports. Pfizer Inc. ( PFE ) is trading lower Monday afternoon heading into its fourth-quarter report, which are expected out before the market opens on Tuesday. On average, Pfizer has beat earnings views by 4.6 percent over the last 5 quarters. | Competitors like Abbott ( ABT ), Bristol Myers-Squibb ( BMY ), and -- to a lesser extent -- Johnson & Johnson ( JNJ ) have all signaled warnings following quarterly reports. On average, Pfizer has beat earnings views by 4.6 percent over the last 5 quarters. With Pfizer trading near annual highs of $22.17, investors might end up being cautious this quarter. |
34476.0 | 2012-01-27 00:00:00 UTC | Amgen Misses; 2012 Outlook Strong - Analyst Blog | ABT | https://www.nasdaq.com/articles/amgen-misses-2012-outlook-strong-analyst-blog-2012-01-27 | nan | nan | Amgen ( AMGN ) reported fourth quarter earnings per share of $1.19, 5 cents below the Zacks Consensus Estimate. Earnings, however, increased 3.5% from the year-ago period. A lower tax rate, lower share count and higher revenues contributed to the year-over-year increase in earnings.
Total revenue increased 3% to $3,973 million in the fourth quarter of 2011. Revenues also missed the Zacks Consensus Estimate of $3,894 million.
Full year 2011 earnings came in at $5.26 per share, 2.7% above the year-ago period but 3 cents below the Zacks Consensus Estimate. Revenues increased 4% from the year-ago period to $15,582 million in 2011. Full year revenues were just above the Zacks Consensus Estimate of $15, 503 million.
The Quarter in Detail
Fourth quarter total product sales increased 4% to $3,907 million. US product revenues increased 5% during the quarter to $3,007 million. Meanwhile, international | Amgen ( AMGN ) reported fourth quarter earnings per share of $1.19, 5 cents below the Zacks Consensus Estimate. Full year 2011 earnings came in at $5.26 per share, 2.7% above the year-ago period but 3 cents below the Zacks Consensus Estimate. Full year revenues were just above the Zacks Consensus Estimate of $15, 503 million. | Amgen ( AMGN ) reported fourth quarter earnings per share of $1.19, 5 cents below the Zacks Consensus Estimate. Full year 2011 earnings came in at $5.26 per share, 2.7% above the year-ago period but 3 cents below the Zacks Consensus Estimate. The Quarter in Detail Fourth quarter total product sales increased 4% to $3,907 million. | Total revenue increased 3% to $3,973 million in the fourth quarter of 2011. Full year 2011 earnings came in at $5.26 per share, 2.7% above the year-ago period but 3 cents below the Zacks Consensus Estimate. The Quarter in Detail Fourth quarter total product sales increased 4% to $3,907 million. | Amgen ( AMGN ) reported fourth quarter earnings per share of $1.19, 5 cents below the Zacks Consensus Estimate. Full year 2011 earnings came in at $5.26 per share, 2.7% above the year-ago period but 3 cents below the Zacks Consensus Estimate. Revenues increased 4% from the year-ago period to $15,582 million in 2011. |
34477.0 | 2012-01-26 00:00:00 UTC | The Zacks Analyst Blog Highlights: The Boeing, Lockheed Martin, Abbott Labs, Bristol-Myers Squibb and Biogen - Press Releases | ABT | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-the-boeing-lockheed-martin-abbott-labs-bristol-myers | nan | nan | For Immediate Release
Chicago, IL - January 26, 2012 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include The Boeing Company ( BA ), Lockheed Martin Corporation ( LMT ), Abbott Labs ( ABT ), Bristol-Myers Squibb ( BMY ) and Biogen ( BIIB ).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Wednesday's Analyst Blog:
Boeing Tops on Higher Deliveries
In the fourth quarter of 2011, The Boeing Company ( BA ) soaring on higher deliveries of commercial airplanes posted strong numbers. In the reported quarter, the company posted operating EPS (excluding special items) of $1.32, beating both the Zacks Consensus Estimate of $1.02 and year-ago EPS of $1.06. The company's strong numbers came from higher commercial planes deliveries which more than offset a tepid quarter for defense.
On a reported basis, Boeing reported quarterly EPS of $1.84 per share versus $1.56 in the year-ago quarter. The 52 cents difference between reported and operating earnings, during the reported quarter, was owing to the effects of a favorable tax settlement.
Fiscal 2011 operating EPS (excluding special items) came in at $4.81, above the Zacks Consensus Estimate of $3.81 and fiscal 2010 earnings of $4.16. On a reported basis, earnings came in at $5.34 in fiscal 2011 versus $4.45 in fiscal 2010.
Operating Statistics
On the revenue front, higher airplane deliveries pulled up the quarterly revenue year-over-year by 18% to $19.6 billion, above the Zacks Consensus Estimate of $19.3 billion. Fiscal 2011 revenue rose 7% to $68.7 billion, moderately above the Zacks Consensus Estimate of $68.5 billion.
Segment Results
Commercial Airplane segment
Boeing's Commercial Airplane segment in the reported quarter saw a 10% rise in deliveries to 128 units. As a result, Commercial Airplanes revenue increased by 31% to $10.7 billion on higher delivery volume and mix. In the reported quarter the company delivered 9 747 series and 2 787 series airplanes versus zero deliveries in the year-ago period. The company also delivered a higher number of 767 and 777 series airplanes (6 & 20) versus the year-ago period (3 & 18). The upsurge was partially offset by a lower number of 737 deliveries (91 versus 95) year over year.
Operating margin rose 150 basis points to 9.2%, reflecting lower Research & Development expenditure. This was partially offset by the dilutive impact of initial 787 and 747-8 deliveries and higher period costs.
Commercial Airplanes booked 379 net orders during the reported quarter. Backlog at fiscal 2011-end remains strong with more than 3,700 airplanes valued at a record $296 billion.
Boeing Defense, Space & Security
Boeing Defense, Space & Security segment witnessed a 4% rise in its quarterly revenue to $8.5 billion. Of these sub-segments Boeing Military Aircraft ( BMA ) and Global Services & Support (GS&S) witnessed a top line climb of 9% and 21%, respectively. Only the sub-segment, Network & Space Systems (N&SS) recorded a 19% fall in revenues.
Quarterly operating margin rose by 20 basis points to 10.2%. This was due to strong execution across various BMA programs. However, this was partially offset by lower margins at the N&SS and GS&S units. In the N&SS sub-segment, margin fell owing to higher R&D. Similarly GS&S margins were affected by the downcast in current defense contracting environment.
Backlog at Defense, Space & Security was $60.0 billion.
Boeing Capital Corporation (BCC)
Boeing Capital Corporation reported quarterly revenues of $116 million compared with $145 million in the year-ago quarter. The segment digested a loss of $8 million compared to earnings of $6 million in the year-ago period. At fiscal 2011-end, BCC's portfolio balance declined to $4.3 billion, flat versus the beginning of the reported quarter.
Financial Condition
Boeing ended fiscal 2011 with cash and cash equivalents of $10.0 billion and short-term investments of $1.2 billion. At fiscal-end 2010, the company had $5.4 billion in cash and cash equivalents and $5.2 billion of short-term investments. The company generated more than $4.0 billion of cash from operating activities in fiscal 2011, compared with approximately $3.0 billion generated in fiscal 2010. Long-term debt decreased to $10.0 billion at the end of the reported fiscal from $11.5 billion at the end of fiscal 2010.
Outlook
Boeing has a unique position as the largest aircraft manufacturer in the world in terms of revenues, orders and deliveries, and is one of the largest aerospace and defense contractors in the world. Besides, its revenues are spread across more than 90 countries around the globe.
Boeing expects its fiscal 2012 GAAP earnings to be in the range of $4.05-$4.25 per share, and adjusted earnings of $5.06-5.26 per share. Revenue for 2012 is expected to be between $78 billion and $80 billion. Commercial Airplanes' 2012 deliveries are expected to be between 585 and 600 airplanes and are already sold out. This includes an expected 70 to 85 787 and 747-8 deliveries. Commercial Airplanes' 2012 revenue is expected to be between $47.5 billion and $49.5 billion with operating margins between 8.5% and 9%.
In the defense space, the company also secured big contracts like the sale of 84 new F-15SA aircraft and upgrades to an additional 70 F-15Ss to Saudi Arabia; P-8A low rate initial production lot II production award from the U.S. Navy; development and sustainment contract for Ground-based Midcourse Defense from the U.S. Missile Defense Agency; and the C-17 Globemaster III Integrated Sustainment Program from the U.S. Air Force. However, the threat of defense cutbacks will loom over the company going forward. Overall, the company expects defense revenue for 2012 to be between $30.0 billion and $30.5 billion with operating margin greater than 9%.
Boeing Capital Corporation expects that its aircraft finance portfolio will continue to decline in 2012, as new aircraft financing of less than $0.5 billion is expected to be lower than the normal portfolio runoff through customer payments and depreciation. BCC's debt-to-equity ratio is expected to return to 5.0-to-1 in the first quarter of 2012 due to the repayment of maturing debt.
Boeing's 2012 R&D forecast is between $3.3 billion and $3.5 billion. Capital expenditures for 2012 are expected to be approximately $2.0 billion.
Boeing currently retains a Zacks #3 Rank, which translates into a short-term Hold rating. Considering the fundamentals, we are maintaining our Neutral recommendation on the stock. This is in sync with other aerospace and defense behemoths. A clearer picture will emerge tomorrow when the big daddy of defense Lockheed Martin Corporation ( LMT ) comes out with 2011 earnings.
Abbott Beats, Guides In-Line
Abbott Labs ( ABT ) reported fourth quarter earnings of $1.45 per share, a penny above the Zacks Consensus Estimate and at the higher end of the guidance range provided by the company. Fourth quarter earnings increased 11.5% from the year-earlier period. Including one-time items, fourth quarter earnings increased 10.9% to $1.02 per share.
Fourth quarter revenues increased 4.1% to $10.4 billion, just shy of the Zacks Consensus Estimate of $10.6 billion.
Full year earnings came in at $4.66 per share, a penny above the Zacks Consensus Estimate and 11.8% above the year-ago earnings. Full year earnings came in at the higher end of the guidance range of $4.64 - $4.66 per share. 2011 revenues increased 10.5% to $38.9 billion, just shy of the Zacks Consensus Estimate of $39 billion.
In-Line Outlook for 2012
Along with releasing fourth quarter results, Abbott Labs provided guidance for 2012. The company expects 2012 earnings in the range of $4.95 to $5.05 per share. Guidance was in-line with expectations with the Zacks Consensus Estimate, currently standing at $5.04 per share. The company intends to resume share buybacks in 2012.
Abbott Labs provided an update on its intention to split into two separate publicly traded companies: the company said that it expects to complete the separation by year end. While one company will deal in diversified medical products, the other will focus on research-based pharmaceuticals
Pipeline Update
Abbott Labs also provided an update on its pipeline. The company currently has 20 candidates in phase II/phase III development. The acquisition of Facet Biotech has helped strengthen Abbott Labs' early- and mid-stage oncology portfolio. The company moved elotuzumab, which is being developed with Bristol-Myers Squibb ( BMY ), into phase III studies for multiple myeloma.
Abbott Labs is also working on strengthening its neuroscience portfolio and has several candidates in different stages of development for the treatment of diseases like schizophrenia, pain, Parkinson's Alzheimer's and multiple sclerosis. Abbott Labs, along with partner Biogen ( BIIB ), moved daclizumab into a phase III study for the treatment of relapsing-remitting multiple sclerosis ( RRMS ). Abbott Labs is also working on an intestinal gel for advanced Parkinson's disease - the company expects to file for US approval in 2012.
Another promising pipeline candidate is bardoxolone, which is in phase III studies for chronic kidney disease.
Neutral on Abbott Labs
We currently have a Neutral recommendation on Abbott Labs, which carries a Zacks #3 Rank (short-term Hold rating). We believe Abbott Labs' strong business segments, contributions from recent acquisitions and impressive late-stage pipeline will help fortify long-term earnings growth. Humira should continue to be a strong growth driver in the years to come.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515 .
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns instock market datathat would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518 .
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
ABBOTT LABS ( ABT ): Free Stock Analysis Report
BOEING CO ( BA ): Free Stock Analysis Report
BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report
BRISTOL-MYERS (BMY): Free Stock Analysis Report
LOCKHEED MARTIN (LMT): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include The Boeing Company ( BA ), Lockheed Martin Corporation ( LMT ), Abbott Labs ( ABT ), Bristol-Myers Squibb ( BMY ) and Biogen ( BIIB ). Abbott Beats, Guides In-Line Abbott Labs ( ABT ) reported fourth quarter earnings of $1.45 per share, a penny above the Zacks Consensus Estimate and at the higher end of the guidance range provided by the company. 9339 support@zacks.com http://www.zacks.com ABBOTT LABS ( ABT ): Free Stock Analysis Report BOEING CO ( BA ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report LOCKHEED MARTIN (LMT): Free Stock Analysis Report To read this article on Zacks.com click here. | Stocks recently featured in the blog include The Boeing Company ( BA ), Lockheed Martin Corporation ( LMT ), Abbott Labs ( ABT ), Bristol-Myers Squibb ( BMY ) and Biogen ( BIIB ). 9339 support@zacks.com http://www.zacks.com ABBOTT LABS ( ABT ): Free Stock Analysis Report BOEING CO ( BA ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report LOCKHEED MARTIN (LMT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Beats, Guides In-Line Abbott Labs ( ABT ) reported fourth quarter earnings of $1.45 per share, a penny above the Zacks Consensus Estimate and at the higher end of the guidance range provided by the company. | Abbott Beats, Guides In-Line Abbott Labs ( ABT ) reported fourth quarter earnings of $1.45 per share, a penny above the Zacks Consensus Estimate and at the higher end of the guidance range provided by the company. 9339 support@zacks.com http://www.zacks.com ABBOTT LABS ( ABT ): Free Stock Analysis Report BOEING CO ( BA ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report LOCKHEED MARTIN (LMT): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include The Boeing Company ( BA ), Lockheed Martin Corporation ( LMT ), Abbott Labs ( ABT ), Bristol-Myers Squibb ( BMY ) and Biogen ( BIIB ). | Stocks recently featured in the blog include The Boeing Company ( BA ), Lockheed Martin Corporation ( LMT ), Abbott Labs ( ABT ), Bristol-Myers Squibb ( BMY ) and Biogen ( BIIB ). Abbott Beats, Guides In-Line Abbott Labs ( ABT ) reported fourth quarter earnings of $1.45 per share, a penny above the Zacks Consensus Estimate and at the higher end of the guidance range provided by the company. 9339 support@zacks.com http://www.zacks.com ABBOTT LABS ( ABT ): Free Stock Analysis Report BOEING CO ( BA ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report LOCKHEED MARTIN (LMT): Free Stock Analysis Report To read this article on Zacks.com click here. |
34478.0 | 2012-01-25 00:00:00 UTC | Focus Moves Toward the Fed - Analyst Blog | ABT | https://www.nasdaq.com/articles/focus-moves-toward-fed-analyst-blog-2012-01-25 | nan | nan | The focus today will be on the Fed, as the Central Bank unveils a new measure as part of its ongoing efforts to improve communication with the markets. The prospect of an even longer timeframe for lower interest rates, as many in the markets are hoping to come out of today's Fed releases, has the potential to pull stocks out of the slumber of the last two trading sessions.
A mixed earnings season thus far and the reemergence of Greece worries have prompted stocks to take a pause lately. It will be interesting to see if Apple's ( AAPL ) blockbuster results after the close yesterday will have any resonance beyond its own stock price.
In this morning's key earnings releases, Boeing ( BA ) came out ahead of expectations on both the bottom- and top-lines, but the company's full-year 2012 earnings guidance came in below current expectations. Automatic Data Processing ( ADP ), the payroll processor, handily beat EPS expectations on in-line revenue. United Technologies ( UTX ) beat on EPS, but missed revenue expectations. Dover ( DOV ) and Abbott Labs ( ABT ) beat on earnings, but modestly missed revenue expectations.
At the conclusion of its first meeting of 2012 today, the Fed will be releasing the Fed Funds rate forecasts by the individual Fed districts through 2015. This will be in addition to the customary FOMC statement after the meeting and the quarterly Bernanke news conference. We will also get when the individual Fed districts see the FOMC starting to raise interest rates again.
This is a significant development as it likely will show that the Central Bank districts expect near-zero interests for longer than the current FOMC policy of through mid-2013 only. It will be interesting to see how Treasury yields will respond to this expected disclosure. Will this result in greater flattening of the yield curve, particularly given growing expectations of another round of quantitative easing despite the recent favorable run of economic reports?
APPLE INC ( AAPL ): Free Stock Analysis Report
ABBOTT LABS ( ABT ): Free Stock Analysis Report
AUTOMATIC DATA ( ADP ): Free Stock Analysis Report
BOEING CO ( BA ): Free Stock Analysis Report
DOVER CORP ( DOV ): Free Stock Analysis Report
UTD TECHS CORP (UTX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Dover ( DOV ) and Abbott Labs ( ABT ) beat on earnings, but modestly missed revenue expectations. APPLE INC ( AAPL ): Free Stock Analysis Report ABBOTT LABS ( ABT ): Free Stock Analysis Report AUTOMATIC DATA ( ADP ): Free Stock Analysis Report BOEING CO ( BA ): Free Stock Analysis Report DOVER CORP ( DOV ): Free Stock Analysis Report UTD TECHS CORP (UTX): Free Stock Analysis Report To read this article on Zacks.com click here. The focus today will be on the Fed, as the Central Bank unveils a new measure as part of its ongoing efforts to improve communication with the markets. | Dover ( DOV ) and Abbott Labs ( ABT ) beat on earnings, but modestly missed revenue expectations. APPLE INC ( AAPL ): Free Stock Analysis Report ABBOTT LABS ( ABT ): Free Stock Analysis Report AUTOMATIC DATA ( ADP ): Free Stock Analysis Report BOEING CO ( BA ): Free Stock Analysis Report DOVER CORP ( DOV ): Free Stock Analysis Report UTD TECHS CORP (UTX): Free Stock Analysis Report To read this article on Zacks.com click here. This is a significant development as it likely will show that the Central Bank districts expect near-zero interests for longer than the current FOMC policy of through mid-2013 only. | APPLE INC ( AAPL ): Free Stock Analysis Report ABBOTT LABS ( ABT ): Free Stock Analysis Report AUTOMATIC DATA ( ADP ): Free Stock Analysis Report BOEING CO ( BA ): Free Stock Analysis Report DOVER CORP ( DOV ): Free Stock Analysis Report UTD TECHS CORP (UTX): Free Stock Analysis Report To read this article on Zacks.com click here. Dover ( DOV ) and Abbott Labs ( ABT ) beat on earnings, but modestly missed revenue expectations. In this morning's key earnings releases, Boeing ( BA ) came out ahead of expectations on both the bottom- and top-lines, but the company's full-year 2012 earnings guidance came in below current expectations. | Dover ( DOV ) and Abbott Labs ( ABT ) beat on earnings, but modestly missed revenue expectations. APPLE INC ( AAPL ): Free Stock Analysis Report ABBOTT LABS ( ABT ): Free Stock Analysis Report AUTOMATIC DATA ( ADP ): Free Stock Analysis Report BOEING CO ( BA ): Free Stock Analysis Report DOVER CORP ( DOV ): Free Stock Analysis Report UTD TECHS CORP (UTX): Free Stock Analysis Report To read this article on Zacks.com click here. The focus today will be on the Fed, as the Central Bank unveils a new measure as part of its ongoing efforts to improve communication with the markets. |
34479.0 | 2012-01-25 00:00:00 UTC | Abbott Labs Q4 Profit Rises, but Revenue Misses (ABT) | ABT | https://www.nasdaq.com/articles/abbott-labs-q4-profit-rises-revenue-misses-abt-2012-01-25 | nan | nan | Healthcare products maker Abbott Laboratories ( ABT ) on Wednesday posted higher-than-expected fourth quarter earnings, but revenue totals missed Wall Street's view.
The Abbott Park, IL-based company reported fourth quarter net income of $1.62 billion, or $1.02 per share, compared with $1.44 billion, or 92 cents per share, in the year-ago period. Excluding special items, adjusted profit was $1.45 per share.
Sales rose 4% from last year to $10.38 billion.
On average, Wall Street analysts expected a slightly smaller profit of $1.44 per share, albeit on slightly higher revenue of $10.63 billion.
Looking ahead, ABT forecast 2012 adjusted earnings of $4.95 to $5.05 per share, while analysts are looking for $5.02 per share for the year.
Abbott shares fell 28 cents, or -0.5%, in premarket trading Wednesday.
The Bottom Line
We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. The company has a 3.43% dividend yield, based on last night's closing stock price of $55.98.
Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars.
Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Created by Dividend.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Healthcare products maker Abbott Laboratories ( ABT ) on Wednesday posted higher-than-expected fourth quarter earnings, but revenue totals missed Wall Street's view. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Looking ahead, ABT forecast 2012 adjusted earnings of $4.95 to $5.05 per share, while analysts are looking for $5.02 per share for the year. | Healthcare products maker Abbott Laboratories ( ABT ) on Wednesday posted higher-than-expected fourth quarter earnings, but revenue totals missed Wall Street's view. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars. Looking ahead, ABT forecast 2012 adjusted earnings of $4.95 to $5.05 per share, while analysts are looking for $5.02 per share for the year. | Looking ahead, ABT forecast 2012 adjusted earnings of $4.95 to $5.05 per share, while analysts are looking for $5.02 per share for the year. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Healthcare products maker Abbott Laboratories ( ABT ) on Wednesday posted higher-than-expected fourth quarter earnings, but revenue totals missed Wall Street's view. | Healthcare products maker Abbott Laboratories ( ABT ) on Wednesday posted higher-than-expected fourth quarter earnings, but revenue totals missed Wall Street's view. Looking ahead, ABT forecast 2012 adjusted earnings of $4.95 to $5.05 per share, while analysts are looking for $5.02 per share for the year. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars. |
34480.0 | 2012-01-25 00:00:00 UTC | Ahead of Wall Street - January 25, 2012 - Ahead of Wall Street | ABT | https://www.nasdaq.com/articles/ahead-wall-street-january-25-2012-ahead-wall-street-2012-01-25 | nan | nan | Wednesday, January 25, 2012
The focus today will be on the Fed, as the central bank unveils a new measure as part of its ongoing efforts to improve communication with the markets. The prospect of an even longer timeframe for lower interest rates, as many in the markets are hoping to come out of today's Fed releases, has the potential to put stocks out of the slumber of the last two trading sessions. A mixed earnings season thus far and the reemergence of Greece worries have prompted stocks to take a pause lately. It will be interesting to see if Apple's ( AAPL ) blockbuster results after the close yesterday will have any resonance beyond its own stock price.
In this morning's key earnings releases, Boeing ( BA ) came out ahead of expectations on both the bottom- and top-lines, but the company's full-year 2012 earnings guidance came in below current expectations. Automatic Data Processing ( ADP ), the payroll processor, handily beat EPS expectations on in-line revenue. United Technologies ( UTX ) beat on EPS, but missed revenue expectations. Dover ( DOV ) and Abbot Labs ( ABT ) beat on earnings, but modestly missed expectations.
At the conclusion of its first meeting of 2012, the Fed will be releasing the Fed Funds rate forecasts by the individual Fed districts through 2015. This will be in addition to the customary FOMC statement after the meeting and the quarterly Bernanke news conference. We will also get when the individual Fed districts see the FOMC starting to raise interest rates again.
This is a significant development as it likely will show that the central bank districts expect near-zero interests for longer than the current FOMC policy of through mid-2013 only. It will be interesting to see how Treasury yields will respond to this expected disclosure. Will this result in greater flattening of the yield curve, particularly given growing expectations of another round of quantitative easing despite the recent favorable run of economic reports?
Sheraz Mian
Director of Research
APPLE INC ( AAPL ): Free Stock Analysis Report
ABBOTT LABS ( ABT ): Free Stock Analysis Report
AUTOMATIC DATA ( ADP ): Free Stock Analysis Report
BOEING CO ( BA ): Free Stock Analysis Report
DOVER CORP ( DOV ): Free Stock Analysis Report
UTD TECHS CORP (UTX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Dover ( DOV ) and Abbot Labs ( ABT ) beat on earnings, but modestly missed expectations. Sheraz Mian Director of Research APPLE INC ( AAPL ): Free Stock Analysis Report ABBOTT LABS ( ABT ): Free Stock Analysis Report AUTOMATIC DATA ( ADP ): Free Stock Analysis Report BOEING CO ( BA ): Free Stock Analysis Report DOVER CORP ( DOV ): Free Stock Analysis Report UTD TECHS CORP (UTX): Free Stock Analysis Report To read this article on Zacks.com click here. Wednesday, January 25, 2012 The focus today will be on the Fed, as the central bank unveils a new measure as part of its ongoing efforts to improve communication with the markets. | Sheraz Mian Director of Research APPLE INC ( AAPL ): Free Stock Analysis Report ABBOTT LABS ( ABT ): Free Stock Analysis Report AUTOMATIC DATA ( ADP ): Free Stock Analysis Report BOEING CO ( BA ): Free Stock Analysis Report DOVER CORP ( DOV ): Free Stock Analysis Report UTD TECHS CORP (UTX): Free Stock Analysis Report To read this article on Zacks.com click here. Dover ( DOV ) and Abbot Labs ( ABT ) beat on earnings, but modestly missed expectations. This is a significant development as it likely will show that the central bank districts expect near-zero interests for longer than the current FOMC policy of through mid-2013 only. | Sheraz Mian Director of Research APPLE INC ( AAPL ): Free Stock Analysis Report ABBOTT LABS ( ABT ): Free Stock Analysis Report AUTOMATIC DATA ( ADP ): Free Stock Analysis Report BOEING CO ( BA ): Free Stock Analysis Report DOVER CORP ( DOV ): Free Stock Analysis Report UTD TECHS CORP (UTX): Free Stock Analysis Report To read this article on Zacks.com click here. Dover ( DOV ) and Abbot Labs ( ABT ) beat on earnings, but modestly missed expectations. The prospect of an even longer timeframe for lower interest rates, as many in the markets are hoping to come out of today's Fed releases, has the potential to put stocks out of the slumber of the last two trading sessions. | Dover ( DOV ) and Abbot Labs ( ABT ) beat on earnings, but modestly missed expectations. Sheraz Mian Director of Research APPLE INC ( AAPL ): Free Stock Analysis Report ABBOTT LABS ( ABT ): Free Stock Analysis Report AUTOMATIC DATA ( ADP ): Free Stock Analysis Report BOEING CO ( BA ): Free Stock Analysis Report DOVER CORP ( DOV ): Free Stock Analysis Report UTD TECHS CORP (UTX): Free Stock Analysis Report To read this article on Zacks.com click here. The prospect of an even longer timeframe for lower interest rates, as many in the markets are hoping to come out of today's Fed releases, has the potential to put stocks out of the slumber of the last two trading sessions. |
34481.0 | 2012-01-20 00:00:00 UTC | Earnings Season in Full Swing - Earnings Preview | ABT | https://www.nasdaq.com/articles/earnings-season-full-swing-earnings-preview-2012-01-20 | nan | nan | Earnings Preview 1/20/12
Earnings season will be in full swing this week. 422 firms are scheduled to report, and 117 of those will be members of the S&P 500. By the end of the week we should have a very good handle on just how weak or strong this earnings season will be.
The firms reporting next week read like a who's who of American industry. They.include: Abbott Labs ( ABT ), Apple ( AAPL ), Automatic Data Processing ( ADP ), AT&T ( T ), Boeing ( BA ), Bristol Myers ( BMY ), Caterpillar ( CAT ), CSX ( CSX ), Chevron ( CVX ), Colgate Palmolive ( CL ), Conoco Phillips (COP - Analyst Report) and DuPont ( DD ) - and that is just in the first four letters of the alphabet!
It will also be a moderate week for economic data. Things will be slow early in the week, with no major news until Wednesday, when we get the Pending Home Sales data and the Fed releases the policy statement following their meeting. Thursday will be the busiest day of the week with New Orders for Druable Goods and New Home Sales, along with the regular weekly Initial Jobless Claims data. The biggest report of the week, however, is on Friday, when we get the first look at GDP growth in the fourth quarter.
Monday
Nothing of particular significance.
Tuesday
No major economic reports, but in the evening President Obama will present his third State of the Union address.
Wednesday
Pending home sales are expected to have declined 3.0% after a 7.3% surge in November. However, given the high number of contract cancellations recently due to people unable to get mortgages, and due to appraisals coming in lower than expected, this number has been less accurate than in the past in predicting existing home sales.
The Fed is expected to keep the Fed Funds rate in the 0-0.25% range it has been locked in since December 2008. There is a chance that they will announce another round of quantitative easing, but the probability is less than 50% they will do so. The post-meeting statement will be closely examined for any clues as to the direction the Fed will be taking.
Thursday
Weekly Initial Claims for Unemployment Insurance plunged by 52,000 to 352,000. However, that shocking drop came after a surprisingly large rise the week before. My sense is that they were both flukes, but in offsetting directions. The consensus seems to agree and is looking for claims to rise to 375,000 which would be just a little bit below the average of the last two weeks. These past two weeks illustrate just how volatile week-to-week numbers can be, so the four-week average is the thing to focus on (at 379,000 last week). Keep an eye on the prior week's revision as well as the change from the revised number.
Continuing Jobless Claims have been in a downtrend of late, but the road down has been bumpy. Last week they fell by 215,000 to 3.432 million. That is down 518,000, or 13.1% from a year ago. The consensus is looking for a rise to 3.550 million. Some (most?) of the longer-term decline is due to people simply exhausting their regular state benefits, which run out after 26 weeks. Those, however, don't last forever either. Federally paid extended claims rose by 105,000 to 3.460 million last week but are down 1.192 million, or 24.5%, over the last year. Looking at just the regular continuing claims numbers is a serious mistake. They only include a little over half of the unemployed now, given the unprecedentedly high duration of unemployment figures. A better measure is the total number of people getting unemployment benefits -- currently at 7.887 million. The total number of people getting benefits is now 1.762 million below year-ago levels. What is not known is how many people have left the extended claims via the road to prosperity -- finding a new job -- and how many have left on the road to poverty, having simply exhausted even the extended benefits. Unless the program is renewed, all extended benefits will end at the start of March. Make sure to look at both sets of numbers! Many of the press reports will not, but we will here at Zacks.
New Orders for Durable Goods are expected to rise 2.0% for December, on top of a 3.8% surge in November. While those are simply fantastic numbers, they are also a bit deceptive. Most of the strength is from the extremely volatile and lumpy Transportation Equipment segment, specifically from orders for jetliners. Since they are such big-ticket items, a few orders here and there can swamp the rest of the numbers. If Transportation Equipment is excluded, orders are expected to be up 0.7% on top of a 0.3% rise in November. That's still a pretty healthy growth rate, but nowhere near as spectacular as the headline number would suggest.
New Home Sales are expected to rise to a seasonally adjusted annual rate of 322,000, up 2.2% from the November rate. While it is nice to see new home sales picking up, it is still an extremely low rate. The 20 lowest months in the history of New Home Sales data (back to 1963) have all been in the last 20 months, and if the consensus is right, it will make it 21 out of the last 21 months. Recently, though, the housing data has been coming in a bit better than expected, particularly when it comes to single family homes. New home sales are what have powered every single previous post-war recovery. The extraodinarily low level of new home sales is one of the most important reasons that this recovery has been relatively slow. If housing does get into gear in 2012, U.S. economic growth is likely to be much higher than most people expect. The key word in that last sentence, though, is "if."
The Index of Leading Economic Indicators is expected to rise by 0.7%, on top of a 0.5% increase last month.
Friday
We get the "Big Kahuna" of economic reports: GDP for the fourth quarter. This will be the first of three realeases of the data, which is subject to significant revisions in the later releases. The pattern of accelerating economic growth is expected to continue, with growth of 3.1% growth expected. That is up from 1.8% in the third quarter, 1.3% on the second and just 0.4% in the first quarter. The composition of the growth can be just as important and interesting as the overall level. Growth that simply comes from inventory accumulation is not as bullish as growth that comes from businesses investing in new plant and equipment, for example. We will provide a complete breakdown, not just of the level of growth in the the quarter, but where in the economy it came from.
The Univeristy of Michigan Consumer Sentiment index is expected to edge up to 74.2 from 74.0. It has been moveing up in recent months but is still at a low level. However, since what consumers say in the survey is often very different than what they actually do, I think this is one of the most overrated economic indicators around.
Potential Positive or Negative Surprises
The best indicators of firms likely to report positive surprises are a recent history of positive surprises and rising estimates going into the report. The Zacks Rank is also a good indicator of potential surprises. Similarly, a recent history of earnings disappointments, cuts in the average estimate for the quarter in the month before the report is due and a poor Zacks Rank (#4 or #5) are often red flags pointing to a potential disappointing earnings report.
In the Earnings Calendar below, $999.00 should be read as N.A.
Potential Positive Surprises:
Caterpillar ( CAT ) is expected to earn $1.73, up from $1.47 a year ago. Last time out, it had a positive surprise of 21.38%, and over the last four weeks analysts have raised their estimates for the quarter by 0.35%. CAT is a Zacks #1 Rank stock.
W.W. Grainger ( GWW ) is expected to earn $2.10, up from $1.79 a year ago. Last time out, it had a positive surprise of 7.26%, and over the last four weeks analysts have raised their estimates for the quarter by 0.16%. GWW is a Zacks #1 Rank stock.
Western Digital ( WDC ) is expected to earn $0.72, down from $0.96 a year ago. Last time out, it had a positive surprise of 15.79%, and over the last four weeks analysts have raised their estimates for the quarter by 2.88%. WDC is a number two Zacks #2 Rank stock.
Potential Negative Surprises:
DeVry ( DV ) is expected to earn $1.00, down from $1.25 a year ago. Last time out, it had a negative surprise of 13.54%, and over the last four weeks analysts have not changed their estimates for the quarter. DV is a Zacks #5 Rank stock.
Juniper Networks ( JNPR ) is expected to earn $0.21, down from $0.36 a year ago. Last time out, it had a negative surprise of 5.00%, and over the last four weeks analysts have slashed their estimates for the quarter by 19.14%. JNPR is a Zacks #4 Rank stock.
APPLE INC ( AAPL ): Free Stock Analysis Report
ABBOTT LABS ( ABT ): Free Stock Analysis Report
BOEING CO ( BA ): Free Stock Analysis Report
BRISTOL-MYERS ( BMY ): Free Stock Analysis Report
CATERPILLAR INC (CAT): Free Stock Analysis Report
COLGATE PALMOLI (CL): Free Stock Analysis Report
CONOCOPHILLIPS (COP): Free Stock Analysis Report
CSX CORP (CSX): Free Stock Analysis Report
CHEVRON CORP (CVX): Free Stock Analysis Report
DU PONT ( EI ) DE (DD): Free Stock Analysis Report
AT&T INC (T): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | They.include: Abbott Labs ( ABT ), Apple ( AAPL ), Automatic Data Processing ( ADP ), AT&T ( T ), Boeing ( BA ), Bristol Myers ( BMY ), Caterpillar ( CAT ), CSX ( CSX ), Chevron ( CVX ), Colgate Palmolive ( CL ), Conoco Phillips (COP - Analyst Report) and DuPont ( DD ) - and that is just in the first four letters of the alphabet! APPLE INC ( AAPL ): Free Stock Analysis Report ABBOTT LABS ( ABT ): Free Stock Analysis Report BOEING CO ( BA ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report CATERPILLAR INC (CAT): Free Stock Analysis Report COLGATE PALMOLI (CL): Free Stock Analysis Report CONOCOPHILLIPS (COP): Free Stock Analysis Report CSX CORP (CSX): Free Stock Analysis Report CHEVRON CORP (CVX): Free Stock Analysis Report DU PONT ( EI ) DE (DD): Free Stock Analysis Report AT&T INC (T): Free Stock Analysis Report To read this article on Zacks.com click here. Things will be slow early in the week, with no major news until Wednesday, when we get the Pending Home Sales data and the Fed releases the policy statement following their meeting. | They.include: Abbott Labs ( ABT ), Apple ( AAPL ), Automatic Data Processing ( ADP ), AT&T ( T ), Boeing ( BA ), Bristol Myers ( BMY ), Caterpillar ( CAT ), CSX ( CSX ), Chevron ( CVX ), Colgate Palmolive ( CL ), Conoco Phillips (COP - Analyst Report) and DuPont ( DD ) - and that is just in the first four letters of the alphabet! APPLE INC ( AAPL ): Free Stock Analysis Report ABBOTT LABS ( ABT ): Free Stock Analysis Report BOEING CO ( BA ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report CATERPILLAR INC (CAT): Free Stock Analysis Report COLGATE PALMOLI (CL): Free Stock Analysis Report CONOCOPHILLIPS (COP): Free Stock Analysis Report CSX CORP (CSX): Free Stock Analysis Report CHEVRON CORP (CVX): Free Stock Analysis Report DU PONT ( EI ) DE (DD): Free Stock Analysis Report AT&T INC (T): Free Stock Analysis Report To read this article on Zacks.com click here. Potential Positive or Negative Surprises The best indicators of firms likely to report positive surprises are a recent history of positive surprises and rising estimates going into the report. | APPLE INC ( AAPL ): Free Stock Analysis Report ABBOTT LABS ( ABT ): Free Stock Analysis Report BOEING CO ( BA ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report CATERPILLAR INC (CAT): Free Stock Analysis Report COLGATE PALMOLI (CL): Free Stock Analysis Report CONOCOPHILLIPS (COP): Free Stock Analysis Report CSX CORP (CSX): Free Stock Analysis Report CHEVRON CORP (CVX): Free Stock Analysis Report DU PONT ( EI ) DE (DD): Free Stock Analysis Report AT&T INC (T): Free Stock Analysis Report To read this article on Zacks.com click here. They.include: Abbott Labs ( ABT ), Apple ( AAPL ), Automatic Data Processing ( ADP ), AT&T ( T ), Boeing ( BA ), Bristol Myers ( BMY ), Caterpillar ( CAT ), CSX ( CSX ), Chevron ( CVX ), Colgate Palmolive ( CL ), Conoco Phillips (COP - Analyst Report) and DuPont ( DD ) - and that is just in the first four letters of the alphabet! Potential Positive or Negative Surprises The best indicators of firms likely to report positive surprises are a recent history of positive surprises and rising estimates going into the report. | They.include: Abbott Labs ( ABT ), Apple ( AAPL ), Automatic Data Processing ( ADP ), AT&T ( T ), Boeing ( BA ), Bristol Myers ( BMY ), Caterpillar ( CAT ), CSX ( CSX ), Chevron ( CVX ), Colgate Palmolive ( CL ), Conoco Phillips (COP - Analyst Report) and DuPont ( DD ) - and that is just in the first four letters of the alphabet! APPLE INC ( AAPL ): Free Stock Analysis Report ABBOTT LABS ( ABT ): Free Stock Analysis Report BOEING CO ( BA ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report CATERPILLAR INC (CAT): Free Stock Analysis Report COLGATE PALMOLI (CL): Free Stock Analysis Report CONOCOPHILLIPS (COP): Free Stock Analysis Report CSX CORP (CSX): Free Stock Analysis Report CHEVRON CORP (CVX): Free Stock Analysis Report DU PONT ( EI ) DE (DD): Free Stock Analysis Report AT&T INC (T): Free Stock Analysis Report To read this article on Zacks.com click here. A better measure is the total number of people getting unemployment benefits -- currently at 7.887 million. |
34482.0 | 2012-01-20 00:00:00 UTC | Neutral on Biogen - Analyst Blog | ABT | https://www.nasdaq.com/articles/neutral-on-biogen-analyst-blog-2012-01-20 | nan | nan | We recently reiterated our Neutral recommendation on Biogen Idec ( BIIB ). Biogen is the market leader in therapies for the treatment of multiple sclerosis ( MS ). We believe the company will continue to retain a leading position in the MS market.
Biogen's largest product, Avonex, posted sales of $2,518.4 million, up 8.4%, in 2010. We expect Avonex to continue contributing significantly to the top-line thanks to price increases, focused marketing effort, expansion into new markets and positive clinical data.
Meanwhile, Tysabri, the company's second MS product, continues to see an increase in patients despite carrying a "black box" warning for the risk of progressive multifocal leukoencephalopathy ( PML ) and other cautionary language. Tysabri posted $1.2 billion in sales in 2010. Tysabri's launch in new markets like India, Brazil, Argentina, the Middle East and Southeast Asia among others should help drive growth. Tysabri sales should reach $1.5 billion in 2011.
We are also pleased with Biogen's efforts to consolidate its position in the MS market. The most promising candidate in the company's MS pipeline in BG-12, which could become a leader in the oral MS market once launched. With impressive phase III data in hand, Biogen expects to file for approval in the first half of 2012.
We believe BG-12 could become a leader in the oral MS market once launched. Biogen is also studying BG-12 as a combination therapy. Other interesting candidates in the MS pipeline daclizumab, which is being developed in collaboration with Abbott Labs ( ABT ), and PEGylated interferon. Biogen's pipeline also has candidates for other ailments like amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, and hemophilia.
While we are impressed with Biogen's progress with its MS franchise, our biggest concern remains the competitive threat posed by Novartis' ( NVS ) Gilenya that was launched in early October 2010. Gilenya is competing primarily with Avonex and Tysabri for a share of the MS market. We remain concerned that being the first oral treatment to have gained US approval for the treatment of MS, Gilenya could take share from Biogen's products.
Also, we expect some cannibalization of Avonex sales once BG-12 is launched. Longer-term, Biogen's MS products could face additional competition as companies like Sanofi ( SNY ) are working on developing MS treatments. The entry of additional competitors could make it challenging for Biogen to maintain its position in the MS market.
ABBOTT LABS ( ABT ): Free Stock Analysis Report
BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report
NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other interesting candidates in the MS pipeline daclizumab, which is being developed in collaboration with Abbott Labs ( ABT ), and PEGylated interferon. ABBOTT LABS ( ABT ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, Tysabri, the company's second MS product, continues to see an increase in patients despite carrying a "black box" warning for the risk of progressive multifocal leukoencephalopathy ( PML ) and other cautionary language. | ABBOTT LABS ( ABT ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Other interesting candidates in the MS pipeline daclizumab, which is being developed in collaboration with Abbott Labs ( ABT ), and PEGylated interferon. While we are impressed with Biogen's progress with its MS franchise, our biggest concern remains the competitive threat posed by Novartis' ( NVS ) Gilenya that was launched in early October 2010. | ABBOTT LABS ( ABT ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Other interesting candidates in the MS pipeline daclizumab, which is being developed in collaboration with Abbott Labs ( ABT ), and PEGylated interferon. The most promising candidate in the company's MS pipeline in BG-12, which could become a leader in the oral MS market once launched. | Other interesting candidates in the MS pipeline daclizumab, which is being developed in collaboration with Abbott Labs ( ABT ), and PEGylated interferon. ABBOTT LABS ( ABT ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Biogen is the market leader in therapies for the treatment of multiple sclerosis ( MS ). |
34483.0 | 2012-01-19 00:00:00 UTC | Meridian Intros HyperPAGE II Marker - Analyst Blog | ABT | https://www.nasdaq.com/articles/meridian-intros-hyperpage-ii-marker-analyst-blog-2012-01-19 | nan | nan | Bioline, a fully owned subsidiary of diagnostic test kits maker Meridian Bioscience ( VIVO ), has broadened its HyperPAGE line of prestained molecular weight protein markers with the launch of the new HyperPAGE II protein marker.
HyperPAGE II, a broad range protein marker, is prestained with different fluorescent dyes and contains nine highly purified protein bands with molecular weights ranging from 10 to 250kDa (kilodalton). The fluorescence dyes facilitate easy identification and orientation of the protein bands while performing protein electrophoresis (a method for analyzing proteins). HyperPAGE II is available in a convenient, ready-to-use format.
HyperPAGE II is geared to monitor efficiency in protein electrophoresis and protein transfer from gel to membrane in Western blotting (a widely used method to detect specific protein in a sample). It is also suitable for measuring the molecular weight of protein samples.
Cincinnati-based Meridian specializes in developing diagnostic test kits for multiple serious and infectious diseases. The company's diagnostics business faces strong competition from Abbott Laboratories ( ABT ), Becton, Dickinson and Company ( BDX ), Thermo Fisher ( TMO ) and Siemens ( SI ).
Meridian's $23.3 million acquisition of London-based molecular biology reagents maker Bioline in July 2010 has unlocked opportunities for growth through expanded product range and geographic expansion.
Meridian, in August 2011, released its outlook for fiscal 2012. The company hopes that sales for the year would be boosted by its illumigene molecular tests and Bioline products as well as its foodborne and H. pylori tests.
Meridian is optimistic that sustained adoption of the illumigene platform, growth in core products and opportunities in Europe will help it drive significant growth in sales and earnings in fiscal 2012 and beyond.
ABBOTT LABS ( ABT ): Free Stock Analysis Report
BECTON DICKINSO ( BDX ): Free Stock Analysis Report
SIEMENS AG-ADR ( SI ): Free Stock Analysis Report
THERMO FISHER ( TMO ): Free Stock Analysis Report
MERIDIAN BIOSCI ( VIVO ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company's diagnostics business faces strong competition from Abbott Laboratories ( ABT ), Becton, Dickinson and Company ( BDX ), Thermo Fisher ( TMO ) and Siemens ( SI ). ABBOTT LABS ( ABT ): Free Stock Analysis Report BECTON DICKINSO ( BDX ): Free Stock Analysis Report SIEMENS AG-ADR ( SI ): Free Stock Analysis Report THERMO FISHER ( TMO ): Free Stock Analysis Report MERIDIAN BIOSCI ( VIVO ): Free Stock Analysis Report To read this article on Zacks.com click here. Bioline, a fully owned subsidiary of diagnostic test kits maker Meridian Bioscience ( VIVO ), has broadened its HyperPAGE line of prestained molecular weight protein markers with the launch of the new HyperPAGE II protein marker. | The company's diagnostics business faces strong competition from Abbott Laboratories ( ABT ), Becton, Dickinson and Company ( BDX ), Thermo Fisher ( TMO ) and Siemens ( SI ). ABBOTT LABS ( ABT ): Free Stock Analysis Report BECTON DICKINSO ( BDX ): Free Stock Analysis Report SIEMENS AG-ADR ( SI ): Free Stock Analysis Report THERMO FISHER ( TMO ): Free Stock Analysis Report MERIDIAN BIOSCI ( VIVO ): Free Stock Analysis Report To read this article on Zacks.com click here. Bioline, a fully owned subsidiary of diagnostic test kits maker Meridian Bioscience ( VIVO ), has broadened its HyperPAGE line of prestained molecular weight protein markers with the launch of the new HyperPAGE II protein marker. | ABBOTT LABS ( ABT ): Free Stock Analysis Report BECTON DICKINSO ( BDX ): Free Stock Analysis Report SIEMENS AG-ADR ( SI ): Free Stock Analysis Report THERMO FISHER ( TMO ): Free Stock Analysis Report MERIDIAN BIOSCI ( VIVO ): Free Stock Analysis Report To read this article on Zacks.com click here. The company's diagnostics business faces strong competition from Abbott Laboratories ( ABT ), Becton, Dickinson and Company ( BDX ), Thermo Fisher ( TMO ) and Siemens ( SI ). Bioline, a fully owned subsidiary of diagnostic test kits maker Meridian Bioscience ( VIVO ), has broadened its HyperPAGE line of prestained molecular weight protein markers with the launch of the new HyperPAGE II protein marker. | The company's diagnostics business faces strong competition from Abbott Laboratories ( ABT ), Becton, Dickinson and Company ( BDX ), Thermo Fisher ( TMO ) and Siemens ( SI ). ABBOTT LABS ( ABT ): Free Stock Analysis Report BECTON DICKINSO ( BDX ): Free Stock Analysis Report SIEMENS AG-ADR ( SI ): Free Stock Analysis Report THERMO FISHER ( TMO ): Free Stock Analysis Report MERIDIAN BIOSCI ( VIVO ): Free Stock Analysis Report To read this article on Zacks.com click here. Bioline, a fully owned subsidiary of diagnostic test kits maker Meridian Bioscience ( VIVO ), has broadened its HyperPAGE line of prestained molecular weight protein markers with the launch of the new HyperPAGE II protein marker. |
34484.0 | 2012-01-12 00:00:00 UTC | Qiagen Expands with New Deals - Analyst Blog | ABT | https://www.nasdaq.com/articles/qiagen-expands-with-new-deals-analyst-blog-2012-01-12 | nan | nan | In an attempt to expand its companion diagnostic portfolio for several types of new anti-cancer drugs, Qiagen ( QGEN ) recently entered into two different agreements with US biotech companies, namely Insight Genetics, Inc. and Personal Genome Diagnostics Inc. Through the agreement, the company seeks to obtain worldwide exclusive rights for biomarkers for gene mutation.
In collaboration with the Tennessee-based molecular diagnostics company Insight Genetics, Qiagen will provide a genetic test with a biomarker for non-small cell lung cancers (NSCLC) that express the abnormal anaplastic lymphoma kinase ( ALK ) gene.
Meanwhile, under the agreement with Maryland-based Personal Genome Diagnostics, Qiagen's 89% subsidiary Ipsogen obtained rights to genetic testing for mutations of the IDH1 and IDH2 genes for brain cancers, acute myelogenous leukemia (AML) and other malignancies.
With the companion diagnostics market expected to remain a major growth driver going forward, several clinical laboratory companies in the US are coming up with their comprehensive portfolio of biomarkers and genetic tests.
Qiagen's current initiatives to expand its biomarker portfolio through the addition of the ALK and IDH1/IDH2 biomarkers are expected to strengthen its position in the strongly growing molecular diagnostics market. This should bring in incremental sales for the company globally. Qiagen also plans to develop companion diagnostics to make these biomarkers available in combination with new medicines.
We are encouraged by Qiagen's focus on strategic initiatives to drive growth and profitability in the companion diagnostics market. Its innovative tests in the genomic/esoteric arena, specifically in the area of cancer with a focus on the high-margin esoteric testing business, are expected to accelerate sales growth in next several quarters.
Major Peers in Companion Diagnostics Space
However, Qiagen is facing mounting competition in the molecular diagnostic space especially from players like Laboratory Corporation of America Holdings ( LH ) and Myriad Genetics ( MYGN ). LabCorp has already expanded its companion diagnostic portfolio with the ALK biomarker for Pfizer's ( PFE ) Xalkori.
Xalkori received FDA approval along with a test (Vysis ALK Break Apart FISH Probe Kit) for certain patients with late-stage (locally advanced or metastatic) NSCLC who express ALK gene. This companion diagnostic test is exclusively available through LabCorp.
Myriad is also aiming to establish itself as a strong player in the companion diagnostic market. In 2011, the company entered into an agreement with BioMarin Pharmaceuticals ( BMRN ) to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in the latter's phase I/II clinical study of BMN 673. BMN 673 is a PARP-inhibitor drug candidate for the treatment of genetically defined cancers. Myriad also has agreements with Abbott Laboratories ( ABT ) and AstraZeneca ( AZN ).
Currently, Qiagen retains a Zacks #3 Rank (short-term Hold). Over the long term, we are Neutral on the stock, at par with LabCorp and Myriad.
ABBOTT LABS ( ABT ): Free Stock Analysis Report
ASTRAZENECA PLC ( AZN ): Free Stock Analysis Report
BIOMARIN PHARMA ( BMRN ): Free Stock Analysis Report
LABORATORY CP ( LH ): Free Stock Analysis Report
MYRIAD GENETICS (MYGN): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
QIAGEN NV (QGEN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Myriad also has agreements with Abbott Laboratories ( ABT ) and AstraZeneca ( AZN ). ABBOTT LABS ( ABT ): Free Stock Analysis Report ASTRAZENECA PLC ( AZN ): Free Stock Analysis Report BIOMARIN PHARMA ( BMRN ): Free Stock Analysis Report LABORATORY CP ( LH ): Free Stock Analysis Report MYRIAD GENETICS (MYGN): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report QIAGEN NV (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, under the agreement with Maryland-based Personal Genome Diagnostics, Qiagen's 89% subsidiary Ipsogen obtained rights to genetic testing for mutations of the IDH1 and IDH2 genes for brain cancers, acute myelogenous leukemia (AML) and other malignancies. | ABBOTT LABS ( ABT ): Free Stock Analysis Report ASTRAZENECA PLC ( AZN ): Free Stock Analysis Report BIOMARIN PHARMA ( BMRN ): Free Stock Analysis Report LABORATORY CP ( LH ): Free Stock Analysis Report MYRIAD GENETICS (MYGN): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report QIAGEN NV (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Myriad also has agreements with Abbott Laboratories ( ABT ) and AstraZeneca ( AZN ). Meanwhile, under the agreement with Maryland-based Personal Genome Diagnostics, Qiagen's 89% subsidiary Ipsogen obtained rights to genetic testing for mutations of the IDH1 and IDH2 genes for brain cancers, acute myelogenous leukemia (AML) and other malignancies. | ABBOTT LABS ( ABT ): Free Stock Analysis Report ASTRAZENECA PLC ( AZN ): Free Stock Analysis Report BIOMARIN PHARMA ( BMRN ): Free Stock Analysis Report LABORATORY CP ( LH ): Free Stock Analysis Report MYRIAD GENETICS (MYGN): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report QIAGEN NV (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Myriad also has agreements with Abbott Laboratories ( ABT ) and AstraZeneca ( AZN ). In an attempt to expand its companion diagnostic portfolio for several types of new anti-cancer drugs, Qiagen ( QGEN ) recently entered into two different agreements with US biotech companies, namely Insight Genetics, Inc. and Personal Genome Diagnostics Inc. | Myriad also has agreements with Abbott Laboratories ( ABT ) and AstraZeneca ( AZN ). ABBOTT LABS ( ABT ): Free Stock Analysis Report ASTRAZENECA PLC ( AZN ): Free Stock Analysis Report BIOMARIN PHARMA ( BMRN ): Free Stock Analysis Report LABORATORY CP ( LH ): Free Stock Analysis Report MYRIAD GENETICS (MYGN): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report QIAGEN NV (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. In an attempt to expand its companion diagnostic portfolio for several types of new anti-cancer drugs, Qiagen ( QGEN ) recently entered into two different agreements with US biotech companies, namely Insight Genetics, Inc. and Personal Genome Diagnostics Inc. |
34485.0 | 2012-01-05 00:00:00 UTC | FDA OKs Meridian's GDH Test - Analyst Blog | ABT | https://www.nasdaq.com/articles/fda-oks-meridians-gdh-test-analyst-blog-2012-01-05 | nan | nan | Diagnostic test kit maker Meridian Bioscience ( VIVO ) recently won the approval of the U.S. Food and Drug Administration ("FDA") for its new C. difficile(Clostridium difficile) test dubbed ImmunoCard C. difficile GDH. The Cincinnati-based company launched the test in Europe in August 2011.
C. difficile is a highly drug-resistant bacterium, which exists in the environment in spore (or inactive) form and produces a toxin that causes diarrhea and more serious intestinal conditions such as colitis. C. difficile spores are frequently found in hospitals, nursing homes and extended care facilities. Although spores cannot cause infection directly, they transform into the active (or infectious) form when ingested.
The prevalence of C. difficile has been growing at a brisk rate over the past few years. Study reveals that more than 7,000 patients in a hospital environment are prone to infection by C. difficile ea ch day with an estimated associated healthcare costs ranging between $18 million and $52 million per day.
ImmunoCard C. difficile GDH is geared to detect a common antigen, known as Glutamate dehydrogenase ("GHD"), produced by the toxigenic and non-toxigenic forms of C. difficile bacteria.
The toxic forms of the bacteria are generally associated with hospital and community-acquired diarrhea and can cause a life-threatening inflammation of the colon. The new, highly-sensitive test is intended for use by clinical laboratories for screening patients with diarrhea for C. difficile .
Meridian specializes in developing diagnostic test kits for multiple serious and infectious diseases. The company launched its first GHD test, the ImmunoCard C. difficile GDH, in 1993. Meridian's diagnostics business faces strong competition from Abbott Laboratories ( ABT ), Becton, Dickinson and Company ( BDX ), Thermo Fisher ( TMO ) and Siemens ( SI ).
The U.S. approval and launch of ImmunoCard C. difficile GDH underscores the company's sustained commitment to bring out breakthrough products for the detection of C. difficile .
ABBOTT LABS ( ABT ): Free Stock Analysis Report
BECTON DICKINSO ( BDX ): Free Stock Analysis Report
SIEMENS AG-ADR ( SI ): Free Stock Analysis Report
THERMO FISHER ( TMO ): Free Stock Analysis Report
MERIDIAN BIOSCI ( VIVO ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Meridian's diagnostics business faces strong competition from Abbott Laboratories ( ABT ), Becton, Dickinson and Company ( BDX ), Thermo Fisher ( TMO ) and Siemens ( SI ). ABBOTT LABS ( ABT ): Free Stock Analysis Report BECTON DICKINSO ( BDX ): Free Stock Analysis Report SIEMENS AG-ADR ( SI ): Free Stock Analysis Report THERMO FISHER ( TMO ): Free Stock Analysis Report MERIDIAN BIOSCI ( VIVO ): Free Stock Analysis Report To read this article on Zacks.com click here. C. difficile is a highly drug-resistant bacterium, which exists in the environment in spore (or inactive) form and produces a toxin that causes diarrhea and more serious intestinal conditions such as colitis. | Meridian's diagnostics business faces strong competition from Abbott Laboratories ( ABT ), Becton, Dickinson and Company ( BDX ), Thermo Fisher ( TMO ) and Siemens ( SI ). ABBOTT LABS ( ABT ): Free Stock Analysis Report BECTON DICKINSO ( BDX ): Free Stock Analysis Report SIEMENS AG-ADR ( SI ): Free Stock Analysis Report THERMO FISHER ( TMO ): Free Stock Analysis Report MERIDIAN BIOSCI ( VIVO ): Free Stock Analysis Report To read this article on Zacks.com click here. The company launched its first GHD test, the ImmunoCard C. difficile GDH, in 1993. | ABBOTT LABS ( ABT ): Free Stock Analysis Report BECTON DICKINSO ( BDX ): Free Stock Analysis Report SIEMENS AG-ADR ( SI ): Free Stock Analysis Report THERMO FISHER ( TMO ): Free Stock Analysis Report MERIDIAN BIOSCI ( VIVO ): Free Stock Analysis Report To read this article on Zacks.com click here. Meridian's diagnostics business faces strong competition from Abbott Laboratories ( ABT ), Becton, Dickinson and Company ( BDX ), Thermo Fisher ( TMO ) and Siemens ( SI ). Diagnostic test kit maker Meridian Bioscience ( VIVO ) recently won the approval of the U.S. Food and Drug Administration ("FDA") for its new C. difficile(Clostridium difficile) test dubbed ImmunoCard C. difficile GDH. | Meridian's diagnostics business faces strong competition from Abbott Laboratories ( ABT ), Becton, Dickinson and Company ( BDX ), Thermo Fisher ( TMO ) and Siemens ( SI ). ABBOTT LABS ( ABT ): Free Stock Analysis Report BECTON DICKINSO ( BDX ): Free Stock Analysis Report SIEMENS AG-ADR ( SI ): Free Stock Analysis Report THERMO FISHER ( TMO ): Free Stock Analysis Report MERIDIAN BIOSCI ( VIVO ): Free Stock Analysis Report To read this article on Zacks.com click here. ImmunoCard C. difficile GDH is geared to detect a common antigen, known as Glutamate dehydrogenase ("GHD"), produced by the toxigenic and non-toxigenic forms of C. difficile bacteria. |
34486.0 | 2011-12-29 00:00:00 UTC | Ring in Generics in 2012 and Beyond - Analyst Blog | ABT | https://www.nasdaq.com/articles/ring-in-generics-in-2012-and-beyond-analyst-blog-2011-12-29 | nan | nan | The New Year is expected to be a happy beginning for generic companies like Teva Pharmaceuticals ( TEVA ), Mylan, Inc. ( MYL ), Watson Pharma ( WPI ), Dr. Reddy's ( RDY ) and Sandoz, the generic arm of Novartis ( NVS ). A large number of high-value branded pharmaceuticals have begun to go off-patent, and many more will lose patent exclusivity in the next few years.
Major revenue generating blockbuster medicines like Pfizer 's ( PFE ) cholesterol drug Lipitor, Eli Lily 's ( LLY ) antipsychotic drug Zyprexa and Johnson & Johnson 's ( JNJ ) Levaquin lost patent exclusivity in the US in November, October and June of this year, respectively. While Teva and Dr. Reddy's have launched their generic version of Zyprexa, India's largest generic maker Ranbaxy Laboratories Ltd. has launched a generic of Lipitor in partnership with Teva. Watson has launched the authorized generic version of Lipitor.
Generics Coming Home to Roost
Further, in the 2012-2018 timeframe, many more blockbuster drugs are expected to lose patent protection in the US. Important among these are: Forest Laboratories ' ( FRX ) depression drug Lexapro (March 2012), Bristol-Myers Squibb/Sanofi 's ( BMY / SNY ) hypertension drug Avapro (March 2012) and blood thinner Plavix (May 2012), Swiss drug maker Novartis ' ( NVS ) hypertension drug Diovan (September 2012), Merck 's ( MRK ) asthma drug Singulair (August 2012), Pfizer's erectile dysfunction drug Viagra (2012), Abbott Laboratories ' ( ABT ) dyslipidemia drug TriCor (mid-2012), Eli Lily's depression drug Cymbalta (2013) and diabetes product Humalog (2013), Teva's multiple sclerosis drug Copaxone (2014), Forest's Alzheimer's drug Namenda (early 2015) and Pfizer's central nervous system drug Lyrica (2018).
The generic makers with a robust pipeline are sure to exploit the patent cliff overhanging the pharma industry, especially with so many blockbuster branded medicines slated to lose patent protection in 2012, the year stands out as a beacon for these companies with a slew of product launches already lined up.
Important 2012 US generic launches for Mylan include Provigil, Diovan, Zyprexa, Plavix, Actos/Actoplus, Viramune, Clarinex, Singulair and Avapro. Teva, another force in the generic space, has drugs like Avandia, Avandamet, and Avandaryl, Actos/Actoplus and Entocort EC ready for 2012 launch while Watson has Xopenex.
Further, the industry stands to gain from an increasing awareness of generic products. Given the uncertain economic outlook, various government agencies as well as privately managed care organizations are taking initiatives to promote generics in place of costlier branded treatments.
These factors, together with an aging population and a corresponding increase in healthcare costs, should lead to continued expansion of the generics marketplace. Besides, US healthcare reform that works at bringing more people under the purview of prescription drug benefit would catalyze generics uptake.
Data from IMS Health substantiate that the growth rate of generics is twice that of branded drugs the world over. In Europe, too, generics make up almost half of total volume sales.
Big Pharma in the Pale
While the generic companies are expected to shine going ahead, large pharmaceutical players like Pfizer, Eli Lilly, Merck, Forest, Johnson & Johnson and Bristol Myers would have a tough time in the coming years. Obviously, one's gain is another's loss. The loss of patent exclusivity for these biggies would definitely affect their top line.
The influx of generic competition will not only put downward pressure on pricing, it will also result in gross margin contraction over the next several years. At the same time, the loss of revenues due to genericization is unlikely to be compensated sufficiently by new product launches for most of these branded companies. The extent to which branded companies can replace lost sales, from generic lapses, by new product launches is still to be seen.
Reliable data from IMS Health reveal that market share for branded medicines fell from 70% in 2005 to 64% in 2010, a function surely due to sour economic conditions. The percentage is expected to deteriorate further, to 53%, through 2015.
Beyond the Bubble
With success guaranteed till 2017-2018, the question for investors is what lies beyond. With most large branded drugs due to lose patent exclusivity within 2017-2018, we have little visibility into the growth prospects for generic companies beyond that timeframe.
Moreover, large pharmaceutical players are not willing to take the blows lying down. These well-capitalized companies are continuously launching new products, entering into in-licensing deals and indulging in tuck-in acquisitions.
These companies are also undertaking measures like work force reduction and share repurchases to shore up the bottom line. The last laugh may well be theirs. Meanwhile, generic players are geared up to make the best use of the current favorable market conditions.
ABBOTT LABS ( ABT ): Free Stock Analysis Report
BRISTOL-MYERS ( BMY ): Free Stock Analysis Report
FOREST LABS A ( FRX ): Free Stock Analysis Report
JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report
LILLY ELI & CO ( LLY ): Free Stock Analysis Report
MERCK & CO INC (MRK): Free Stock Analysis Report
MYLAN INC (MYL): Free Stock Analysis Report
NOVARTIS AG-ADR (NVS): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
DOCTOR REDDYS (RDY): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
TEVA PHARM ADR (TEVA): Free Stock Analysis Report
WATSON PHARMA (WPI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Important among these are: Forest Laboratories ' ( FRX ) depression drug Lexapro (March 2012), Bristol-Myers Squibb/Sanofi 's ( BMY / SNY ) hypertension drug Avapro (March 2012) and blood thinner Plavix (May 2012), Swiss drug maker Novartis ' ( NVS ) hypertension drug Diovan (September 2012), Merck 's ( MRK ) asthma drug Singulair (August 2012), Pfizer's erectile dysfunction drug Viagra (2012), Abbott Laboratories ' ( ABT ) dyslipidemia drug TriCor (mid-2012), Eli Lily's depression drug Cymbalta (2013) and diabetes product Humalog (2013), Teva's multiple sclerosis drug Copaxone (2014), Forest's Alzheimer's drug Namenda (early 2015) and Pfizer's central nervous system drug Lyrica (2018). ABBOTT LABS ( ABT ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report FOREST LABS A ( FRX ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report LILLY ELI & CO ( LLY ): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report DOCTOR REDDYS (RDY): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report To read this article on Zacks.com click here. Teva, another force in the generic space, has drugs like Avandia, Avandamet, and Avandaryl, Actos/Actoplus and Entocort EC ready for 2012 launch while Watson has Xopenex. | Important among these are: Forest Laboratories ' ( FRX ) depression drug Lexapro (March 2012), Bristol-Myers Squibb/Sanofi 's ( BMY / SNY ) hypertension drug Avapro (March 2012) and blood thinner Plavix (May 2012), Swiss drug maker Novartis ' ( NVS ) hypertension drug Diovan (September 2012), Merck 's ( MRK ) asthma drug Singulair (August 2012), Pfizer's erectile dysfunction drug Viagra (2012), Abbott Laboratories ' ( ABT ) dyslipidemia drug TriCor (mid-2012), Eli Lily's depression drug Cymbalta (2013) and diabetes product Humalog (2013), Teva's multiple sclerosis drug Copaxone (2014), Forest's Alzheimer's drug Namenda (early 2015) and Pfizer's central nervous system drug Lyrica (2018). ABBOTT LABS ( ABT ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report FOREST LABS A ( FRX ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report LILLY ELI & CO ( LLY ): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report DOCTOR REDDYS (RDY): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report To read this article on Zacks.com click here. Major revenue generating blockbuster medicines like Pfizer 's ( PFE ) cholesterol drug Lipitor, Eli Lily 's ( LLY ) antipsychotic drug Zyprexa and Johnson & Johnson 's ( JNJ ) Levaquin lost patent exclusivity in the US in November, October and June of this year, respectively. | Important among these are: Forest Laboratories ' ( FRX ) depression drug Lexapro (March 2012), Bristol-Myers Squibb/Sanofi 's ( BMY / SNY ) hypertension drug Avapro (March 2012) and blood thinner Plavix (May 2012), Swiss drug maker Novartis ' ( NVS ) hypertension drug Diovan (September 2012), Merck 's ( MRK ) asthma drug Singulair (August 2012), Pfizer's erectile dysfunction drug Viagra (2012), Abbott Laboratories ' ( ABT ) dyslipidemia drug TriCor (mid-2012), Eli Lily's depression drug Cymbalta (2013) and diabetes product Humalog (2013), Teva's multiple sclerosis drug Copaxone (2014), Forest's Alzheimer's drug Namenda (early 2015) and Pfizer's central nervous system drug Lyrica (2018). ABBOTT LABS ( ABT ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report FOREST LABS A ( FRX ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report LILLY ELI & CO ( LLY ): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report DOCTOR REDDYS (RDY): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report To read this article on Zacks.com click here. While Teva and Dr. Reddy's have launched their generic version of Zyprexa, India's largest generic maker Ranbaxy Laboratories Ltd. has launched a generic of Lipitor in partnership with Teva. | Important among these are: Forest Laboratories ' ( FRX ) depression drug Lexapro (March 2012), Bristol-Myers Squibb/Sanofi 's ( BMY / SNY ) hypertension drug Avapro (March 2012) and blood thinner Plavix (May 2012), Swiss drug maker Novartis ' ( NVS ) hypertension drug Diovan (September 2012), Merck 's ( MRK ) asthma drug Singulair (August 2012), Pfizer's erectile dysfunction drug Viagra (2012), Abbott Laboratories ' ( ABT ) dyslipidemia drug TriCor (mid-2012), Eli Lily's depression drug Cymbalta (2013) and diabetes product Humalog (2013), Teva's multiple sclerosis drug Copaxone (2014), Forest's Alzheimer's drug Namenda (early 2015) and Pfizer's central nervous system drug Lyrica (2018). ABBOTT LABS ( ABT ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report FOREST LABS A ( FRX ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report LILLY ELI & CO ( LLY ): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report DOCTOR REDDYS (RDY): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report To read this article on Zacks.com click here. Generics Coming Home to Roost Further, in the 2012-2018 timeframe, many more blockbuster drugs are expected to lose patent protection in the US. |
34487.0 | 2011-12-28 00:00:00 UTC | Pharma & Biotech Stock Review & Outlook - Industry Outlook | ABT | https://www.nasdaq.com/articles/pharma-biotech-stock-review-outlook-industry-outlook-2011-12-28-0 | nan | nan | With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years, with major revenue-generating drugs like Lipitor, Plavix, Lexapro and Zyprexa losing exclusivity.
In fact, by the end of 2011, drugs worth more than a total of $30 billion will lose patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the same time, new products are not expected to generate the same level of sales as products losing patent protection.
Moreover, the government is exploring options which will help increase the availability of generics. Recently, the Obama administration announced that it is looking to implement a proposal under which the exclusivity period for biologics will be cut down by 5 years, thereby allowing generics to enter the market sooner. The government is looking to bring this proposal into effect from 2012.
The government is also seeking to increase the availability of generics by preventing companies from entering into anti-competitive or "pay for delay" agreements which push out the availability of generics. These initiatives, if implemented, would result in additional pricing competition and genericization in the pharma industry.
With revenue growth stalling or slowing down, pharma companies have been resorting to cost-cutting and share buybacks to drive bottom-line growth.
M&A Activity
The merger & acquisition (M&A) activity that was witnessed in the pharma sector in 2010 continued in 2011. With most of the big pharma companies already facing or likely to face patent challenges for their blockbuster products, the companies have been looking towards M&As and in-licensing activities to make up for the loss of revenues that will arise with key products losing patent exclusivity.
We saw huge M&A activity over the last few months. Major deals included Johnson & Johnson's ( JNJ ) upcoming acquisition of Synthes, which should help strengthen its medical device portfolio.
Pfizer ( PFE ) acquired King Pharmaceuticals to strengthen its presence in the pain management market. Pfizer has been adding to its portfolio with other acquisitions as well including that of Icagen and Excaliard. Merck ( MRK ) is looking to expand its ophthalmology product portfolio through its acquisition of Inspire Pharmaceuticals, Inc.
Another pharma major, Bristol-Myers Squibb ( BMY ), is also not far behind where acquisitions and deals are concerned. The company has been looking to expand via acquisitions and partnerships to counter the loss of revenues that will arise following the genericization of its key drugs, including the blockbuster blood thinner Plavix.
Oncology also remains a much sought-after therapeutic area with companies like Sanofi ( SNY ) and Celgene ( CELG ) strengthening their presence in this market through acquisitions. Meanwhile, generic players are not far behind in the acquisition game. While Teva ( TEVA ) acquired Cephalon, Inc., Watson Pharmaceuticals ( WPI ) acquired generic company Specifar Pharmaceuticals to expand and strengthen its presence in Europe.
Elsewhere, companies have been looking towards biotech firms to build their product portfolios. A prime example is French pharma giant Sanofi's acquisition of biotech company Genzyme Corp. With this acquisition, Sanofi is looking to create a new source of growth. The Genzyme acquisition will boost Sanofi's revenues as well as its pipeline.
In April 2011, Gilead Sciences ( GILD ) acquired biotechnology firm Calistoga Pharmaceuticals, which focuses on developing therapies to combat cancer and inflammatory diseases.
Going forward, we expect the M&A trend to continue. We also expect a significant pickup in in-licensing activities and collaborations for the development of pipeline candidates. Instead of developing a product from scratch, which involves a lot of funds, pharma companies are shopping for mid-to-late stage pipeline candidates that look promising.
Small biotech companies are also game for in-licensing activities and collaborations. Most of these companies find it challenging to raise cash, thereby making it difficult for them to survive and continue with the development of promising pipeline candidates. Therefore, it makes sense for them to seek deals with pharma companies that are sitting on huge piles of cash.
We would recommend investors to put their money in biotech stocks that have attractive pipeline candidates or technology that can be used for the development of novel therapeutics. Therapeutic areas which could see a lot of in-licensing activity include oncology, central nervous system disorders, diabetes and immunology/inflammation. The hepatitis C virus (HCV) market is also attracting a lot of attention.
Another trend that we are seeing in recent months is the divestment of non-core business segments. Pfizer sold its Capsugel unit in August 2011 and is currently exploring strategic alternatives for its Animal Health and Nutrition businesses. Meanwhile, GlaxoSmithKline ( GSK ) is divesting non-core brands from its Consumer Healthcare segment.
In August 2011, AstraZeneca sold its Astra Tech business to DENTSPLY ( XRAY ). The monetization of non-core assets will allow the pharma/biotech companies to focus on their areas of expertise. 2012 will see Abbott Labs ( ABT ) splitting into two separate publicly traded companies. While one company will deal in diversified medical products, the other will focus on research-based pharmaceuticals.
Emerging Markets
Another recent trend seen in the pharmaceutical sector is a focus on emerging markets. Companies like Mylan ( MYL ), Pfizer, Merck, Eli Lilly ( LLY ), Glaxo and Sanofi are all looking to expand their presence in India, China, Brazil and other emerging markets. Until recently, most of the commercialization efforts were focused on the US market -- the largest pharmaceutical market -- along with Europe and Japan.
However, emerging markets are slowly and steadily gaining more importance and several companies are now shifting their focus to these areas. Emerging markets should see strong sales thanks to higher demand for medicines. Several factors like government initiatives for healthcare, new patient population, and increasing use of generics should help drive demand. Growth in emerging markets could help stabilize the base business during the industry's 2010-15 patent cliff.
According to the IMS Institute, spending on medicines in pharmerging markets will double to $285-$315 billion in the next five years from $151 billion in 2010. This will catapult pharmerging markets to the second position where spending on medicines is concerned.
Branded Drugs Market Share to Decline
According to the IMS Institute, market share for branded drugs will continue declining in the next five years. Branded drugs market share, which declined from 70% in 2005 to 64% in 2010, is expected to decline to 53% by 2015. The decline will be driven by patent expiries, with generics accounting for a significant part of pharma spending. Spending on branded medicines in 2015 is expected to remain at the same level as in 2010.
While the US will witness a major increase in generics, generic spending in Japan will continue to be the lowest even though significant efforts are being made to increase their use in the country. Overall spending in generics is expected to increase from 20% in 2005 to 39% in 2015.
Global spending for medicines is expected to reach almost $1.1 trillion by 2015, according to the IMS Institute. However, the five year compound annual growth rate of 3-6% represents a significant slowdown from the 6.2% annual growth seen in the last five years.
Moreover, the US' share of global spending is expected to decline from 41% in 2005 to 31% in 2015. The share of spending from the top 5 European countries is also expected to decline (from 20% in 2005 to 13% in 2015) with spending by pharmerging markets expected to increase from 12% in 2005 to 28% by 2015.
OPPORTUNITIES
We continue to have a Neutral outlook on large-cap pharma stocks (Zacks #3 Rank). While the companies will continue to face challenges like pricing pressure and genericization, growth in emerging markets and product approvals could help reduce the impact.
About 35 new molecular entities have been approved by the FDA up to mid-November 2011. Important product approvals include Johnson & Johnson's prostate cancer therapy, Zytiga, Merck's hepatitis C virus (HCV) treatment, Victrelis, Bristol-Myers' melanoma treatment, Yervoy, AstraZeneca's Brilinta, Vertex Pharma's ( VRTX ) HCV treatment, Incivek, Pfizer's lung cancer treatment, Xalkori, and Glaxo/ Human Genome Sciences Inc.'s ( HGSI ) lupus drug Benlysta, among others.
In the biotech space, we are positive on Biogen Idec ( BIIB ). Biogen started 2011 on a strong note with revenues being driven by Tysabri and Avonex. Earnings estimates for Biogen have been increasing based on continued strong performance of the multiple sclerosis franchise. Longer term, we are optimistic on BG-12, the company's oral multiple sclerosis candidate.
We currently have an Outperform recommendation on Perrigo Company ( PRGO ) -- we believe Perrigo's strong position in the brand OTC pharmaceutical market and growing generics and API businesses will help it deliver solid top- and bottom-line growth in the coming years. Perrigo also has a very strong and impressive pipeline which could drive growth in fiscal 2012 and beyond.
In spite of a Neutral recommendation on Bristol-Myers, we are positive on the stock. 2011 has been a fruitful year for Bristol-Myers so far, with many key drugs getting approved. Growth in the coming quarters is expected to be driven by new product launches and acquisitions and deals.
WEAKNESSES
We recommend avoiding names that offer little growth or opportunity for a take-out. These include companies which are developing drugs that are likely to face regulatory hurdles. The US Food and Drug Administration (FDA) has been exercising more caution in granting approval to new products and several candidates are facing delays in receiving final approval.
We would also avoid companies like Eli Lilly, which are facing patent expirations on key products and whose new products may not be enough to make up for the loss of revenues that will take place once generics enter the market. 2012 will be a challenging year for Eli Lilly with the company losing patent exclusivity on Zyprexa in October 2011. Zyprexa sales should erode rapidly with the entry of generics. Moreover, we expect continued erosion of Gemzar sales due to genericization. Another company that is highly exposed to a patent cliff is Forest Labs ( FRX ).
We currently have a Zacks #4 Rank (short-term Sell rating) on Alkermes, Inc. ( ALKS ). The company, which merged with Elan Corp.'s ( ELN ) Elan Drug Technologies, delivered average results in the second quarter of fiscal 2012.
Moreover, while releasing the revenue guidance for fiscal 2012, the company did not alter the earlier projection of the standalone unit and merely added the expected sales of the purchased unit to it. We believe that it will take some time for the newly formed entity to start delivering and prefer to remain on the sidelines until then.
ABBOTT LABS ( ABT ): Free Stock Analysis Report
BRISTOL-MYERS ( BMY ): Free Stock Analysis Report
CELGENE CORP ( CELG ): Free Stock Analysis Report
GILEAD SCIENCES ( GILD ): Free Stock Analysis Report
GLAXOSMITHKLINE ( GSK ): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
LILLY ELI & CO (LLY): Free Stock Analysis Report
MERCK & CO INC (MRK): Free Stock Analysis Report
MYLAN INC (MYL): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
TEVA PHARM ADR (TEVA): Free Stock Analysis Report
VERTEX PHARM (VRTX): Free Stock Analysis Report
WATSON PHARMA (WPI): Free Stock Analysis Report
DENTSPLY INTL (XRAY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | 2012 will see Abbott Labs ( ABT ) splitting into two separate publicly traded companies. ABBOTT LABS ( ABT ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report CELGENE CORP ( CELG ): Free Stock Analysis Report GILEAD SCIENCES ( GILD ): Free Stock Analysis Report GLAXOSMITHKLINE ( GSK ): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. | ABBOTT LABS ( ABT ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report CELGENE CORP ( CELG ): Free Stock Analysis Report GILEAD SCIENCES ( GILD ): Free Stock Analysis Report GLAXOSMITHKLINE ( GSK ): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. 2012 will see Abbott Labs ( ABT ) splitting into two separate publicly traded companies. While Teva ( TEVA ) acquired Cephalon, Inc., Watson Pharmaceuticals ( WPI ) acquired generic company Specifar Pharmaceuticals to expand and strengthen its presence in Europe. | ABBOTT LABS ( ABT ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report CELGENE CORP ( CELG ): Free Stock Analysis Report GILEAD SCIENCES ( GILD ): Free Stock Analysis Report GLAXOSMITHKLINE ( GSK ): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. 2012 will see Abbott Labs ( ABT ) splitting into two separate publicly traded companies. With most of the big pharma companies already facing or likely to face patent challenges for their blockbuster products, the companies have been looking towards M&As and in-licensing activities to make up for the loss of revenues that will arise with key products losing patent exclusivity. | 2012 will see Abbott Labs ( ABT ) splitting into two separate publicly traded companies. ABBOTT LABS ( ABT ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report CELGENE CORP ( CELG ): Free Stock Analysis Report GILEAD SCIENCES ( GILD ): Free Stock Analysis Report GLAXOSMITHKLINE ( GSK ): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. With most of the big pharma companies already facing or likely to face patent challenges for their blockbuster products, the companies have been looking towards M&As and in-licensing activities to make up for the loss of revenues that will arise with key products losing patent exclusivity. |
34488.0 | 2011-12-28 00:00:00 UTC | More Generic Launches for Mylan - Analyst Blog | ABT | https://www.nasdaq.com/articles/more-generic-launches-for-mylan-analyst-blog-2011-12-28 | nan | nan | Generic maker, Mylan Inc. ( MYL ) received final approval from the US Food & Drug Administration (FDA) to launch its generic versions of Abbott Laboratories ' ( ABT ) hypertension tablets Teveten and UCB Pharma 's ( UCBJF ) partial onset seizures medicine Keppra. Mylan was the first company to have filed abbreviated new drug applications (ANDAs) to market generic versions of these drugs. The early bird will thus enjoy a 180-day period of exclusivity. Mylan has begun shipments of both the drugs.
As of December 27, 2011, the company had 170 ANDAs pending clearance by the FDA, targeting $98.4 billion in branded sales. Mylan believes that about 42 of these ANDAs are first-to-file opportunities, representing more than $26.8 billion in branded sales. Mylan expects 2012 to be a year of significant growth driven by a slew of product launches in the US. In 2012, Mylan anticipates the launch of more than 500 new products which are expected to generate $800 million in revenue.
Our Recommendation
We currently have a Neutral long-term recommendation on Mylan. The shares carry a Zacks #2 Rank (short-term Buy rating). Mylan is one of the leading players in the US generics market. We are encouraged by the company's geographic reach and product depth along with its robust generic product pipeline. Nevertheless, we are concerned about lackluster growth in the European generics business. We intend to remain watchful until better visibility is obtained on top-line growth prospects in Europe.
Moreover, competition in the generic segment is strong with players like Teva Pharmaceuticals ( TEVA ), Watson Pharma ( WPI ) and Sandoz, the generics arm of Novartis ( NVS ), in the field.
ABBOTT LABS ( ABT ): Free Stock Analysis Report
MYLAN INC ( MYL ): Free Stock Analysis Report
NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report
TEVA PHARM ADR ( TEVA ): Free Stock Analysis Report
WATSON PHARMA ( WPI ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Generic maker, Mylan Inc. ( MYL ) received final approval from the US Food & Drug Administration (FDA) to launch its generic versions of Abbott Laboratories ' ( ABT ) hypertension tablets Teveten and UCB Pharma 's ( UCBJF ) partial onset seizures medicine Keppra. ABBOTT LABS ( ABT ): Free Stock Analysis Report MYLAN INC ( MYL ): Free Stock Analysis Report NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report TEVA PHARM ADR ( TEVA ): Free Stock Analysis Report WATSON PHARMA ( WPI ): Free Stock Analysis Report To read this article on Zacks.com click here. As of December 27, 2011, the company had 170 ANDAs pending clearance by the FDA, targeting $98.4 billion in branded sales. | Generic maker, Mylan Inc. ( MYL ) received final approval from the US Food & Drug Administration (FDA) to launch its generic versions of Abbott Laboratories ' ( ABT ) hypertension tablets Teveten and UCB Pharma 's ( UCBJF ) partial onset seizures medicine Keppra. ABBOTT LABS ( ABT ): Free Stock Analysis Report MYLAN INC ( MYL ): Free Stock Analysis Report NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report TEVA PHARM ADR ( TEVA ): Free Stock Analysis Report WATSON PHARMA ( WPI ): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, competition in the generic segment is strong with players like Teva Pharmaceuticals ( TEVA ), Watson Pharma ( WPI ) and Sandoz, the generics arm of Novartis ( NVS ), in the field. | Generic maker, Mylan Inc. ( MYL ) received final approval from the US Food & Drug Administration (FDA) to launch its generic versions of Abbott Laboratories ' ( ABT ) hypertension tablets Teveten and UCB Pharma 's ( UCBJF ) partial onset seizures medicine Keppra. ABBOTT LABS ( ABT ): Free Stock Analysis Report MYLAN INC ( MYL ): Free Stock Analysis Report NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report TEVA PHARM ADR ( TEVA ): Free Stock Analysis Report WATSON PHARMA ( WPI ): Free Stock Analysis Report To read this article on Zacks.com click here. Mylan was the first company to have filed abbreviated new drug applications (ANDAs) to market generic versions of these drugs. | Generic maker, Mylan Inc. ( MYL ) received final approval from the US Food & Drug Administration (FDA) to launch its generic versions of Abbott Laboratories ' ( ABT ) hypertension tablets Teveten and UCB Pharma 's ( UCBJF ) partial onset seizures medicine Keppra. ABBOTT LABS ( ABT ): Free Stock Analysis Report MYLAN INC ( MYL ): Free Stock Analysis Report NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report TEVA PHARM ADR ( TEVA ): Free Stock Analysis Report WATSON PHARMA ( WPI ): Free Stock Analysis Report To read this article on Zacks.com click here. Mylan was the first company to have filed abbreviated new drug applications (ANDAs) to market generic versions of these drugs. |
34489.0 | 2011-12-28 00:00:00 UTC | Pharma & Biotech Stock Review & Outlook - Industry Outlook | ABT | https://www.nasdaq.com/articles/pharma-biotech-stock-review-outlook-industry-outlook-2011-12-28 | nan | nan | With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years, with major revenue-generating drugs like Lipitor, Plavix, Lexapro and Zyprexa losing exclusivity.
In fact, by the end of 2011, drugs worth more than a total of $30 billion will lose patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the same time, new products are not expected to generate the same level of sales as products losing patent protection.
Moreover, the government is exploring options which will help increase the availability of generics. Recently, the Obama administration announced that it is looking to implement a proposal under which the exclusivity period for biologics will be cut down by 5 years, thereby allowing generics to enter the market sooner. The government is looking to bring this proposal into effect from 2012.
The government is also seeking to increase the availability of generics by preventing companies from entering into anti-competitive or "pay for delay" agreements which push out the availability of generics. These initiatives, if implemented, would result in additional pricing competition and genericization in the pharma industry.
With revenue growth stalling or slowing down, pharma companies have been resorting to cost-cutting and share buybacks to drive bottom-line growth.
M&A Activity
The merger & acquisition (M&A) activity that was witnessed in the pharma sector in 2010 continued in 2011. With most of the big pharma companies already facing or likely to face patent challenges for their blockbuster products, the companies have been looking towards M&As and in-licensing activities to make up for the loss of revenues that will arise with key products losing patent exclusivity.
We saw huge M&A activity over the last few months. Major deals included Johnson & Johnson's ( JNJ ) upcoming acquisition of Synthes, which should help strengthen its medical device portfolio.
Pfizer ( PFE ) acquired King Pharmaceuticals to strengthen its presence in the pain management market. Pfizer has been adding to its portfolio with other acquisitions as well including that of Icagen and Excaliard. Merck ( MRK ) is looking to expand its ophthalmology product portfolio through its acquisition of Inspire Pharmaceuticals, Inc.
Another pharma major, Bristol-Myers Squibb ( BMY ), is also not far behind where acquisitions and deals are concerned. The company has been looking to expand via acquisitions and partnerships to counter the loss of revenues that will arise following the genericization of its key drugs, including the blockbuster blood thinner Plavix.
Oncology also remains a much sought-after therapeutic area with companies like Sanofi ( SNY ) and Celgene ( CELG ) strengthening their presence in this market through acquisitions. Meanwhile, generic players are not far behind in the acquisition game. While Teva ( TEVA ) acquired Cephalon, Inc., Watson Pharmaceuticals ( WPI ) acquired generic company Specifar Pharmaceuticals to expand and strengthen its presence in Europe.
Elsewhere, companies have been looking towards biotech firms to build their product portfolios. A prime example is French pharma giant Sanofi's acquisition of biotech company Genzyme Corp. With this acquisition, Sanofi is looking to create a new source of growth. The Genzyme acquisition will boost Sanofi's revenues as well as its pipeline.
In April 2011, Gilead Sciences ( GILD ) acquired biotechnology firm Calistoga Pharmaceuticals, which focuses on developing therapies to combat cancer and inflammatory diseases.
Going forward, we expect the M&A trend to continue. We also expect a significant pickup in in-licensing activities and collaborations for the development of pipeline candidates. Instead of developing a product from scratch, which involves a lot of funds, pharma companies are shopping for mid-to-late stage pipeline candidates that look promising.
Small biotech companies are also game for in-licensing activities and collaborations. Most of these companies find it challenging to raise cash, thereby making it difficult for them to survive and continue with the development of promising pipeline candidates. Therefore, it makes sense for them to seek deals with pharma companies that are sitting on huge piles of cash.
We would recommend investors to put their money in biotech stocks that have attractive pipeline candidates or technology that can be used for the development of novel therapeutics. Therapeutic areas which could see a lot of in-licensing activity include oncology, central nervous system disorders, diabetes and immunology/inflammation. The hepatitis C virus (HCV) market is also attracting a lot of attention.
Another trend that we are seeing in recent months is the divestment of non-core business segments. Pfizer sold its Capsugel unit in August 2011 and is currently exploring strategic alternatives for its Animal Health and Nutrition businesses. Meanwhile, GlaxoSmithKline ( GSK ) is divesting non-core brands from its Consumer Healthcare segment.
In August 2011, AstraZeneca sold its Astra Tech business to DENTSPLY ( XRAY ). The monetization of non-core assets will allow the pharma/biotech companies to focus on their areas of expertise. 2012 will see Abbott Labs ( ABT ) splitting into two separate publicly traded companies. While one company will deal in diversified medical products, the other will focus on research-based pharmaceuticals.
Emerging Markets
Another recent trend seen in the pharmaceutical sector is a focus on emerging markets. Companies like Mylan ( MYL ), Pfizer, Merck, Eli Lilly ( LLY ), Glaxo and Sanofi are all looking to expand their presence in India, China, Brazil and other emerging markets. Until recently, most of the commercialization efforts were focused on the US market -- the largest pharmaceutical market -- along with Europe and Japan.
However, emerging markets are slowly and steadily gaining more importance and several companies are now shifting their focus to these areas. Emerging markets should see strong sales thanks to higher demand for medicines. Several factors like government initiatives for healthcare, new patient population, and increasing use of generics should help drive demand. Growth in emerging markets could help stabilize the base business during the industry's 2010-15 patent cliff.
According to the IMS Institute, spending on medicines in pharmerging markets will double to $285-$315 billion in the next five years from $151 billion in 2010. This will catapult pharmerging markets to the second position where spending on medicines is concerned.
Branded Drugs Market Share to Decline
According to the IMS Institute, market share for branded drugs will continue declining in the next five years. Branded drugs market share, which declined from 70% in 2005 to 64% in 2010, is expected to decline to 53% by 2015. The decline will be driven by patent expiries, with generics accounting for a significant part of pharma spending. Spending on branded medicines in 2015 is expected to remain at the same level as in 2010.
While the US will witness a major increase in generics, generic spending in Japan will continue to be the lowest even though significant efforts are being made to increase their use in the country. Overall spending in generics is expected to increase from 20% in 2005 to 39% in 2015.
Global spending for medicines is expected to reach almost $1.1 trillion by 2015, according to the IMS Institute. However, the five year compound annual growth rate of 3-6% represents a significant slowdown from the 6.2% annual growth seen in the last five years.
Moreover, the US' share of global spending is expected to decline from 41% in 2005 to 31% in 2015. The share of spending from the top 5 European countries is also expected to decline (from 20% in 2005 to 13% in 2015) with spending by pharmerging markets expected to increase from 12% in 2005 to 28% by 2015.
OPPORTUNITIES
We continue to have a Neutral outlook on large-cap pharma stocks (Zacks #3 Rank). While the companies will continue to face challenges like pricing pressure and genericization, growth in emerging markets and product approvals could help reduce the impact.
About 35 new molecular entities have been approved by the FDA up to mid-November 2011. Important product approvals include Johnson & Johnson's prostate cancer therapy, Zytiga, Merck's hepatitis C virus (HCV) treatment, Victrelis, Bristol-Myers' melanoma treatment, Yervoy, AstraZeneca's Brilinta, Vertex Pharma's ( VRTX ) HCV treatment, Incivek, Pfizer's lung cancer treatment, Xalkori, and Glaxo/ Human Genome Sciences Inc.'s ( HGSI ) lupus drug Benlysta, among others.
In the biotech space, we are positive on Biogen Idec ( BIIB ). Biogen started 2011 on a strong note with revenues being driven by Tysabri and Avonex. Earnings estimates for Biogen have been increasing based on continued strong performance of the multiple sclerosis franchise. Longer term, we are optimistic on BG-12, the company's oral multiple sclerosis candidate.
We currently have an Outperform recommendation on Perrigo Company ( PRGO ) -- we believe Perrigo's strong position in the brand OTC pharmaceutical market and growing generics and API businesses will help it deliver solid top- and bottom-line growth in the coming years. Perrigo also has a very strong and impressive pipeline which could drive growth in fiscal 2012 and beyond.
In spite of a Neutral recommendation on Bristol-Myers, we are positive on the stock. 2011 has been a fruitful year for Bristol-Myers so far, with many key drugs getting approved. Growth in the coming quarters is expected to be driven by new product launches and acquisitions and deals.
WEAKNESSES
We recommend avoiding names that offer little growth or opportunity for a take-out. These include companies which are developing drugs that are likely to face regulatory hurdles. The US Food and Drug Administration (FDA) has been exercising more caution in granting approval to new products and several candidates are facing delays in receiving final approval.
We would also avoid companies like Eli Lilly, which are facing patent expirations on key products and whose new products may not be enough to make up for the loss of revenues that will take place once generics enter the market. 2012 will be a challenging year for Eli Lilly with the company losing patent exclusivity on Zyprexa in October 2011. Zyprexa sales should erode rapidly with the entry of generics. Moreover, we expect continued erosion of Gemzar sales due to genericization. Another company that is highly exposed to a patent cliff is Forest Labs ( FRX ).
We currently have a Zacks #4 Rank (short-term Sell rating) on Alkermes, Inc. ( ALKS ). The company, which merged with Elan Corp.'s ( ELN ) Elan Drug Technologies, delivered average results in the second quarter of fiscal 2012.
Moreover, while releasing the revenue guidance for fiscal 2012, the company did not alter the earlier projection of the standalone unit and merely added the expected sales of the purchased unit to it. We believe that it will take some time for the newly formed entity to start delivering and prefer to remain on the sidelines until then.
ABBOTT LABS ( ABT ): Free Stock Analysis Report
BRISTOL-MYERS ( BMY ): Free Stock Analysis Report
CELGENE CORP ( CELG ): Free Stock Analysis Report
GILEAD SCIENCES ( GILD ): Free Stock Analysis Report
GLAXOSMITHKLINE ( GSK ): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
LILLY ELI & CO (LLY): Free Stock Analysis Report
MERCK & CO INC (MRK): Free Stock Analysis Report
MYLAN INC (MYL): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
TEVA PHARM ADR (TEVA): Free Stock Analysis Report
VERTEX PHARM (VRTX): Free Stock Analysis Report
WATSON PHARMA (WPI): Free Stock Analysis Report
DENTSPLY INTL (XRAY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | 2012 will see Abbott Labs ( ABT ) splitting into two separate publicly traded companies. ABBOTT LABS ( ABT ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report CELGENE CORP ( CELG ): Free Stock Analysis Report GILEAD SCIENCES ( GILD ): Free Stock Analysis Report GLAXOSMITHKLINE ( GSK ): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. | ABBOTT LABS ( ABT ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report CELGENE CORP ( CELG ): Free Stock Analysis Report GILEAD SCIENCES ( GILD ): Free Stock Analysis Report GLAXOSMITHKLINE ( GSK ): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. 2012 will see Abbott Labs ( ABT ) splitting into two separate publicly traded companies. While Teva ( TEVA ) acquired Cephalon, Inc., Watson Pharmaceuticals ( WPI ) acquired generic company Specifar Pharmaceuticals to expand and strengthen its presence in Europe. | ABBOTT LABS ( ABT ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report CELGENE CORP ( CELG ): Free Stock Analysis Report GILEAD SCIENCES ( GILD ): Free Stock Analysis Report GLAXOSMITHKLINE ( GSK ): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. 2012 will see Abbott Labs ( ABT ) splitting into two separate publicly traded companies. With most of the big pharma companies already facing or likely to face patent challenges for their blockbuster products, the companies have been looking towards M&As and in-licensing activities to make up for the loss of revenues that will arise with key products losing patent exclusivity. | 2012 will see Abbott Labs ( ABT ) splitting into two separate publicly traded companies. ABBOTT LABS ( ABT ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report CELGENE CORP ( CELG ): Free Stock Analysis Report GILEAD SCIENCES ( GILD ): Free Stock Analysis Report GLAXOSMITHKLINE ( GSK ): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. With most of the big pharma companies already facing or likely to face patent challenges for their blockbuster products, the companies have been looking towards M&As and in-licensing activities to make up for the loss of revenues that will arise with key products losing patent exclusivity. |
34490.0 | 2011-12-23 00:00:00 UTC | Teva Provides In-Line 2012 Outlook - Analyst Blog | ABT | https://www.nasdaq.com/articles/teva-provides-in-line-2012-outlook-analyst-blog-2011-12-23 | nan | nan | Teva Pharmaceutical Industries Ltd. ( TEVA ) recently provided guidance for 2012. The company expects to earn $5.48 and $5.68 per share on total net sales of about $22 billion. Guidance was generally in line with expectations. While the Zacks Consensus Earnings Estimate, prior to the release of guidance, was $5.62, the Zacks Consensus Revenue Estimate was about $21.8 billion. The Cephalon acquisition is expected to boost 2012 earnings by 20-25 cents.
Teva expects to generate $11 billion sales in the US with the EU and Rest of the World (RoW) generating sales of $6.6 billion and $4.4 billion, respectively. The major chunk of revenues ($11.8 billion) will be provided by the generics business.
US Generics Biz to Rebound
Teva's US generics business, which has been performing below expectations over the past few quarters, is expected to rebound in 2012. The company is guiding towards sales of $5 billion, with sales slated to benefit from patent expirations and product launches. New generic launches are expected to contribute $650 million to sales. However, we were disappointed to hear that new product launches do not include the generic version of Abbott Laboratories' ( ABT ) TriCor.
Performance in the EU generics business will remain strong at $4 billion with Teva holding a leading position in several EU markets. RoW generic product sales are expected to be about $2.8 billion, with Japan and Russia continuing to perform well.
Meanwhile, branded products are expected to contribute $8.2 billion to the top line with multiple sclerosis drug, Copaxone, contributing $3.8 billion. Oncology product, Treanda (a part of Cephalon's portfolio), is expected to generate sales of $550 million. Sleep disorder drugs Provigil and Nuvigil are expected to generate sales of $375 million and $300 million, respectively.
While Women's Health products are expected to contribute $525 million to revenues, ProAir HFA is expected to generate revenues of $490 million. QVAR and Azilect are slated to post revenues of $400 million and $350 million, respectively. Finally, OTC sales are expected to be about $1 billion. Teva has a partnership agreement with Procter & Gamble ( PG ) that will target the consumer health care market. Other net sales are also expected to be $1 billion.
Teva expects to spend between 6.9% to $7.3% of net sales on R&D. With the Cephalon acquisition, Teva now has 40 late stage clinical programs, most of which are in phase III. We expect detailed information on the company's innovative pipeline mid-2012.
Selling & marketing expenses (including royalties of about $400 million) are expected to range between 18.4% and 20% of net sales. General and administrative expenses are expected in the range of 5.1% - 5.5% of net sales.
First and Last Quarters to be Strong
As far as quarterly performance is concerned, the first quarter is expected to be relatively strong mainly due to Provigil and the launch of a generic version of ForestLaboratories' ( FRX ) Lexapro. The second and third quarters of 2012 will be lighter with the entry of generic versions of Provigil. The fourth quarter is expected to be strong on the back of several generic launches and the winter seasonality effect.
Positive on Share Buyback Program
Teva also announced a share buyback program. The company will be repurchasing shares worth up to $3 billion, potentially over a three-year time frame. The share buyback will be financed out of free cash flow, which is expected to be about $3 billion in 2012. We are positive on this program which will return value to shareholders.
Our Take
We currently have a Neutral recommendation on Teva, which carries a Zacks #3 Rank (short-term Hold rating). We are encouraged to see that the company has set achievable targets for 2012. However, we expect the stock to remain range-bound given the lack of significant catalysts.
ABBOTT LABS ( ABT ): Free Stock Analysis Report
FOREST LABS A ( FRX ): Free Stock Analysis Report
PROCTER & GAMBL ( PG ): Free Stock Analysis Report
TEVA PHARM ADR ( TEVA ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | However, we were disappointed to hear that new product launches do not include the generic version of Abbott Laboratories' ( ABT ) TriCor. ABBOTT LABS ( ABT ): Free Stock Analysis Report FOREST LABS A ( FRX ): Free Stock Analysis Report PROCTER & GAMBL ( PG ): Free Stock Analysis Report TEVA PHARM ADR ( TEVA ): Free Stock Analysis Report To read this article on Zacks.com click here. Teva has a partnership agreement with Procter & Gamble ( PG ) that will target the consumer health care market. | ABBOTT LABS ( ABT ): Free Stock Analysis Report FOREST LABS A ( FRX ): Free Stock Analysis Report PROCTER & GAMBL ( PG ): Free Stock Analysis Report TEVA PHARM ADR ( TEVA ): Free Stock Analysis Report To read this article on Zacks.com click here. However, we were disappointed to hear that new product launches do not include the generic version of Abbott Laboratories' ( ABT ) TriCor. Performance in the EU generics business will remain strong at $4 billion with Teva holding a leading position in several EU markets. | However, we were disappointed to hear that new product launches do not include the generic version of Abbott Laboratories' ( ABT ) TriCor. ABBOTT LABS ( ABT ): Free Stock Analysis Report FOREST LABS A ( FRX ): Free Stock Analysis Report PROCTER & GAMBL ( PG ): Free Stock Analysis Report TEVA PHARM ADR ( TEVA ): Free Stock Analysis Report To read this article on Zacks.com click here. Teva expects to generate $11 billion sales in the US with the EU and Rest of the World (RoW) generating sales of $6.6 billion and $4.4 billion, respectively. | However, we were disappointed to hear that new product launches do not include the generic version of Abbott Laboratories' ( ABT ) TriCor. ABBOTT LABS ( ABT ): Free Stock Analysis Report FOREST LABS A ( FRX ): Free Stock Analysis Report PROCTER & GAMBL ( PG ): Free Stock Analysis Report TEVA PHARM ADR ( TEVA ): Free Stock Analysis Report To read this article on Zacks.com click here. The company expects to earn $5.48 and $5.68 per share on total net sales of about $22 billion. |
34491.0 | 2011-12-21 00:00:00 UTC | UCB Launches RA Drug Study - Analyst Blog | ABT | https://www.nasdaq.com/articles/ucb-launches-ra-drug-study-analyst-blog-2011-12-21 | nan | nan | Confirming previously disclosed plans, UCB ( UCBJF ) recently announced the initiation of an efficacy study (EXXELERATE) on Cimizia (certolizumab pegol). The study is designed to evaluate the short- (12 weeks) and long-term (104 weeks) efficacy of Cimzia plus methotrexate ( MTX ) compared with Humira (adalimumab) plus MTX in the treatment of patients with moderate to severe rheumatoid arthritis ( RA ).
The EXXELERATE study will enroll about 900 adult patients from the US, Canada and Europe, suffering from moderate-to-severe RA, who have inadequately responded to MTX and who previously have not received anti-TNF treatment. The patients will be dosed either Cimzia plus MTX or Humira plus MTX. At the end of 12 weeks, patients who respond to the treatment will continue their initial treatment, while non-responders will switch to the alternative treatment arm until the study ends at 104 weeks. The headline results from the study are expected in 2016.
Abbott Labs ( ABT ) markets Humira as a treatment for RA, psoriatic arthritis (PA), ankylosing spondylitis (AS), CD, plaque psoriasis, and juvenile idiopathic arthritis.
While Cimzia is currently marketed by UCB as a treatment for moderate-to-severe Crohn's disease (CD) in the US and Switzerland, it is marketed as a treatment for RA in the US and European Union ( EU ). The company is also studying the drug as a treatment for juvenile RA, psoriatic arthritis and ankylosing spondylitis. UCB plans to report phase III results on Cimzia in psoriatic arthritis and ankylosing spondylitis in the first quarter of 2012. Further, a phase III trial of the drug in juvenile RA is also expected to begin in the first quarter of 2012.
Approval for any of the aforesaid indications of Cimzia would be a major boost for the stock.
We currently have a Zacks #3 Rank (short-term Hold rating) on UCB.
ABBOTT LABS ( ABT ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ( ABT ) markets Humira as a treatment for RA, psoriatic arthritis (PA), ankylosing spondylitis (AS), CD, plaque psoriasis, and juvenile idiopathic arthritis. ABBOTT LABS ( ABT ): Free Stock Analysis Report To read this article on Zacks.com click here. Confirming previously disclosed plans, UCB ( UCBJF ) recently announced the initiation of an efficacy study (EXXELERATE) on Cimizia (certolizumab pegol). | Abbott Labs ( ABT ) markets Humira as a treatment for RA, psoriatic arthritis (PA), ankylosing spondylitis (AS), CD, plaque psoriasis, and juvenile idiopathic arthritis. ABBOTT LABS ( ABT ): Free Stock Analysis Report To read this article on Zacks.com click here. The company is also studying the drug as a treatment for juvenile RA, psoriatic arthritis and ankylosing spondylitis. | Abbott Labs ( ABT ) markets Humira as a treatment for RA, psoriatic arthritis (PA), ankylosing spondylitis (AS), CD, plaque psoriasis, and juvenile idiopathic arthritis. ABBOTT LABS ( ABT ): Free Stock Analysis Report To read this article on Zacks.com click here. The study is designed to evaluate the short- (12 weeks) and long-term (104 weeks) efficacy of Cimzia plus methotrexate ( MTX ) compared with Humira (adalimumab) plus MTX in the treatment of patients with moderate to severe rheumatoid arthritis ( RA ). | Abbott Labs ( ABT ) markets Humira as a treatment for RA, psoriatic arthritis (PA), ankylosing spondylitis (AS), CD, plaque psoriasis, and juvenile idiopathic arthritis. ABBOTT LABS ( ABT ): Free Stock Analysis Report To read this article on Zacks.com click here. The EXXELERATE study will enroll about 900 adult patients from the US, Canada and Europe, suffering from moderate-to-severe RA, who have inadequately responded to MTX and who previously have not received anti-TNF treatment. |
34492.0 | 2011-12-14 00:00:00 UTC | FDA Clears Meridian illumigene GBS - Analyst Blog | ABT | https://www.nasdaq.com/articles/fda-clears-meridian-illumigene-gbs-analyst-blog-2011-12-14 | nan | nan | Diagnostic test kits maker Meridian Bioscience ( VIVO ) has won the approval of the U.S. Food and Drug Administration ("FDA") for its new illumigene GBS (Group B streptococcus) test. This is the company's second molecular test in its illumigene platform.
GBS, a bacterial infection, can cause serious illnesses and is associa ted with maternal and neonatal morbidity. It can also affect babies during pregnancies. The U.S. Centers for Disease Control and Prevention ("CDC") has recommended a universal culture-based screening for GBS, to be performed between 35 and 37 weeks of pregnancy.
The illumigene GBS test, which leverages loop-mediated isothermal DNA amplification technology to detect the pathogen in samples, produces results in less than an hour. The test, which is being conducted through a simple procedure (including heat treatment, amplification and detection), allows laboratories to comply with the CDC recommendations.
The company feels that the novel illumigene GBS test will provide hospitals and laboratories a simple, highly sensitive and economical test, helping them in early detection and proper management of GBS.
Meridian specializes in developing diagnostic test kits for serious and infectious diseases. Its diagnostics business faces stro ng competition from Abbott Laboratories ( ABT ), Becton, Dickinson and Company ( BDX ), Thermo Fisher ( TMO ) and Siemens ( SI ).
Meridian, in August 2011, released its outlook for fiscal 2012. The company hopes sales for the year to be boosted by illumigene and Bioline products as well as its foodborne and H. pylori tests.
Meridian is optimistic that sustained adoption of the illumigene platform, growth in core products and opportunities in Europe will help it drive significant growth in sales and earnings in fiscal 2012 and beyond. The company noted that its fiscal 2012 outlook includes full year sales from its C. difficile test illumigene as well as revenues from illumigene GBS.
ABBOTT LABS ( ABT ): Free Stock Analysis Report
BECTON DICKINSO ( BDX ): Free Stock Analysis Report
SIEMENS AG-ADR ( SI ): Free Stock Analysis Report
THERMO FISHER ( TMO ): Free Stock Analysis Report
MERIDIAN BIOSCI ( VIVO ): Free Stock Analysis Report
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Its diagnostics business faces stro ng competition from Abbott Laboratories ( ABT ), Becton, Dickinson and Company ( BDX ), Thermo Fisher ( TMO ) and Siemens ( SI ). ABBOTT LABS ( ABT ): Free Stock Analysis Report BECTON DICKINSO ( BDX ): Free Stock Analysis Report SIEMENS AG-ADR ( SI ): Free Stock Analysis Report THERMO FISHER ( TMO ): Free Stock Analysis Report MERIDIAN BIOSCI ( VIVO ): Free Stock Analysis Report Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The U.S. Centers for Disease Control and Prevention ("CDC") has recommended a universal culture-based screening for GBS, to be performed between 35 and 37 weeks of pregnancy. | Its diagnostics business faces stro ng competition from Abbott Laboratories ( ABT ), Becton, Dickinson and Company ( BDX ), Thermo Fisher ( TMO ) and Siemens ( SI ). ABBOTT LABS ( ABT ): Free Stock Analysis Report BECTON DICKINSO ( BDX ): Free Stock Analysis Report SIEMENS AG-ADR ( SI ): Free Stock Analysis Report THERMO FISHER ( TMO ): Free Stock Analysis Report MERIDIAN BIOSCI ( VIVO ): Free Stock Analysis Report Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The company noted that its fiscal 2012 outlook includes full year sales from its C. difficile test illumigene as well as revenues from illumigene GBS. | ABBOTT LABS ( ABT ): Free Stock Analysis Report BECTON DICKINSO ( BDX ): Free Stock Analysis Report SIEMENS AG-ADR ( SI ): Free Stock Analysis Report THERMO FISHER ( TMO ): Free Stock Analysis Report MERIDIAN BIOSCI ( VIVO ): Free Stock Analysis Report Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Its diagnostics business faces stro ng competition from Abbott Laboratories ( ABT ), Becton, Dickinson and Company ( BDX ), Thermo Fisher ( TMO ) and Siemens ( SI ). The company feels that the novel illumigene GBS test will provide hospitals and laboratories a simple, highly sensitive and economical test, helping them in early detection and proper management of GBS. | ABBOTT LABS ( ABT ): Free Stock Analysis Report BECTON DICKINSO ( BDX ): Free Stock Analysis Report SIEMENS AG-ADR ( SI ): Free Stock Analysis Report THERMO FISHER ( TMO ): Free Stock Analysis Report MERIDIAN BIOSCI ( VIVO ): Free Stock Analysis Report Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Its diagnostics business faces stro ng competition from Abbott Laboratories ( ABT ), Becton, Dickinson and Company ( BDX ), Thermo Fisher ( TMO ) and Siemens ( SI ). The test, which is being conducted through a simple procedure (including heat treatment, amplification and detection), allows laboratories to comply with the CDC recommendations. |
34493.0 | 2011-12-08 00:00:00 UTC | The Zacks Analyst Blog Highlights: Pfizer, Bristol - Myers Squibb, Eli Lilly, Forest Laboratories and Abbott Laboratories - Press Releases | ABT | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-pfizer-bristol-myers-squibb-eli-lilly-forest | nan | nan | For Immediate Release
Chicago, IL - December 8, 2011 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Pfizer ( PFE ), Bristol - Myers Squibb ( BMY ), Eli Lilly ( LLY ), Forest Laboratories ( FRX ) and Abbott Laboratories ( ABT ).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513 | Stocks recently featured in the blog include Pfizer ( PFE ), Bristol - Myers Squibb ( BMY ), Eli Lilly ( LLY ), Forest Laboratories ( FRX ) and Abbott Laboratories ( ABT ). For Immediate Release Chicago, IL - December 8, 2011 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. | Stocks recently featured in the blog include Pfizer ( PFE ), Bristol - Myers Squibb ( BMY ), Eli Lilly ( LLY ), Forest Laboratories ( FRX ) and Abbott Laboratories ( ABT ). For Immediate Release Chicago, IL - December 8, 2011 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. | Stocks recently featured in the blog include Pfizer ( PFE ), Bristol - Myers Squibb ( BMY ), Eli Lilly ( LLY ), Forest Laboratories ( FRX ) and Abbott Laboratories ( ABT ). For Immediate Release Chicago, IL - December 8, 2011 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. | Stocks recently featured in the blog include Pfizer ( PFE ), Bristol - Myers Squibb ( BMY ), Eli Lilly ( LLY ), Forest Laboratories ( FRX ) and Abbott Laboratories ( ABT ). For Immediate Release Chicago, IL - December 8, 2011 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. |
34494.0 | 2011-12-07 00:00:00 UTC | Emerging Markets: The Way Forward - Analyst Blog | ABT | https://www.nasdaq.com/articles/emerging-markets%3A-the-way-forward-analyst-blog-2011-12-07 | nan | nan | According to Irish orator, philosopher, & politician Edmund Burke, change is the most powerful law of nature. The winds of change seem to be sweeping across the pharmaceutical industry as well.
Until recently, most commercialization efforts were focused on the U.S. -- the largest pharmaceutical market -- along with Europe and Japan. However, with factors like pricing pressure in the European Union ( EU ) and intensifying generic competition affecting sales in large pharmaceutical markets, many leading players in the pharmaceutical space such as Pfizer ( PFE ), Bristol - Myers Squibb Company ( BMY ), Merck ( MRK ), Eli Lilly ( LLY ), GlaxoSmithKline ( GSK) , Astra Zeneca ( AZN ) and Sanofi-Aventis ( SNY ), have shifted their focus on emerging ("pharmerging") markets.
The key emerging markets targeted by big players in the pharmaceutical space (aka "Big Pharma") include China, Russia, Brazil, Mexico, Turkey, Korea and India.
Emerging markets represent significant commercial potential thanks to increased demand for medicines. Factors like increases in chronic diseases, population growth, government initiatives for healthcare, increasing use of generics and increasing prosperity are expected to drive growth in emerging markets.
The US and European markets are turning out to be relatively less attractive due to the impact of the health care legislation in the former and austerity measures in the latter.
According to data provided by the IMS Institute, spending on medicines in emerging markets will double to $285-$315 billion in the next five years from $151 billion in 2010, driven by strong economic growth coupled with endeavors of governments to expand access to healthcare. This will catapult "pharmerging" markets to the second position by 2015 in terms of spending on medicines.
Generic Threat? Emerging Markets to the Rescue
Since most of the Big Pharma players are likely to suffer significant losses in revenues following the genericization of key products, they are banking on growth in emerging markets to mitigate their losses.
With blockbuster drugs such as Pfizer's Lipitor (anti-cholesterol) and Eli Lilly's Zyprexa (schizophrenia and bipolar disorder) already off-patent in the US and other blockbuster drugs such as Bristol-Myers/Sanofi's blood thinner Plavix, Forest Laboratories' ( FRX ) Lexapro (anti-depressant) expected to follow suit shortly, sales of branded drugs in the US and EU are likely to suffer significantly in the coming years. Consequently, growth in emerging markets could help stabilize the core business during the industry's patent cliff in the 2010-15 period.
M&A Activity: Emerging Markets in Focus
With sales in the once dominant markets (US and EU) being impacted by the headwinds mentioned above, many leading players in the pharma space are increasing their exposure to emerging markets through mergers and acquisitions (M&A). By doing so, the companies are gaining access to low-cost manufacturing. Moreover, the Chinese, Indian, Brazilian, Eastern European and Russian markets are growing faster than the more mature US and European ones.
For example, pharma giant Abbott Laboratories ( ABT ) is leaving no stone unturned to expand its overall presence in emerging markets. Through the 2010 acquisitions of the pharmaceutical business Solvay Pharma (which has a strong presence in emerging markets) and Piramal Healthcare Solutions coupled with the licensing agreement with Zydus Cadila, Abbott has taken concrete steps to expand its presence in several highly populated, fast-growing emerging markets.
With the generic market going strong and likely to expand further thanks to patent expiries of blockbuster drugs, leading players such as Mylan Inc. ( MYL ) (Indian subsidiary Mylan Laboratories) and Novartis ( NVS ) (generic arm Sandoz having a strong presence in emerging markets like India) have been trying to make further inroads in the emerging markets.
The dominance of the generic market can be gauged from the data provided by the IMS Institute. The data reveals that market share for branded drugs will continue declining over the next five years. Branded drugs' market share, which declined from 70% in 2005 to 64% in 2010, is expected to decline to 53% by 2015, with generics accounting for a significant part of pharma spending.
Conclusion
In view of the above facts, we can safely say that the future of the pharmaceutical business is tied to emerging markets. In the face of increasing generic competition and other headwinds, the big names in the pharmaceutical world are turning to emerging markets to sustain growth and profitability.
ABBOTT LABS ( ABT ): Free Stock Analysis Report
ASTRAZENECA PLC ( AZN ): Free Stock Analysis Report
BRISTOL-MYERS ( BMY ): Free Stock Analysis Report
FOREST LABS A ( FRX ): Free Stock Analysis Report
GLAXOSMITHKLINE (GSK): Free Stock Analysis Report
LILLY ELI & CO (LLY): Free Stock Analysis Report
MERCK & CO INC (MRK): Free Stock Analysis Report
MYLAN INC (MYL): Free Stock Analysis Report
NOVARTIS AG-ADR (NVS): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | For example, pharma giant Abbott Laboratories ( ABT ) is leaving no stone unturned to expand its overall presence in emerging markets. ABBOTT LABS ( ABT ): Free Stock Analysis Report ASTRAZENECA PLC ( AZN ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report FOREST LABS A ( FRX ): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. However, with factors like pricing pressure in the European Union ( EU ) and intensifying generic competition affecting sales in large pharmaceutical markets, many leading players in the pharmaceutical space such as Pfizer ( PFE ), Bristol - Myers Squibb Company ( BMY ), Merck ( MRK ), Eli Lilly ( LLY ), GlaxoSmithKline ( GSK) , Astra Zeneca ( AZN ) and Sanofi-Aventis ( SNY ), have shifted their focus on emerging ("pharmerging") markets. | ABBOTT LABS ( ABT ): Free Stock Analysis Report ASTRAZENECA PLC ( AZN ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report FOREST LABS A ( FRX ): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. For example, pharma giant Abbott Laboratories ( ABT ) is leaving no stone unturned to expand its overall presence in emerging markets. However, with factors like pricing pressure in the European Union ( EU ) and intensifying generic competition affecting sales in large pharmaceutical markets, many leading players in the pharmaceutical space such as Pfizer ( PFE ), Bristol - Myers Squibb Company ( BMY ), Merck ( MRK ), Eli Lilly ( LLY ), GlaxoSmithKline ( GSK) , Astra Zeneca ( AZN ) and Sanofi-Aventis ( SNY ), have shifted their focus on emerging ("pharmerging") markets. | ABBOTT LABS ( ABT ): Free Stock Analysis Report ASTRAZENECA PLC ( AZN ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report FOREST LABS A ( FRX ): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. For example, pharma giant Abbott Laboratories ( ABT ) is leaving no stone unturned to expand its overall presence in emerging markets. M&A Activity: Emerging Markets in Focus With sales in the once dominant markets (US and EU) being impacted by the headwinds mentioned above, many leading players in the pharma space are increasing their exposure to emerging markets through mergers and acquisitions (M&A). | For example, pharma giant Abbott Laboratories ( ABT ) is leaving no stone unturned to expand its overall presence in emerging markets. ABBOTT LABS ( ABT ): Free Stock Analysis Report ASTRAZENECA PLC ( AZN ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report FOREST LABS A ( FRX ): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The winds of change seem to be sweeping across the pharmaceutical industry as well. |
34495.0 | 2011-12-05 00:00:00 UTC | Good News for Mylan - Analyst Blog | ABT | https://www.nasdaq.com/articles/good-news-for-mylan-analyst-blog-2011-12-05 | nan | nan | Generic maker, Mylan Inc . ( MYL ) recently announced that its Indian subsidiary Mylan Laboratories has received tentative approval from the US Food & Drug Administration (FDA) for a fixed-dose combination of generic versions of Bristol Myers Squibb 's ( BMY ) drug Reyataz and AbbottLabs ' ( ABT ) Norvir for the treatment of HIV/AIDS. The fixed drug combination has been pre-qualified to be used in treatment of experienced patients by the World Health Organization (WHO). It can also be used in combination with other antiretroviral (ARV) agents and will be eligible for purchase in certain developing countries. The drug was approved through the President's Emergency Plan for AIDS Relief (PEPFAR). The drug will boost Mylan's already strong portfolio of ARV's in India.
In a separate development, Mylan announced that Warner Chilcott Company ( WCRX ) filed a patent infringement lawsuit in connection with the abbreviated new drug application (ANDA) filed by Mylan and partner Famy Care Ltd. with the FDA for the generic version of Warner Chilcott's oral contraceptive Generess Fe. Mylan believes it is the first company to file an ANDA for generic Generess Fe with the hope of being granted 180 days of marketing exclusivity once approved. Mylan has a partnership with Famy Care Ltd. for the development and supply of oral contraceptives.
Mylan also recently launched the generic version of Pfizer 's ( PFE ) hypertension tablets, Caduet. The branded drug recorded sales of $339 million for the trailing twelve months ended on September 30, 2011.
Our Recommendation
We currently have a Neutral long-term recommendation on Mylan. The shares carry a Zacks #3 Rank (short-term Hold rating). Mylan is one of the leading players in the US generics market. We are encouraged by the company's geographic reach and product depth along with its robust generic product pipeline. Nevertheless, we are concerned about lackluster growth in the European generics business. We intend to remain watchful until better visibility is obtained on top-line growth prospects in Europe.
Moreover, competition in the generic segment is strong with players like Teva Pharmaceuticals ( TEVA ), Watson Pharma ( WPI ) and Sandoz, the generics arm of Novartis ( NVS ), in the field.
ABBOTT LABS ( ABT ): Free Stock Analysis Report
BRISTOL-MYERS ( BMY ): Free Stock Analysis Report
MYLAN INC ( MYL ): Free Stock Analysis Report
NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report
PFIZER INC ( PFE ): Free Stock Analysis Report
TEVA PHARM ADR (TEVA): Free Stock Analysis Report
WARNER CHIL PLC (WCRX): Free Stock Analysis Report
WATSON PHARMA (WPI): Free Stock Analysis Report
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ( MYL ) recently announced that its Indian subsidiary Mylan Laboratories has received tentative approval from the US Food & Drug Administration (FDA) for a fixed-dose combination of generic versions of Bristol Myers Squibb 's ( BMY ) drug Reyataz and AbbottLabs ' ( ABT ) Norvir for the treatment of HIV/AIDS. ABBOTT LABS ( ABT ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report MYLAN INC ( MYL ): Free Stock Analysis Report NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report WARNER CHIL PLC (WCRX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In a separate development, Mylan announced that Warner Chilcott Company ( WCRX ) filed a patent infringement lawsuit in connection with the abbreviated new drug application (ANDA) filed by Mylan and partner Famy Care Ltd. with the FDA for the generic version of Warner Chilcott's oral contraceptive Generess Fe. | ABBOTT LABS ( ABT ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report MYLAN INC ( MYL ): Free Stock Analysis Report NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report WARNER CHIL PLC (WCRX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ( MYL ) recently announced that its Indian subsidiary Mylan Laboratories has received tentative approval from the US Food & Drug Administration (FDA) for a fixed-dose combination of generic versions of Bristol Myers Squibb 's ( BMY ) drug Reyataz and AbbottLabs ' ( ABT ) Norvir for the treatment of HIV/AIDS. In a separate development, Mylan announced that Warner Chilcott Company ( WCRX ) filed a patent infringement lawsuit in connection with the abbreviated new drug application (ANDA) filed by Mylan and partner Famy Care Ltd. with the FDA for the generic version of Warner Chilcott's oral contraceptive Generess Fe. | ( MYL ) recently announced that its Indian subsidiary Mylan Laboratories has received tentative approval from the US Food & Drug Administration (FDA) for a fixed-dose combination of generic versions of Bristol Myers Squibb 's ( BMY ) drug Reyataz and AbbottLabs ' ( ABT ) Norvir for the treatment of HIV/AIDS. ABBOTT LABS ( ABT ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report MYLAN INC ( MYL ): Free Stock Analysis Report NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report WARNER CHIL PLC (WCRX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In a separate development, Mylan announced that Warner Chilcott Company ( WCRX ) filed a patent infringement lawsuit in connection with the abbreviated new drug application (ANDA) filed by Mylan and partner Famy Care Ltd. with the FDA for the generic version of Warner Chilcott's oral contraceptive Generess Fe. | ( MYL ) recently announced that its Indian subsidiary Mylan Laboratories has received tentative approval from the US Food & Drug Administration (FDA) for a fixed-dose combination of generic versions of Bristol Myers Squibb 's ( BMY ) drug Reyataz and AbbottLabs ' ( ABT ) Norvir for the treatment of HIV/AIDS. ABBOTT LABS ( ABT ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report MYLAN INC ( MYL ): Free Stock Analysis Report NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report WARNER CHIL PLC (WCRX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In a separate development, Mylan announced that Warner Chilcott Company ( WCRX ) filed a patent infringement lawsuit in connection with the abbreviated new drug application (ANDA) filed by Mylan and partner Famy Care Ltd. with the FDA for the generic version of Warner Chilcott's oral contraceptive Generess Fe. |
34496.0 | 2011-11-23 00:00:00 UTC | FDA Approves BSX Promus Element - Analyst Blog | ABT | https://www.nasdaq.com/articles/fda-approves-bsx-promus-element-analyst-blog-2011-11-23 | nan | nan | In a major breakthrough, Boston Scientific ( BSX ) received approval from the US Food and Drug Administration (FDA) for Promus Element stent, the company's next generation drug-eluting stent ( DES ) technology. The company plans to launch the product in the US shortly. This approval comes well ahead of the company's original expectation of a US launch in mid-2012.
The approval grants Boston Scientific the green signal to switch to the high margin, internally manufactured Promus Element stent from Promus in the US. The company expects to receive regulatory approval of the Promus Element stent and launch the product by mid-2012 in Japan.
Under the current agreement, Boston Scientific will market Abbott Laboratories ' ( ABT ) everolimus eluting stent, Xience, under the brand name Promus in the US and Japan till the second quarter of 2012. Boston Scientific had earlier launched the internally developed Promus Element stent system in the Europe/Middle East/Africa (EMEA | Under the current agreement, Boston Scientific will market Abbott Laboratories ' ( ABT ) everolimus eluting stent, Xience, under the brand name Promus in the US and Japan till the second quarter of 2012. The company expects to receive regulatory approval of the Promus Element stent and launch the product by mid-2012 in Japan. Boston Scientific had earlier launched the internally developed Promus Element stent system in the Europe/Middle East/Africa (EMEA | Under the current agreement, Boston Scientific will market Abbott Laboratories ' ( ABT ) everolimus eluting stent, Xience, under the brand name Promus in the US and Japan till the second quarter of 2012. The approval grants Boston Scientific the green signal to switch to the high margin, internally manufactured Promus Element stent from Promus in the US. The company expects to receive regulatory approval of the Promus Element stent and launch the product by mid-2012 in Japan. | Under the current agreement, Boston Scientific will market Abbott Laboratories ' ( ABT ) everolimus eluting stent, Xience, under the brand name Promus in the US and Japan till the second quarter of 2012. In a major breakthrough, Boston Scientific ( BSX ) received approval from the US Food and Drug Administration (FDA) for Promus Element stent, the company's next generation drug-eluting stent ( DES ) technology. The approval grants Boston Scientific the green signal to switch to the high margin, internally manufactured Promus Element stent from Promus in the US. | Under the current agreement, Boston Scientific will market Abbott Laboratories ' ( ABT ) everolimus eluting stent, Xience, under the brand name Promus in the US and Japan till the second quarter of 2012. The approval grants Boston Scientific the green signal to switch to the high margin, internally manufactured Promus Element stent from Promus in the US. The company expects to receive regulatory approval of the Promus Element stent and launch the product by mid-2012 in Japan. |
34497.0 | 2011-11-09 00:00:00 UTC | Biotech Update: Pharmasset’s Hepatitis C Drug Shows 100% Cure Rate in Ph2 Trial | ABT | https://www.nasdaq.com/articles/biotech-update-pharmassets-hepatitis-c-drug-shows-100-cure-rate-ph2-trial-2011-11-09 | nan | nan | (By Alexander Crawford)
The landscape of treatment options for hepatitis C is looking brighter – biotech company Pharmasset Inc (VRUS) just released clinical results showing that their experimental drug cured all 40 patients of hepatitis C in a Phase II trial. The company plans to move into the final third phase, with two studies involving 500 and 225 patients each.
This follows two new hepatitis C drugs hitting the market this year – Merck’s (MRK) Victrelis and Vertex Pharmaceuticals’ (VRTX) Incivek. According to Bizmology, neither have as high of a cure rate as Pharmasset’s demonstrated 100% success.
The drug (called PSI-7977) is being studied in Phase III without the common combination with interferon, making it an injection-free treatment possibly with fewer side effects.
Bizmology also reports that other hepatitis C therapies are currently being developed by Inhibitex (INHX), Achillion (ACHN), Roche, and Abbott Labs (ABT), but none of these drugs including PSI-7977 will hit the market until at least 2013.
“Although patient numbers are small, we believe the results are extremely impressive,” Brian Abrahams of Wells Fargo Securities wrote with regard to Pharmasset’s report (via Bloomberg).
How do you think these other contenders will be affected by the promising results of PSI-7977?
For a closer look at the companies involved in therapies for hepatitis C, we list them below.
Analyze These Ideas (Tools Will Open In A New Window)
1. Access a thorough description of all companies mentioned
2. Compare analyst ratings for all stocks mentioned below
3. Visualize annual returns for all stocks mentioned
List sorted alphabetically.
1. Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. Market cap of $83.48B.
2. Achillion Pharmaceuticals, Inc. (ACHN): Engages in the discovery, development, and commercialization of treatments for infectious diseases. Market cap of $422.50M.
3. Inhibitex, Inc. (INHX): Focuses on the development of differentiated anti-infective products to prevent or treat serious infections, primarily shingles and chronic infections caused by hepatitis C virus (HCV). Market cap of $760.01M.
4. Merck & Co. Inc. (MRK): Provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. Market cap of $105.73B.
5. Vertex Pharmaceuticals Incorporated (VRTX): Engages in the discovery, development, and commercialization of small molecule drugs for the treatment of serious diseases worldwide. Market cap of $6.93B.
6. Pharmasset, Inc. (VRUS): Focuses on discovering, developing, and commercializing novel drugs to treat viral infections. Market cap of $5.45B.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Bizmology also reports that other hepatitis C therapies are currently being developed by Inhibitex (INHX), Achillion (ACHN), Roche, and Abbott Labs (ABT), but none of these drugs including PSI-7977 will hit the market until at least 2013. Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. The drug (called PSI-7977) is being studied in Phase III without the common combination with interferon, making it an injection-free treatment possibly with fewer side effects. | Bizmology also reports that other hepatitis C therapies are currently being developed by Inhibitex (INHX), Achillion (ACHN), Roche, and Abbott Labs (ABT), but none of these drugs including PSI-7977 will hit the market until at least 2013. Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. Achillion Pharmaceuticals, Inc. (ACHN): Engages in the discovery, development, and commercialization of treatments for infectious diseases. | Bizmology also reports that other hepatitis C therapies are currently being developed by Inhibitex (INHX), Achillion (ACHN), Roche, and Abbott Labs (ABT), but none of these drugs including PSI-7977 will hit the market until at least 2013. Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. (By Alexander Crawford) The landscape of treatment options for hepatitis C is looking brighter – biotech company Pharmasset Inc (VRUS) just released clinical results showing that their experimental drug cured all 40 patients of hepatitis C in a Phase II trial. | Bizmology also reports that other hepatitis C therapies are currently being developed by Inhibitex (INHX), Achillion (ACHN), Roche, and Abbott Labs (ABT), but none of these drugs including PSI-7977 will hit the market until at least 2013. Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. The company plans to move into the final third phase, with two studies involving 500 and 225 patients each. |
34498.0 | 2011-11-02 00:00:00 UTC | Medical Devices: Venture Capitalists Lobby to Change FDA Approval Process | ABT | https://www.nasdaq.com/articles/medical-devices-venture-capitalists-lobby-change-fda-approval-process-2011-11-02 | nan | nan | (Written by Alexander Crawford)
Complaints from the healthcare industry that the FDA is too slow in approving new drugs and devices are not rare. Now it appears that venture capitalists are putting their money towards streamlining how the FDA approves medical devices, reports the New York Times.
Minnesota representative Erik Paulsen is currently sponsoring a bill to smooth the FDA’s approval process of devices, making the process less uncertain. He argues that the current system is stifling investment that will cost states 400,000 jobs.
The bill seems to have the backing of industry lobbyists. The New York Times reports, “Mr. Paulsen’s campaign committee took in $74,000 from people with a stake in device regulation, much of it from executives affiliated with venture capital funds and their spouses.”
The device industry is lobbying for change because they argue the FDA experiences high personnel turnover, cumbersome bureaucracy, and a system that requires start-up firms to run new and costly tests that often duplicate past efforts.
One lobbying group National Venture Capital Association has donated about $350,000 in 2010 for devices, drugs, and health care, according to data from the nonpartisan Center for Responsive Politics.
Congress must reauthorize a law that requires medical device makers to pay fees to the FDA for their operating costs, and this upcoming year is an opportunity for a regulatory change. Paulsen’s bill is not alone. 10 bills have been introduced by House Republicans just this October to speed up the FDA’s approval process of devices.
If one of the bills is successful, it could be a boon to many device-makers. For a closer look at the firms, we list the ten largest firms involved with medical devices.
Do you think these firms stand to benefit from new regulations?
Analyze These Ideas (Tools Will Open In A New Window)
1. Access a thorough description of all companies mentioned
2. Compare analyst ratings for all stocks mentioned below
3. Visualize annual returns for all stocks mentioned
List sorted by market cap.
1. Johnson & Johnson (JNJ): Engages in the research and development, manufacture, and sale of various products in the health care field worldwide. Market cap of $176.73B.
2. Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. Market cap of $83.51B.
3. Medtronic, Inc. (MDT): Manufactures and sells device-based medical therapies worldwide. Market cap of $35.85B.
4. Allergan Inc. (AGN): Operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. Market cap of $25.75B.
5. Covidien plc (COV): Develops, manufactures, and sells healthcare products for use in clinical and home settings in the United States and internationally. Market cap of $22.09B.
6. Becton, Dickinson and Company (BDX): Develops, manufactures, and sells medical devices, instrument systems, and reagents worldwide. Market cap of $16.68B.
7. St. Jude Medical Inc. (STJ): Develops, manufactures, and distributes cardiovascular and implantable neurostimulation medical devices worldwide. Market cap of $13.35B.
8. Quest Diagnostics Inc. (DGX): Provides diagnostic testing, information, and services in the United States and internationally. Market cap of $8.88B.
9. Boston Scientific Corporation (BSX): Develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. Market cap of $8.36B.
10. Smith & Nephew plc (SNN): Develops, manufactures, markets, and sells medical devices in the orthopaedics, endoscopy, and advanced wound management sectors worldwide. Market cap of $8.12B.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. One lobbying group National Venture Capital Association has donated about $350,000 in 2010 for devices, drugs, and health care, according to data from the nonpartisan Center for Responsive Politics. Congress must reauthorize a law that requires medical device makers to pay fees to the FDA for their operating costs, and this upcoming year is an opportunity for a regulatory change. | Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. Now it appears that venture capitalists are putting their money towards streamlining how the FDA approves medical devices, reports the New York Times. Smith & Nephew plc (SNN): Develops, manufactures, markets, and sells medical devices in the orthopaedics, endoscopy, and advanced wound management sectors worldwide. | Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. Paulsen’s campaign committee took in $74,000 from people with a stake in device regulation, much of it from executives affiliated with venture capital funds and their spouses.” The device industry is lobbying for change because they argue the FDA experiences high personnel turnover, cumbersome bureaucracy, and a system that requires start-up firms to run new and costly tests that often duplicate past efforts. Boston Scientific Corporation (BSX): Develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. | Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. Paulsen’s campaign committee took in $74,000 from people with a stake in device regulation, much of it from executives affiliated with venture capital funds and their spouses.” The device industry is lobbying for change because they argue the FDA experiences high personnel turnover, cumbersome bureaucracy, and a system that requires start-up firms to run new and costly tests that often duplicate past efforts. Visualize annual returns for all stocks mentioned List sorted by market cap. |
34499.0 | 2011-10-20 00:00:00 UTC | Stocks in Red at Session's Half; Investors Again Eying Europe, Overshadows Data | ABT | https://www.nasdaq.com/articles/stocks-red-sessions-half-investors-again-eying-europe-overshadows-data-2011-10-20 | nan | nan | Stocks have slipped into negative territory as Europe worries return to center stage, overshadowing new data showing signs of life in regional manufacturing and a drop in first-time unemployment claims.
The U.S. Federal Reserve's Philly Fed index rose to 8.7 in October from negative 17.5 last month, MarketWatch noted in a report on the data. Economists had expected a negative 10 reading, the report said.
Also, the Labor Department said initial jobless claims fell by 6,000 to 403,000 in the week ended Oct. 15. Initial claims from two weeks ago were revised up to 409,000 from an original reading of 404,000, however. The average of new claims over the past four weeks, seen as a more accurate gauge of labor trends, fell by 6,250 to 403,000, the lowest since mid-April.
Overseas, an unexpected meeting between French President Nicolas Sarkozy and German Chancellor Angela Merkel and other international officials in Frankfurt late Wednesday fueled worries over a potential rift between Berlin and Paris over elements of a comprehensive package of reforms expected to be presented by euro-zone leaders at a Brussels summit meeting on Sunday, news reports said. There was no official comment from the Wednesday gathering, however.
U.S. economic news helped cement those early mild futures gains, though brought little fresh hope for aggressive labor market improvement.
In other company news:
Abbott Laboratories ( ABT ) are higher on a Bloomberg report that the breakup of the drug maker into two separate firms will result in a $54 billion target for acquisitive drug makers. A Jefferies Group analyst noted that Merck & Co. ( MRK ), Roche ( RHHBY ) and Bayer ( BAYRY ) are potentially interested parties.
Shares of Apple ( AAPL ) are lower after the company reported that it held down costs for its iPhone 4S even as it made several design improvements, such as the capacity t be used with multiple wireless systems. The report cited an assessment from industry research firm IHS iSuppli.
Shares Neoprobe (NEOP) are sharply higher after it announced that its New Drug Application for Lymphoseek has been accepted for review by the U.S. Food and Drug Administration. Neoprobe submitted the Lymphoseek NDA last month.
Cisco (CSCO) is down after it today announced its intent to acquire privately-held BNI Video. Under the terms of the agreement, Cisco will pay $99 million in cash and retention-based incentives in exchange for all shares of BNI Video. The acquisition is subject to various standard closing conditions and is expected to be complete in the second quarter of Cisco's fiscal year 2012.
In earnings news:
--Shares of The New York Times Co. (NYT) are higher after the media company reported Q3 EPS, excluding items, of $0.05 per share, ahead of the analyst consensus of $0.04 per share on Thomson Reuters. However, revenue came in at $537.2 million, below expectations of $541 million.
--Shares of Philip Morris (PM) are up 2.79%, or $1.84, to $67.7 after the company issued its third quarter report. The company said Q3 EPS were $1.37, ahead of analyst expectations of $1.24. Revenue rose 26.4% from the year ago period to $8.36 billion, comfortably beating estimates of $7.57 billion. The company also says it sees FY11 EPS of $4.75-4.80, higher than estimates of $4.74.
--Shares of Nokia (NOK) are higher after the mobile phone company reported a $93.1 million Q3 loss, which was less than analysts had expected, The New York Times reports. Chief Executive Stephen Elop said despite the result, the firm's sales execution and inventory situation had improved, the report said.
Natural gas futures gained after a new report showed inventories rose 103 billion cubic feet for the week ended Oct. 14, less than analysts had predicted.
Commodities are down. December gold contracts fell 2.27% to $1,610 an ounce while December crude oil contacts are down $1.27 to $86.29 a barrel.
In energy ETFs, the United States Oil Fund (USO) is down 1.32% to $32.87 and the United States Natural Gas fund (UNG) is up 1.71%, to $8.91.
In precious metal ETFs, the SPDR Gold Trust (GLD) is down 1.91% to $156.81. Market Vectors Gold Miners (GDX) is down 1.68% to $52.65. iShares Silver Trust (SLV) is down 2.2% to $29.57.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In other company news: Abbott Laboratories ( ABT ) are higher on a Bloomberg report that the breakup of the drug maker into two separate firms will result in a $54 billion target for acquisitive drug makers. Stocks have slipped into negative territory as Europe worries return to center stage, overshadowing new data showing signs of life in regional manufacturing and a drop in first-time unemployment claims. U.S. economic news helped cement those early mild futures gains, though brought little fresh hope for aggressive labor market improvement. | In other company news: Abbott Laboratories ( ABT ) are higher on a Bloomberg report that the breakup of the drug maker into two separate firms will result in a $54 billion target for acquisitive drug makers. Natural gas futures gained after a new report showed inventories rose 103 billion cubic feet for the week ended Oct. 14, less than analysts had predicted. In energy ETFs, the United States Oil Fund (USO) is down 1.32% to $32.87 and the United States Natural Gas fund (UNG) is up 1.71%, to $8.91. | In other company news: Abbott Laboratories ( ABT ) are higher on a Bloomberg report that the breakup of the drug maker into two separate firms will result in a $54 billion target for acquisitive drug makers. In earnings news: --Shares of The New York Times Co. (NYT) are higher after the media company reported Q3 EPS, excluding items, of $0.05 per share, ahead of the analyst consensus of $0.04 per share on Thomson Reuters. --Shares of Nokia (NOK) are higher after the mobile phone company reported a $93.1 million Q3 loss, which was less than analysts had expected, The New York Times reports. | In other company news: Abbott Laboratories ( ABT ) are higher on a Bloomberg report that the breakup of the drug maker into two separate firms will result in a $54 billion target for acquisitive drug makers. --Shares of Nokia (NOK) are higher after the mobile phone company reported a $93.1 million Q3 loss, which was less than analysts had expected, The New York Times reports. Natural gas futures gained after a new report showed inventories rose 103 billion cubic feet for the week ended Oct. 14, less than analysts had predicted. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.